Streptococcus B_BACTERIUM[BIO]
ursoris I_BACTERIUM[BIO]
sp I_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
nov I_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
, O
isolated O
from O
the O
oral O
cavities O
of O
bears O
. O

Three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
Gram I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
catalase B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
coccus B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- O
shaped O
organisms B_BIO
were O
isolated O
from O
the O
oral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cavities I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
bears B_SPECIES[BIO]/B_PERSON
. O

The O
isolates B_BIO
were O
tentatively O
identified O
as O
a O
streptococcal B_BACTERIUM[BIO]
species I_BACTERIUM[BIO]
based O
on O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
biochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
16S I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rRNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
confirmed O
that O
the O
organisms B_BIO/B_GENE
were O
members B_PERSON/B_LOCATION
of O
the O
genus B_BIO/B_MEASURE
Streptococcus I_BIO/I_MEASURE
, O
but O
they O
did O
not O
correspond O
to O
any O
recognized O
species B_BIO/B_PERSON
of O
the O
genus B_BACTERIUM[BIO]/B_MEASURE
. O

The O
nearest O
phylogenetic O
relative O
of O
the O
new O
isolates O
was O
Streptococcus B_BACTERIUM[BIO]/B_PROTEIN[GENE]
ratti B_BACTERIUM[BIO]/I_PROTEIN[GENE]
ATCC B_BACTERIUM[BIO]/I_PROTEIN[GENE]
19645 B_BACTERIUM[BIO]/I_PROTEIN[GENE]
( O
T O
) O
( O
98 O
. O
6 O
% O
) O
, O
however O
, O
DNA O
- O
DNA O
hybridization O
analysis O
showed O
that O
the O
isolates O
displayed O
less O
than O
15 O
% O
DNA O
- O
DNA O
relatedness O
with O
the O
type O
strain O
of O
S B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
ratti I_BACTERIUM[BIO]/I_DISEASE
. O

colonies B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
novel B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
grown O
on O
mitis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
salivarius I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
agar I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
showed O
an O
extracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
polysaccharide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
- O
producing O
colony B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphology B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
phenotypic O
and O
phylogenetic O
evidence O
, O
it O
is O
proposed O
that O
the O
novel O
isolates O
are O
classified O
in O
the O
genus O
Streptococcus O
as O
Streptococcus B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ursoris B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
sp B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
nov B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
type O
strain O
of O
S B_BACTERIUM[BIO]/B_LOCATION
. B_BACTERIUM[BIO]/I_LOCATION
ursoris B_BACTERIUM[BIO]/I_LOCATION
is O
NUM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1615 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
= O
JCM O
16316 O
( O
T O
) O
= O
DSM O
22768 O
( O
T O
) O
) O
. O

Larkinella B_BACTERIUM[BIO]/B_MEASURE
bovis I_BACTERIUM[BIO]/I_MEASURE
SP O
. O
Nov O
. O
, O
isolated O
from O
fermented O
bovine O
products O
, O
and O
emended O
descriptions O
of O
the O
genus O
Larkinella O
and O
of O
Larkinella B_BIO/B_PERSON
insperata I_BIO/I_PERSON
Vancanneyt O
et O
al O
. O

2006 B_NUMBER[MEASURE]
. O

A O
novel O
bacterial O
strain O
, O
designated O
M2T2B15 B_PROTEIN[GENE]/B_LOCATION
( O
T O
) O
, O
was O
isolated O
from O
fermented O
bovine O
products O
and O
was O
characterized O
by O
using O
a O
polyphasic O
approach O
. O

colonies B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reddish B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
pink I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
and O
circular B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
entire B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
margins I_COLOR/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
strictly O
aerobic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
Gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
oxidase B_ENZYME[GENE]
- O
and O
catalase B_ENZYME[GENE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rods I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
that O
lacked O
flagella B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
motile B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O
gliding O
. O

Flexirubin B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- O
type B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pigments I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

16S O
rRNA O
gene O
sequence O
analysis O
indicated O
that O
strain O
M2T2B15 B_MEASURE/B_GENE
( O
T O
) O
was O
related O
most O
closely O
to O
Larkinella B_BIO/B_LOCATION
insperata I_BIO/I_LOCATION
LMG O
22510 O
( O
T O
) O
( O
94 O
. O
4 O
% O
similarity O
) O
but O
shared O
& O
Lt O
; O
87 O
% O
similarity O
with O
other O
members O
of O
the O
phylum O
Bacteroidetes O
. O

The O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cellular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fatty I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
acids I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
C B_PROTEIN[GENE]/B_LOCATION
( O
16 B_MEASURE
: O
1 B_MEASURE
) O
omega5c B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
iso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
C B_PROTEIN[GENE]/B_LOCATION
( O
15 B_MEASURE
: O
0 B_MEASURE
) O
and O
iso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
C B_PROTEIN[GENE]/B_LOCATION
( O
17 B_MEASURE
: O
0 B_MEASURE
) O
3 B_MEASURE/B_LOCATION
- O
OH O
. O

The O
polar B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lipids I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
phosphatidylethanolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
phosphatidylserine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
unidentified I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminophospholipids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unidentified I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polar I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Menaquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Mk B_PROTEIN[GENE]/B_LOCATION
- O
7 B_MEASURE
) O
was O
the O
major B_PERSON
respiratory I_PERSON
quinone I_PERSON
. O

The O
G O
+ O
C O
content O
of O
the O
DNA O
of O
strain O
M2T2B15 B_MEASURE/B_PROTEIN[GENE]
( O
T O
) O
was O
52 O
& O
amp O
; O
emsp14 O
; O
mol O
% O
. O

The O
phenotypic O
, O
genotypic O
and O
phylogenetic O
data O
presented O
clearly O
indicate O
that O
strain O
M2T2B15 B_NUMBER[MEASURE]/B_PERSON
( O
T O
) O
represents O
a O
novel O
species O
of O
the O
genus O
Larkinella O
, O
for O
which O
the O
name O
Larkinella B_BACTERIUM[BIO]
bovis I_BACTERIUM[BIO]
SP O
. O
Nov O
. O

is B_LOCATION/B_ORGANIZATION
proposed O
. O

The O
type O
strain O
is O
M2T2B15 B_PROTEIN[GENE]/B_DISEASE
( O
T O
) O
( O
= O
KACC O
14040 O
( O
T O
) O
= O
NBRC O
106324 O
( O
T O
) O
) O
. O

Emended O
descriptions O
of O
the O
genus O
Larkinella O
and O
of O
Larkinella B_BIO/B_LOCATION
insperata I_BIO/I_LOCATION
Vancanneyt O
et O
al O
. O

2006 B_NUMBER[MEASURE]/B_LOCATION
are O
also O
proposed O
. O

Methanobacterium B_MEASURE/B_BACTERIUM[BIO]
arcticum I_MEASURE/I_BACTERIUM[BIO]
SP I_MEASURE/I_BACTERIUM[BIO]
. O
nov B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
a O
methanogenic B_BIO/B_LOCATION
archaeon I_BIO/I_LOCATION
from O
Holocene B_LOCATION
Arctic I_LOCATION
permafrost I_LOCATION
. O

A O
mesophilic O
, O
non O
- O
motile O
, O
hydrogenotrophic O
, O
rod O
- O
shaped O
methanogen O
, O
designated O
M2 B_PROTEIN[GENE]/B_MEASURE
( I_PROTEIN[GENE]/I_MEASURE
T I_PROTEIN[GENE]/I_MEASURE
) I_PROTEIN[GENE]/I_MEASURE
, O
was O
isolated O
from O
Holocene O
permafrost O
sediments O
of O
the O
Kolyma O
lowland O
in O
the O
Russian O
Arctic O
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
3 B_NUMBER[MEASURE]
- O
6 B_MEASURE/B_PERSON
mum I_MEASURE/I_PERSON
long O
and O
0 B_MEASURE/B_LOCATION
. O
45 B_MEASURE
- O
0 B_MEASURE
. O
5 B_MEASURE/B_PERSON
mum I_MEASURE/I_PERSON
wide O
. O

strain O
M2 B_GENE/B_MEASURE
( B_GENE/I_MEASURE
T B_GENE/I_MEASURE
) B_GENE/I_MEASURE
grew O
on O
H O
( O
2 O
) O
/ O
CO O
( O
2 O
) O
and O
formate O
. O

optimum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
conditions I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
37 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
^ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
0C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
pH O
6 B_MEASURE
. O
8 B_MEASURE
- O
7 B_MEASURE
. O
2 B_MEASURE
and O
0 B_MEASURE
. O
1 B_MEASURE
M I_MEASURE
NaCl I_MEASURE
. O

The O
DNA B_MEASURE/B_ORGANIZATION
G I_MEASURE/I_ORGANIZATION
+ I_MEASURE/I_ORGANIZATION
C I_MEASURE/I_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
was O
38 B_MEASURE
. O
1 B_MEASURE
mol I_MEASURE
% I_MEASURE
. O

On O
the O
basis O
of O
16S O
rRNA O
gene O
sequence O
comparison O
with O
known O
methanogens O
, O
strain O
M2 B_MEASURE/B_GENE
( I_MEASURE/I_GENE
T I_MEASURE/I_GENE
) I_MEASURE/I_GENE
was O
affiliated O
with O
the O
genus O
Methanobacterium O
and O
was O
most O
closely O
related O
to O
Methanobacterium B_BACTERIUM[BIO]
veterum I_BACTERIUM[BIO]
MK4 I_BACTERIUM[BIO]
( I_BACTERIUM[BIO]
T I_BACTERIUM[BIO]
) I_BACTERIUM[BIO]
and O
Methanobacterium B_PROTEIN[GENE]/B_BACTERIUM[BIO]
bryantii I_PROTEIN[GENE]/I_BACTERIUM[BIO]
DSM I_PROTEIN[GENE]/I_BACTERIUM[BIO]
863 I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( I_PROTEIN[GENE]/I_BACTERIUM[BIO]
T I_PROTEIN[GENE]/I_BACTERIUM[BIO]
) I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( O
both O
99 O
% O
16S O
rRNA O
gene O
sequence O
similarity O
) O
. O

However O
, O
no O
significant O
DNA O
- O
DNA O
relatedness O
was O
observed O
between O
strain O
M2 B_PROTEIN[GENE]/B_MEASURE
( I_PROTEIN[GENE]/I_MEASURE
T I_PROTEIN[GENE]/I_MEASURE
) I_PROTEIN[GENE]/I_MEASURE
and O
these O
type O
strains O
. O

We O
propose O
that O
strain O
M2 B_PROTEIN[GENE]
( I_PROTEIN[GENE]
T I_PROTEIN[GENE]
) I_PROTEIN[GENE]
represents O
a O
novel O
species O
, O
with O
the O
name O
Methanobacterium O
arcticum O
SP O
. O
Nov O
. O
, O
with O
type O
strain O
M2 B_PROTEIN[GENE]/B_DISEASE
( I_PROTEIN[GENE]/I_DISEASE
T I_PROTEIN[GENE]/I_DISEASE
) I_PROTEIN[GENE]/I_DISEASE
( O
= O
DSM O
19844 O
( O
T O
) O
= O
VKM O
B O
- O
2371 O
( O
T O
) O
) O
. O

Thiomonas B_BACTERIUM[BIO]
islandica I_BACTERIUM[BIO]
SP O
. O
Nov O
. O
, O
a O
moderately O
thermophilic O
, O
hydrogen O
- O
and O
sulfur O
- O
oxidizing O
betaproteobacterium B_BIO
isolated O
from O
a O
hot O
spring O
. O

A O
novel O
, O
hydrogen O
- O
and O
sulfur O
- O
oxidizing O
bacterium O
, O
designated O
strain O
6C B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
isolated O
from O
a O
hot O
spring O
in O
Graendalur O
, O
south O
- O
western O
Iceland O
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
this O
organism B_BIO
were O
Gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rod B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
- O
shaped O
and O
motile B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
strain B_BIO/B_DISEASE
grew O
aerobically O
and O
was O
capable B_PERSON
of O
chemolithotrophic B_ORGANISM_FUNCTION/B_BACTERIUM[BIO]
growth I_ORGANISM_FUNCTION/I_BACTERIUM[BIO]
on O
thiosulfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
heterotrophic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
on O
pyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
oxalate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
acetate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
on O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
yeast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extract I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mixotrophic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
on O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
organic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
thiosulfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
/ O
or O
hydrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

During O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
thiosulfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
final B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
product I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
sulfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulting O
in O
a O
drop B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
pH B_MEASURE
from O
6 B_MEASURE
. O
8 B_MEASURE
to O
2 B_MEASURE
. O
7 B_MEASURE
. O

Heterotrophic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
growth I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
on O
pyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
observed O
at O
pH B_MEASURE
4 I_MEASURE
- O
7 B_MEASURE
( O
optimum B_MEASURE/B_LOCATION
pH B_MEASURE/I_LOCATION
4 B_MEASURE/I_LOCATION
) O
and O
35 B_MEASURE
- O
50 B_MEASURE
^ O
0C B_MEASURE
( O
optimum B_MEASURE/B_LOCATION
45 I_MEASURE/I_LOCATION
^ I_MEASURE/I_LOCATION
0C I_MEASURE/I_LOCATION
) O
. O

The O
DNA B_MEASURE/B_ORGANIZATION
G I_MEASURE/I_ORGANIZATION
+ I_MEASURE/I_ORGANIZATION
C I_MEASURE/I_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
was O
65 B_MEASURE
. O
2 B_MEASURE
mol I_MEASURE
% I_MEASURE
. O

As O
determined O
by O
16S O
rRNA O
gene O
sequence O
analysis O
, O
strain O
6C B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O
a O
distinct O
species O
belonging O
to O
the O
class O
Betaproteobacteria B_BACTERIUM[BIO]
and O
is O
most O
closely O
related O
to O
Thiomonas B_BACTERIUM[BIO]
intermedia I_BACTERIUM[BIO]
DSM I_BACTERIUM[BIO]
18155 I_BACTERIUM[BIO]
( I_BACTERIUM[BIO]
T I_BACTERIUM[BIO]
) I_BACTERIUM[BIO]
and O
Thiomonas B_BACTERIUM[BIO]/B_LOCATION
perometabolis B_BACTERIUM[BIO]/I_LOCATION
DSM B_BACTERIUM[BIO]/I_LOCATION
18570 B_BACTERIUM[BIO]/I_LOCATION
( B_BACTERIUM[BIO]/I_LOCATION
T B_BACTERIUM[BIO]/I_LOCATION
) B_BACTERIUM[BIO]/I_LOCATION
. O

DNA O
- O
DNA O
hybridization O
between O
strain O
6C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
Thiomonas B_BIO/B_PROTEIN[GENE]
intermedia B_BIO/I_PROTEIN[GENE]
DSM B_BIO/I_PROTEIN[GENE]
18155 B_BIO/I_PROTEIN[GENE]
( B_BIO/I_PROTEIN[GENE]
T B_BIO/I_PROTEIN[GENE]
) B_BIO/I_PROTEIN[GENE]
and O
Thiomonas B_BIO/B_GENE
perometabolis B_BIO/I_GENE
DSM B_BIO/I_GENE
18570 B_BIO/I_GENE
( B_BIO/I_GENE
T B_BIO/I_GENE
) B_BIO/I_GENE
gave O
relatedness O
values O
below O
32 O
% O
. O

These O
results O
, O
together O
with O
physiological O
characteristics O
, O
showed O
that O
strain O
6C B_NUMBER[MEASURE]
( I_NUMBER[MEASURE]
T I_NUMBER[MEASURE]
) I_NUMBER[MEASURE]
represents O
a O
novel O
species O
within O
the O
genus O
Thiomonas O
, O
for O
which O
the O
name O
Thiomonas B_BACTERIUM[BIO]
islandica I_BACTERIUM[BIO]
SP O
. O
Nov O
. O

is B_LOCATION/B_ORGANIZATION
proposed O
. O

The O
type O
strain O
is O
6C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
T I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
= O
DSM B_DISEASE
21436 I_DISEASE
( I_DISEASE
T I_DISEASE
) I_DISEASE
= O
JCM B_MEASURE/B_DISEASE
16107 I_MEASURE/I_DISEASE
( I_MEASURE/I_DISEASE
T I_MEASURE/I_DISEASE
) I_MEASURE/I_DISEASE
) O
. O

Nocardioides B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
caricicola I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
sp I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
nov I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
an O
endophytic O
bacterium O
isolated O
from O
a O
halophyte O
, O
Carex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
scabrifolia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Steud O
. O

A O
Gram O
- O
staining O
- O
positive O
, O
coccoid O
to O
rod O
- O
shaped O
bacterium O
, O
designated O
strain O
YC6903 B_MEASURE/B_PERSON
( O
T O
) O
, O
was O
isolated O
from O
a O
halophytic O
plant O
( O
Carex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
scabrifolia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Steud O
. O
) O
collected O
from O
sand O
dunes O
at O
Namhae O
Island O
, O
Korea O
, O
and O
its O
taxonomic O
position O
was O
investigated O
by O
using O
a O
polyphasic O
approach O
. O

strain O
YC6903 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
T O
) O
grew O
optimally O
at O
30 O
^ O
0C O
and O
at O
pH O
8 O
. O
0 O
. O

phylogenetic O
analysis O
based O
on O
16S O
rRNA O
gene O
sequences O
indicated O
that O
strain O
YC6903 B_MEASURE/B_PERSON
( O
T O
) O
belongs O
to O
the O
genus O
Nocardioides O
in O
the O
family O
Nocardioidaceae O
. O

strain O
YC6903 B_MEASURE/B_PERSON
( O
T O
) O
was O
related O
most O
closely O
to O
Nocardioides B_BACTERIUM[BIO]
pyridinolyticus I_BACTERIUM[BIO]
OS4 I_BACTERIUM[BIO]
( O
T O
) O
( O
97 O
. O
0 O
% O
16S O
rRNA O
gene O
sequence O
similarity O
) O
, O
Nocardioides B_BIO/B_PROTEIN[GENE]
dokdonensis B_BIO/I_PROTEIN[GENE]
FR1436 B_BIO/I_PROTEIN[GENE]
( O
T O
) O
( O
96 O
. O
6 O
% O
) O
, O
Nocardioides B_BACTERIUM[BIO]/B_PROTEIN[GENE]
aquiterrae B_BACTERIUM[BIO]/I_PROTEIN[GENE]
GW B_BACTERIUM[BIO]/I_PROTEIN[GENE]
- B_BACTERIUM[BIO]/I_PROTEIN[GENE]
9 B_BACTERIUM[BIO]/I_PROTEIN[GENE]
( O
T O
) O
( O
96 O
. O
6 O
% O
) O
and O
Nocardioides B_BIO/B_MEASURE
hankookensis B_BIO/I_MEASURE
DS B_BIO/I_MEASURE
- B_BIO/I_MEASURE
30 B_BIO/I_MEASURE
( O
T O
) O
( O
96 O
. O
6 O
% O
) O
. O

The O
cell B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
wall B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
peptidoglycan I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BACTERIUM[BIO]
contained O
LL B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diaminopimelic B_MEASURE
acid I_MEASURE
and O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_NUMBER[MEASURE]
( O
H B_OTHER/B_PROTEIN[GENE]
( O
4 B_NUMBER[MEASURE]/B_LOCATION
) O
) O
was O
the O
major B_PERSON/B_BACTERIUM[BIO]
respiratory I_PERSON/I_BACTERIUM[BIO]
quinone I_PERSON/I_BACTERIUM[BIO]
. O

The O
mean O
( O
+ O
/ O
- O
SD O
) O
level O
of O
DNA O
- O
DNA O
relatedness O
between O
strain O
YC6903 B_MEASURE/B_PERSON
( O
T O
) O
and O
N B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
pyridinolyticus I_BACTERIUM[BIO]
OS4 I_BACTERIUM[BIO]
( O
T O
) O
was O
53 O
. O
5 O
+ O
/ O
- O
5 O
. O
5 O
% O
. O

The O
predominant O
cellular O
fatty O
acid O
of O
strain O
YC6903 B_MEASURE/B_PERSON
( O
T O
) O
was O
ISO O
- O
C O
( O
16 O
: O
0 O
) O
( O
28 O
. O
9 O
% O
) O
. O

The O
DNA B_MEASURE/B_ORGANIZATION
G I_MEASURE/I_ORGANIZATION
+ I_MEASURE/I_ORGANIZATION
C I_MEASURE/I_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
was O
71 B_MEASURE
. O
7 B_MEASURE
mol I_MEASURE
% I_MEASURE
. O

Phenotypic O
, O
phylogenetic O
and O
chemotaxonomic O
data O
indicated O
that O
strain O
YC6903 B_NUMBER[MEASURE]/B_PERSON
( O
T O
) O
represents O
a O
novel O
species O
of O
the O
genus O
Nocardioides O
, O
for O
which O
the O
name O
Nocardioides B_TIME[MEASURE]/B_DISEASE
caricicola I_TIME[MEASURE]/I_DISEASE
sp I_TIME[MEASURE]/I_DISEASE
. I_TIME[MEASURE]/I_DISEASE
nov I_TIME[MEASURE]/I_DISEASE
. I_TIME[MEASURE]/I_DISEASE
. O

is B_LOCATION/B_ORGANIZATION
proposed O
. O

The O
type O
strain O
is O
YC6903 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
T O
) O
( O
= O
KACC O
13778 O
( O
T O
) O
= O
DSM O
22177 O
( O
T O
) O
) O
. O

radionuclide B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
hybrid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
imaging I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
recurrent B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
prostate I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Prostate B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
is O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
cancers I_DISEASE_ADJECTIVE[DISEASE]
in O
men B_PERSON/B_LOCATION
, O
leading O
to O
substantial B_DISEASE
morbidity I_DISEASE
and O
mortality B_DISEASE/B_MEASURE
. O

After O
definitive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
surgery B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
many B_PERSON/B_BIO
patients I_PERSON/I_BIO
have O
biochemical B_DISEASE_ADJECTIVE[DISEASE]
relapse I_DISEASE_ADJECTIVE[DISEASE]
of O
disease B_DISEASE/B_GENE
- O
- O
ie B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
their O
prostate B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_MEASURE/B_DISEASE
antigen I_MEASURE/I_DISEASE
level I_MEASURE/I_DISEASE
- O
- O
which O
often O
precedes O
clinically O
apparent B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
by O
months B_TIME[MEASURE]
or O
even B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

Therefore O
, O
imaging B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
site B_LOCATION/B_MEASURE
and O
extent B_DISEASE/B_MEASURE
of O
tumour B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recurrence I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
local B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
regional B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
distant B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
or O
a O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
) O
is O
of O
great B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
interest I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

Conventional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
morphological I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
recurrent B_DISEASE
prostate I_DISEASE
cancer I_DISEASE
; O
however O
, O
in O
recent B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
years I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
, O
functional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
molecular B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O
offered O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
imaging O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
individual B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tumours I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
often O
with O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
accuracy B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hybrid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
imaging I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
modalities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
single B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
photon B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
emission I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
CT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SPECT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
have O
been O
introduced O
that O
combine O
functional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
allow O
whole B_NUMBER[MEASURE]/B_PERSON
- O
body B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
imaging I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Here O
, O
we O
review O
the O
contribution B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
radionuclide B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
hybrid B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
recurrent B_DISEASE_ADJECTIVE[DISEASE]
prostate I_DISEASE_ADJECTIVE[DISEASE]
cancer I_DISEASE_ADJECTIVE[DISEASE]
( O
local B_DISEASE
vs I_DISEASE
regional I_DISEASE
vs I_DISEASE
distant I_DISEASE
disease I_DISEASE
) O
. O

We O
discuss O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
Pet B_LOCATION
- O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
SPECT B_LOCATION
- O
CT B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
provide O
an O
overview B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
experimental B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tracers I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
their O
preclinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Finally O
, O
we O
present O
a O
perspective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
future B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hybrid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
magnetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
resonance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

fertility B_BODY_PART_OR_ORGAN_COMPONENT
- O
sparing O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON
with O
cervical B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

There O
are O
several B_MEASURE
types I_MEASURE
of O
fertility B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
saving I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
can O
be O
done O
in O
patients B_PERSON
with O
cervical B_DISEASE
cancer I_DISEASE
, O
which O
differ O
in O
terms B_LOCATION/B_MEASURE
of O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
approach B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O
extent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
paracervical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
resection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

This O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assesses O
oncological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
pregnancy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
different B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedures B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
oncological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vaginal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
radical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
trachelectomies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
VRT B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
and O
abdominal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
radical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
trachelectomies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
Art B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
are O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
tumours B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
2 B_MEASURE/B_LOCATION
cm I_MEASURE/I_LOCATION
in O
size B_MEASURE/B_LOCATION
, O
and O
are O
now O
considered O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgical I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedures I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

oncological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
VRT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
and O
ART B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O
tumours B_MEASURE/B_PERSON
larger I_MEASURE/I_PERSON
than O
2 B_NUMBER[MEASURE]/B_PERSON
cm I_NUMBER[MEASURE]/I_PERSON
are O
also O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
but O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cannot O
be O
considered O
satisfactory B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
less O
radical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
ie B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
deep B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cone I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
simple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
trachelectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PROTEIN[GENE]
) O
in O
patients B_PERSON/B_BIO
with O
tumours B_TIME[MEASURE]/B_ENT
less I_TIME[MEASURE]/I_ENT
than O
2 B_NUMBER[MEASURE]
cm I_NUMBER[MEASURE]
, O
and O
negative B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sentinel I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
other B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pelvic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lymph I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
nodes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
are O
comparable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
VRT B_PERSON
and O
ART B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Downstaging B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tumours B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
larger B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
2 B_NUMBER[MEASURE]/B_PERSON
cm I_NUMBER[MEASURE]/I_PERSON
by O
neoadjuvant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
still O
an O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
will O
need O
multicentre B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cooperation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
verify O
its O
oncological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
safety I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Pregnancy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
vary O
statistically O
with O
the O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

morphology O
and O
ultrastructure O
of O
multiple O
life O
cycle O
stages O
of O
the O
photosynthetic O
relative O
of O
apicomplexa O
, O
Chromera B_BIO/B_GENE
velia B_BIO/I_GENE
. O

Chromera B_BACTERIUM[BIO]/B_DISEASE
velia I_BACTERIUM[BIO]/I_DISEASE
is O
a O
photosynthetic O
alga O
with O
a O
secondary O
plastid O
that O
represents O
the O
closest O
known O
photosynthetic O
relative O
of O
the O
apicomplexan O
parasites O
. O

The O
original O
description O
of O
this O
organism O
was O
based O
on O
brownish O
, O
immotile O
coccoid O
cells O
, O
which O
is O
the O
predominating O
stage O
of O
C B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
velia B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
culture O
. O

Here O
we O
provide O
a O
detailed O
light O
and O
electron O
microscopy O
description O
of O
coccoid O
cells O
of O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
velia I_SPECIES[BIO]/I_PERSON
and O
a O
previously O
undocumented O
bi O
- O
flagellated O
stage O
that O
is O
highly O
motile O
and O
moves O
in O
a O
characteristic O
zig O
- O
zag O
pattern O
. O

transformation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
a O
coccoid B_SPECIES[BIO]
into O
a O
flagellate B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
stage I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
occurs O
in O
exponentially O
growing O
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
is O
accelerated O
by O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
light B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
C B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
velia I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cells O
contain O
a O
pseudoconoid O
, O
which O
is O
likely O
homologous O
to O
the O
corresponding O
structure O
in O
the O
apical O
complex O
of O
Apicomplexa O
, O
cortical O
alveoli O
subtended O
by O
subpellicular O
microtubules O
, O
mitochondrion O
with O
tubular O
cristae O
, O
a O
micropyle O
, O
and O
a O
distinctive O
chromerosome O
, O
an O
apparently O
novel O
type O
of O
extrusion O
organelle O
. O

ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
flagellate B_BIO/B_GENE
supports O
its O
close B_PERSON
association I_PERSON
with O
colpodellids B_SPECIES[BIO]
and O
apicomplexans B_SPECIES[BIO]
and O
provides O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insight I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O
their O
evolution B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Introns O
, O
alternative O
splicing O
, O
spliced O
leader O
trans O
- O
splicing O
and O
differential O
expression O
of O
pcna O
and O
cyclin O
in O
Perkinsus B_DISEASE/B_BIO
marinus I_DISEASE/I_BIO
. O

To O
gain O
understanding O
on O
the O
structure O
and O
regulation O
of O
growth O
- O
related O
genes O
of O
the O
parasitic O
alveolate O
Perkinsus B_SPECIES[BIO]/B_LOCATION
marinus I_SPECIES[BIO]/I_LOCATION
, O
we O
analyzed O
genes O
encoding O
proliferating O
cell O
nuclear O
antigen O
( O
pcna O
) O
and O
cyclins O
( O
cyclin O
) O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
full B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
length B_GENE/B_MEASURE
cDNAs I_GENE/I_MEASURE
with O
the O
corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequences O
revealedtrans B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
splicing B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mRNAs B_SEQUENCE[MEASURE]/B_PERSON
of O
these O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O
a O
conserved B_MEASURE/B_LOCATION
21 I_MEASURE/I_LOCATION
- O
22 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nt B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spliced O
leader B_PERSON/B_LOCATION
. O

Over O
10 B_MEASURE/B_GENE
copies I_MEASURE/I_GENE
of O
PCNA B_GENE
were O
detected O
, O
with O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
similar B_LOCATION/B_GENE
nucleotide B_LOCATION/I_GENE
( O
nt B_LOCATION
) O
sequences B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
88 B_MEASURE
- O
99 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
encoding O
largely O
identical B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
aa B_GENE/B_DISEASE
) O
. O

Two B_NUMBER[MEASURE]/B_PERSON
distinct I_NUMBER[MEASURE]/I_PERSON
types I_NUMBER[MEASURE]/I_PERSON
ofcyclin O
( O
Pmacyclin1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Pmacyclin2 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
identified O
, O
with O
66 B_MEASURE
- O
69 B_MEASURE
% I_MEASURE
nt I_MEASURE
and O
81 B_MEASURE
- O
85 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
AA I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
similarities I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O
Pmacyclin2 B_GENE/B_PERSON
was O
organized O
in O
tandem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
was O
alternatively O
spliced O
, O
giving O
rise B_NUMBER[MEASURE]/B_LOCATION
to O
five B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subtypes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

For O
both O
PCNA B_GENE
and O
cyclin B_GENE
genes I_GENE
, O
6 B_NUMBER[MEASURE]/B_LOCATION
- O
10 B_GENE/B_LOCATION
introns I_GENE/I_LOCATION
were O
found O
. O

quantitative B_MEASURE/B_LOCATION
RT B_MEASURE/I_LOCATION
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
PCNA B_GENE
and O
Pmacyclin2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O
a O
28 B_MEASURE
- O
h B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
course I_TIME[MEASURE]/I_LOCATION
, O
whereas O
Pmacyclin1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abundance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
10 B_MEASURE
- O
100 B_MEASURE
times I_MEASURE
higher I_MEASURE
, O
and O
increased O
markedly O
during O
active B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
division B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
suggesting O
that O
it O
is O
a O
mitoticcyclinand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
can O
be O
a O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
marker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
this O
species B_BIO
. O

The O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
expression B_GENE
features O
along O
with O
phylogenetic B_TIME[MEASURE]/B_LOCATION
results I_TIME[MEASURE]/I_LOCATION
position I_TIME[MEASURE]/I_LOCATION
this O
organism B_BIO/B_GENE
between O
dinoflagellates B_SPECIES[BIO]
and O
apicomplexans B_SPECIES[BIO]
, O
but O
its O
definitive B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affiliation B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
alveolates B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
requires O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

highly O
diverse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
seasonally O
dynamic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protist I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
community I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
pristine B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peat I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bog I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
based O
on O
the O
amplification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
cloning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
small B_NUMBER[MEASURE]/B_DISEASE
- O
subunit B_GENE/B_LOCATION
ribosomal I_GENE/I_LOCATION
RNA I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
( O
SSU B_GENE/B_BIO
rDNAs I_GENE/I_BIO
) O
are O
powerful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tools I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
study O
the O
diversity B_PERSON/B_BIO
of O
microorganisms B_SPECIES[BIO]/B_GENE
. O

Despite O
so O
, O
the O
eukaryotic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
microbial I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
diversity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
many B_LOCATION/B_BIO
ecosystems I_LOCATION/I_BIO
, O
including O
peatlands B_LOCATION/B_BIO
has O
not O
yet O
received O
much B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
attention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

We O
analysed O
the O
eukaryotic B_BIO/B_LOCATION
diversity I_BIO/I_LOCATION
by O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
surveys I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
water B_MEASURE/B_BIO
from O
the O
centre B_LOCATION/B_BIO
of O
a O
pristine B_BIO/B_LOCATION
Sphagnum I_BIO/I_LOCATION
- O
dominated O
peatland B_LOCATION
in O
the O
Jura B_LOCATION
Mountains I_LOCATION
of O
Switzerland B_LOCATION
during O
a O
complete B_TIME[MEASURE]/B_LOCATION
seasonal B_TIME[MEASURE]/I_LOCATION
cycle B_TIME[MEASURE]/I_LOCATION
. O

The O
clone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
libraries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
constructed O
from O
five B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temporal I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samplings I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
diversity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
protists B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
representatives B_PERSON
of O
all O
major B_BIO/B_MEASURE
eukaryotic I_BIO/I_MEASURE
phyla I_BIO/I_MEASURE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
four B_BIO/B_PERSON
sequence I_BIO/I_PERSON
types I_BIO/I_PERSON
could O
not O
be O
assigned O
to O
any O
known O
high B_GENE/B_BIO
- O
level B_BIO/B_MEASURE
eukaryotic B_BIO/I_MEASURE
taxon B_BIO/I_MEASURE
but O
branched O
together O
with O
a O
rather O
good B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
statistic I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
raising O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
deep B_BIO/B_MEASURE
branching I_BIO/I_MEASURE
eukaryotic I_BIO/I_MEASURE
clade I_BIO/I_MEASURE
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
seasonal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
phylotypes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
showed O
a O
clear B_MEASURE
change I_MEASURE
in O
the O
eukaryotic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
communities I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
warm B_TIME[MEASURE]/B_DISEASE
period I_TIME[MEASURE]/I_DISEASE
( O
late B_TIME[MEASURE]/B_LOCATION
spring I_TIME[MEASURE]/I_LOCATION
and O
summer B_TIME[MEASURE]
) O
and O
the O
cold B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
( O
autumn B_TIME[MEASURE]/B_LOCATION
and O
winter B_TIME[MEASURE]/B_LOCATION
) O
. O

Chrysophytes B_BACTERIUM[BIO]/B_PERSON
dominated O
the O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
cold B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
while O
testate B_BIO/B_PERSON
amoebae I_BIO/I_PERSON
( O
Arcellinida B_BACTERIUM[BIO]
and O
Euglyphida B_BACTERIUM[BIO]
) O
and O
a O
few B_BIO
other I_BIO
groups I_BIO
peaked O
in O
summer B_MEASURE/B_LOCATION
. O

A O
few B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phylotypes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
cryptomonad B_SPECIES[BIO]
and O
a O
perkinsid B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
abundant B_DISEASE_ADJECTIVE[DISEASE]
at O
given O
sampling O
times B_MEASURE/B_LOCATION
and O
then O
almost O
disappeared O
, O
suggesting O
bloom B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
like B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

comparing O
potential B_DISEASE/B_GENE
COI B_DISEASE/I_GENE
and O
SSU B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rDNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
barcodes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O
assessing O
the O
diversity B_BIO
and O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relationships I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cyphoderiid B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
testate I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
amoebae I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
Rhizaria B_BIO/B_PERSON
: O
Euglyphida B_MEASURE/B_LOCATION
) O
. O

The O
mitochondrial B_GENE
cytochrome I_GENE
oxidase I_GENE
subunit I_GENE
1 I_GENE
gene I_GENE
( O
COI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
has O
been O
promoted O
as O
an O
ideal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
& O
quot B_LOCATION/B_BIO
; O
DNA B_GENE/B_MEASURE
barcode B_GENE/I_MEASURE
& O
quot B_LOCATION/B_BIO
; O
for O
animal B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
species I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
eukaryotes B_BIO
. O

However O
, O
the O
utility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
COI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
species B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
level I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
discrimination I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
for O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
has O
yet O
to O
be O
tested O
within O
the O
Rhizaria B_BIO/B_LOCATION
. O

Accordingly O
, O
we O
analysed O
mitochondrial B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
COI B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sequences B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
nuclear B_GENE
small I_GENE
subunit I_GENE
rDNA I_GENE
( O
SSU B_DISEASE/B_GENE
) O
sequences B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
several B_BIO/B_GENE
morphospecies I_BIO/I_GENE
of O
euglyphid B_BIO
testate I_BIO
amoebae I_BIO
( O
Cercozoa B_BACTERIUM[BIO]/B_LOCATION
, O
Rhizaria B_MEASURE/B_BACTERIUM[BIO]
) O
in O
order B_LOCATION/B_DISEASE
to O
evaluate O
the O
utility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
species B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discrimination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reconstructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
from O
eleven B_BIO/B_PERSON
populations I_BIO/I_PERSON
belonging O
to O
six B_BIO/B_PERSON
Cyphoderia I_BIO/I_PERSON
morphospecies I_BIO/I_PERSON
that O
were O
isolated O
from O
field B_LOCATION/B_BIO
samples I_LOCATION/I_BIO
in O
North B_LOCATION
America I_LOCATION
and O
Europe B_LOCATION
. O

Mean B_MEASURE/B_LOCATION
inter I_MEASURE/I_LOCATION
- O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
COI I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dissimilarities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
on O
average B_MEASURE
2 I_MEASURE
. O
9 B_TIME[MEASURE]
times I_TIME[MEASURE]
greater I_TIME[MEASURE]
than O
in O
the O
SSU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
while O
the O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dissimilarities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
SSU B_DISEASE/B_LOCATION
( O
0 B_MEASURE/B_LOCATION
- O
0 B_MEASURE
. O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
than O
in O
the O
COI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
0 B_MEASURE
% I_MEASURE
) O
; O
this O
suggests O
that O
the O
COI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
fragment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
valuable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
discriminating O
Cyphoderiidae B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolates I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
demonstrated O
that O
COI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
inferring O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
relationships I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
among O
Cyphoderiidae B_BIO
isolates I_BIO
. O

COI B_DISEASE/B_LOCATION
and O
SSU B_DISEASE/B_LOCATION
tree I_DISEASE/I_LOCATION
topologies I_DISEASE/I_LOCATION
were O
very O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
though O
the O
COI B_GENE
fragment I_GENE
used O
in O
these O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
500bp B_MEASURE/B_PROTEIN[GENE]
) O
was O
much O
shorter B_TIME[MEASURE]
than O
the O
SSU B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1600bp B_MEASURE/B_GENE
) O
. O

altogether O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
the O
utility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
COI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
a O
potential B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taxonomic I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barcode I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
assessing O
cyphoderiid B_MEASURE/B_BIO
species I_MEASURE/I_BIO
diversity I_MEASURE/I_BIO
and O
for O
inferring O
phylogenetic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
relationships I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
group B_ORGANIZATION/B_PERSON
. O

expanding O
character B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sampling O
for O
ciliate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
mitochondrial B_PROTEIN[GENE]/B_BACTERIUM[BIO]
SSU I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O
rDNA B_MEASURE/B_BIO
as O
a O
molecular B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marker I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
systematics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
ciliates B_BIO/B_ORGANISM_FUNCTION
, O
particularly O
at O
deep B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
nodes B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
has O
largely O
focused O
on O
increasing O
taxon B_BIO/B_GENE
sampling O
using O
the O
nuclear B_GENE
small I_GENE
subunit I_GENE
rDNA I_GENE
( O
nSSU B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rDNA B_MEASURE/B_GENE
) O
locus B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
have O
generally O
been O
congruent B_DISEASE_ADJECTIVE[DISEASE]
with O
morphologically O
- O
based O
classifications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
although O
there O
is O
extensive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
non O
- O
monophyly O
at O
many B_TIME[MEASURE]/B_PERSON
levels I_TIME[MEASURE]/I_PERSON
. O

However O
, O
caution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
needed O
in O
interpreting O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O
nSSU B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rDNA B_MEASURE
is O
just O
a O
single B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marker B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
the O
mitochondrial B_GENE
small I_GENE
subunit I_GENE
rDNA I_GENE
( O
mtSSU B_LOCATION
- O
rDNA B_MEASURE/B_PROTEIN[GENE]
) O
is O
evaluated O
for O
deep B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ciliate B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nodes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
Colpodea B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
as O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Overall B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
well O
- O
supported O
nodes B_LOCATION/B_PERSON
in O
the O
mtSSU B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
rDNA B_GENE/B_BIO
and O
concatenated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
topologies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
well O
supported O
in O
the O
nSSU B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
rDNA B_GENE/B_BIO
topology I_GENE/I_BIO
; O
e O
. O
g B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
, O
the O
non B_DISEASE
- O
monophyly B_LOCATION/B_PERSON
of O
the O
Cyrtolophosidida B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
two O
moderately O
- O
to O
well O
- O
supported O
incongruences O
between O
the O
loci O
are O
the O
placement O
of O
the O
Sorogenida O
and O
Colpoda B_BACTERIUM[BIO]/B_PERSON
aspera I_BACTERIUM[BIO]/I_PERSON
. O
Our O
analyses O
of O
mtSSU O
- O
rDNA O
support O
the O
conclusion O
, O
originally O
derived O
from O
nSSU O
- O
rDNA O
, O
that O
the O
morphological O
characters O
used O
in O
taxonomic O
circumscriptions O
of O
the O
Colpodea O
represent O
a O
mixture O
of O
ancestral O
and O
derived O
states O
. O

This O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
efficacy B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mtSSU B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
rDNA B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
enable O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reconstructions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
deep B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
nodes B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
the O
ciliate B_BIO/B_LOCATION
tree B_BIO/I_LOCATION
of O
life B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
move O
from O
a O
single B_NUMBER[MEASURE]/B_LOCATION
- O
locus B_GENE/B_MEASURE
to O
a O
multi B_NUMBER[MEASURE]/B_ENT
- O
locus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Diversification O
and O
evolution O
of O
the O
avirulence O
gene O
AVR O
- O
Pita1 O
in O
field O
isolates O
of O
Magnaporthe B_BACTERIUM[BIO]/B_DISEASE
oryzae I_BACTERIUM[BIO]/I_DISEASE
. O

Rice O
blast O
disease O
is O
the O
single O
most O
destructive O
plant O
disease O
that O
threatens O
stable O
rice B_BIO/B_LOCATION
production O
worldwide O
. O

race B_PERSON/B_BIO
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resistance I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
rice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blast B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogen B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
durable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
which O
the O
resistance B_DISEASE_ADJECTIVE[DISEASE]
is O
overcome O
remains O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
report O
the O
molecular O
mechanisms O
of O
diversification O
and O
the O
instability O
of O
the O
avirulence O
gene O
AVR O
- O
Pita1 O
in O
field O
strains O
of O
Magnaporthe B_SPECIES[BIO]/B_DISEASE
oryzae I_SPECIES[BIO]/I_DISEASE
interacting O
with O
the O
host O
resistance O
gene O
Pi O
- O
ta O
and O
triggering O
race O
- O
specific O
resistance O
. O

Two B_NUMBER[MEASURE]/B_LOCATION
- O
base B_LOCATION/B_BIO
- O
pair B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
insertions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resulting O
in O
frame B_LOCATION
- O
shift B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
and O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
complete B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deletions I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AVR B_DISEASE/B_GENE
- O
Pita1 B_PROTEIN[GENE]/B_MEASURE
were O
identified O
in O
virulent B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
isolates I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
a O
total B_MEASURE
of O
38 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
AVR I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
Pita1 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
haplotypes I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
27 B_DISEASE/B_GENE
AVR B_DISEASE/I_GENE
- O
Pita1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
identified O
among O
151 B_PERSON
avirulent I_PERSON
isolates I_PERSON
. O

Most B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
DNA I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
sequence I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
variation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O
found O
to O
occur O
in O
the O
exon B_GENE/B_LOCATION
region I_GENE/I_LOCATION
resulting O
in O
amino B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
acid I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
substitution I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
AVR B_DISEASE/B_PROTEIN[GENE]
- O
Pita1 B_PROTEIN[GENE]/B_MEASURE
is O
under O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
of O
AVR B_DISEASE/B_PROTEIN[GENE]
- O
Pita1 B_PROTEIN[GENE]/B_MEASURE
are O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
defeating O
race B_SPORT[ENT]/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resistance I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
nature B_BIO/B_DISEASE
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
niche B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
structure B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
coexisting O
tidepool B_LOCATION/B_ORGANIZATION
fishes I_LOCATION/I_ORGANIZATION
: O
null B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
multi B_DISEASE/B_LOCATION
- O
scale B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

fundamental O
and O
realized O
spatial O
niches O
were O
investigated O
through O
a O
combination O
of O
laboratory O
and O
mesocosm O
experiments O
, O
field O
observations O
and O
null O
model O
analysis O
in O
three O
intertidal O
gobiid O
species O
( O
Bathygobius B_BIO/B_LOCATION
fuscus I_BIO/I_LOCATION
, O
Chaenogobius B_SPECIES[BIO]/B_LOCATION
annularis I_SPECIES[BIO]/I_LOCATION
and O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
gulosus I_SPECIES[BIO]
) O
. O

null B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
single B_NUMBER[MEASURE]/B_LOCATION
- O
species B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
used O
to O
assess O
interspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spatial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
coexistence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
scales B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
( O
i O
) O
microhabitats B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
a O
tidepool B_LOCATION/B_BIO
( O
' O
microhabitat B_LOCATION/B_MEASURE
' O
scale B_MEASURE/B_LOCATION
) O
; O
and O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
distribution B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
a O
set B_PROTEIN[GENE]/B_LOCATION
of O
tidepools B_LOCATION/B_BIO
( O
' O
habitat B_LOCATION
- O
wide B_LOCATION/B_DISEASE
' O
scale B_MEASURE
) O
. O

2 B_NUMBER[MEASURE]
. O

patterns B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
microhabitat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
varied O
from O
single B_MEASURE/B_PERSON
to O
paired O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
, O
depending O
on O
paired O
species B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

realized O
overlap B_MEASURE/B_PERSON
of O
microhabitat B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
use I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
smaller B_MEASURE
than O
would O
be O
expected O
from O
single B_PERSON/B_DISEASE
- O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
situations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
intraspecific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
combinations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
but O
not O
for O
interspecific B_PERSON/B_ENT
ones I_PERSON/I_ENT
. O

3 B_NUMBER[MEASURE]
. O

patterns B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
tidepool B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occupancy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
a O
measure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
niche B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
breadth B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
) O
in O
the O
mesocosm B_LOCATION
were O
influenced O
by O
interspecific B_LOCATION
interactions I_LOCATION
. O

Two O
Chaenogobius O
species O
, O
but O
not O
B B_NUMBER[MEASURE]/B_BIO
. I_NUMBER[MEASURE]/I_BIO
fuscus I_NUMBER[MEASURE]/I_BIO
, O
decreased O
tidepool O
occupancy O
in O
the O
hetero O
- O
specific O
treatments O
compared O
with O
the O
mono O
- O
specific O
ones O
. O

For O
all O
interspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
combinations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
spatial B_LOCATION/B_BIO
overlap O
( O
habitat B_LOCATION/B_MEASURE
- O
wide B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
) O
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
values B_MEASURE
expected O
from O
mono B_LOCATION/B_DISEASE
- O
specific B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
situations I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
indicated O
a O
possible B_DISEASE/B_LOCATION
trade I_DISEASE/I_LOCATION
- O
off B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
between O
competitiveness B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
efficiency I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
these O
fishes B_BIO/B_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

interspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
spatial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
overlap O
in O
the O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
in O
the O
mesocosm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
the O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
coexistence B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
gobiids B_BIO/B_LOCATION
can O
be O
explained O
by O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
our O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

5 B_NUMBER[MEASURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O
that O
niches B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
intertidal B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
fishes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O
experience O
modifications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
under O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
species B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
null B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
controlled B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
experiments I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
can O
greatly O
facilitate O
the O
deciphering B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
such B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
niche B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

linking O
disease O
and O
community O
ecology O
through O
behavioural O
indicators O
: O
immunochallenge O
of O
white B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
footed I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
its O
ecological O
impacts O
. O

1 B_NUMBER[MEASURE]
. O

pathogens B_DISEASE
and O
immune B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
challenges I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O
induce O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
host B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
phenotype B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
ways B_LOCATION/B_BIO
that O
indirectly O
impact O
important B_DISEASE/B_BIO
community I_DISEASE/I_BIO
interactions I_DISEASE/I_BIO
, O
including O
those O
that O
affect O
host B_PERSON/B_SPECIES[BIO]
- O
pathogen B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
interactions B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

2 B_NUMBER[MEASURE]
. O

To O
explore O
host O
behavioural O
response O
to O
immune O
challenge O
, O
we O
exposed O
wild O
white B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
footed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Peromyscus B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leucopus I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
to O
an O
immunogen O
from O
an O
endemic O
, O
zoonotic O
pathogen O
, O
the O
spirochete O
Borrelia B_BACTERIUM[BIO]
burgdorferi I_BACTERIUM[BIO]
. O

White B_BIO/B_PERSON
- I_BIO/I_PERSON
footed I_BIO/I_PERSON
mice I_BIO/I_PERSON
are O
a O
major O
reservoir O
host O
of O
Lyme O
disease O
( O
LD O
) O
spirochetes O
in O
northeastern O
USA O
and O
an O
abundant O
member O
of O
forest O
communities O
. O

The O
activity O
patterns O
, O
foraging O
behaviour O
, O
and O
space O
use O
of O
white B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
footed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
implications O
for O
population O
growth O
rates O
of O
community O
members O
upon O
which O
mice O
incidentally O
prey O
( O
i O
. O
e O
. O
Gypsy O
moths O
and O
native O
thrushes O
) O
, O
as O
well O
as O
potentially O
determining O
host O
- O
vector O
encounter O
rates O
and O
human B_PERSON/B_SPECIES[BIO]
risk O
of O
LD O
. O

3 B_NUMBER[MEASURE]
. O

Immunochallenge B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
led O
to O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
humoral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
cellular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
i O
. O
e O
. O
elevated O
neutrophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
eosinophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
) O
immune B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
supporting O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
immunogen B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
as O
a O
surrogate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
pathogenic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

4 B_NUMBER[MEASURE]
. O

Immunochallenged B_PERSON
mice I_PERSON
had O
reduced O
wheel B_LOCATION
- O
running O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
early O
in O
the O
night B_TIME[MEASURE]
when O
measured O
in O
the O
lab B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
mouse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
as O
measured O
by O
track B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
natural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
field I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
experiments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
did O
not O
differ O
between O
mice B_BIO/B_PERSON
exposed O
to O
the O
immunogen B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O
unexposed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

5 B_NUMBER[MEASURE]
. O

Foraging O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
wild B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
field B_LOCATION
- O
assessed O
with O
giving O
- O
up O
densities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
seed B_BIO/B_PERSON
at O
artificial B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feeding I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stations I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
was O
affected O
by O
exposure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
the O
immunogen B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

Whereas O
immunochallenge B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
influence O
whether O
foraging O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gained O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
patch B_MEASURE/B_BIO
quality B_MEASURE/I_BIO
while O
foraging O
, O
it O
led O
to O
reductions B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
predator B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
avoidance B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O
foraging O
, O
suggesting O
that O
the O
proportion B_MEASURE/B_LOCATION
of O
space B_LOCATION/B_BIO
used O
by O
foraging O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
greater B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
immunochallenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

This O
increased O
space B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
predicted O
to O
increase O
encounter B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
patchily O
distributed O
LD B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vectors I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ticks B_BIO/B_PROTEIN[GENE]
) O
and O
with O
incidental B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prey I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
items I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

6 B_NUMBER[MEASURE]
. O

Thus O
, O
immunochallenge O
in O
white B_DISEASE/B_BIO
- B_DISEASE/I_BIO
footed B_DISEASE/I_BIO
mice B_DISEASE/I_BIO
, O
and O
potentially O
pathogenic O
infection O
, O
have O
the O
potential O
to O
indirectly O
impact O
community O
interactions O
, O
including O
those O
important O
for O
pathogen O
transmission O
. O

amino O
acid O
divergence O
between O
the O
CHS O
domain O
contributes O
to O
the O
different O
intracellular O
behaviour O
of O
Family O
II O
fungal O
chitin O
synthases O
in O
Saccharomyces B_SPECIES[BIO]
cerevisiae I_SPECIES[BIO]
. O

Family B_BIO/B_GENE
II I_BIO/I_GENE
chitin I_BIO/I_GENE
synthases I_BIO/I_GENE
( O
CS B_DISEASE
) O
, O
including O
classes B_PROTEIN[GENE]/B_MEASURE
IV I_PROTEIN[GENE]/I_MEASURE
and O
V B_TIME[MEASURE]/B_PROTEIN[GENE]
enzymes I_TIME[MEASURE]/I_PROTEIN[GENE]
, O
share B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conserved O
catalytic B_LOCATION/B_PERSON
domains I_LOCATION/I_PERSON
flanked O
by O
transmembrane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Here O
we O
addressed O
the O
characterization O
of O
Family O
II O
fungal O
CSs O
by O
heterologous O
expression O
in O
Saccharomyces B_BIO
cerevisiae I_BIO
. O

Full O
- O
length O
CSs O
from O
classes O
V O
or O
IV O
were O
not O
functional O
when O
expressed O
in O
S B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cerevisiae B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
accumulated O
in O
different O
intracellular O
compartments O
. O

However O
, O
the O
exchange B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
different B_MEASURE
class I_MEASURE
IV I_MEASURE
, O
but O
not O
of O
class B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
V I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
CHS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
domains I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
resulted O
in O
functional B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DISEASE_ADJECTIVE[DISEASE]
both O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
afford O
the O
chimeric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
distinct I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intracellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behaviours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ranging O
from O
endoplasmic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
reticulum B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
retention B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
to O
reduced O
endocytic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
turnover B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
plasma B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
allow O
a O
role B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O
chitin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
be O
assigned O
to O
all O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enzymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
they O
also O
highlight O
the O
involvement B_PERSON/B_DISEASE
of O
the O
intracellular B_LOCATION/B_MEASURE
globular I_LOCATION/I_MEASURE
domain I_LOCATION/I_MEASURE
of O
these O
CSS B_ENZYME[GENE]/B_DISEASE
, O
not O
only O
in O
enzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
also O
in O
the O
regulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
their O
intracellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
turnover I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

activation O
of O
the O
heat O
shock O
transcription O
factor O
Hsf1 O
is O
essential O
for O
the O
full O
virulence O
of O
the O
fungal O
pathogen O
Candida B_BACTERIUM[BIO]/B_DISEASE
albicans I_BACTERIUM[BIO]/I_DISEASE
. O

The O
evolutionarily O
conserved O
heat O
shock O
transcription O
factor O
Hsf1 O
plays O
a O
central O
role O
in O
thermal O
adaptation O
in O
the O
major O
fungal O
pathogen O
of O
humans B_SPECIES[BIO]/B_LOCATION
, O
Candida B_SPECIES[BIO]/B_DISEASE
albicans I_SPECIES[BIO]/I_DISEASE
. O

Hsf1 B_GENE
becomes O
hyperphosphorylated O
in O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
heat B_DISEASE/B_MEASURE
shock I_DISEASE/I_MEASURE
and O
activates O
the O
transcription B_GENE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
heat B_GENE/B_PERSON
shock I_GENE/I_PERSON
elements I_GENE/I_PERSON
( O
HSEs B_DISEASE/B_GENE
) O
in O
their O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
these O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributing O
to O
thermal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adaptation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
relevance O
of O
Hsf1 O
activation O
to O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
albicans I_SPECIES[BIO]
virulence O
is O
not O
clear O
as O
this O
pathogen O
is O
thought O
to O
be O
obligately O
associated O
with O
warm O
blooded O
animals O
, O
and O
this O
issue O
has O
not O
been O
tested O
because O
HSF1 O
is O
essential O
for O
viability O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
albicans I_SPECIES[BIO]
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
HSE O
regulon O
is O
active O
in O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
albicans I_PERSON/I_SPECIES[BIO]
cells O
infecting O
the O
kidney O
. O

We O
also O
show O
the O
CE2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
region I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Hsf1 B_GENE
is O
required O
for O
activation B_GENE
and O
that O
the O
phosphorylation B_GENE/B_LOCATION
of O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
residues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
domain B_LOCATION
contributes O
to O
Hsf1 B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

C B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
albicans I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
HSF1 O
mutants O
that O
lack O
this O
CE2 O
region O
are O
viable O
. O

However O
, O
they O
are O
unable B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
activate O
HSE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
containing O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
heat B_DISEASE
shock I_DISEASE
, O
and O
they O
are O
thermosensitive B_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
this O
HSF1 O
CE2 O
deletion O
mutant O
we O
demonstrate O
that O
Hsf1 O
activation O
, O
and O
hence O
thermal O
adaptation O
, O
contributes O
significantly O
to O
the O
virulence O
of O
C B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
albicans I_BACTERIUM[BIO]/I_DISEASE
. O

Early B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
response I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
plant B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
carbon B_DISEASE_ADJECTIVE[DISEASE]
deprivation I_DISEASE_ADJECTIVE[DISEASE]
: O
in O
vivo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
31P I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
NMR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shows O
a O
quasi B_DISEASE/B_MEASURE
- O
instantaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disruption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
cytosolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugars I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phosphorylated O
intermediates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
energy B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
, O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
partitioning I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
pHs B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O
plant B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
starvation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
triggers O
a O
cascade B_DISEASE/B_MEASURE
of O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
the O
scale B_MEASURE/B_LOCATION
of O
1 B_NUMBER[MEASURE]
- O
2 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
. O

However O
, O
very O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolic B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
yet O
been O
investigated O
. O

* O
soluble O
phosphorus O
( O
P O
) O
compounds O
and O
intracellular O
pHs O
were O
analysed O
each O
2 O
. O
5 O
min O
intervals O
in O
heterotrophic O
sycamore B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Acer B_LOCATION/B_BIO
pseudoplatanus I_LOCATION/I_BIO
) O
cells O
using O
in O
vivo O
phosphorus O
nuclear O
magnetic O
resonance O
( O
( O
31 O
) O
P O
- O
NMR O
) O
. O

* B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Upon O
external B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
sugar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
withdrawal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
the O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
P B_MEASURE/B_LOCATION
concentration B_MEASURE/I_LOCATION
dropped O
in O
the O
cytosol B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
but O
not O
in O
plastids B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

The O
released O
inorganic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Pi B_PROTEIN[GENE]
) O
accumulated O
transiently O
in O
the O
cytosol B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
before O
influx B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
into O
the O
vacuole B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
; O
nucleotide B_MEASURE
triphosphate I_MEASURE
concentration I_MEASURE
doubled O
, O
intracellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
pH O
increased O
and O
cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
respiration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decreased O
. O

It O
was O
deduced O
that O
the O
cytosolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
free I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
corresponding O
to O
only O
0 B_MEASURE
. O
5 B_MEASURE
mm I_MEASURE
sucrose I_MEASURE
in O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
supplied O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
The O
release B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
the O
vacuole B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
from O
plastids B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
is O
insufficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
fully O
sustain O
the O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
during O
starvation B_DISEASE/B_ORGANISM_FUNCTION
, O
particularly O
in O
the O
very O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Similarly O
to O
Pi B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
starvation B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
starvation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurs O
in O
the O
cytosol B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
is O
of O
a O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
nature B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Unlike O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
cytosolic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
homeostasis B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
is O
not O
maintained O
during O
starvation B_DISEASE/B_ORGANISM_FUNCTION
. O

The O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O
cytosolic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sugar I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exhaustion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deliver O
early B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
endogenous B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
contribute O
to O
trigger O
rescue B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

habitat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
contrasts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reveal O
a O
shift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
trophic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
position I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
ant B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assemblages I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

1 B_NUMBER[MEASURE]
. O

trophic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
within O
a O
guild B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
influenced O
by O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
resource B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
availability I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
competition B_SPORT[ENT]/B_MEASURE
. O

While O
ants B_BIO/B_PERSON
occupy O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
positions B_LOCATION
in O
food B_LOCATION/B_ORGANIZATION
webs I_LOCATION/I_ORGANIZATION
, O
and O
ant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
community I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
composition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
habitat B_LOCATION/B_MEASURE
, O
it O
is O
not O
well O
understood O
if O
ant B_BIO/B_PERSON
genera I_BIO/I_PERSON
tend O
to O
maintain O
their O
position B_LOCATION/B_PERSON
in O
the O
trophic B_LOCATION
structure I_LOCATION
, O
or O
if O
trophic B_MEASURE/B_PERSON
position I_MEASURE/I_PERSON
varies O
across O
habitats B_LOCATION/B_BIO
. O

2 B_NUMBER[MEASURE]
. O

We O
used O
ratios B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
stable B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
isotopes I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
carbon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
for O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
trophic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
position B_LOCATION/B_MEASURE
of O
assemblages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ants B_BIO
among O
habitat B_LOCATION/B_MEASURE
types I_LOCATION/I_MEASURE
. O

We O
tested O
for O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
assemblages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
replicate B_NUMBER[MEASURE]/B_PERSON
sites I_NUMBER[MEASURE]/I_PERSON
of O
the O
land B_LOCATION
use I_LOCATION
categories I_LOCATION
: O
( O
i O
) O
pastures O
with O
old B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
large I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
trees I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
; O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
recently O
revegetated O
pastures B_LOCATION
with O
small B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
young I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
trees I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
; O
and O
( O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
remnant B_LOCATION/B_BIO
woodlands I_LOCATION/I_BIO
. O

Known O
insect B_BIO
herbivores I_BIO
and O
predatory B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
spiders I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
provided O
baselines B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
herbivorous B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
predaceous B_BIO/B_PERSON
arthropods I_BIO/I_PERSON
. O

soil B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
used O
to O
correct O
for O
the O
base B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isotopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
enrichment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O
each O
site B_LOCATION/B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

We O
found O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
land B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
use I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
ant B_BIO/B_MEASURE
genus B_BIO/I_MEASURE
for O
isotope B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enrichment I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
trophic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
is O
conserved O
across O
land B_LOCATION/B_BIO
use I_LOCATION/I_BIO
categories I_LOCATION/I_BIO
. O

The O
fixed B_PERSON/B_MEASURE
relative I_PERSON/I_MEASURE
positions I_PERSON/I_MEASURE
of O
genera B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
trophic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
might O
be O
re B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
enforced O
by O
competition B_SPORT[ENT]/B_PERSON
or O
some O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
the O
entire B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ant I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assemblage I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
delta B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
15 B_MEASURE/B_LOCATION
) O
N B_TIME[MEASURE]/B_BIO
values I_TIME[MEASURE]/I_BIO
in O
revegetated B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
suggesting O
that O
ants B_BIO/B_PERSON
feed O
lower O
down O
in O
the O
food B_LOCATION/B_ORGANIZATION
chain I_LOCATION/I_ORGANIZATION
i O
. O
e O
. O
they O
are O
more B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O
herbivorous B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
' O
in O
revegetated B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sites B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

This O
may O
be O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
availability I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
plant B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sugars I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
honeydew B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
herbivorous B_BIO
arthropod I_BIO
prey I_BIO
. O

4 B_NUMBER[MEASURE]
. O

surprisingly O
, O
ants B_BIO/B_LOCATION
in O
remnants B_LOCATION/B_PERSON
and O
pastures B_LOCATION/B_ORGANIZATION
with O
trees B_BIO/B_LOCATION
displayed O
similar B_DISEASE_ADJECTIVE[DISEASE]
isotopic I_DISEASE_ADJECTIVE[DISEASE]
compositions I_DISEASE_ADJECTIVE[DISEASE]
. O

interactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
within O
ant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assemblages I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
thus O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
resilient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
land B_LOCATION/B_MEASURE
use I_LOCATION/I_MEASURE
, O
but O
ant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diets I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
successional I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
habitats I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
may O
reflect O
the O
simplicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
communities B_LOCATION/B_BIO
, O
which O
may O
have O
comparatively O
lower B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
saprophagy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O
predation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

Hypoxia B_DISEASE/B_TIME[MEASURE]
responsive I_DISEASE/I_TIME[MEASURE]
gene I_DISEASE/I_TIME[MEASURE]
expression I_DISEASE/I_TIME[MEASURE]
is O
mediated O
by O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subsets B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transcription B_GENE
factors I_GENE
and O
miRNAs B_GENE
that O
are O
determined O
by O
the O
actual B_MEASURE/B_BIO
oxygen B_MEASURE/I_BIO
availability B_MEASURE/I_BIO
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
availability B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
not O
only O
associated O
with O
flooding B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
occurs O
also O
during O
growth B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
development B_DISEASE/B_ORGANISM_FUNCTION
. O

It O
is O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
how O
hypoxia B_DISEASE
is O
perceived O
and O
what O
signaling O
cascade B_DISEASE/B_LOCATION
is O
involved O
in O
activating O
adaptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

* B_OTHER/B_TIME[MEASURE]
We O
analysed O
the O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
over O
1900 B_GENE
transcription I_GENE
factors I_GENE
( O
TFs B_GENE/B_MEASURE
) O
and O
180 B_GENE/B_BIO
microRNA I_GENE/I_BIO
primary I_GENE/I_BIO
transcripts I_GENE/I_BIO
( O
pri B_GENE/B_DISEASE
- O
miRNAs B_GENE
) O
in O
Arabidopsis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
roots I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
exposed O
to O
different B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypoxic B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
analysed O
the O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
hypoxia B_DISEASE/B_PROTEIN[GENE]
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
over O
- O
represented O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
can O
act O
as O
potential B_GENE/B_MEASURE
TF I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
sites I_GENE/I_MEASURE
and O
their O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
verified O
. O

* B_OTHER/B_MEASURE
We O
identified O
various B_LOCATION/B_ENT
subsets I_LOCATION/I_ENT
of O
TFs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
that O
responded O
differentially O
through O
time B_MEASURE
and O
in O
an O
oxygen B_MEASURE
concentration I_MEASURE
- O
dependent B_LOCATION/B_PERSON
manner I_LOCATION/I_PERSON
. O

The O
regulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
potential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
selected O
TFs B_GENE/B_BIO
and O
their O
predicted O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding O
elements B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
validated O
. O

Although O
the O
expression B_GENE/B_MEASURE
of O
pri B_DISEASE/B_MEASURE
- O
miRNAs B_GENE
was O
differentially O
regulated O
under O
hypoxia B_DISEASE
, O
only O
one B_GENE/B_MEASURE
corresponding I_GENE/I_MEASURE
mature I_GENE/I_MEASURE
miRNA I_GENE/I_MEASURE
changed O
accordingly O
. O

Putative B_NUMBER[MEASURE]/B_PERSON
target I_NUMBER[MEASURE]/I_PERSON
transcripts I_NUMBER[MEASURE]/I_PERSON
of O
the O
miRNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
not O
significantly O
affected O
. O

* B_OTHER/B_TIME[MEASURE]
Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
regulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
hypoxia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
controlled O
via O
simultaneous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
various B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
combinations I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
TFs B_GENE
. O

Under O
anoxic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
an O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TFs B_GENE
is O
induced O
. O

Regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
miRNAs B_GENE
appears O
to O
play O
a O
minor B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
role I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
during O
hypoxia B_DISEASE/B_ORGANISM_FUNCTION
. O

rarity B_DISEASE_ADJECTIVE[DISEASE]/B_EDU[ORGANIZATION]
, O
life B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
scaling B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
dynamics B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
time B_TIME[MEASURE]/B_LOCATION
and O
space B_LOCATION/B_MEASURE
of O
British B_TIME[MEASURE]/B_BIO
birds I_TIME[MEASURE]/I_BIO
. O

1 B_NUMBER[MEASURE]
. O

Many B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
macroecology B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
closely O
related B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
total B_MEASURE/B_LOCATION
abundance B_MEASURE/I_LOCATION
of O
a O
species B_BIO/B_LOCATION
in O
a O
region B_LOCATION/B_BIO
. O

Here O
we O
show O
that O
interspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
pattern B_MEASURE/B_DISEASE
of O
population B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fluctuations B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
British B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bird I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
predicted O
from O
knowledge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
their O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abundance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
some O
basic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
life I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O
history B_PERSON/B_TIME[MEASURE]
characteristics B_PERSON/I_TIME[MEASURE]
. O

2 B_NUMBER[MEASURE]
. O

We O
identify O
a O
rarity B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
arises O
through O
an O
increased O
stochastic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
population B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fluctuations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
decreasing O
population B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
, O
mainly O
resulting O
from O
an O
inverse B_MEASURE/B_LOCATION
density I_MEASURE/I_LOCATION
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
demographic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stochasticity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

This O
syndrome B_DISEASE
involves O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
annual B_MEASURE
changes I_MEASURE
in O
population B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
with O
increasing O
rarity B_DISEASE/B_MEASURE
in O
the O
United B_LOCATION/B_PERSON
Kingdom I_LOCATION/I_PERSON
. O

3 B_NUMBER[MEASURE]
. O

The O
relationship B_PERSON/B_MEASURE
between O
the O
magnitude B_MEASURE
of O
temporal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variation B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
local B_MEASURE/B_BIO
mean I_MEASURE/I_BIO
population I_MEASURE/I_BIO
size I_MEASURE/I_BIO
differs O
between O
species B_BIO/B_PERSON
dependent I_BIO/I_PERSON
on O
their O
life B_LOCATION/B_ORGANIZATION
history I_LOCATION/I_ORGANIZATION
, O
i O
. O
e O
. O
species B_BIO/B_PERSON
with O
larger B_MEASURE
clutch I_MEASURE
size I_MEASURE
and O
lower B_MEASURE/B_LOCATION
survival I_MEASURE/I_LOCATION
tended O
to O
have O
larger B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
annual B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
changes B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
population B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
than O
low O
- O
reproducing O
long O
- O
lived O
species B_BIO/B_PERSON
. O

4 B_NUMBER[MEASURE]
. O

The O
probability B_MEASURE
of O
local B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappearance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
a O
study B_LOCATION/B_BIO
plot I_LOCATION/I_BIO
depended O
on O
the O
population B_MEASURE/B_LOCATION
size B_MEASURE/I_LOCATION
and O
was O
hence O
closely O
related O
to O
the O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abundance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
species B_BIO
in O
UK B_LOCATION
. O

For O
a O
given O
population B_MEASURE/B_BIO
size B_MEASURE/I_BIO
, O
this O
probability B_MEASURE
was O
also O
related O
to O
species B_BIO/B_MEASURE
- O
specific B_TIME[MEASURE]/B_PERSON
life I_TIME[MEASURE]/I_PERSON
- O
history B_MEASURE/B_LOCATION
characteristics B_MEASURE/I_LOCATION
, O
being O
higher B_MEASURE
in O
species B_BIO/B_PERSON
with O
larger B_MEASURE
clutch I_MEASURE
sizes I_MEASURE
and O
smaller B_MEASURE/B_LOCATION
survival B_MEASURE/I_LOCATION
rates B_MEASURE/I_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

Rareness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
a O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decoupling I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
temporal B_MEASURE
variation I_MEASURE
in O
population B_MEASURE
size I_MEASURE
. O

6 B_NUMBER[MEASURE]
. O

These O
patterns O
show O
that O
once O
a O
species O
has O
become O
rare O
, O
e O
. O
g O
. O
due O
to O
human B_PERSON/B_BIO
activities O
, O
key O
population O
dynamical O
characteristics O
will O
change O
because O
of O
density O
- O
dependent O
stochastic O
effects O
, O
which O
in O
turn O
are O
dependent O
on O
species O
- O
specific O
life O
- O
history O
characteristics O
. O

Mannitol O
permeation O
and O
radial O
flow O
of O
water O
in O
maize B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
roots O
. O

* B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O
postulated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nonselective B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hydraulic B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
route B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
through O
the O
root B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
apoplast I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
has O
not O
yet O
been O
supported O
by O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
solvent B_BIO
drag I_BIO
. O

* O
Therefore O
, O
mannitol O
transport O
from O
the O
medium O
to O
the O
shoot O
of O
young O
maize B_BIO
plants O
was O
studied O
at O
different O
rates O
of O
transpiration O
in O
hydroculture O
. O

The O
concentration B_MEASURE/B_LOCATION
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
determined O
by O
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

* B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mannitol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utilization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
shoot B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
detectable B_DISEASE_ADJECTIVE[DISEASE]
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
exuding O
roots B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
the O
radial B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
transport I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
mainly O
apoplastic B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
ratio B_MEASURE
alpha I_MEASURE
between O
the O
mannitol B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
xylem B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
vessels B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
that O
of O
the O
external B_BIO
medium I_BIO
was O
calculated O
from O
mannitol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
translocation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
shoot B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
or O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
mannitol B_MEASURE
concentration I_MEASURE
in O
the O
root B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
exudate I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
where O
it O
reached O
c B_OTHER/B_MEASURE
. O

0 O
. O
07 B_MEASURE
in O
the O
steady B_LOCATION
state I_LOCATION
. O

In O
transpiring O
plants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O
with O
increasing O
water B_LOCATION/B_MEASURE
flux B_LOCATION/I_MEASURE
from O
0 B_MEASURE
. O
04 B_MEASURE
to O
values B_MEASURE/B_PROTEIN[GENE]
below O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
the O
root B_MEASURE
reflection I_MEASURE
coefficient I_MEASURE
for O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
above O
0 B_MEASURE
. O
99 B_MEASURE
. O

* B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
It O
is O
concluded O
that O
the O
radial B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
movement B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
water B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
vessels B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
is O
under O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protoplastic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
whereas O
solutes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O
diffuse O
on O
an O
apoplastic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
path B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
significant B_LOCATION
volume I_LOCATION
flux I_LOCATION
through O
the O
root B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
apoplast I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
of O
physiological B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
importance I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
as O
it O
prevents O
the O
coupling B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
apoplastic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ballast B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solutes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
transpiration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Genomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
repeat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
point B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
( O
RIP B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
filamentous B_SPECIES[BIO]/B_DISEASE
ascomycetes I_SPECIES[BIO]/I_DISEASE
. O

The O
genomes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
49 B_BIO
filamentous I_BIO
ascomycetes I_BIO
( O
subphylum B_DISEASE/B_PROTEIN[GENE]
Pezizomycotina B_DISEASE/I_PROTEIN[GENE]
) O
were O
examined O
by O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
independent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
C B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
> B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
T B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
transitions B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
typical B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
RIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

At O
least O
one B_NUMBER[MEASURE]/B_BIO
transposable I_NUMBER[MEASURE]/I_BIO
element I_NUMBER[MEASURE]/I_BIO
or O
other B_GENE
repeat I_GENE
family I_GENE
was O
identified O
in O
each O
genome B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
members B_PERSON/B_BIO
were O
assessed O
for O
transition B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
transversion B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
relative I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
their O
intact B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitor I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

occurrence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
RIP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
indicated O
where O
family B_MEASURE/B_LOCATION
members I_MEASURE/I_LOCATION
differed O
by O
excess B_DISEASE/B_MEASURE
of O
directional B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
transitions I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
over O
transversions B_TIME[MEASURE]/B_PERSON
. O

transition B_DISEASE/B_PERSON
mutations I_DISEASE/I_PERSON
were O
quantified O
by O
an O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
taking O
double B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
in O
CpG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
CPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dinucleotides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

A O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assessed O
dinucleotide B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
frequency I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
distribution I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
anomalies I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
whole B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
genomes I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
allowed O
quantification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fractions B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
of O
the O
non B_GENE/B_DISEASE
- O
coding B_GENE/B_BIO
genome I_GENE/I_BIO
that O
had O
been O
subject B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
extensive B_DISEASE_ADJECTIVE[DISEASE]
directional I_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
that O
RIP B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
varied O
greatly O
, O
both O
in O
extent B_LOCATION/B_DISEASE
of O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
dinucleotide B_MEASURE
context I_MEASURE
for O
C B_OTHER/B_LOCATION
- O
> B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
T B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transitions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
the O
most O
extreme O
case O
, O
75 O
% O
of O
a O
Blastomyces B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
dermatitidis B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
genome O
had O
suffered O
conspicuous O
GC O
- O
depletion O
, O
all O
of O
it O
in O
the O
non O
- O
coding O
fraction O
. O

Many B_PERSON
genomes I_PERSON
carried O
both O
intact B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
others B_PERSON/B_LOCATION
that O
had O
suffered O
heavily O
from O
transitions B_DISEASE
. O

Only O
one O
species O
, O
Chaetomium B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
globosum I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
showed O
no O
evidence O
of O
directional O
mutation O
. O

Accelerometry O
estimates O
field O
metabolic O
rate O
in O
giant B_BIO
Australian I_BIO
cuttlefish I_BIO
Sepia I_BIO
apama I_BIO
during O
breeding O
. O

1 B_NUMBER[MEASURE]
. O

Estimating O
the O
metabolic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
rate I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
animals B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
nature B_LOCATION/B_DISEASE
is O
central B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
understanding O
the O
physiological B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
, O
behavioural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
ecology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Doubly O
labelled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
water B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
heart B_DISEASE/B_MEASURE
- O
rate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
methods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
are O
the O
most O
commonly O
used O
approaches B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
both O
have O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
preclude O
their O
application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
some O
systems B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

2 B_NUMBER[MEASURE]
. O

Accelerometry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
emerged O
as O
a O
powerful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
estimating O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expenditure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
range B_MEASURE
of O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
is O
yet O
to O
be O
used O
to O
estimate O
field B_MEASURE/B_ORGANIZATION
metabolic B_MEASURE/I_ORGANIZATION
rate B_MEASURE/I_ORGANIZATION
in O
aquatic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
taxa I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
combined O
two O
- O
dimensional O
accelerometry O
and O
swim O
- O
tunnel O
respirometry O
to O
estimate O
patterns O
of O
energy O
expenditure O
in O
giant B_SPECIES[BIO]/B_PERSON
Australian I_SPECIES[BIO]/I_PERSON
cuttlefish I_SPECIES[BIO]/I_PERSON
Sepia I_SPECIES[BIO]/I_PERSON
apama I_SPECIES[BIO]/I_PERSON
during O
breeding O
. O

3 B_NUMBER[MEASURE]
. O

Both O
oxygen B_MEASURE
consumption I_MEASURE
rate I_MEASURE
( O
VO2 B_PROTEIN[GENE]/B_LOCATION
) O
and O
swimming B_MEASURE/B_DISEASE
speed I_MEASURE/I_DISEASE
showed O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
positive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
associations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
body B_DISEASE
acceleration I_DISEASE
, O
with O
coefficients B_MEASURE
of O
determination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparable I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
those O
using O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accelerometers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
terrestrial B_LOCATION
vertebrates I_LOCATION
. O

Despite O
increased O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
during O
the O
day B_TIME[MEASURE]
, O
field B_MEASURE/B_PERSON
metabolic B_MEASURE/I_PERSON
rate B_MEASURE/I_PERSON
rarely O
approached O
Vo2 B_MEASURE/B_LOCATION
, O
and O
night B_TIME[MEASURE]/B_LOCATION
- O
time B_MEASURE/B_ORGANISM_FUNCTION
Vo2 I_MEASURE/I_ORGANISM_FUNCTION
was O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
at O
rest B_LOCATION/B_TIME[MEASURE]
. O

4 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
life B_TIME[MEASURE]/B_PERSON
- O
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
species B_SPECIES[BIO]
, O
which O
has O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
capacity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
exercise O
anaerobically O
, O
and O
a O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
visually O
based O
. O

With O
the O
logistical B_DISEASE_ADJECTIVE[DISEASE]
difficulties I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
aquatic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
environments I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
accelerometry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
prove O
a O
valuable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
estimating O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expenditure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
aquatic B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Generation O
of O
Se O
- O
fortified O
broccoli B_BIO
as O
functional O
food O
: O
impact O
of O
Se O
fertilization O
on O
S O
metabolism O
. O

Selenium O
( O
Se O
) O
- O
fortified O
broccoli B_BIO
( O
Brassica B_LOCATION/B_ORGANIZATION
oleracea I_LOCATION/I_ORGANIZATION
var I_LOCATION/I_ORGANIZATION
. I_LOCATION/I_ORGANIZATION
italica I_LOCATION/I_ORGANIZATION
) O
has O
been O
proposed O
as O
a O
functional O
food O
for O
cancer O
prevention O
, O
based O
on O
its O
high O
glucosinolate O
( O
GSL O
) O
content O
and O
capacity O
for O
Se O
accumulation O
. O

However O
, O
as O
selenate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
sulphate B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
share I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
the O
initial B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assimilation B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Se B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
fertilization I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
could O
interfere O
with O
sulphur B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
plant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

Consequently O
, O
GSL B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
compromised O
. O

To O
evaluate O
these O
potentially O
adverse O
effects O
of O
Se O
fertilization O
, O
we O
performed O
a O
comprehensive O
study O
on O
sand O
- O
grown O
young O
broccoli B_BIO
plants O
( O
weekly O
selenate O
applications O
of O
0 O
. O
8 O
mumol O
plant O
( O
- O
1 O
) O
via O
the O
root O
) O
and O
field O
- O
grown O
adult O
broccoli B_BIO/B_PERSON
plants O
during O
head O
formation O
( O
single O
foliar O
selenate O
application O
: O
25 O
. O
3 O
or O
253 O
mumol O
plant O
( O
- O
1 O
) O
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
under O
these O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
Se B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
application I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
does O
not O
affect O
plant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
contents B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
GSL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
glucoraphanin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
major B_LOCATION/B_PROTEIN[GENE]
aliphatic B_LOCATION/I_PROTEIN[GENE]
GSL B_LOCATION/I_PROTEIN[GENE]
) O
or O
the O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BoMYB28 B_GENE/B_DISEASE
( O
encoding O
a O
functionally O
confirmed O
master B_ENZYME[GENE]/B_PERSON
regulator I_ENZYME[GENE]/I_PERSON
for O
aliphatic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GSL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
biosynthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
. O

Conversely O
, O
due O
to O
the O
changed O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
sulphate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
BoSULTR1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
1 B_MEASURE/B_LOCATION
, O
1 B_NUMBER[MEASURE]/B_LOCATION
; O
2 B_NUMBER[MEASURE]/B_LOCATION
, O
2 B_NUMBER[MEASURE]/B_LOCATION
; O
1 B_NUMBER[MEASURE]
, O
and O
2 B_NUMBER[MEASURE]
; O
2 B_NUMBER[MEASURE]
) O
, O
sulphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
increased O
in O
the O
shoot B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
of O
young B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
plants I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
while O
decreasing O
in O
the O
root B_TIME[MEASURE]/B_BIO
. O

We O
conclude O
that O
broccoli B_BIO
can O
be O
fertilized O
with O
Se O
without O
reduction O
in O
GSL O
content O
, O
even O
with O
Se O
accumulation O
exceeding O
the O
level O
recommended O
for O
human B_BIO/B_LOCATION
consumption O
. O

Arbuscular B_TIME[MEASURE]/B_PERSON
mycorrhizal I_TIME[MEASURE]/I_PERSON
hyphopodia I_TIME[MEASURE]/I_PERSON
and O
germinated B_BIO
spore I_BIO
exudates I_BIO
trigger O
Ca2 B_DISEASE/B_GENE
+ I_DISEASE/I_GENE
spiking I_DISEASE/I_GENE
in O
the O
legume B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nonlegume B_BIO
root I_BIO
epidermis I_BIO
. O

* O
The O
aim O
of O
this O
study O
was O
to O
investigate O
ca O
( O
2 O
+ O
) O
responses O
to O
endosymbiotic O
arbuscular O
mycorrhizal O
( O
AM O
) O
fungi O
in O
the O
host O
root O
epidermis O
following O
pre O
- O
infection O
hyphopodium O
formation O
in O
both O
legumes O
and O
nonlegumes O
, O
and O
to O
determine O
to O
what O
extent O
these O
responses O
could O
be O
mimicked O
by O
germinated O
fungal B_BIO/B_DISEASE
spore O
exudate O
. O

* O
Root O
organ O
cultures O
of O
both O
Medicago B_BIO
truncatula I_BIO
and O
Daucus B_BIO
carota I_BIO
, O
expressing O
the O
nuclear O
- O
localized O
cameleon O
reporter O
NupYC2 O
. O
1 O
, O
were O
used O
to O
monitor O
AM O
- O
elicited O
ca O
( O
2 O
+ O
) O
responses O
in O
host O
root O
tissues O
. O

* B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE/B_LOCATION
+ O
) O
spiking O
was O
observed O
in O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
contacted O
by O
AM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
hyphopodia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
for O
both O
hosts B_PERSON/B_LOCATION
, O
with O
highest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
frequencies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
correlating O
with O
the O
epidermal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
nucleus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
positioned O
facing O
the O
fungal B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
contact I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
site I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Treatment O
with O
AM O
spore O
exudate O
also O
elicited O
ca O
( O
2 O
+ O
) O
spiking O
within O
the O
AM O
- O
responsive O
zone O
of O
the O
root O
and O
, O
in O
both O
cases O
, O
spiking O
was O
dependent O
on O
the O
M B_BIO
. I_BIO
truncatula I_BIO
common O
SYM O
genes O
DMI1 O
/ O
2 O
, O
but O
not O
on O
the O
rhizobial O
nod O
factor O
perception O
gene O
NFP O
. O

* B_OTHER/B_MEASURE
These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
AM B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fungal B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
root B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
penetration B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
preceded O
by O
a O
SYM B_MEASURE/B_GENE
pathway I_MEASURE/I_GENE
- O
dependent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
oscillatory B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
whose O
evolutionary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
origin I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predates O
the O
divergence B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
asterid B_BIO
and O
rosid B_BIO
clades I_BIO
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O
show O
that O
fungal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
symbiotic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
signals B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
already O
generated O
during O
spore B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
germination B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
and O
that O
cameleon B_GENE/B_LOCATION
- O
expressing O
root B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organ I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cultures I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O
a O
novel B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AM I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bio I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
such B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
signals B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
Perigord B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
black I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
truffle I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responds O
to O
cold O
temperature O
with O
an O
extensive O
reprogramming O
of O
its O
transcriptional O
activity O
. O

The O
Tuber B_SPECIES[BIO]
melanosporum I_SPECIES[BIO]
genome O
has O
been O
analysed O
with O
the O
aim O
of O
identifying O
and O
characterizing O
the O
genes O
involved O
in O
the O
environmental O
stress O
response O
. O

A O
whole B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genome I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
array I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
7496 B_GENE
genes I_GENE
/ O
probe B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
was O
used O
to O
verify O
the O
fungal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcriptional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
profiling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
upon O
a O
cold B_TIME[MEASURE]/B_BIO
temperature B_TIME[MEASURE]/I_BIO
period B_TIME[MEASURE]/I_BIO
( O
7 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
at O
4 B_MEASURE/B_LOCATION
^ I_MEASURE/I_LOCATION
0C I_MEASURE/I_LOCATION
) O
. O

A O
total B_MEASURE
of O
423 B_MEASURE
genes I_MEASURE
resulted O
to O
be O
differentially O
expressed O
in O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
> O
2 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
; O
p B_PROTEIN[GENE]/B_LOCATION
- O
value B_MEASURE/B_LOCATION
& O
Lt B_PROTEIN[GENE]/B_DISEASE
; O
0 B_MEASURE/B_LOCATION
. O
05 B_MEASURE
) O
in O
the O
mycelia B_BIO
exposed O
to O
cold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
compared O
to O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ones I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
187 B_MEASURE
of O
these O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
up O
- O
regulated O
, O
while O
236 B_MEASURE
were O
down O
- O
regulated O
. O

sixty B_NUMBER[MEASURE]
- O
six B_NUMBER[MEASURE]
and O
fifty B_NUMBER[MEASURE]
- O
one B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
, O
respectively O
, O
of O
the O
up O
- O
or O
down O
- O
regulated O
transcripts B_BIO/B_GENE
had O
no O
KOG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
were O
clustered O
as O
unclassified B_PROTEIN[GENE]/B_MEASURE
proteins I_PROTEIN[GENE]/I_MEASURE
, O
which O
was O
the O
most O
abundant B_DISEASE_ADJECTIVE[DISEASE]
category I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
both O
up O
- O
and O
down O
- O
regulated O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subset I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
containing O
a O
range B_LOCATION/B_MEASURE
of O
biological B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
was O
chosen O
to O
validate O
the O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
through O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
real I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
qRT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirmed O
the O
array B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
16 B_NUMBER[MEASURE]
out O
of O
22 B_MEASURE
of O
the O
considered O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
confirming O
that O
a O
cold B_GENE
temperature I_GENE
period I_GENE
influences O
the O
truffle B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
global B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
expressed O
genes B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
mostly O
resulted O
to O
be O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
heat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
shock I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HSPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
genes B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wall I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
could O
be O
involved O
in O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
are O
responsible B_DISEASE_ADJECTIVE[DISEASE]
for O
fungal B_DISEASE
adaptation I_DISEASE
. O

Since O
truffle B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
ascomata I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
develop O
during O
the O
winter B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
, O
we O
hypothesize O
that O
these O
differentially O
expressed O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
help O
the O
truffle B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
to O
adapt O
to O
low B_DISEASE/B_LOCATION
temperatures I_DISEASE/I_LOCATION
and O
/ O
or O
perceive O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
regulate O
the O
fructification B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

The O
rapid O
production O
of O
high O
- O
titer O
porcine B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
endogenous I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
retrovirus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PERV O
) O
- O
B O
env O
pseudotype O
and O
construction O
of O
an O
EGFP O
- O
expressing O
replication O
competent O
PERV O
- O
A O
vector O
. O

Porcine B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
endogenous I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
retroviruses I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PERVs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
present O
a O
unique O
concern O
associated O
with O
xenotransplantation O
because O
they O
have O
been O
shown O
to O
infect O
certain O
human B_PERSON/B_SPECIES[BIO]
cells O
in O
vitro O
and O
it O
is O
also O
difficult O
to O
generate O
herds O
of O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
free O
of O
PERVs B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
production B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
titer B_MEASURE
MoMLV I_MEASURE
- O
PERV B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
pseudotypes B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
is O
reported O
; O
an O
EGFP B_GENE/B_DISEASE
- O
expressing O
replication B_TIME[MEASURE]/B_GENE
- O
competent B_GENE/B_LOCATION
molecular I_GENE/I_LOCATION
clone I_GENE/I_LOCATION
that O
allows O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
titer B_GENE/B_DISEASE
was O
also O
constructed O
. O

To O
improve O
the O
MLV O
- O
based O
retroviral B_DISEASE/B_VIRUS[BIO]
vector O
system O
, O
a O
2 O
. O
1 O
- O
kb O
PERV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
B O
env O
product O
was O
amplified O
from O
PK O
- O
15 O
genomic O
DNA O
and O
cloned O
into O
the O
pCL O
- O
Eco O
retroviral O
vector O
. O

The O
titer O
of O
lacZ O
( O
PERV B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
from O
the O
293 O
cells O
was O
about O
1 O
. O
0x10 O
( O
4 O
) O
CFU O
/ O
ml O
. O

In O
contrast O
, O
the O
titer O
of O
lacZ O
( O
PERV O
- O
B O
) O
from O
a O
conventional O
murine O
retroviral B_DISEASE/B_VIRUS[BIO]
vector O
( O
split O
genome O
) O
was O
found O
to O
be O
1 O
. O
2x10 O
( O
2 O
) O
CFU O
/ O
ml O
when O
the O
PERV B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
env O
expression O
vector O
was O
transfected O
into O
TELCeB6 O
cells O
, O
which O
harbor O
MFGnlslacZ O
and O
the O
gag O
- O
Pol O
- O
expressing O
vector O
. O

In O
addition O
, O
an O
infectious O
PERV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
clone O
containing O
enhanced O
GFP O
( O
EGFP O
) O
by O
using O
a O
PCR O
- O
based O
method O
was O
developed O
. O

This O
EGFP B_GENE/B_DISEASE
- O
expressing O
PERV B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
IRES B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
EGFP B_PROTEIN[GENE]/B_LOCATION
molecular I_PROTEIN[GENE]/I_LOCATION
clone I_PROTEIN[GENE]/I_LOCATION
was O
found O
to O
be O
stable B_DISEASE_ADJECTIVE[DISEASE]
genetically O
on O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O
293 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

Rhizomastix B_MEASURE/B_BIO
biflagellata I_MEASURE/I_BIO
SP I_MEASURE/I_BIO
. O
Nov B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
a O
new B_SPECIES[BIO]
amoeboflagellate I_SPECIES[BIO]
of O
uncertain B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phylogenetic I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolated O
from O
frogs B_LOCATION/B_BIO
. O

The O
genus B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Rhizomastix I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
contains O
five B_BIO/B_ENT
species I_BIO/I_ENT
of O
amoeboflagellates B_SPECIES[BIO]
with O
a O
single B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
anterior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
flagellum I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
which O
live O
as O
intestinal B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
symbionts I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O
insects B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amphibians B_BIO
. O

Though O
established O
in O
1911 B_MEASURE
, O
Rhizomastix B_SPECIES[BIO]/B_PERSON
has O
been O
neglected O
for O
decades B_TIME[MEASURE]
and O
its O
phylogenetic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
uncertain B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O
the O
morphology B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
first B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
cultivated I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
strain I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
of O
Rhizomastix B_BACTERIUM[BIO]
. O

The O
organism B_BIO
was O
isolated O
from O
an O
argentine B_BIO/B_LOCATION
horned I_BIO/I_LOCATION
frog I_BIO/I_LOCATION
and O
differs O
from O
the O
known O
Rhizomastix B_BIO/B_PERSON
species I_BIO/I_PERSON
by O
the O
presence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
biflagellate B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
isolate B_BIO/B_MEASURE
is O
described O
as O
Rhizomastix B_BIO/B_GENE
biflagellata B_BIO/I_GENE
sp B_BIO/I_GENE
. O
Nov B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relationship I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
Rhizomastix B_BACTERIUM[BIO]
to O
Archamoebae B_DISEASE/B_SPECIES[BIO]
is O
discussed O
. O

Whole O
- O
genome O
sequences O
of O
thirteen O
isolates O
of O
Borrelia B_BACTERIUM[BIO]/B_LOCATION
burgdorferi B_BACTERIUM[BIO]/I_LOCATION
. O

Borrelia B_BACTERIUM[BIO]/B_DISEASE
burgdorferi I_BACTERIUM[BIO]/I_DISEASE
is O
a O
causative O
agent O
of O
Lyme O
disease O
in O
North O
America O
and O
Eurasia O
. O

The O
first O
complete O
genome O
sequence O
of O
B B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
burgdorferi I_SPECIES[BIO]/I_DISEASE
strain I_SPECIES[BIO]/I_DISEASE
31 I_SPECIES[BIO]/I_DISEASE
, O
available O
for O
more O
than O
a O
decade O
, O
has O
assisted O
research O
on O
the O
pathogenesis O
of O
Lyme O
disease O
. O

Because O
a O
single O
genome O
sequence O
is O
not O
sufficient O
to O
understand O
the O
relationship O
between O
genotypic O
and O
geographic O
variation O
and O
disease O
phenotype O
, O
we O
determined O
the O
whole O
- O
genome O
sequences O
of O
13 O
additional O
B B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
burgdorferi I_SPECIES[BIO]/I_DISEASE
isolates O
that O
span O
the O
range O
of O
natural O
variation O
. O

These O
sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
allow O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pathogenesis B_DISEASE
and O
provide O
a O
foundation B_ORGANIZATION/B_LOCATION
for O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Association O
between O
nonsynonymous O
mutations O
of O
starch O
synthase O
IIa O
and O
starch O
quality O
in O
rice B_BIO
( O
Oryza B_MEASURE/B_BIO
sativa I_MEASURE/I_BIO
) O
. O

Starch O
quality O
is O
one O
of O
the O
most O
important O
agronomic O
traits O
in O
Asian B_BIO/B_LOCATION
rice I_BIO/I_LOCATION
, O
Oryza B_LOCATION/B_BIO
sativa I_LOCATION/I_BIO
. O

starch B_PROTEIN[GENE]
synthase I_PROTEIN[GENE]
IIa I_PROTEIN[GENE]
( O
SsIIa B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
major B_PERSON/B_MEASURE
candidate I_PERSON/I_MEASURE
gene I_PERSON/I_MEASURE
for O
starch B_DISEASE
quality I_DISEASE
variation I_DISEASE
. O

Within O
SsIIa O
, O
three O
nonsynonymous O
mutations O
in O
exon O
8 O
have O
been O
shown O
to O
affect O
enzyme O
activity O
when O
expressed O
in O
Escherichia B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
coli B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

To O
search O
for O
the O
variation O
in O
SsIIa O
that O
is O
responsible O
for O
starch O
quality O
variation O
in O
rice B_BIO/B_LOCATION
, O
we O
sequenced O
the O
SsIIa O
exon O
8 O
region O
and O
measured O
starch O
quality O
as O
starch O
disintegration O
in O
alkali O
for O
289 O
accessions O
of O
cultivated O
rice B_BIO/B_GENE
and O
57 O
accessions O
of O
its O
wild O
ancestor O
, O
Oryza B_LOCATION/B_BIO
rufipogon B_LOCATION/I_BIO
. O

A O
general B_MEASURE
linear I_MEASURE
model I_MEASURE
and O
nested B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clade I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
used O
to O
identify O
the O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nonsynonymous I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
single I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymorphisms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SNPs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
starch B_DISEASE/B_LOCATION
quality I_DISEASE/I_LOCATION
. O

Among O
the O
three B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nonsynonymous I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
SNPs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
we O
found O
strong B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
at O
one B_PROTEIN[GENE]
nucleotide I_PROTEIN[GENE]
site I_PROTEIN[GENE]
( O
' O
SNP B_PROTEIN[GENE]/B_LOCATION
3 I_PROTEIN[GENE]/I_LOCATION
' O
) O
, O
corresponding B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
Leu B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
/ O
Phe B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
replacement I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
at O
codon B_TIME[MEASURE]/B_PERSON
781 I_TIME[MEASURE]/I_PERSON
. O

A O
second B_GENE
SNP I_GENE
, O
corresponding B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
Val B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Met B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
replacement I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
codon B_PROTEIN[GENE]
737 I_PROTEIN[GENE]
, O
could O
potentially O
show O
an O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
increased O
sample B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sizes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

variation O
in O
SsIIa O
enzyme O
activity O
is O
associated O
with O
the O
cohesiveness O
of O
rice B_PERSON/B_BIO
grains O
when O
cooked O
, O
and O
our O
findings O
are O
consistent O
with O
selection O
for O
more O
cohesive O
grains O
during O
the O
domestication O
of O
tropical B_BIO/B_LOCATION
japonica I_BIO/I_LOCATION
rice I_BIO/I_LOCATION
. O

ecological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
xylem B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cavitation I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
stem B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
leaf B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
structural I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
traits I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Cavitation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistance B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
a O
critical B_MEASURE/B_LOCATION
determinant I_MEASURE/I_LOCATION
of O
drought B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
tolerance B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
tropical B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tree I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
little B_PERSON
is O
known O
of O
its O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
life B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
particularly O
for O
seasonal B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
dry I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
forests I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
critically O
driven O
by O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_LOCATION/B_BIO
availability I_LOCATION/I_BIO
. O

We O
analysed O
vulnerability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
curves I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
saplings B_BIO/B_PERSON
of O
13 B_BIO/B_PERSON
tropical I_BIO/I_PERSON
dry I_BIO/I_PERSON
forest I_BIO/I_PERSON
tree I_BIO/I_PERSON
species I_BIO/I_PERSON
differing O
in O
life B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
leaf B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phenology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

We O
examined O
how O
vulnerability B_DISEASE/B_MEASURE
to O
cavitation B_DISEASE_ADJECTIVE[DISEASE]
( O
P50 B_LOCATION
) O
related O
to O
dry B_BIO/B_MEASURE
season I_BIO/I_MEASURE
leaf I_BIO/I_MEASURE
water I_BIO/I_MEASURE
potentials I_BIO/I_MEASURE
and O
stem B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
leaf B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
traits I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

P50 B_PROTEIN[GENE]/B_MEASURE
- O
values B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ranged O
from O
- O
0 B_MEASURE
. O
8 B_MEASURE
to O
- O
6 B_MEASURE
. O
2 B_MEASURE
MPa I_MEASURE
, O
with O
pioneers B_PERSON/B_BIO
on O
average B_LOCATION/B_BIO
38 I_LOCATION/I_BIO
% I_LOCATION/I_BIO
more O
vulnerable B_DISEASE_ADJECTIVE[DISEASE]
to O
cavitation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
shade B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tolerants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

vulnerability B_DISEASE
to O
cavitation B_DISEASE
was O
related O
to O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
traits B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conferring O
tissue B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
stress I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
vulnerability I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
being O
negatively O
correlated O
with O
wood B_MEASURE/B_DISEASE
density I_MEASURE/I_DISEASE
, O
and O
surprisingly O
maximum B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
vessel B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
length B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

vulnerability B_DISEASE
to O
cavitation B_DISEASE_ADJECTIVE[DISEASE]
was O
negatively O
related O
to O
the O
Huber B_DISEASE/B_PROTEIN[GENE]
- O
value B_MEASURE/B_BIO
and O
leaf B_MEASURE
dry I_MEASURE
matter I_MEASURE
content I_MEASURE
, O
and O
positively O
with O
leaf B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
. O

It O
was O
not O
related O
to O
SLA B_PERSON/B_LOCATION
. O

We O
found O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trade I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
off B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
between O
cavitation B_MEASURE
resistance I_MEASURE
and O
hydraulic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
efficiency B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Most B_BIO/B_LOCATION
species I_BIO/I_LOCATION
in O
the O
field B_LOCATION/B_BIO
were O
operating O
at O
leaf B_MEASURE/B_LOCATION
water B_MEASURE/I_LOCATION
potentials B_MEASURE/I_LOCATION
well O
above O
their O
P50 B_MEASURE/B_LOCATION
, O
but O
pioneers B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
deciduous B_PERSON
species I_PERSON
had O
smaller B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hydraulic B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
safety B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
margins B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
shade B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tolerants B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
evergreens B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
trade B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
off B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
between O
hydraulic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
safety I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
efficiency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
underlies O
ecological B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
across O
these O
tropical B_LOCATION/B_ORGANIZATION
dry I_LOCATION/I_ORGANIZATION
forest I_LOCATION/I_ORGANIZATION
tree I_LOCATION/I_ORGANIZATION
species I_LOCATION/I_ORGANIZATION
. O

genetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lung B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
cancer B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
susceptibility I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Lung B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
is O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
form I_DISEASE_ADJECTIVE[DISEASE]
of O
cancer B_DISEASE
death I_DISEASE
worldwide I_DISEASE
. O

Although O
reduction O
of O
tobacco B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
consumption O
remains O
the O
most O
appropriate O
strategy O
to O
reduce O
lung O
- O
cancer O
burden O
, O
identification O
of O
genes O
involved O
in O
the O
cause O
of O
disease O
could O
contribute O
to O
further O
understanding O
of O
the O
underlying O
mechanisms O
, O
and O
eventually O
lead O
to O
additional O
prevention O
strategies O
and O
targeted O
treatments O
. O

Common B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
lung B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
have O
been O
recently O
identified O
through O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
collaborative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
genome B_BIO/B_GENE
- O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
association I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
identified O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
separate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
associated O
with O
lung B_DISEASE
cancer I_DISEASE
( O
5p15 B_GENE/B_DISEASE
, O
6p21 B_MEASURE/B_GENE
, O
and O
15q25 B_MEASURE/B_GENE
) O
and O
include O
genes B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
regulate O
acetylcholine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nicotinic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
telomerase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
much B_TIME[MEASURE]/B_PERSON
about O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
remains O
to O
be O
discovered O
, O
and O
rarer B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
variants I_GENE/I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
those O
of O
the O
CHEK2 B_GENE/B_PERSON
gene I_GENE/I_PERSON
, O
likely O
account O
for O
most B_DISEASE/B_MEASURE
of O
the O
remaining O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

There O
is O
also O
a O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
investigate O
how O
genetic B_DISEASE/B_GENE
susceptibility I_DISEASE/I_GENE
is O
associated O
with O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
including O
treatment B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tumour B_DISEASE_ADJECTIVE[DISEASE]
relapse I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
validation O
of O
a O
real O
- O
time O
RT O
- O
PCR O
assay O
which O
detects O
influenza O
A O
and O
types O
simultaneously O
for O
influenza B_DISEASE/B_MEASURE
A I_DISEASE/I_MEASURE
H1N1 I_DISEASE/I_MEASURE
( O
2009 O
) O
and O
oseltamivir O
- O
resistant O
( O
H275Y O
) O
influenza O
A O
H1N1 O
( O
2009 O
) O
. O

Influenza B_LOCATION/B_DISEASE
A I_LOCATION/I_DISEASE
H1N1 I_LOCATION/I_DISEASE
( O
2009 B_MEASURE
) O
was O
declared O
by O
the O
World B_PERSON/B_ORGANIZATION
Health B_PERSON/I_ORGANIZATION
Organisation B_PERSON/I_ORGANIZATION
( O
WHO B_ORGANIZATION/B_MEASURE
) O
as O
the O
first B_DISEASE
influenza I_DISEASE
pandemic I_DISEASE
of O
the O
21st B_LOCATION/B_ENT
century I_LOCATION/I_ENT
. O

Rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
influenza B_DISEASE/B_BIO
A I_DISEASE/I_BIO
and O
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
influenza B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
A I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
H1N1 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
2009 B_NUMBER[MEASURE]/B_LOCATION
) O
and O
seasonal B_DISEASE/B_LOCATION
influenza B_DISEASE/I_LOCATION
A B_DISEASE/I_LOCATION
is O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
antiviral B_DISEASE/B_ORGANISM_FUNCTION
resistant I_DISEASE/I_ORGANISM_FUNCTION
strains I_DISEASE/I_ORGANISM_FUNCTION
of O
influenza B_DISEASE
A I_DISEASE
H1N1 I_DISEASE
( O
2009 B_NUMBER[MEASURE]/B_LOCATION
) O
would O
be O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
clinicians B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
allow O
for O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
an O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O
a O
much O
earlier B_MEASURE
stage I_MEASURE
if O
resistance B_DISEASE
is O
found O
. O

It O
was O
the O
aim O
of O
this O
study O
to O
develop O
a O
real O
- O
time O
RT O
- O
PCR O
that O
can O
detect O
all O
influenza B_BIO/B_GENE
A I_BIO/I_GENE
viruses I_BIO/I_GENE
and O
type O
simultaneously O
for O
influenza B_DISEASE_ADJECTIVE[DISEASE]
A I_DISEASE_ADJECTIVE[DISEASE]
H1N1 I_DISEASE_ADJECTIVE[DISEASE]
( O
2009 O
) O
and O
oseltamivir O
resistant O
( O
H275Y O
) O
influenza B_DISEASE/B_PROTEIN[GENE]
A B_DISEASE/I_PROTEIN[GENE]
H1N1 B_DISEASE/I_PROTEIN[GENE]
( O
2009 O
) O
. O

This O
multiplex O
assay O
will O
allow O
laboratories O
to O
screen O
respiratory O
samples O
for O
all O
types O
of O
influenza B_VIRUS[BIO]/B_DISEASE
A I_VIRUS[BIO]/I_DISEASE
, O
influenza B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
A B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
H1N1 B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
2009 O
) O
virus O
and O
oseltamivir O
resistant O
( O
H275Y O
) O
influenza B_DISEASE/B_PROTEIN[GENE]
A B_DISEASE/I_PROTEIN[GENE]
H1N1 B_DISEASE/I_PROTEIN[GENE]
( O
2009 O
) O
virus O
in O
a O
rapid O
and O
cost O
effective O
format O
, O
ensuring O
that O
typing O
methods O
for O
seasonal O
and O
avian O
viruses O
are O
used O
on O
a O
smaller O
subset O
of O
samples O
. O

Since O
most B_MEASURE/B_PERSON
virology B_MEASURE/I_PERSON
laboratories B_MEASURE/I_PERSON
already O
offer O
a O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
service I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
influenza B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
easily O
be O
implemented O
into O
most B_LOCATION/B_BIO
areas I_LOCATION/I_BIO
at O
little B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cost I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therefore O
increasing O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
access I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
to O
resistance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
seasonal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
use B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
efficiency I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
calculated O
from O
the O
carbon B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isotope B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composition B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tree B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rings B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
flux B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
a O
temperate B_LOCATION
forest I_LOCATION
. O

Tree B_BIO/B_NUMBER[MEASURE]
- O
ring B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
delta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
13 B_MEASURE/B_LOCATION
) O
C B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
often O
interpreted O
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
intrinsic B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
use B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiency I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
WUE B_PROTEIN[GENE]/B_LOCATION
) O
using O
a O
carbon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
isotope I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
discrimination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
established O
at O
the O
leaf B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
. O

We O
examined O
whether O
intra B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ring B_LOCATION
delta I_LOCATION
( O
13 B_MEASURE/B_LOCATION
) O
C B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
be O
used O
to O
assess O
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
intrinsic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WUE B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
the O
ratio B_MEASURE/B_PERSON
of O
carbon B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
assimilation I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
stomatal B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conductance I_ORGANISM_FUNCTION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O
and O
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
ecosystem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WUE I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
t B_MEASURE/B_DISEASE
) O
, O
the O
ratio B_MEASURE/B_PERSON
of O
C B_BIO/B_ORGANISM_FUNCTION
assimilation B_BIO/I_ORGANISM_FUNCTION
and O
transpiration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
) O
at O
a O
seasonal B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
. O

Intra O
- O
ring O
delta O
( O
13 O
) O
C O
was O
measured O
in O
30 O
- O
to O
60 O
- O
mum O
- O
thick O
slices O
in O
eight O
oak O
trees O
( O
Quercus B_MEASURE/B_PERSON
petraea I_MEASURE/I_PERSON
) O
. O

canopy B_LOCATION/B_PERSON
W I_LOCATION/I_PERSON
( O
g B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
was O
simulated O
using O
a O
physiologically O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
based O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

High B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
between O
- O
tree B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
the O
seasonal B_LOCATION
variations I_LOCATION
of O
intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
ring B_LOCATION/B_TIME[MEASURE]
delta B_LOCATION/I_TIME[MEASURE]
( O
13 B_TIME[MEASURE]/B_LOCATION
) O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Six B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
trees I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
showed O
significant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
g B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
calculated O
from O
intra B_NUMBER[MEASURE]/B_LOCATION
- O
ring B_LOCATION
delta I_LOCATION
( O
13 B_MEASURE/B_LOCATION
) O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
canopy B_LOCATION/B_ORGANIZATION
W I_LOCATION/I_ORGANIZATION
( O
g B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
averaged O
over O
several B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
during O
latewood B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O
that O
latewood B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
seasonal B_PERSON/B_MEASURE
recorder I_PERSON/I_MEASURE
of O
W B_PROTEIN[GENE]/B_LOCATION
( O
g B_PROTEIN[GENE]/B_MEASURE
) O
trends B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
with O
a O
temporal B_MEASURE/B_PERSON
lag I_MEASURE/I_PERSON
corresponding I_MEASURE/I_PERSON
to O
the O
mixing O
time B_MEASURE
of O
sugars B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
phloem B_LOCATION/B_BIO
. O

These O
six B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
trees I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
also O
showed O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
negative I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
correlations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
photosynthetic B_MEASURE
discrimination I_MEASURE
Delta I_MEASURE
calculated O
from O
intra B_NUMBER[MEASURE]/B_LOCATION
- O
ring B_LOCATION
delta I_LOCATION
( O
13 B_MEASURE/B_LOCATION
) O
C B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
ecosystem B_PROTEIN[GENE]/B_LOCATION
W I_PROTEIN[GENE]/I_LOCATION
( O
t B_OTHER/B_MEASURE
) O
, O
during O
latewood B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
formation B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Despite O
the O
observed O
between O
- O
tree B_MEASURE/B_LOCATION
variability I_MEASURE/I_LOCATION
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indicate O
that O
intra B_NUMBER[MEASURE]/B_LOCATION
- O
ring B_LOCATION/B_TIME[MEASURE]
delta B_LOCATION/I_TIME[MEASURE]
( O
13 B_TIME[MEASURE]/B_LOCATION
) O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
be O
used O
to O
access O
seasonal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
past B_PROTEIN[GENE]/B_LOCATION
W I_PROTEIN[GENE]/I_LOCATION
( O
t B_OTHER/B_MEASURE
) O
. O

Resistance O
and O
recovery O
of O
soil O
microbial O
communities O
in O
the O
face O
of O
Alliaria B_BIO/B_LOCATION
petiolata I_BIO/I_LOCATION
invasions O
. O

invaders B_PERSON/B_BIO
can O
gain O
ecological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
because O
of O
their O
evolutionary B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
novelty B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
but O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
how O
these O
novel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O
change O
over O
time B_TIME[MEASURE]
as O
the O
invader B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
invaded O
community B_ORGANIZATION/B_LOCATION
evolve O
in O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
each O
other B_TIME[MEASURE]/B_DISEASE
. O

invasive B_PERSON/B_BIO
plants I_PERSON/I_BIO
often O
gain O
such O
an O
advantage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
alteration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
soil B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
microbial B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
communities B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

In O
soil O
communities O
sampled O
from O
sites O
along O
a O
gradient O
of O
invasion O
history O
with O
Alliaria B_BIO/B_TIME[MEASURE]
petiolata B_BIO/I_TIME[MEASURE]
, O
microbial O
richness O
tended O
to O
decline O
, O
but O
the O
community O
' O
s O
resistance O
to O
A B_BIO/B_DISEASE
. B_BIO/I_DISEASE
petiolata B_BIO/I_DISEASE
' O
s O
effects O
generally O
increased O
with O
increasing O
history O
of O
invasion O
. O

However O
, O
sensitive B_BIO/B_MEASURE
microbial I_BIO/I_MEASURE
taxa I_BIO/I_MEASURE
appeared O
to O
recover O
in O
the O
two B_TIME[MEASURE]/B_LOCATION
oldest I_TIME[MEASURE]/I_LOCATION
sites I_TIME[MEASURE]/I_LOCATION
, O
leading O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
richness B_MEASURE/B_DISEASE
, O
but O
consequent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
resistance B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
may O
be O
because O
of O
evolutionary O
changes O
in O
the O
A B_BIO
. I_BIO
petiolata I_BIO
populations O
, O
which O
tend O
to O
reduce O
their O
investment O
to O
allelopathic O
compounds O
over O
time O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
show O
that O
, O
over O
time B_TIME[MEASURE]/B_LOCATION
, O
microbial B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
communities I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O
develop O
resistance B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
an O
invasive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plant B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
at O
the O
cost B_MEASURE/B_LOCATION
of O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
richness I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
over O
longer B_TIME[MEASURE]
time I_TIME[MEASURE]
- O
scales B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
invasive B_BIO/B_LOCATION
species B_BIO/I_LOCATION
may O
allow O
for O
the O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
soil B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
microbial I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
communities I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Differentiating O
between O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
invasion B_DISEASE/B_BIO
and O
diversity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
impacts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
aboveground B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
plant B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
communities B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
on O
belowground B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
fungal I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
communities I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

exotic B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plant B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
affect O
soil B_LOCATION/B_BIO
microbial I_LOCATION/I_BIO
communities I_LOCATION/I_BIO
with O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
community B_EDU[ORGANIZATION]/B_PERSON
and O
ecosystem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
feedbacks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Yet O
, O
separating O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exotics B_DISEASE_ADJECTIVE[DISEASE]
from O
confounded B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
plant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
community B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diversity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
remains O
a O
challenge B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

We O
focused O
on O
how O
plant B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
diversity B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
native B_PERSON/B_LOCATION
or O
exotic B_PERSON/B_LOCATION
life I_PERSON/I_LOCATION
history I_PERSON/I_LOCATION
affected O
root B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
fungi B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
because O
of O
their O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
roles I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
community B_BIO/B_LOCATION
and O
ecosystem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
processes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

Specifically O
, O
we O
examined O
how O
fungi B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
colonizing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
plant I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
roots I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
affected O
by O
plant B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
richness I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
one B_NUMBER[MEASURE]/B_LOCATION
, O
two B_NUMBER[MEASURE]/B_PERSON
or O
four B_NUMBER[MEASURE]/B_ENT
species I_NUMBER[MEASURE]/I_ENT
) O
replicated O
across O
a O
range B_LOCATION/B_MEASURE
of O
plant B_LOCATION/B_ORGANIZATION
community I_LOCATION/I_ORGANIZATION
mixtures I_LOCATION/I_ORGANIZATION
( O
natives B_PERSON/B_BIO
, O
exotics B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
native B_PERSON/B_LOCATION
- O
exotic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mixtures I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O
. O

fungal B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biomass B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inside O
roots B_BIO/B_LOCATION
was O
affected O
independently O
by O
plant B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
richness I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
mixture B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
root B_BIO
fungal I_BIO
community I_BIO
composition I_BIO
was O
affected O
only O
by O
plant B_BIO/B_LOCATION
richness B_BIO/I_LOCATION
. O

Extraradical B_PERSON/B_ORGANIZATION
networks I_PERSON/I_ORGANIZATION
also O
increased O
in O
size B_MEASURE/B_LOCATION
with O
plant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
richness I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
plant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
biomass B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
a O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
plant B_BIO/B_LOCATION
mixture B_BIO/I_LOCATION
, O
with O
natives B_PERSON/B_BIO
consistently O
smaller B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
exotics B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
native B_PERSON/B_LOCATION
- O
exotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mixtures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
intermediate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Plant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
have O
an O
impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
belowground B_LOCATION/B_BIO
community I_LOCATION/I_BIO
primarily O
through O
their O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
diversity B_BIO/B_LOCATION
, O
at O
least O
in O
the O
short B_PERSON/B_MEASURE
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Disentangling O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
diversity B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
invasion B_MEASURE/B_DISEASE
on O
belowground B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
microbial B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
communities B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
can O
help O
us O
to O
understand O
both O
the O
controllers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
belowground B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
resilience I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
mechanisms B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
colonization I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
spread B_DISEASE/B_ORGANISM_FUNCTION
of O
exotic B_BIO/B_DISEASE
plants I_BIO/I_DISEASE
. O

Neuropeptide O
precursor O
gene O
discovery O
in O
the O
Chagas O
disease O
vector O
Rhodnius B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolixus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

We O
show O
a O
straightforward O
workflow O
combining O
homology O
search O
in O
Rhodnius B_PERSON/B_SPECIES[BIO]
prolixus I_PERSON/I_SPECIES[BIO]
genome O
sequence O
with O
cloning O
by O
rapid O
amplification O
of O
cDNA O
ends O
and O
mass O
spectrometry O
. O

We O
have O
identified O
32 B_GENE/B_BIO
genes I_GENE/I_BIO
and O
their O
transcripts B_GENE/B_LOCATION
that O
encode O
a O
number B_MEASURE/B_LOCATION
of O
neuropeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
precursors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
leading O
to O
194 B_DISEASE/B_ORGANISM_FUNCTION
putative I_DISEASE/I_ORGANISM_FUNCTION
peptides I_DISEASE/I_ORGANISM_FUNCTION
. O

We O
validated O
by O
mass O
spectrometry O
82 O
of O
those O
predicted O
neuropeptides O
in O
the O
brain O
of O
R B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolixus I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
achieve O
the O
first O
comprehensive O
genomic O
, O
transcriptomic O
and O
neuropeptidomic O
analysis O
of O
an O
insect O
disease O
vector O
. O

comparisons O
of O
available O
insect O
neuropeptide O
sequences O
revealed O
that O
the O
R B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolixus I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome O
contains O
most O
of O
the O
conserved O
neuropeptides O
in O
insects O
, O
many O
of O
them O
displaying O
specific O
features O
at O
the O
sequence O
level O
. O

Some O
gene O
families O
reported O
here O
are O
identified O
for O
the O
first O
time O
in O
the O
order O
Hemiptera O
, O
a O
highly O
biodiverse O
group O
of O
insects O
that O
includes O
many O
human B_SPECIES[BIO]
, O
animal O
and O
plant O
disease O
agents O
. O

The O
alphaherpesvirus B_GENE/B_BIO
US3 I_GENE/I_BIO
/ O
ORF66 B_NUMBER[MEASURE]/B_PERSON
protein I_NUMBER[MEASURE]/I_PERSON
kinases O
direct B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_LOCATION
phosphorylation I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_LOCATION
of O
the O
nuclear B_GENE
matrix I_GENE
protein I_GENE
matrin I_GENE
3 I_GENE
. O

The O
protein O
kinase O
found O
in O
the O
short O
region O
of O
alphaherpesviruses O
, O
termed O
US3 O
in O
herpes B_DISEASE/B_VIRUS[BIO]
simplex B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
type B_DISEASE/I_VIRUS[BIO]
1 B_DISEASE/I_VIRUS[BIO]
( O
HSV B_VIRUS[BIO]/B_DISEASE
- I_VIRUS[BIO]/I_DISEASE
1 I_VIRUS[BIO]/I_DISEASE
) O
and O
pseudorabies B_DISEASE/B_PROTEIN[GENE]
virus B_DISEASE/I_PROTEIN[GENE]
( O
PRV B_PROTEIN[GENE]/B_DISEASE
) O
and O
ORF66 O
in O
varicella B_DISEASE/B_VIRUS[BIO]
- B_DISEASE/I_VIRUS[BIO]
zoster B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
VZV B_VIRUS[BIO]/B_DISEASE
) O
, O
affects O
several O
viral O
and O
host O
cell O
processes O
, O
and O
its O
specific O
targets O
remain O
an O
area O
of O
active O
investigation O
. O

Reports O
suggesting O
that O
HSV B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
1 B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
US3 O
substrates O
overlap O
with O
those O
of O
cellular O
protein O
kinase O
A O
( O
PKA O
) O
prompted O
the O
use O
of O
an O
antibody O
specific O
for O
phosphorylated O
PKA O
substrates O
to O
identify O
US3 O
/ O
ORF66 O
targets O
. O

HSV B_VIRUS[BIO]/B_MEASURE
- I_VIRUS[BIO]/I_MEASURE
1 I_VIRUS[BIO]/I_MEASURE
, O
VZV B_VIRUS[BIO]/B_DISEASE
, O
and O
PRV B_VIRUS[BIO]/B_DISEASE
induced O
very O
different O
substrate O
profiles O
that O
were O
US3 O
/ O
ORF66 O
kinase O
dependent O
. O

The O
predominant O
VZV B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
phosphorylated O
125 O
- O
kDa O
species O
was O
identified O
as O
matrin O
3 O
, O
one O
of O
the O
major O
nuclear O
matrix O
proteins O
. O

Matrin O
3 O
was O
also O
phosphorylated O
by O
HSV B_VIRUS[BIO]/B_DISEASE
- I_VIRUS[BIO]/I_DISEASE
1 I_VIRUS[BIO]/I_DISEASE
and O
PRV B_GENE/B_VIRUS[BIO]
in O
a O
US3 O
kinase O
- O
dependent O
manner O
and O
by O
VZV B_VIRUS[BIO]/B_DISEASE
ORF66 O
kinase O
at O
a O
novel O
residue O
( O
KRRRT150EE O
) O
. O

Since O
VZV B_VIRUS[BIO]/B_GENE
- O
directed O
T150 O
phosphorylation O
was O
not O
blocked O
by O
PKA O
inhibitors O
and O
was O
not O
induced O
by O
PKA O
activation O
, O
and O
since O
PKA O
predominantly O
targeted O
matrin O
3 O
S188 O
, O
it O
was O
concluded O
that O
phosphorylation O
by O
VZV B_VIRUS[BIO]/B_GENE
was O
PKA O
independent O
. O

However O
, O
purified O
VZV B_SPECIES[BIO]
ORF66 O
kinase O
did O
not O
phosphorylate O
matrin O
3 O
in O
vitro O
, O
suggesting O
that O
additional O
cellular O
factors O
were O
required O
. O

In O
VZV B_DISEASE/B_VIRUS[BIO]
- O
infected O
cells O
in O
the O
absence O
of O
the O
ORF66 O
kinase O
, O
matrin O
3 O
displayed O
intranuclear O
changes O
, O
while O
matrin O
3 O
showed O
a O
pronounced O
cytoplasmic O
distribution O
in O
late O
- O
stage O
cells O
infected O
with O
US3 O
- O
negative O
HSV B_VIRUS[BIO]/B_GENE
- I_VIRUS[BIO]/I_GENE
1 I_VIRUS[BIO]/I_GENE
or O
PRV B_VIRUS[BIO]/B_DISEASE
. O

This O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
identifies O
phosphorylation B_TIME[MEASURE]/B_LOCATION
of O
the O
nuclear B_GENE
matrix I_GENE
protein I_GENE
matrin I_GENE
3 I_GENE
as O
a O
new B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conserved I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
kinase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Small O
- O
molecule O
inhibition O
of O
human B_DISEASE/B_VIRUS[BIO]
immunodeficiency B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
type B_DISEASE/I_VIRUS[BIO]
1 B_DISEASE/I_VIRUS[BIO]
infection O
by O
virus O
capsid O
destabilization O
. O

Human B_DISEASE
immunodeficiency I_DISEASE
virus I_DISEASE
type I_DISEASE
1 I_DISEASE
( O
HIV B_DISEASE
- I_DISEASE
1 I_DISEASE
) O
infection O
is O
dependent O
on O
the O
proper O
disassembly O
of O
the O
viral O
capsid O
, O
or O
& O
quot O
; O
uncoating O
, O
& O
quot O
; O
in O
target O
cells O
. O

The O
HIV B_VIRUS[BIO]/B_DISEASE
- I_VIRUS[BIO]/I_DISEASE
1 I_VIRUS[BIO]/I_DISEASE
capsid O
consists O
of O
a O
conical O
multimeric O
complex O
of O
the O
viral O
capsid O
protein O
( O
CA O
) O
arranged O
in O
a O
hexagonal O
lattice O
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
CA B_GENE/B_DISEASE
that O
destabilize O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
capsid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
result O
in O
impaired B_DISEASE
infection I_DISEASE
owing O
to O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
reverse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
target B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
here O
the O
mechanism O
of O
action O
of O
a O
small O
molecule O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
, O
PF O
- O
3450074 O
( O
PF74 O
) O
, O
which O
targets O
CA O
. O

PF74 O
acts O
at O
an O
early O
stage O
of O
HIV B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
infection O
and O
inhibits O
reverse O
transcription O
in O
target O
cells O
. O

We O
show O
that O
PF74 O
binds O
specifically O
to O
HIV B_DISEASE/B_GENE
- I_DISEASE/I_GENE
1 I_DISEASE/I_GENE
particles O
, O
and O
substitutions O
in O
CA O
that O
confer O
resistance O
to O
the O
compound O
prevent O
binding O
. O

A O
single O
point O
mutation O
in O
CA O
that O
stabilizes O
the O
HIV B_VIRUS[BIO]/B_PROTEIN[GENE]
- B_VIRUS[BIO]/I_PROTEIN[GENE]
1 B_VIRUS[BIO]/I_PROTEIN[GENE]
core O
also O
conferred O
strong O
resistance O
to O
the O
virus O
without O
inhibiting O
compound O
binding O
. O

Treatment O
of O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
particles O
or O
purified O
cores O
with O
PF74 O
destabilized O
the O
viral O
capsid O
in O
vitro O
. O

Furthermore O
, O
the O
compound O
induced O
the O
rapid O
dissolution O
of O
the O
HIV B_DISEASE/B_VIRUS[BIO]
- B_DISEASE/I_VIRUS[BIO]
1 B_DISEASE/I_VIRUS[BIO]
capsid O
in O
target O
cells O
. O

PF74 O
antiviral O
activity O
was O
promoted O
by O
binding O
of O
the O
host O
protein O
cyclophilin O
A O
to O
the O
HIV B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
capsid O
, O
and O
PF74 O
and O
cyclosporine O
exhibited O
mutual O
antagonism O
. O

Our O
data O
suggest O
that O
PF74 O
triggers O
premature O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
uncoating O
in O
target O
cells O
, O
thereby O
mimicking O
the O
activity O
of O
the O
retrovirus O
restriction O
factor O
TRIM5alpha O
. O

This O
study O
highlights O
uncoating O
as O
a O
step O
in O
the O
HIV B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
life O
cycle O
that O
is O
susceptible O
to O
small O
molecule O
intervention O
. O

PB2 O
residue O
158 O
is O
a O
pathogenic O
determinant O
of O
pandemic O
H1N1 B_DISEASE/B_PROTEIN[GENE]
and O
H5 B_DISEASE/B_BIO
influenza I_DISEASE/I_BIO
a I_DISEASE/I_BIO
viruses I_DISEASE/I_BIO
in O
mice B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Influenza B_BACTERIUM[BIO]/B_DISEASE
A I_BACTERIUM[BIO]/I_DISEASE
viruses I_BACTERIUM[BIO]/I_DISEASE
are O
human B_PERSON/B_SPECIES[BIO]
and O
animal O
pathogens O
that O
cause O
morbidity O
and O
mortality O
, O
which O
range O
from O
mild O
to O
severe O
. O

The O
2009 O
H1N1 B_DISEASE
pandemic O
was O
caused O
by O
the O
emergence O
of O
a O
reassortant O
H1N1 B_DISEASE/B_PROTEIN[GENE]
subtype O
( O
H1N1pdm B_DISEASE/B_PROTEIN[GENE]
) O
influenza B_DISEASE/B_GENE
A B_DISEASE/I_GENE
virus B_DISEASE/I_GENE
containing O
gene O
segments O
that O
originally O
circulated O
in O
human B_SPECIES[BIO]/B_LOCATION
, O
avian O
, O
and O
swine B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus O
reservoirs O
. O

The O
molecular O
determinants O
of O
replication O
and O
pathogenesis O
of O
H1N1pdm B_DISEASE
viruses I_DISEASE
in O
humans B_SPECIES[BIO]
and O
other O
mammals O
are O
poorly O
understood O
. O

Therefore O
, O
we O
set O
out O
to O
elucidate O
viral O
determinants O
critical O
to O
the O
pathogenesis O
of O
this O
novel O
reassortant O
using O
a O
mouse B_SPECIES[BIO]/B_DISEASE
model O
. O

We O
found O
that O
a O
glutamate O
- O
to O
- O
glycine O
substitution O
at O
residue O
158 O
of O
the O
PB2 O
gene O
( O
PB2 O
- O
E158G O
) O
increased O
the O
morbidity O
and O
mortality O
of O
the O
parental O
H1N1pdm B_SPECIES[BIO]/B_PERSON
virus I_SPECIES[BIO]/I_PERSON
. O

Results O
from O
mini O
- O
genome O
replication O
assays O
in O
human B_PERSON/B_SPECIES[BIO]
cells O
and O
virus O
titration O
in O
mouse B_SPECIES[BIO]/B_DISEASE
tissues O
demonstrated O
that O
PB2 O
- O
E158G O
is O
a O
pathogenic O
determinant O
, O
because O
it O
significantly O
increases O
viral O
replication O
rates O
. O

The O
virus O
load O
in O
PB2 O
- O
E158G O
- O
infected O
mouse B_SPECIES[BIO]/B_DISEASE
lungs O
was O
1 O
, O
300 O
- O
fold O
higher O
than O
that O
of O
the O
wild O
- O
type O
virus O
. O

Our O
data O
also O
show O
that O
PB2 O
- O
E158G O
had O
a O
much O
stronger O
influence O
on O
the O
RNA O
replication O
and O
pathogenesis O
of O
H1N1pdm B_DISEASE
viruses I_DISEASE
than O
PB2 O
- O
E627K O
, O
which O
is O
a O
known O
pathogenic O
determinant O
. O

remarkably O
, O
PB2 O
- O
E158G O
substitutions O
also O
altered O
the O
pathotypes O
of O
two O
avian O
H5 B_DISEASE/B_BIO
viruses I_DISEASE/I_BIO
in O
mice B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
indicating O
that O
this O
residue O
impacts O
genetically O
divergent O
influenza B_BIO/B_DISEASE
A I_BIO/I_DISEASE
viruses I_BIO/I_DISEASE
and O
suggesting O
that O
this O
region O
of O
PB2 O
could O
be O
a O
new O
antiviral O
target O
. O

collectively O
, O
the O
data O
presented O
in O
this O
study O
demonstrate O
that O
PB2 O
- O
E158G O
is O
a O
novel O
pathogenic O
determinant O
of O
influenza B_DISEASE/B_BIO
A I_DISEASE/I_BIO
viruses I_DISEASE/I_BIO
in O
the O
mouse B_SPECIES[BIO]/B_DISEASE
model O
. O

We O
speculate O
that O
PB2 O
- O
E158G O
may O
be O
important O
in O
the O
adaptation O
of O
avian O
PB2 O
genes O
to O
other O
mammals O
, O
and O
blast O
sequence O
analysis O
identified O
a O
naturally O
occurring O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
H1N1pdm I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
isolate O
that O
has O
this O
substitution O
. O

Therefore O
, O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
surveillance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O
include O
scrutiny B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
region B_LOCATION/B_MEASURE
of O
PB2 B_GENE/B_LOCATION
because O
of O
its O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pathogenesis B_DISEASE/B_BIO
. O

Hepatitis B_DISEASE
C I_DISEASE
virus I_DISEASE
NS2 O
protein O
serves O
as O
a O
scaffold O
for O
virus O
assembly O
by O
interacting O
with O
both O
structural O
and O
nonstructural O
proteins O
. O

Many O
aspects O
of O
the O
assembly O
of O
hepatitis B_DISEASE/B_VIRUS[BIO]
C B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
HCV B_DISEASE
) O
remain O
incompletely O
understood O
. O

To O
characterize O
the O
role O
of O
NS2 O
in O
the O
production O
of O
infectious O
virus O
, O
we O
determined O
NS2 O
interaction O
partners O
among O
other O
HCV B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proteins O
during O
productive O
infection O
. O

Pulldown B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
NS2 B_GENE/B_PERSON
forms I_GENE/I_PERSON
complexes I_GENE/I_PERSON
with O
both O
structural B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
nonstructural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
E1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
E2 O
, O
p7 O
, O
NS3 B_PROTEIN[GENE]
, O
and O
NS5A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

confocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
demonstrated O
that O
NS2 B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
colocalizes I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O
E1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
E2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
NS5A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
dot B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
like B_LOCATION/B_MEASURE
structures I_LOCATION/I_MEASURE
near O
lipid B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
droplets I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
NS5A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
did O
not O
coprecipitate B_LOCATION/B_MEASURE
with O
E2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
interacted O
only O
weakly O
with O
NS3 B_GENE
in O
pulldown B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
assays B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Also O
, O
there O
was O
no O
demonstrable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
p7 B_GENE
and O
E2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
NS3 B_GENE
in O
such B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
NS2 B_GENE/B_SPECIES[BIO]
is O
uniquely O
capable B_PERSON
of O
interacting O
with O
both O
structural B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
nonstructural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Among O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
p7 B_PROTEIN[GENE]
, O
NS2 B_PROTEIN[GENE]/B_SPECIES[BIO]
, O
and O
NS3 B_PROTEIN[GENE]/B_MEASURE
that O
prevent O
production B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
infectious B_DISEASE/B_GENE
virus B_DISEASE/I_GENE
, O
only O
p7 B_NUMBER[MEASURE]/B_PERSON
mutations I_NUMBER[MEASURE]/I_PERSON
significantly O
reduced O
NS2 B_GENE/B_SPECIES[BIO]
- O
mediated O
protein B_DISEASE/B_GENE
interactions I_DISEASE/I_GENE
. O

These O
p7 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
altered O
the O
intracellular B_LOCATION
distribution I_LOCATION
of O
NS2 B_PROTEIN[GENE]/B_SPECIES[BIO]
and O
E2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
appeared O
to O
modulate O
the O
membrane B_LOCATION/B_TIME[MEASURE]
topology B_LOCATION/I_TIME[MEASURE]
of O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_MEASURE
domain I_LOCATION/I_MEASURE
of O
NS2 B_PROTEIN[GENE]/B_SPECIES[BIO]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
NS2 B_DISEASE/B_LOCATION
acts B_DISEASE/I_LOCATION
to O
coordinate O
virus B_DISEASE/B_ORGANISM_FUNCTION
assembly I_DISEASE/I_ORGANISM_FUNCTION
by O
mediating O
interactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
envelope B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
NS3 B_PROTEIN[GENE]/B_DISEASE
and O
NS5A B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
within O
replication B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjacent B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
droplets B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
where O
virus B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
particle B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
assembly B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
is O
thought O
to O
occur O
. O

p7 O
may O
play O
an O
accessory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
regulating O
NS2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
topology I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
NS2 B_GENE/B_SPECIES[BIO]
- O
mediated O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
therefore O
NS2 B_DISEASE/B_GENE
function I_DISEASE/I_GENE
. O

alcohol O
dehydrogenase O
and O
hydrogenase O
transcript O
fluctuations O
during O
a O
day O
- O
night O
cycle O
in O
Chlamydomonas B_BIO
reinhardtii I_BIO
: O
the O
role O
of O
anoxia O
. O

* O
The O
unicellular O
green O
alga O
Chlamydomonas B_BIO
reinhardtii I_BIO
contains O
two O
iron O
( O
Fe O
) O
- O
hydrogenases O
which O
are O
responsible O
for O
hydrogen O
production O
under O
anoxia O
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
the O
patterns B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
expression B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alcohol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
typical B_BACTERIUM[BIO]/B_ENZYME[GENE]
anaerobic B_BACTERIUM[BIO]/I_ENZYME[GENE]
gene B_BACTERIUM[BIO]/I_ENZYME[GENE]
in O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
of O
the O
hydrogenases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HYD1 B_PROTEIN[GENE]/B_DISEASE
, O
HYD2 B_PROTEIN[GENE]/B_DISEASE
) O
and O
of O
the O
genes B_GENE/B_LOCATION
responsible I_GENE/I_LOCATION
for O
their O
maturation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
HYDEF B_DISEASE/B_GENE
, O
HYDG B_PROTEIN[GENE]/B_DISEASE
) O
, O
were O
analysed O
. O

* B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
The O
expression B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
analysed O
by O
real B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_MEASURE/B_BIO
reverse I_MEASURE/I_BIO
- O
transcription B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
Chlamydomonas B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
cultures B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
during O
the O
day B_TIME[MEASURE]
- O
night B_TIME[MEASURE]/B_ENT
cycle I_TIME[MEASURE]/I_ENT
, O
as O
well O
as O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
availability B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O
that O
ADH1 B_GENE
, O
HYD1 B_GENE
, O
HYD2 B_GENE/B_DISEASE
, O
HYDEF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
HYDG B_GENE
were O
expressed O
following O
precise B_TIME[MEASURE]
day I_TIME[MEASURE]
- O
night B_TIME[MEASURE]/B_LOCATION
fluctuations I_TIME[MEASURE]/I_LOCATION
. O

ADH1 B_GENE
and O
HYD2 B_GENE
were O
modulated O
by O
the O
day B_TIME[MEASURE]/B_LOCATION
- O
night B_TIME[MEASURE]/B_LOCATION
cycle B_TIME[MEASURE]/I_LOCATION
. O

Low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plays O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
HYD1 B_GENE
, O
HYDEF B_DISEASE/B_GENE
and O
HYDG B_GENE/B_LOCATION
, O
while O
ADH1 B_GENE/B_DISEASE
and O
HYD2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
relatively O
insensitive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
oxygen B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
availability B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
The O
regulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
anaerobic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Chlamydomonas B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
only O
partly O
explained O
by O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
anoxia B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cell B_MEASURE/B_COLOR
cycle I_MEASURE/I_COLOR
and O
light B_COLOR
- O
dark B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cycles I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
are O
equally O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulatory B_LOCATION/B_ORGANIZATION
network I_LOCATION/I_ORGANIZATION
modulating O
the O
anaerobic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O
Chlamydomonas B_BIO
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
Virus B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
counter I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
baculovirus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
quantitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
utility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
virus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
quantitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
the O
virus B_ORGANIZATION/B_LOCATION
Counter I_ORGANIZATION/I_LOCATION
, O
was O
evaluated O
in O
a O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducted O
at O
three B_LOCATION/B_ENT
sites I_LOCATION/I_ENT
. O

This O
instrument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
a O
substantially O
improved O
version B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
academic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
described O
previously O
by O
Stoffel B_PERSON/B_LOCATION
and O
Rowlen B_PERSON
( O
2005a B_TIME[MEASURE]
) O
. O

The O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
hydrodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
focusing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
, O
a O
self B_PERSON/B_LOCATION
- O
contained O
fluidics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
customized B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
has O
resulted O
in O
a O
commercially O
viable B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Baculovirus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
provided O
by O
protein B_PERSON/B_ORGANIZATION
Sciences I_PERSON/I_ORGANIZATION
Corporation I_PERSON/I_ORGANIZATION
and O
blinded O
to O
InDevR B_ORGANIZATION/B_LOCATION
and O
Baylor B_LOCATION/B_ORGANIZATION
College B_LOCATION/I_ORGANIZATION
of O
Medicine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

protein B_ORGANIZATION/B_LOCATION
Sciences B_ORGANIZATION/I_LOCATION
Corporation B_ORGANIZATION/I_LOCATION
and O
Baylor B_LOCATION/B_ORGANIZATION
College B_LOCATION/I_ORGANIZATION
of O
Medicine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analyzed O
the O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
by O
plaque B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
InDevR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyzed O
the O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
using O
the O
Virus B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counter I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dilution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
stock B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viruses I_BIO
into O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
buffer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O
for O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
measured B_MEASURE/B_PERSON
versus B_MEASURE/I_PERSON
intended O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Direct B_MEASURE/B_PERSON
log I_MEASURE/I_PERSON
- O
scale B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
pooled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Virus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
counter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
pooled B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
plaque I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O
a O
linear B_MEASURE/B_LOCATION
relationship I_MEASURE/I_LOCATION
( O
slope B_PROTEIN[GENE]/B_MEASURE
= O
1 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
, O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE
) O
= O
0 B_MEASURE
. O
86 B_MEASURE
) O
with O
statistically O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Pearson I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
correlation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
r B_PROTEIN[GENE]/B_OTHER
= O
0 B_MEASURE
. O
93 B_MEASURE
, O
p O
& O
Lt B_PERSON/B_GENE
; O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
. O

Applied O
biotechnology O
for O
production O
of O
immunoglobulin O
Y O
specific O
to O
hepatitis B_DISEASE
A I_DISEASE
virus I_DISEASE
. O

A O
new O
protocol O
for O
producing O
polyclonal O
antibody O
against O
hepatitis B_DISEASE
A I_DISEASE
virus I_DISEASE
( O
HAV B_DISEASE
) O
is O
described O
. O

Twenty O
hens B_PERSON/B_SPECIES[BIO]
were O
immunized O
three O
times O
with O
a O
commercial O
HAV B_DISEASE/B_GENE
vaccine O
and O
HAV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
cell O
culture O
with O
three O
types O
of O
adjuvants O
: O
CpG O
oligodeoxynucleotides O
( O
CpG O
- O
ODN O
) O
, O
incomplete O
Freund O
' O
s O
adjuvant O
and O
an O
alum O
adjuvant O
. O

In O
each O
of O
the O
last O
two O
booster O
inoculations O
, O
blood O
from O
the O
birds O
was O
collected O
and O
tested O
for O
HAV B_DISEASE
antibodies O
. O

egg B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yolk I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
separated O
from O
egg B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
white I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Y O
( O
IgY B_PROTEIN[GENE]/B_LOCATION
) O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
then O
purified O
by O
polyethylene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6000 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mean B_MEASURE
yield I_MEASURE
of O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
yolk B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O
22 B_MEASURE
. O
62 B_MEASURE
mg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
. O

specific O
activity O
of O
the O
antibody O
was O
tested O
using O
commercial O
ELISA O
, O
Western O
blotting O
, O
and O
in O
vitro O
neutralization O
assay O
demonstrating O
that O
anti O
- O
HAV B_SPECIES[BIO]/B_DISEASE
IgY O
bound O
specifically O
. O

After O
the O
first O
immunization O
, O
birds O
immunized O
with O
HAV B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
cell O
culture O
plus O
incomplete O
Freund O
' O
s O
adjuvant O
with O
/ O
without O
CpG O
- O
ODN O
showed O
highest O
levels O
of O
anti O
- O
HAV B_DISEASE
IgY O
in O
serum O
( O
p O
& O
Lt O
; O
0 O
. O
05 O
) O
. O

viral O
combination O
with O
CpG O
- O
ODN O
resulted O
in O
early O
response O
of O
anti O
- O
HAV B_GENE/B_DISEASE
serum O
in O
hens B_PERSON/B_SPECIES[BIO]
, O
reflecting O
the O
amount O
of O
IgY O
transferred O
to O
the O
egg O
yolk O
( O
p O
& O
Lt O
; O
0 O
. O
05 O
) O
. O

The O
results O
suggest O
that O
egg O
yolk O
may O
be O
a O
large O
scale O
source O
of O
specific O
antibodies O
against O
hepatitis B_DISEASE/B_VIRUS[BIO]
A B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
. O

Further B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
yet O
to O
be O
tested O
. O

Cotterillia B_BIO/B_SEQUENCE[MEASURE]
bromelicola B_BIO/I_SEQUENCE[MEASURE]
nov B_BIO/I_SEQUENCE[MEASURE]
. B_BIO/I_SEQUENCE[MEASURE]
gen B_BIO/I_SEQUENCE[MEASURE]
. B_BIO/I_SEQUENCE[MEASURE]
, B_BIO/I_SEQUENCE[MEASURE]
nov B_BIO/I_SEQUENCE[MEASURE]
. B_BIO/I_SEQUENCE[MEASURE]
spec B_BIO/I_SEQUENCE[MEASURE]
. B_BIO/I_SEQUENCE[MEASURE]
, O
a O
gonostomatid O
ciliate O
( O
Ciliophora O
, O
Hypotricha O
) O
from O
tank O
bromeliads O
( O
Bromeliaceae O
) O
with O
de O
novo O
originating O
dorsal O
kineties O
. O

Cotterillia B_BIO
bromelicola I_BIO
nov I_BIO
. I_BIO
gen I_BIO
. I_BIO
, I_BIO
nov I_BIO
. I_BIO
spec I_BIO
. I_BIO
. O

was O
discovered O
in O
the O
tanks O
of O
the O
Mexican O
bromeliad O
Tillandsia B_BIO/B_LOCATION
heterophylla B_BIO/I_LOCATION
. O

Its O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
ontogenesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
18S B_GENE/B_ORGANISM_FUNCTION
rDNA B_GENE/I_ORGANISM_FUNCTION
were O
studied O
with O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cotterillia B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
has O
many O
cirral O
rows O
on O
both O
sides O
of O
the O
body O
. O

uniquely O
, O
and O
thus O
used O
to O
diagnose O
the O
new O
genus O
Cotterillia B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
it O
has O
dorsal O
kineties O
originating O
de O
novo O
, O
producing O
neokinetal O
waves O
where O
the O
parental O
dorsal O
kineties O
reorganize O
to O
& O
quot O
; O
combined O
rows O
& O
quot O
; O
, O
consisting O
of O
dorsal O
bristles O
anteriorly O
and O
of O
cirri O
posteriorly O
. O

Thus O
, O
up O
to O
four B_NUMBER[MEASURE]
generations I_NUMBER[MEASURE]
of O
bristles B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cirri B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
occur O
on O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
body B_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
surface B_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

Cotterillia B_PERSON/B_BIO
bromelicola I_PERSON/I_BIO
has O
a O
gonostomatid O
body O
and O
adoral O
zone O
of O
membranelles O
, O
while O
the O
dense O
ciliature O
and O
the O
neokinetal O
waves O
resemble O
kahliellid O
hypotrichs O
. O

However O
, O
the O
de O
novo O
origin O
of O
anlage O
1 O
and O
the O
molecular O
analyses O
show O
convincingly O
that O
Cotterillia B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
belongs O
to O
the O
Gonostomatidae O
Small O
and O
Lynn O
, O
1985 O
, O
for O
which O
an O
improved O
diagnosis O
is O
provided O
. O

Thus O
, O
neokinetal B_PERSON/B_LOCATION
waves I_PERSON/I_LOCATION
originated O
several B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
independently O
. O

The O
molecular O
differences O
between O
Trachelostyla O
, O
Gonostomum O
, O
and O
Cotterillia B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
are O
small O
( O
= O
< O
5 O
% O
) O
compared O
to O
their O
distinct O
morphologies O
and O
ontogeneses O
, O
suggesting O
that O
the O
18S O
rDNA O
underestimates O
generic O
diversity O
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
combined O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
ontogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigations B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
unravel O
the O
complex B_ORGANIZATION/B_LOCATION
phylogeny I_ORGANIZATION/I_LOCATION
and O
evolution B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypotrich B_BIO
ciliates I_BIO
. O

The O
nodulation O
of O
alfalfa O
by O
the O
acid O
- O
tolerant O
Rhizobium B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sp I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
strain I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
LPU83 I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
does O
not O
require O
sulfated O
forms O
of O
lipochitooligosaccharide O
nodulation O
signals O
. O

The O
induction B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
root B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nodules I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
majority B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
rhizobia B_BIO
has O
a O
strict B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
requirement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
secretion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
symbiosis B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lipochitooligosaccharides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
nodulation B_DISEASE/B_PROTEIN[GENE]
factors B_DISEASE/I_PROTEIN[GENE]
[ B_DISEASE/I_PROTEIN[GENE]
NFs B_DISEASE/I_PROTEIN[GENE]
] B_DISEASE/I_PROTEIN[GENE]
) O
. O

The O
nature B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
chemical B_DISEASE_ADJECTIVE[DISEASE]
substitution I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
NFs B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
depends O
on O
the O
particular B_BIO/B_LOCATION
rhizobium B_BIO/I_LOCATION
and O
contributes O
to O
the O
host B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imparted O
by O
the O
NFs B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
present O
here O
a O
description O
of O
the O
genetic O
organization O
of O
the O
nod O
gene O
cluster O
and O
the O
characterization O
of O
the O
chemical O
structure O
of O
the O
NFs O
associated O
with O
the O
broad O
- O
host O
- O
range O
Rhizobium B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sp I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
strain I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
LPU83 I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
bacterium O
capable O
of O
nodulating O
at O
least O
alfalfa B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
bean O
, O
and O
Leucena B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
leucocephala I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
nod B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
located O
on O
the O
plasmid B_GENE/B_LOCATION
pLPU83b I_GENE/I_LOCATION
. O

The O
organization O
of O
the O
cluster O
showed O
synteny O
with O
those O
of O
the O
alfalfa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
nodulating O
rhizobia O
, O
Sinorhizobium B_BIO
meliloti I_BIO
and O
Sinorhizobium B_BIO/B_GENE
medicae I_BIO/I_GENE
. O

Interestingly O
, O
the O
strongest O
sequence O
similarity O
observed O
was O
between O
the O
partial O
nod O
sequences O
of O
Rhizobium B_BIO
mongolense I_BIO
USDA I_BIO
1844 I_BIO
and O
the O
corresponding O
LPU83 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nod O
genes O
sequences O
. O

The O
phylogenetic O
analysis O
of O
the O
intergenic O
region O
nodEG O
positions O
strain O
LPU83 B_MEASURE
and O
the O
type O
strain O
R B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mongolense I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1844 I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
same O
branch O
, O
which O
indicates O
that O
Rhizobium B_PERSON/B_LOCATION
sp I_PERSON/I_LOCATION
. I_PERSON/I_LOCATION
strain I_PERSON/I_LOCATION
LPU83 I_PERSON/I_LOCATION
might O
represent O
an O
early O
alfalfa B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
nodulating O
genotype O
. O

The O
NF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
for O
the O
wild B_BIO
- O
type B_BIO/B_GENE
strain I_BIO/I_GENE
consist O
of O
a O
trimeric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
tetrameric B_BACTERIUM[BIO]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
pentameric B_LOCATION/B_PROTEIN[GENE]
chitin B_LOCATION/I_PROTEIN[GENE]
backbone B_LOCATION/I_PROTEIN[GENE]
that O
shares O
some O
substitutions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
both O
alfalfa B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
bean B_BIO/B_DISEASE
- O
nodulating O
rhizobia B_BIO/B_PROTEIN[GENE]
. O

remarkably O
, O
while O
in O
strain O
LPU83 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
most O
of O
the O
NFs O
were O
sulfated O
in O
their O
reducing O
terminal O
residue O
, O
none O
of O
the O
NFs O
isolated O
from O
the O
nodH O
mutant O
LPU83 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
sulfated O
. O

The O
evidence O
obtained O
supports O
the O
notion O
that O
the O
sulfate O
decoration O
of O
NFs O
in O
LPU83 B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
necessary O
for O
alfalfa B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nodulation O
. O

The O
Rcs O
signal O
transduction O
pathway O
is O
triggered O
by O
enterobacterial O
common O
antigen O
structure O
alterations O
in O
Serratia B_SPECIES[BIO]
marcescens I_SPECIES[BIO]
. O

The O
enterobacterial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
common I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
ECA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
is O
a O
highly O
conserved B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
exopolysaccharide I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
Gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
whose O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
largely O
uncharacterized B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. O

In O
a O
previous O
work O
, O
we O
have O
demonstrated O
that O
disrupting O
the O
integrity O
of O
the O
ECA O
biosynthetic O
pathway O
imposed O
severe O
deficiencies O
to O
the O
Serratia B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
marcescens B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
motile O
( O
swimming O
and O
swarming O
) O
capacity O
. O

In O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
show O
that O
alterations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
ECA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activate O
the O
Rcs B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phosphorelay I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
results O
in O
the O
repression B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
the O
flagellar B_GENE/B_LOCATION
biogenesis I_GENE/I_LOCATION
regulatory I_GENE/I_LOCATION
cascade I_GENE/I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
a O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
wec B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cluster B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strains B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
provoke O
the O
disruption B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
ECA B_GENE/B_BACTERIUM[BIO]
biosynthesis I_GENE/I_BACTERIUM[BIO]
at O
different B_LOCATION/B_MEASURE
levels I_LOCATION/I_MEASURE
of O
the O
pathway B_DISEASE/B_GENE
, O
suggests O
that O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
periplasmic B_GENE/B_MEASURE
ECA I_GENE/I_MEASURE
cyclic I_GENE/I_MEASURE
structure I_GENE/I_MEASURE
could O
constitute O
a O
potential B_DISEASE_ADJECTIVE[DISEASE]
signal I_DISEASE_ADJECTIVE[DISEASE]
detected O
by O
the O
RcsF B_DISEASE/B_GENE
- O
RcsCDB B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
phosphorelay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
also O
identify O
SMA1167 O
as O
a O
member O
of O
the O
S B_SPECIES[BIO]
. I_SPECIES[BIO]
marcescens I_SPECIES[BIO]
Rcs O
regulon O
and O
show O
that O
high O
osmolarity O
induces O
Rcs O
activity O
in O
this O
bacterium O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
perspective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
which O
to O
understand O
the O
phylogenetic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conservation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ECA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
among O
enterobacteria B_BACTERIUM[BIO]
and O
the O
basis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
the O
virulence B_DISEASE_ADJECTIVE[DISEASE]
attenuation I_DISEASE_ADJECTIVE[DISEASE]
detected O
in O
wec B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
strains I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
other B_BIO
pathogenic I_BIO
bacteria I_BIO
. O

A O
cis O
- O
encoded O
antisense O
small O
RNA O
regulated O
by O
the O
HP0165 O
- O
HP0166 O
two O
- O
component O
system O
controls O
expression O
of O
ureB O
in O
Helicobacter B_BIO
pylori I_BIO
. O

expression O
of O
urease O
is O
essential O
for O
gastric O
colonization O
by O
Helicobacter B_BACTERIUM[BIO]/B_DISEASE
pylori I_BACTERIUM[BIO]/I_DISEASE
. O

The O
increased O
level B_MEASURE
of O
urease B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
in O
gastric B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
acidity B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
is O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
acid O
activation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
two B_NUMBER[MEASURE]/B_DISEASE
- O
component B_LOCATION/B_PERSON
system I_LOCATION/I_PERSON
( O
TCS B_DISEASE/B_LOCATION
) O
consisting O
of O
the O
membrane B_ENZYME[GENE]
sensor I_ENZYME[GENE]
HP0165 I_ENZYME[GENE]
and O
its O
response B_GENE/B_PERSON
regulator I_GENE/I_PERSON
, O
HP0166 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
regulates O
transcription B_NUMBER[MEASURE]/B_GENE
of O
the O
seven B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
of O
the O
urease B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
gene B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cluster B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

We O
now O
find O
that O
there O
are O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
major I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ureAB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
2 B_MEASURE
. O
7 B_MEASURE
- O
kb B_MEASURE/B_LOCATION
full I_MEASURE/I_LOCATION
- O
length B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ureAB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
1 B_MEASURE
. O
4 B_MEASURE
- O
kb B_GENE/B_MEASURE
truncated B_GENE/I_MEASURE
transcript B_GENE/I_MEASURE
lacking O
3 B_NUMBER[MEASURE]
' O
ureB B_BACTERIUM[BIO]/B_GENE
. O

acidic B_MEASURE/B_COLOR
pH I_MEASURE/I_COLOR
( O
pH O
4 B_MEASURE
. O
5 B_MEASURE
) O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
significant B_DISEASE/B_LOCATION
increase I_DISEASE/I_LOCATION
in O
transcription B_GENE
of O
ureAB B_GENE/B_BACTERIUM[BIO]
, O
while O
neutral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pH O
( O
pH B_MEASURE
7 I_MEASURE
. O
4 B_MEASURE
) O
increases O
the O
truncated O
1 B_MEASURE
. O
4 B_MEASURE
- O
kb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Northern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
sense B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
RNA I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
strand B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oligonucleotide B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
5 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cDNA B_GENE
ends I_GENE
detects O
an O
antisense B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
small I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
sRNA B_GENE/B_BIO
) O
encoded O
by O
the O
5 B_NUMBER[MEASURE]
' O
ureB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
noncoding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strand I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
consisting O
of O
- O
290 B_MEASURE
nucleotides I_MEASURE
( O
5 B_NUMBER[MEASURE]
' O
ureB B_BACTERIUM[BIO]/B_LOCATION
- O
sRNA B_GENE/B_BIO
) O
. O

Deletion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HP0165 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elevates O
the O
level B_MEASURE/B_LOCATION
of O
the O
truncated O
1 B_MEASURE
. O
4 B_MEASURE
- O
kb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
along O
with O
that O
of O
the O
5 B_MEASURE
' O
ureB B_BACTERIUM[BIO]/B_DISEASE
- O
sRNA B_GENE/B_BIO
at O
both O
pH B_MEASURE
7 I_MEASURE
. O
4 B_MEASURE
and O
pH B_MEASURE
4 I_MEASURE
. O
5 B_MEASURE
. O

Overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
5 B_MEASURE/B_LOCATION
' O
ureB B_BACTERIUM[BIO]/B_PROTEIN[GENE]
- O
sRNA B_GENE/B_BIO
increases O
the O
1 B_MEASURE
. O
4 B_MEASURE
- O
kb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
decreases O
the O
2 B_MEASURE
. O
7 B_MEASURE
- O
kb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
decreases O
urease B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

electrophoretic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mobility I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
shift O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shows I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
unphosphorylated O
HP0166 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
to O
the O
5 B_GENE/B_DISEASE
' B_GENE/I_DISEASE
ureB B_GENE/I_DISEASE
- O
sRNA B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
. O

The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
HP0165 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HP0166 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
TCS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O
both O
increase O
and O
decrease O
ureB B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
at O
low B_DISEASE_ADJECTIVE[DISEASE]
and O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pHs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
respectively O
, O
facilitates O
gastric B_DISEASE/B_ORGANISM_FUNCTION
habitation I_DISEASE/I_ORGANISM_FUNCTION
and O
colonization B_DISEASE/B_ORGANISM_FUNCTION
over O
the O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
intragastric B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pHs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experienced O
by O
the O
organism B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Non O
- O
structural O
protein O
1 O
( O
NS1 O
) O
antibody O
- O
based O
assays O
to O
differentiate O
West B_DISEASE
Nile I_DISEASE
( O
WN O
) O
virus O
from O
Japanese O
encephalitis O
virus O
infections O
in O
horses O
: O
effects O
of O
WN B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NS1 O
antibodies O
induced O
by O
inactivated O
WN O
vaccine O
. O

antibodies O
to O
non O
- O
structural O
protein O
1 O
( O
NS1 O
) O
of O
West O
Nile O
virus O
( O
WNV O
) O
have O
been O
used O
to O
differentiate O
WNV O
infection O
from O
infection O
by O
serologically O
cross O
- O
reactive O
flaviviruses O
, O
including O
Japanese B_VIRUS[BIO]/B_DISEASE
encephalitis B_VIRUS[BIO]/I_DISEASE
virus B_VIRUS[BIO]/I_DISEASE
( O
JEV O
) O
, O
in O
horses O
. O

However O
, O
since O
the O
inactivated O
West O
Nile O
( O
WN B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
vaccine O
has O
been O
reported O
to O
induce O
NS1 O
antibodies O
, O
there O
is O
concern O
about O
the O
reliability O
of O
using O
NS1 O
- O
based O
assays O
for O
testing O
vaccinated O
horses O
. O

Therefore O
, O
the O
effect O
of O
inactivated O
WN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vaccine O
- O
induced O
antibodies O
on O
an O
epitope O
- O
blocking O
ELISA O
and O
complement O
- O
dependent O
cytotoxicity O
( O
CDC O
) O
assay O
were O
investigated O
. O

Both O
assays O
are O
based O
on O
NS1 O
antibodies O
and O
were O
established O
previously O
to O
differentiate O
WNV B_DISEASE/B_VIRUS[BIO]
from O
JEV O
infections O
in O
horses O
. O

Groups B_ORGANIZATION/B_NUMBER[MEASURE]
of O
three B_SPECIES[BIO]/B_PERSON
horses I_SPECIES[BIO]/I_PERSON
were O
vaccinated O
with O
two B_NUMBER[MEASURE]/B_LOCATION
or O
three B_NUMBER[MEASURE]/B_PERSON
doses I_NUMBER[MEASURE]/I_PERSON
of O
a O
commercial B_ORGANIZATION/B_MEASURE
inactivated O
WN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
NS1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
by O
a O
conventional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ELISA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
the O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vaccination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

vaccine O
- O
induced O
NS1 O
antibodies O
were O
also O
detected O
by O
blocking O
ELISA O
and O
a O
CDC O
assay O
and O
affected O
the O
ability O
of O
these O
assays O
to O
differentiate O
WNV B_DISEASE/B_VIRUS[BIO]
from O
JEV B_DISEASE/B_BIO
infections O
. O

However O
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
less O
significant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CDC B_LOCATION
assay I_LOCATION
, O
where O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ensured O
effective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
more O
efficient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
infection B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
over O
vaccine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
the O
CDC B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
potentially O
attributable B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
different B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
IgG I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
isotype I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
profiles I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
redundant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
highly O
focused O
on O
V1V2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
early B_DISEASE/B_ORGANISM_FUNCTION
subtype I_DISEASE/I_ORGANISM_FUNCTION
C I_DISEASE/I_ORGANISM_FUNCTION
infection I_DISEASE/I_ORGANISM_FUNCTION
in O
a O
Zambian B_SPECIES[BIO]/B_PERSON
seroconverter I_SPECIES[BIO]/I_PERSON
. O

High O
- O
titer O
autologous O
neutralizing O
antibody O
responses O
have O
been O
demonstrated O
during O
early O
subtype O
C O
human B_DISEASE/B_VIRUS[BIO]
immunodeficiency B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
type B_DISEASE/I_VIRUS[BIO]
1 B_DISEASE/I_VIRUS[BIO]
( O
HIV B_DISEASE
- I_DISEASE
1 I_DISEASE
) O
infection O
. O

However O
, O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
response B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MAb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
level B_MEASURE/B_LOCATION
has O
only O
recently O
begun O
to O
be O
elucidated O
. O

Here O
we O
describe O
five B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
derived O
from O
a O
subtype B_DISEASE
C I_DISEASE
- O
infected O
seroconverter B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O
their O
neutralizing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
pseudoviruses B_BIO/B_GENE
that O
carry O
envelope B_DISEASE/B_GENE
glycoproteins B_DISEASE/I_GENE
from O
48 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
( O
0 B_TIME[MEASURE]
month I_TIME[MEASURE]
) O
, O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
and O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
the O
estimated O
time B_TIME[MEASURE]/B_LOCATION
of O
infection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O
that O
the O
MAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
arose O
from O
three B_DISEASE/B_VIRUS[BIO]
distinct B_DISEASE/I_VIRUS[BIO]
B B_DISEASE/I_VIRUS[BIO]
cell B_DISEASE/I_VIRUS[BIO]
clones B_DISEASE/I_VIRUS[BIO]
, O
and O
their O
pattern B_MEASURE/B_DISEASE
of O
neutralization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
compared O
to O
that O
in O
patient B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
plasma I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suggested O
that O
they O
circulated O
between O
2 B_NUMBER[MEASURE]
and O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
infection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

neutralization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
MAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
representative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
of O
each O
B B_GENE/B_MEASURE
cell I_GENE/I_MEASURE
clone I_GENE/I_MEASURE
was O
mapped O
to O
two B_LOCATION
residues I_LOCATION
: O
position B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
134 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
V1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
position B_MEASURE/B_PERSON
189 I_MEASURE/I_PERSON
in O
V2 B_PROTEIN[GENE]
. O

mutational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
cooperative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
between O
glycans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
residues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
these O
two B_LOCATION/B_BIO
positions I_LOCATION/I_BIO
, O
arguing O
that O
they O
contribute O
to O
a O
single B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epitope B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cognate B_LOCATION/B_GENE
gp120 I_LOCATION/I_GENE
sequence I_LOCATION/I_GENE
through O
homology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modeling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
places O
this O
potential B_GENE/B_LOCATION
epitope B_GENE/I_LOCATION
near O
the O
interface B_LOCATION
between O
the O
V1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
V2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
loops I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Additionally O
, O
the O
escape B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
R189S I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
V2 B_PROTEIN[GENE]
, O
which O
conferred O
resistance B_DISEASE
against O
all O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAbs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
had O
no O
detrimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
virus B_DISEASE
replication I_DISEASE
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

taken O
together O
, O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
independent B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeatedly O
targeted O
a O
single B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
structure B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
V1V2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
during O
early B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
infection B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Despite O
this O
assault B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
single B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
confer O
complete B_DISEASE_ADJECTIVE[DISEASE]
escape I_DISEASE_ADJECTIVE[DISEASE]
with O
minimal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
replication B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fitness B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
nuclear B_GENE/B_MEASURE
inhibitor I_GENE/I_MEASURE
of O
NF B_DISEASE/B_GENE
- O
kappaB B_PROTEIN[GENE]/B_LOCATION
encoded O
by O
a O
poxvirus B_SPECIES[BIO]/B_GENE
. O

Poxviruses B_BIO/B_PERSON
have O
evolved O
various B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
strategies B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
inhibit O
cytoplasmic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
leading O
to O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
nuclear B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
kappaB I_GENE/I_DISEASE
( O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
) O
signaling O
pathway B_LOCATION/B_BIO
, O
with O
individual B_BIO/B_PERSON
viruses I_BIO/I_PERSON
often O
encoding O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
NF B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
kappaB B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
inhibitors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Here O
, O
the O
novel O
orf B_VIRUS[BIO]/B_DISEASE
virus I_VIRUS[BIO]/I_DISEASE
( O
ORFV B_VIRUS[BIO]
) O
- O
encoded O
protein O
ORFV002 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
shown O
to O
inhibit O
nuclear O
events O
regulating O
NF O
- O
kappaB O
transcriptional O
activity O
. O

ORFV002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O
decreased O
wild B_VIRUS[BIO]/B_DISEASE
- O
type B_DISEASE/B_MEASURE
- O
virus B_GENE/B_BIO
- O
, O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
alpha B_PROTEIN[GENE]/B_LOCATION
) O
- O
, O
and O
lipopolysaccharide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
induced O
NF B_DISEASE/B_GENE
- O
kappaB B_PROTEIN[GENE]/B_LOCATION
- O
mediated O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ORFV002 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
while O
not O
affecting O
phosphorylation B_GENE
or O
nuclear B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
translocation I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
- O
p65 B_GENE
, O
markedly O
decreased O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
alpha B_PROTEIN[GENE]
- O
and O
wild B_PERSON/B_VIRUS[BIO]
- O
type B_DISEASE/B_MEASURE
- O
virus B_GENE/B_BIO
- O
induced O
acetylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
- O
p65 B_GENE
, O
a O
P300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
nuclear B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
modification I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
- O
p65 B_GENE
that O
regulates O
its O
transactivating B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ORFV002 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
shown O
to O
colocalize O
and O
interact O
with O
NF B_GENE/B_DISEASE
- O
kappaB B_GENE
- O
p65 B_GENE
, O
and O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ORFV002 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultures B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
resulted O
in O
a O
reduced O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
- O
p65 B_GENE
with O
P300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggesting O
that O
ORFV002 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interferes O
with O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE
- O
p65 B_GENE
/ O
P300 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
association I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ORFV002 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
the O
OV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
IA82 B_GENE/B_BIO
genome I_GENE/I_BIO
had O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
ORFV B_DISEASE
pathogenesis I_DISEASE
in O
sheep B_BIO
, O
indicating O
that O
ORFV002 B_GENE/B_MEASURE
is O
nonessential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
virus B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
virulence I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
natural B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
host I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
represents O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
nuclear B_GENE/B_MEASURE
inhibitor I_GENE/I_MEASURE
of O
NF B_DISEASE/B_GENE
- O
kappaB B_PROTEIN[GENE]/B_LOCATION
encoded O
by O
a O
poxvirus B_SPECIES[BIO]/B_GENE
. O

Norovirus B_MEASURE
GII I_MEASURE
. O
4 B_MEASURE/B_PERSON
strain O
antigenic B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
variation I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Noroviruses B_BACTERIUM[BIO]/B_PERSON
are O
the O
principal B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cause I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
epidemic B_DISEASE
gastroenteritis I_DISEASE
worldwide I_DISEASE
. O

Multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
concluded O
that O
the O
major B_BIO/B_GENE
capsid B_BIO/I_GENE
proteins B_BIO/I_GENE
of O
GII B_MEASURE/B_PROTEIN[GENE]
. O
4 B_MEASURE
strains I_MEASURE
, O
which O
cause O
80 B_MEASURE/B_DISEASE
% I_MEASURE/I_DISEASE
of O
norovirus B_DISEASE/B_PERSON
infections I_DISEASE/I_PERSON
worldwide I_DISEASE/I_PERSON
, O
are O
evolving O
rapidly O
, O
resulting O
in O
new B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
epidemic I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
strains I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Surrogate O
neutralization O
assays O
using O
sera O
from O
outbreaks O
and O
from O
immunized O
mice O
suggest O
that O
, O
as O
with O
influenza B_DISEASE
virus I_DISEASE
, O
antigenic O
variation O
maintains O
GII O
. O
4 O
persistence O
in O
the O
face O
of O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
population O
herd O
immunity O
. O

To O
test O
this O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
hyperimmunized O
with O
virus B_VIRUS[BIO]/B_DISEASE
- O
like B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VLPs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
representing O
an O
early B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
GII B_TIME[MEASURE]/B_PROTEIN[GENE]
. O
4 B_NUMBER[MEASURE]
- O
1987 B_MEASURE
) O
and O
a O
contemporary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
GII B_MEASURE/B_DISEASE
. O
4 B_MEASURE
- O
2006 B_MEASURE
) O
GII B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O
4 B_MEASURE
strain I_MEASURE
. O

Anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
GII B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
. O
4 B_MEASURE
- O
1987 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IgG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
monoclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
MAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
strongly O
reacted O
with O
GII B_MEASURE/B_DISEASE
. O
4 B_NUMBER[MEASURE]/B_LOCATION
VLPs I_NUMBER[MEASURE]/I_LOCATION
derived O
between O
only O
1987 B_MEASURE
and O
2002 B_MEASURE
. O

ligand B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
blockade I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
more O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
GII B_TIME[MEASURE]/B_PROTEIN[GENE]
. O
4 B_MEASURE
- O
1987 B_MEASURE
and O
GII B_MEASURE/B_PROTEIN[GENE]
. O
4 B_MEASURE
- O
1997 B_MEASURE/B_ENT
VLPs I_MEASURE/I_ENT
than O
with O
GII B_TIME[MEASURE]/B_PROTEIN[GENE]
. O
4 B_MEASURE
- O
2002 B_MEASURE
. O

Anti B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
GII B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O
4 B_MEASURE
- O
2006 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgG I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAbs I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognized O
either O
a O
broad B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
GII B_MEASURE/B_DISEASE
. O
4 B_MEASURE
VLPs I_MEASURE
( O
1987 B_MEASURE
to O
2006 B_MEASURE
) O
or O
a O
subset B_MEASURE/B_LOCATION
of O
contemporary B_TIME[MEASURE]/B_LOCATION
( O
2004 B_MEASURE
to O
2006 B_MEASURE
) O
VLPs B_PERSON/B_BIO
. O

Most B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
recognize O
or O
only O
poorly O
recognized O
GII B_MEASURE/B_PROTEIN[GENE]
. O
4 B_TIME[MEASURE]/B_PERSON
VLPs I_TIME[MEASURE]/I_PERSON
of O
2007 B_MEASURE
or O
2008 B_TIME[MEASURE]/B_LOCATION
, O
documenting O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigenic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evolution I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
GII B_MEASURE/B_PROTEIN[GENE]
. O
4 B_NUMBER[MEASURE]
capsids I_NUMBER[MEASURE]
. O

Generally O
, O
2006 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MAbs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
blocked O
homotypic B_GENE
VLP I_GENE
- O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
but O
were O
unable B_DISEASE_ADJECTIVE[DISEASE]
to O
block O
VLPs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representing O
strains B_BIO/B_PERSON
primarily O
circulating O
during O
or O
earlier B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
2002 B_TIME[MEASURE]/B_PERSON
. O

These O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
both O
subtle B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
evolutionary I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
change I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
has O
occurred O
within O
antibody B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
epitopes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
between O
epidemic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
providing O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
the O
GII B_DISEASE/B_PROTEIN[GENE]
. O
4 B_SPECIES[BIO]
noroviruses I_SPECIES[BIO]
are O
undergoing O
antigenic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
variation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
likely O
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
herd B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

As O
with O
influenza B_DISEASE
virus I_DISEASE
, O
HIV O
, O
and O
hepatitis B_DISEASE
C I_DISEASE
virus I_DISEASE
, O
norovirus O
antigenic O
variation O
will O
significantly O
influence O
the O
design O
of O
efficacious O
vaccines O
and O
immunotherapeutics O
against O
these O
important O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogens O
. O

dominant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibition B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Akt B_GENE
/ O
protein B_GENE
kinase I_GENE
B I_GENE
signaling O
by O
the O
matrix B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
negative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
strand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
RNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
virus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Vesicular B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
stomatitis I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
VSV B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
a O
rhabdovirus O
that O
alters O
host O
nuclear O
and O
cytoplasmic O
function O
upon O
infection O
. O

We O
have O
investigated O
the O
effect O
of O
VSV B_DISEASE/B_VIRUS[BIO]
infection O
on O
cellular O
signaling O
through O
the O
phosphatidylinositol O
- O
3 O
kinase O
( O
PI3k O
) O
/ O
Akt O
signaling O
pathway O
. O

Akt O
phosphorylation O
at O
both O
threonine O
308 O
( O
Thr308 O
) O
and O
serine O
473 O
( O
Ser473 O
) O
was O
inhibited O
in O
cells O
infected O
with O
VSV B_DISEASE/B_VIRUS[BIO]
. O

This O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
beginning O
within O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
2 I_SEQUENCE[MEASURE]/I_LOCATION
to O
3 B_MEASURE
h O
postinfection B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O
and O
correlated O
with O
the O
dephosphorylation B_ENZYME[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
downstream B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectors I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Akt B_GENE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
glycogen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GSK3Beta B_GENE
) O
and O
mammalian B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
target I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
rapamycin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mTOR B_GENE
) O
. O

The O
dephosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Akt B_GENE
occurred O
in O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
was O
not O
overcome O
through O
constitutive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
membrane B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
targeting B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Akt B_GENE
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
phosphatidylinositol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
- O
triphosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PIP3 B_GENE
) O
accumulation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
membrane B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Akt B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dephosphorylation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O
not O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
alterations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
PDK1 B_GENE
phosphorylation I_GENE
or O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
, O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
phosphatase B_ENZYME[GENE]
and O
tensin B_GENE/B_DISEASE
homologue I_GENE/I_DISEASE
deleted O
on O
chromosome B_NUMBER[MEASURE]/B_GENE
10 I_NUMBER[MEASURE]/I_GENE
( O
PTEN B_GENE/B_DISEASE
) O
levels B_GENE
, O
or O
the O
downregulation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
PI3K B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

inactivation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Akt B_GENE
was O
caused O
by O
the O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
M I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
absence B_DISEASE/B_LOCATION
of O
other B_DISEASE/B_GENE
viral B_DISEASE/I_GENE
components B_DISEASE/I_GENE
, O
and O
an O
M B_GENE
protein I_GENE
mutant I_GENE
that O
does O
not O
inhibit O
RNA B_GENE
polymerase I_GENE
II I_GENE
( O
Pol B_PROTEIN[GENE]/B_DISEASE
II I_PROTEIN[GENE]/I_DISEASE
) O
transcription B_GENE
and O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O
cytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transport B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
was O
also O
defective B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
inhibiting O
Akt B_GENE
phosphorylation I_GENE
. O

These O
data O
illustrate O
that O
VSV B_DISEASE/B_GENE
utilizes O
a O
novel O
mechanism O
to O
alter O
this O
central O
player O
in O
cell O
signaling O
and O
oncogenesis O
. O

It O
also O
suggests O
an O
inside O
- O
out O
model O
of O
signal O
transduction O
where O
VSV B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
interruption O
of O
nuclear O
events O
has O
a O
rapid O
and O
significant O
effect O
on O
membrane O
signaling O
events O
. O

activation O
of O
plasmacytoid O
dendritic O
cells O
by O
Kaposi B_DISEASE/B_GENE
' B_DISEASE/I_GENE
s B_DISEASE/I_GENE
sarcoma B_DISEASE/I_GENE
- B_DISEASE/I_GENE
associated B_DISEASE/I_GENE
herpesvirus B_DISEASE/I_GENE
. O

Kaposi B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
' I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
s I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
associated I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
herpesvirus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
KSHV B_VIRUS[BIO]/B_LOCATION
) O
is O
associated O
with O
multiple O
human B_PERSON/B_BIO
malignancies O
, O
including O
Kaposi O
' O
s O
sarcoma O
, O
primary O
effusion O
lymphoma O
, O
and O
multicentric O
Castleman O
' O
s O
disease O
. O

Following O
primary O
infection O
, O
KSHV B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
typically O
goes O
through O
a O
brief O
period O
of O
lytic O
replication O
prior O
to O
the O
establishment O
of O
latency O
. O

Plasmacytoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
dendritic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
( O
pDCs B_GENE/B_LOCATION
) O
are O
the O
major B_PERSON/B_LOCATION
producers I_PERSON/I_LOCATION
of O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
primarily O
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
virus B_DISEASE_ADJECTIVE[DISEASE]
infection I_DISEASE_ADJECTIVE[DISEASE]
. O

Toll B_GENE
- O
like B_GENE/B_LOCATION
receptors I_GENE/I_LOCATION
( O
TLRs B_GENE
) O
are O
key B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
components I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
innate B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
immune B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
system B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
they O
serve O
as O
pathogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
recognition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
stimulate O
the O
host B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antiviral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

pDCs B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
express O
exclusively O
TLR7 B_GENE
and O
TLR9 B_MEASURE/B_GENE
, O
and O
it O
is O
through O
these O
TLRs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
interferon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
activated O
in O
pDCs B_DISEASE/B_LOCATION
. O

Currently O
, O
it O
is O
not O
known O
whether O
KSHV B_VIRUS[BIO]/B_GENE
is O
recognized O
by O
pDCs O
and O
whether O
activation O
of O
pDCs O
occurs O
in O
response O
to O
KSHV B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
infection O
. O

We O
now O
report O
evidence O
that O
KSHV B_VIRUS[BIO]
can O
infect O
human B_PERSON/B_SPECIES[BIO]
pDCs O
and O
that O
pDCs O
are O
activated O
upon O
KSHV B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
infection O
, O
as O
measured O
by O
upregulation O
of O
CD83 O
and O
CD86 O
and O
by O
IFN O
- O
alpha O
secretion O
. O

We O
further O
show O
that O
induction O
of O
IFN O
- O
alpha O
occurs O
through O
activation O
of O
TLR9 O
signaling O
and O
that O
a O
TLR9 O
inhibitor O
diminishes O
the O
production O
and O
secretion O
of O
IFN O
- O
alpha O
by O
KSHV B_VIRUS[BIO]/B_DISEASE
- O
infected O
pDCs O
. O

An O
in O
- O
depth O
analysis O
of O
original O
antigenic O
sin O
in O
dengue B_DISEASE/B_SPECIES[BIO]
virus I_DISEASE/I_SPECIES[BIO]
infection O
. O

The O
evolution O
of O
dengue B_VIRUS[BIO]/B_DISEASE
viruses B_VIRUS[BIO]/I_DISEASE
has O
resulted O
in O
four O
antigenically O
similar O
yet O
distinct O
serotypes O
. O

Infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
one B_DISEASE
serotype I_DISEASE
likely O
elicits O
lifelong B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunity B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
that O
serotype B_BACTERIUM[BIO]/B_DISEASE
, O
but O
generally O
not O
against O
the O
other B_NUMBER[MEASURE]/B_PERSON
three B_NUMBER[MEASURE]/I_PERSON
. O

Secondary B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
or O
sequential B_DISEASE_ADJECTIVE[DISEASE]
infections I_DISEASE_ADJECTIVE[DISEASE]
are O
common B_DISEASE_ADJECTIVE[DISEASE]
, O
as O
multiple B_DISEASE/B_PERSON
viral I_DISEASE/I_PERSON
serotypes I_DISEASE/I_PERSON
frequently O
cocirculate O
. O

Dengue B_DISEASE
infection O
, O
although O
frequently O
mild O
, O
can O
lead O
to O
dengue B_DISEASE_ADJECTIVE[DISEASE]
hemorrhagic O
fever O
( O
DHF O
) O
which O
can O
be O
life O
threatening O
. O

DHF O
is O
more O
common O
in O
secondary O
dengue B_DISEASE/B_VIRUS[BIO]
infections O
, O
implying O
a O
role O
for O
the O
adaptive O
immune O
response O
in O
the O
disease O
. O

There O
is O
currently O
much B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effort I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
toward O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
implementation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
dengue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vaccine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
but O
these O
efforts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O
made O
more O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
challenge B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
inducing O
durable B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neutralizing B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunity B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
all O
four B_BIO
viruses I_BIO
. O

Domain O
3 O
of O
the O
dengue B_SPECIES[BIO]
virus I_SPECIES[BIO]
envelope O
protein O
( O
ED3 O
) O
has O
been O
suggested O
as O
one O
such O
candidate O
because O
it O
contains O
neutralizing O
epitopes O
and O
it O
was O
originally O
thought O
that O
relatively O
few O
cross O
- O
reactive O
antibodies O
are O
directed O
to O
this O
domain O
. O

In O
this O
study O
, O
we O
performed O
a O
detailed O
analysis O
of O
the O
anti O
- O
ED3 O
response O
in O
a O
cohort O
of O
patients O
suffering O
either O
primary O
or O
secondary O
dengue B_DISEASE/B_VIRUS[BIO]
infections O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
original B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigenic I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sin I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
infections B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
both O
in O
terms B_LOCATION/B_MEASURE
of O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
enhancement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
has O
important O
implications O
for O
dengue B_DISEASE
vaccine O
design O
because O
heterologous O
boosting O
is O
likely O
to O
maintain O
the O
immunological O
footprint O
of O
the O
first O
vaccination O
. O

On O
the O
basis O
of O
these O
findings O
, O
we O
propose O
a O
simple O
in O
vitro O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
to O
diagnose O
the O
original O
dengue B_DISEASE
infection O
in O
secondary O
dengue B_DISEASE/B_PERSON
cases O
. O

When O
it O
is O
too O
hot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
photosynthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
: O
heat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
instability B_DISEASE
of O
photosynthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
burst B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeability B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
H2O2 B_DISEASE
formation I_DISEASE
. O

photosynthesis B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
n B_MEASURE/B_PROTEIN[GENE]
) O
) O
becomes O
unstable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
above O
a O
threshold B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
, O
and O
the O
recovery B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
upon O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
temperature B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
varies O
because O
of O
reasons B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
not O
fully O
understood O
. O

We O
investigated O
responses O
of O
A O
( O
n O
) O
, O
dark O
respiration O
and O
chlorophyll O
fluorescence O
to O
supraoptimal O
temperatures O
of O
varying O
duration O
and O
kinetics O
in O
Phaseolus B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
vulgaris I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
asking O
whether O
the O
instability O
of O
photosynthesis O
under O
severe O
heat O
stress O
is O
associated O
with O
cellular O
damage O
. O

Cellular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
assessed O
by O
Evans B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blue B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
penetration B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
enhanced B_GENE/B_LOCATION
membrane I_GENE/I_LOCATION
permeability I_GENE/I_LOCATION
) O
and O
by O
H2O2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
generation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ I_MEASURE
3 I_MEASURE
, O
3 B_NUMBER[MEASURE]
' I_MEASURE
- O
diaminobenzidine B_PROTEIN[GENE]
4HCl I_PROTEIN[GENE]
( O
dab B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
staining O
] O
. O

Critical B_MEASURE
temperature I_MEASURE
for O
dark B_MEASURE/B_LOCATION
fluorescence I_MEASURE/I_LOCATION
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
0 B_MEASURE/B_LOCATION
) O
) O
rise O
( O
T B_PROTEIN[GENE]/B_LOCATION
( O
F B_MEASURE/B_DISEASE
) O
) O
was O
at O
46 B_MEASURE
- O
48 B_MEASURE
^ I_MEASURE
0C I_MEASURE
, O
and O
a O
burst B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
respiration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
observed O
near O
T B_PROTEIN[GENE]/B_LOCATION
( O
F B_MEASURE/B_PROTEIN[GENE]
) O
. O

However O
, O
A O
( O
n B_OTHER/B_MEASURE
) O
was O
strongly O
inhibited O
already O
before O
T B_PROTEIN[GENE]/B_LOCATION
( O
F B_MEASURE/B_DISEASE
) O
was O
reached O
. O

Membrane B_DISEASE/B_MEASURE
permeability I_DISEASE/I_MEASURE
increased O
with O
temperature B_MEASURE
according O
to O
a O
switch B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
with O
enhanced O
permeability B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
observed O
above O
48 B_MEASURE
^ O
0C B_MEASURE/B_PROTEIN[GENE]
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
varying O
heat B_MEASURE
pulse I_MEASURE
lengths I_MEASURE
and O
intensities B_MEASURE/B_LOCATION
underscored O
the O
threshold B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loss B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
photosynthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
function I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
and O
indicated O
that O
the O
degree B_MEASURE
of O
photosynthetic B_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
and O
cellular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depended O
on O
accumulated O
heat B_DISEASE/B_BIO
- O
dose B_MEASURE/B_DISEASE
. O

Beyond O
the O
' O
point B_LOCATION/B_MEASURE
of O
no O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
' O
, O
propagation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
photosynthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
continued O
upon O
transfer B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
lower B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
temperatures I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O
photosynthetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
was O
slow B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
conclude O
that O
instability B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
photosynthesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
severe B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heat I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
associated O
with O
time B_MEASURE/B_LOCATION
- O
dependent B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
propagation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
cellular B_DISEASE/B_BIO
lesions I_DISEASE/I_BIO
. O

A O
fluorescence O
resonance O
energy O
transfer O
- O
based O
fluorometer O
assay O
for O
screening O
anti O
- O
coxsackievirus B_DISEASE/B_BIO
B3 I_DISEASE/I_BIO
compounds O
. O

In O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
develop O
a O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
screen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
a O
fluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resonance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
energy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transfer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
FRET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
- O
based O
reporter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
consisting O
of O
engineered B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mammalian I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressing O
a O
cyan B_COLOR/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescent I_COLOR/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_COLOR/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
yellow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
fluorescent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
CFP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
YFP B_PROTEIN[GENE]
) O
pair B_PERSON/B_LOCATION
linked O
by O
a O
short B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peptide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O
the O
cleavage B_GENE/B_LOCATION
site I_GENE/I_LOCATION
of O
viral B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protease I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
2A B_PROTEIN[GENE]/B_DISEASE
( O
pro B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
) O
was O
developed O
. O

By O
detecting O
the O
2A O
( O
pro O
) O
produced O
early O
during O
the O
virus O
infection O
cycle O
, O
the O
CFP O
- O
YFP O
pair O
effectively O
identifies O
infectious O
coxsackievirus B_VIRUS[BIO]/B_PROTEIN[GENE]
B3 B_VIRUS[BIO]/I_PROTEIN[GENE]
( O
CVB3 B_PROTEIN[GENE]/B_BIO
) O
, O
a O
picornavirus O
that O
causes O
viral O
myocarditis O
in O
humans B_SPECIES[BIO]
. O

The O
reporter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O
used O
to O
screen O
a O
library B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
2000 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
potential B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiviral I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
reporter O
cells O
were O
treated O
with O
the O
test O
compounds O
, O
challenged O
with O
CVB3 B_SPECIES[BIO]
, O
and O
then O
examined O
using O
a O
fluorometer O
at O
24h O
post O
- O
infection O
. O

sixty B_NUMBER[MEASURE]/B_PERSON
- O
four B_NUMBER[MEASURE]
compounds I_NUMBER[MEASURE]
, O
mostly O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
unknown B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
functions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
, O
caused O
at O
least O
50 B_MEASURE/B_DISEASE
% I_MEASURE/I_DISEASE
inhibition I_MEASURE/I_DISEASE
of O
2A B_GENE/B_DISEASE
( O
pro O
) O
activity B_ENZYME[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Three B_NUMBER[MEASURE]/B_PERSON
known O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cosmosiin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
baicalein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
were O
also O
identified O
in O
the O
screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
developed O
method O
is O
an O
effective O
strategy O
for O
rapid O
screening O
, O
and O
identifies O
compounds O
that O
inhibit O
CVB3 B_ENZYME[GENE]/B_BIO
2A O
( O
pro O
) O
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
a O
valuable B_PERSON/B_SPORT[ENT]
aid I_PERSON/I_SPORT[ENT]
in O
the O
antiviral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
discovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

One O
- O
step O
real O
- O
time O
reverse O
transcription O
- O
PCR O
assays O
for O
detecting O
and O
subtyping O
pandemic B_DISEASE/B_LOCATION
influenza I_DISEASE/I_LOCATION
A I_DISEASE/I_LOCATION
/ I_DISEASE/I_LOCATION
H1N1 I_DISEASE/I_LOCATION
2009 I_DISEASE/I_LOCATION
, O
seasonal B_MEASURE/B_DISEASE
influenza I_MEASURE/I_DISEASE
A I_MEASURE/I_DISEASE
/ I_MEASURE/I_DISEASE
H1N1 I_MEASURE/I_DISEASE
, O
and O
seasonal B_DISEASE/B_LOCATION
influenza I_DISEASE/I_LOCATION
A I_DISEASE/I_LOCATION
/ I_DISEASE/I_LOCATION
H3N2 I_DISEASE/I_LOCATION
viruses I_DISEASE/I_LOCATION
. O

Pandemic B_DISEASE
influenza I_DISEASE
A I_DISEASE
/ I_DISEASE
H1N1 I_DISEASE
2009 I_DISEASE
( I_DISEASE
A I_DISEASE
/ I_DISEASE
H1N1pdm I_DISEASE
) I_DISEASE
virus I_DISEASE
has O
caused O
significant O
outbreaks O
worldwide O
. O

A O
previous O
one O
- O
step O
real O
- O
time O
reverse O
transcription O
- O
PCR O
( O
rRT O
- O
PCR O
) O
assay O
for O
detecting O
A B_DISEASE/B_VIRUS[BIO]
/ B_DISEASE/I_VIRUS[BIO]
H1N1pdm B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
H1pdm O
rRT O
- O
PCR O
assay O
) O
was O
improved O
since O
the O
former O
probe O
had O
a O
low O
melting O
temperature O
and O
low O
tolerance O
to O
viral O
mutation O
. O

To O
help O
with O
the O
screening O
of O
the O
A B_DISEASE/B_BIO
/ B_DISEASE/I_BIO
H1N1pdm B_DISEASE/I_BIO
virus B_DISEASE/I_BIO
, O
rRT O
- O
PCR O
assays O
were O
also O
developed O
for O
detecting O
human B_DISEASE/B_PROTEIN[GENE]
seasonal B_DISEASE/I_PROTEIN[GENE]
A B_DISEASE/I_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
H1N1 B_DISEASE/I_PROTEIN[GENE]
( O
H1 O
rRT O
- O
PCR O
assay O
) O
and O
A B_DISEASE/B_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
H3N2 B_DISEASE/I_PROTEIN[GENE]
influenza B_DISEASE/I_PROTEIN[GENE]
viruses B_DISEASE/I_PROTEIN[GENE]
( O
H3 O
rRT O
- O
PCR O
assay O
) O
. O

H1pdm B_PROTEIN[GENE]
, O
H1 O
, O
and O
H3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rRT I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assays B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
evaluated O
using O
in O
vitro B_LOCATION
- O
transcribed O
control B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
isolated B_VIRUS[BIO]/B_GENE
viruses B_VIRUS[BIO]/I_GENE
, O
and O
other B_BIO/B_GENE
respiratory B_BIO/I_GENE
pathogenic B_BIO/I_GENE
viruses B_BIO/I_GENE
, O
and O
were O
shown O
to O
have O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
good B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
linearity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_MEASURE/B_LOCATION
) O
= O
0 B_MEASURE
. O
99 B_MEASURE
) O
, O
and O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
, O
the O
improved O
H1pdm O
rRT O
- O
PCR O
assay O
could O
detect O
two O
viral B_DISEASE/B_BIO
strains B_DISEASE/I_BIO
of B_DISEASE/I_BIO
A B_DISEASE/I_BIO
/ B_DISEASE/I_BIO
H1N1pdm B_DISEASE/I_BIO
, O
namely O
, O
A B_DISEASE/B_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
Aichi B_DISEASE/I_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
472 B_DISEASE/I_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
2009 B_DISEASE/I_PROTEIN[GENE]
( B_DISEASE/I_PROTEIN[GENE]
H1N1 B_DISEASE/I_PROTEIN[GENE]
) B_DISEASE/I_PROTEIN[GENE]
pdm B_DISEASE/I_PROTEIN[GENE]
and O
A B_DISEASE/B_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
Sakai B_DISEASE/I_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
89 B_DISEASE/I_PROTEIN[GENE]
/ B_DISEASE/I_PROTEIN[GENE]
2009 B_DISEASE/I_PROTEIN[GENE]
( B_DISEASE/I_PROTEIN[GENE]
H1N1 B_DISEASE/I_PROTEIN[GENE]
) B_DISEASE/I_PROTEIN[GENE]
pdm B_DISEASE/I_PROTEIN[GENE]
, O
which O
have O
mutation O
( O
s O
) O
in O
the O
probe O
- O
binding O
region O
of O
the O
hemagglutinin O
gene O
, O
without O
loss O
of O
sensitivity O
. O

Using O
the O
three B_PROTEIN[GENE]/B_LOCATION
rRT I_PROTEIN[GENE]/I_LOCATION
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
developed O
, O
90 B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
clinical I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
specimens I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
collected O
between O
May B_TIME[MEASURE]/B_LOCATION
and O
October B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2009 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
tested O
. O

Of O
these O
, O
26 O
, O
20 O
, O
and O
2 O
samples O
were O
identified O
as O
positive O
for O
A B_PROTEIN[GENE]/B_DISEASE
/ I_PROTEIN[GENE]/I_DISEASE
H1pdm I_PROTEIN[GENE]/I_DISEASE
, O
A B_PROTEIN[GENE]/B_DISEASE
/ I_PROTEIN[GENE]/I_DISEASE
H3 I_PROTEIN[GENE]/I_DISEASE
, O
and O
A B_GENE/B_VIRUS[BIO]
/ B_GENE/I_VIRUS[BIO]
H1 B_GENE/I_VIRUS[BIO]
, O
respectively O
, O
while O
42 O
samples O
were O
negative O
for O
influenza B_VIRUS[BIO]/B_PROTEIN[GENE]
A B_VIRUS[BIO]/I_PROTEIN[GENE]
viruses B_VIRUS[BIO]/I_PROTEIN[GENE]
. O

The O
present O
results O
suggest O
that O
these O
highly O
sensitive O
and O
specific O
H1pdm O
, O
H1 O
, O
and O
H3 O
rRT O
- O
PCR O
assays O
are O
useful O
not O
only O
for O
diagnosing O
influenza B_DISEASE/B_BIO
viruses I_DISEASE/I_BIO
, O
but O
also O
for O
the O
surveillance O
of O
influenza B_DISEASE/B_BIO
viruses I_DISEASE/I_BIO
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
commercial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
extraction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nucleic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
RNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
respiratory B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathogens B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

This O
study O
compared O
six O
automated O
nucleic O
acid O
extraction O
systems O
and O
one O
manual O
kit O
for O
their O
ability O
to O
recover O
nucleic O
acids O
from O
human B_PERSON/B_SPECIES[BIO]
nasal O
wash O
specimens O
spiked O
with O
five O
respiratory O
pathogens O
, O
representing O
Gram O
- O
positive O
bacteria O
( O
Streptococcus B_BACTERIUM[BIO]/B_DISEASE
pyogenes I_BACTERIUM[BIO]/I_DISEASE
) O
, O
Gram O
- O
negative O
bacteria O
( O
Legionella B_BACTERIUM[BIO]/B_DISEASE
pneumophila I_BACTERIUM[BIO]/I_DISEASE
) O
, O
DNA O
viruses O
( O
adenovirus O
) O
, O
segmented O
RNA O
viruses O
( O
human B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
influenza I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
A I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
non O
- O
segmented O
RNA O
viruses O
( O
respiratory B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
syncytial I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
robots B_PRODUCT[OBJECT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
kit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
evaluated O
represent O
major B_NUMBER[MEASURE]/B_DISEASE
commercially O
available B_MEASURE/B_ORGANIZATION
methods B_MEASURE/I_ORGANIZATION
that O
are O
capable B_PERSON
of O
simultaneous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extraction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
RNA B_GENE/B_BIO
from O
respiratory B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
included O
platforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
based O
on O
magnetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
bead B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
KingFisher B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mL I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Biorobot B_PERSON/B_ORGANIZATION
EZ1 B_PERSON/I_ORGANIZATION
, O
easyMAG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
KingFisher B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Flex I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
MagNA B_GENE/B_LOCATION
pure I_GENE/I_LOCATION
compact I_GENE/I_LOCATION
) O
or O
glass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
fiber I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
filter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
technology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Biorobot B_PERSON/B_ORGANIZATION
MDX B_PERSON/I_ORGANIZATION
and O
the O
manual B_SEQUENCE[MEASURE]/B_PERSON
kit I_SEQUENCE[MEASURE]/I_PERSON
Allprep I_SEQUENCE[MEASURE]/I_PERSON
) O
. O

All O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
yielded O
extracts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
free I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
contamination B_DISEASE/B_BIO
and O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

All O
automated O
systems O
recovered O
L B_VIRUS[BIO]/B_DISEASE
. I_VIRUS[BIO]/I_DISEASE
pneumophila I_VIRUS[BIO]/I_DISEASE
and O
adenovirus O
DNA O
equivalently O
. O

However O
, O
the O
MagNA O
Pure O
protocol O
demonstrated O
more O
than O
4 O
- O
fold O
higher O
DNA O
recovery O
from O
the O
S B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
pyogenes B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
than O
other O
methods O
. O

The O
KingFisher O
mL O
and O
easyMAG O
protocols O
provided O
1 O
- O
to O
3 O
- O
log O
wider O
linearity O
and O
extracted O
3 O
- O
to O
4 O
- O
fold O
more O
RNA O
from O
the O
human B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
influenza I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
respiratory B_DISEASE/B_GENE
syncytial B_DISEASE/I_GENE
virus B_DISEASE/I_GENE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
systems B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
differed O
in O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
reproducibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
linearity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
a O
pathogen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

aerosol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delivery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
developments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
device B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Aerosolised B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
prescribed O
for O
use B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
a O
range B_LOCATION/B_MEASURE
of O
inhaler B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
devices I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
systems B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

delivering O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
inhalation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
requires O
a O
formulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
can O
be O
successfully O
aerosolised O
and O
a O
delivery B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
produces O
a O
useful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
aerosol I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
; O
the O
particles B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
droplets B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
need O
to O
be O
of O
sufficient B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
and O
mass B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
carried O
to O
the O
distal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lung I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
deposited O
on O
proximal B_BODY_PART_OR_ORGAN_COMPONENT
airways I_BODY_PART_OR_ORGAN_COMPONENT
to O
give O
rise B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

patients B_PERSON
and O
caregivers B_PERSON
must O
use O
and O
maintain O
these O
aerosol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
delivery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
devices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
correctly O
. O

In O
recent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
years I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
technical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
innovations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
led O
to O
aerosol O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
delivery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
devices I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
efficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delivery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
with O
novel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
take O
into O
account B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tracking B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
portability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
materials B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
manufacture B_PERSON/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
breath B_MEASURE/B_PERSON
actuation I_MEASURE/I_PERSON
, O
the O
interface B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
patient B_PERSON
, O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delivery I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
have O
improved O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
all O
four B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
categories B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
devices B_PRODUCT[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
metered O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
inhalers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
, O
spacers B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
holding O
chambers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
powder I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
inhalers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
, O
and O
nebulisers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Additionally O
, O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
usually O
given O
by O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
are O
now O
prescribed O
as O
aerosols B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
for O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
in O
a O
range B_LOCATION/B_MEASURE
of O
drug B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
delivery I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
devices I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

In O
this O
Review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
discuss O
recent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
developments I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
aerosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devices I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
past B_TIME[MEASURE]
10 I_TIME[MEASURE]
- O
15 B_TIME[MEASURE]
years I_TIME[MEASURE]
with O
an O
emphasis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
respiratory B_DISEASE
disorders I_DISEASE
. O

Regulation O
of O
horizontal O
gene O
transfer O
in O
Bacillus B_SPECIES[BIO]
subtilis I_SPECIES[BIO]
by O
activation O
of O
a O
conserved O
site O
- O
specific O
protease O
. O

The O
mobile O
genetic O
element O
ICEBs1 O
is O
an O
integrative O
and O
conjugative O
element O
( O
a O
conjugative O
transposon O
) O
found O
in O
Bacillus B_SPECIES[BIO]
subtilis I_SPECIES[BIO]
. O

The O
RecA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
dependent O
SOS B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
RapI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
PhrI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sensory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activate O
ICEBs1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
stimulating O
cleavage B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE
of O
ImmR B_GENE
, O
the O
ICEBs1 B_GENE/B_PERSON
immunity I_GENE/I_PERSON
repressor I_GENE/I_PERSON
, O
by O
the O
protease B_GENE/B_LOCATION
ImmA I_GENE/I_LOCATION
. O

We O
found O
that O
increasing O
the O
amount B_MEASURE
of O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ImmA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
caused O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
derepression I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ICEBs1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
during O
RapI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
derepression B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ICEBs1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
ImmA B_GENE
levels I_GENE
did O
not O
detectably O
increase O
, O
indicating O
that O
RapI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
likely I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O
the O
protease B_ENZYME[GENE]/B_LOCATION
ImmA I_ENZYME[GENE]/I_LOCATION
by O
increasing O
its O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
also O
isolated O
and O
characterized O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
immA B_GENE/B_DISEASE
( O
immA B_GENE/B_DISEASE
( O
h O
) O
) O
that O
cause O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
derepression I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ICEBs1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inducing O
signals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
obtained O
two B_MEASURE/B_LOCATION
types B_MEASURE/I_LOCATION
of O
immA B_GENE/B_DISEASE
( O
h B_PROTEIN[GENE]/B_DISEASE
) O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
: O
one B_NUMBER[MEASURE]/B_PERSON
type I_NUMBER[MEASURE]/I_PERSON
caused O
increased O
amounts B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
but O
no O
detectable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
; O
the O
other B_SEQUENCE[MEASURE]/B_PERSON
type I_SEQUENCE[MEASURE]/I_PERSON
had O
no O
detectable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
amount B_MEASURE
of O
the O
mutant B_GENE
protein I_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
but O
caused O
increased O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
protein B_ENZYME[GENE]/B_BACTERIUM[BIO]
( O
as O
measured O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

Together O
, O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
derepression B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ICEBs1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
likely O
caused O
by O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ImmA B_GENE/B_DISEASE
. O

Homologs B_TIME[MEASURE]/B_LOCATION
of O
ImmA B_GENE/B_DISEASE
and O
ImmR B_GENE/B_LOCATION
are O
found O
in O
many B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mobile I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
genetic I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
elements I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
so O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
regulate O
ImmA B_GENE/B_DISEASE
- O
mediated O
cleavage B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE
of O
ImmR B_GENE
may O
be O
widely O
conserved O
. O

orientation B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SecA B_GENE/B_BACTERIUM[BIO]
and O
SecB B_GENE/B_BACTERIUM[BIO]
in O
complex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
derived O
from O
disulfide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cross I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
linking B_TIME[MEASURE]/B_LOCATION
. O

SecA O
is O
the O
ATPase O
that O
acts O
as O
the O
motor O
for O
protein O
export O
in O
the O
general O
secretory O
, O
or O
SEC O
, O
system O
of O
Escherichia B_BIO
coli I_BIO
. O

The O
tetrameric B_LOCATION
cytoplasmic I_LOCATION
chaperone I_LOCATION
SecB I_LOCATION
binds I_LOCATION
to O
precursors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
exported O
proteins B_GENE/B_DISEASE
before O
they O
can O
become O
stably O
folded O
and O
delivers O
them O
to O
SecA B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

During O
this O
delivery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
SecB B_GENE/B_BACTERIUM[BIO]
binds O
to O
SecA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
complex B_LOCATION
between O
SecA B_GENE/B_BACTERIUM[BIO]
and O
SecB B_GENE/B_BACTERIUM[BIO]
that O
is O
maximally O
active B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
translocation B_DISEASE/B_BIO
contains O
two B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protomers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
SecA B_GENE/B_BACTERIUM[BIO]
bound O
to O
a O
tetramer B_GENE/B_LOCATION
of O
SecB B_GENE/B_BACTERIUM[BIO]
. O

The O
aminoacyl B_LOCATION/B_BIO
residues I_LOCATION/I_BIO
on O
each O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
that O
are O
involved O
in O
binding O
the O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O
previously O
been O
identified O
by O
site B_LOCATION
- O
directed O
spin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paramagnetic I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EPR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
spectroscopy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
however O
, O
that O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
provided O
no O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concerning O
the O
relative B_LOCATION/B_MEASURE
orientation I_LOCATION/I_MEASURE
of O
the O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
within O
the O
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Here O
we O
used O
our O
extensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
single B_MEASURE/B_PROTEIN[GENE]
- O
cysteine B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
the O
two B_GENE/B_MEASURE
proteins I_GENE/I_MEASURE
and O
subjected O
pairwise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combinations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SecA B_GENE/B_BACTERIUM[BIO]
and O
SecB B_GENE/B_BACTERIUM[BIO]
to O
brief O
oxidation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
residues B_MEASURE/B_LOCATION
in O
close B_PERSON/B_LOCATION
proximity I_PERSON/I_LOCATION
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
used O
to O
generate O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
the O
orientation B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
two B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
complex B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Inactivation O
of O
the O
RluD O
pseudouridine O
synthase O
has O
minimal O
effects O
on O
growth O
and O
ribosome O
function O
in O
wild O
- O
type O
Escherichia B_BACTERIUM[BIO]
coli I_BACTERIUM[BIO]
and O
Salmonella B_SPECIES[BIO]
enterica I_SPECIES[BIO]
. O

The O
Escherichia B_SPECIES[BIO]/B_DISEASE
coli I_SPECIES[BIO]/I_DISEASE
rluD O
gene O
encodes O
a O
pseudouridine O
synthase O
responsible O
for O
the O
pseudouridine O
( O
Psi O
) O
modifications O
at O
positions O
1911 O
, O
1915 O
, O
and O
1917 O
in O
helix O
69 O
of O
23S O
rRNA O
. O

It O
has O
been O
reported O
that O
deletion O
of O
rluD O
in O
K B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
12 I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
E I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
coli I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
extremely O
slow O
growth O
, O
increased O
readthrough O
of O
stop O
codons O
, O
and O
defects O
in O
50S O
ribosomal O
subunit O
assembly O
and O
30S O
- O
50S O
subunit O
association O
. O

suppressor B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
prfB B_BACTERIUM[BIO]/B_GENE
and O
prfC B_GENE/B_BIO
genes I_GENE/I_BIO
encoding O
release B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RF2 B_GENE/B_LOCATION
) O
and O
RF3 B_GENE
that O
restore O
the O
wild B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
growth B_MEASURE/B_BIO
rate B_MEASURE/I_BIO
and O
also O
correct O
the O
ribosomal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
defects I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O
now O
been O
isolated O
. O

These O
suppressors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
link O
helix B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
69 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
psi I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
residues I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
termination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

However O
, O
further O
genetic O
analysis O
reported O
here O
also O
reveals O
that O
the O
slow O
growth O
and O
other O
defects O
associated O
with O
inactivation O
of O
rluD O
in O
E B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
. I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
coli I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
K I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
12 I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
strains O
are O
due O
to O
a O
defective O
RF2 O
protein O
, O
with O
a O
threonine O
at O
position O
246 O
, O
which O
is O
present O
in O
all O
K B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strains O
. O

This O
is O
in O
contrast O
to O
the O
more O
typical O
alanine O
found O
at O
this O
position O
in O
most O
bacterial O
RF2s O
, O
including O
those O
of O
other O
E B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
coli I_BACTERIUM[BIO]/I_DISEASE
strains O
. O

Inactivation O
of O
rluD O
in O
E B_PERSON/B_BACTERIUM[BIO]
. I_PERSON/I_BACTERIUM[BIO]
coli I_PERSON/I_BACTERIUM[BIO]
strains O
containing O
the O
prfB O
allele O
from O
E B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
coli I_BACTERIUM[BIO]
B I_BACTERIUM[BIO]
or O
in O
Salmonella B_BIO/B_PERSON
enterica I_BIO/I_PERSON
, O
both O
carrying O
an O
RF2 O
with O
Ala246 O
, O
has O
negligible O
effects O
on O
growth O
, O
termination O
, O
or O
ribosome O
function O
. O

The O
results O
indicate O
that O
, O
in O
contrast O
to O
those O
in O
wild O
bacteria O
, O
termination O
functions O
in O
E B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
coli I_BACTERIUM[BIO]/I_PERSON
K I_BACTERIUM[BIO]/I_PERSON
- I_BACTERIUM[BIO]/I_PERSON
12 I_BACTERIUM[BIO]/I_PERSON
strains O
carrying O
a O
partially O
defective O
RF2 O
protein O
are O
especially O
susceptible O
to O
perturbation O
of O
ribosome O
- O
RF O
interactions O
, O
such O
as O
that O
caused O
by O
loss O
of O
h69 O
Psi O
modifications O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
energetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
constraints B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
distribution B_ORGANIZATION/B_TIME[MEASURE]
and O
winter B_MEASURE/B_ORGANISM_FUNCTION
survival B_MEASURE/I_ORGANISM_FUNCTION
of O
weasel B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
males I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

1 B_NUMBER[MEASURE]
. O

The O
absolute B_MEASURE
energy I_MEASURE
needs I_MEASURE
of O
small B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
generally O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
those O
of O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

This O
should O
drive O
higher B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
mortality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
larger B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
when O
the O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deteriorate O
. O

However O
, O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
energy B_DISEASE/B_MEASURE
constraints B_DISEASE/I_MEASURE
on O
survivals B_MEASURE/B_ORGANIZATION
proved O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
because O
the O
range B_LOCATION/B_MEASURE
of O
body B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mass I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
species B_BIO/B_PERSON
is O
generally O
too O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
produce O
enough B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
studying O
such O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

An O
opportunity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
an O
intraspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comes O
from O
weasels B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
inhabiting O
the O
Bialowieza B_LOCATION
Forest I_LOCATION
( O
north O
- O
eastern B_LOCATION
Poland I_LOCATION
) O
, O
which O
are O
characterized O
by O
a O
threefold B_MEASURE
variation I_MEASURE
in O
body B_MEASURE/B_LOCATION
mass B_MEASURE/I_LOCATION
. O

2 B_NUMBER[MEASURE]
. O

We O
assumed O
that O
in O
summer B_PERSON/B_BIO
larger I_PERSON/I_BIO
weasel I_PERSON/I_BIO
males I_PERSON/I_BIO
are O
favoured O
by O
sexual B_PERSON/B_BIO
selection I_PERSON/I_BIO
, O
because O
they O
are O
more O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
competing O
for O
mates B_PERSON/B_LOCATION
. O

We O
then O
tested O
whether O
they O
suffer O
higher B_DISEASE/B_BIO
mortality I_DISEASE/I_BIO
in O
winter B_TIME[MEASURE]/B_LOCATION
, O
because O
they O
have O
difficulty B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding O
sufficient B_PERSON/B_LOCATION
food I_PERSON/I_LOCATION
to O
satisfy O
their O
energy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
needs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
because O
the O
additional B_TIME[MEASURE]/B_DISEASE
foraging B_TIME[MEASURE]/I_DISEASE
time B_TIME[MEASURE]/I_DISEASE
would O
result O
in O
increased O
exposure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
predation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

3 B_NUMBER[MEASURE]
. O

We O
measured O
daily B_MEASURE/B_LOCATION
energy I_MEASURE/I_LOCATION
expenditures I_MEASURE/I_LOCATION
( O
dee B_LOCATION
) O
of O
overwintering O
weasel B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
males I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
using O
the O
doubly O
labelled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
water B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
DLW B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
constructed O
an O
energetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predicting O
how O
individuals B_PERSON/B_BIO
of O
different B_BIO/B_MEASURE
size I_BIO/I_MEASURE
are O
able B_TIME[MEASURE]/B_PERSON
to O
balance O
their O
energy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
budgets I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
feeding O
on O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prey B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
while O
minimizing O
time B_TIME[MEASURE]/B_LOCATION
spent O
hunting B_PERSON/B_BIO
, O
thereby O
reducing O
their O
own B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
exposure I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
predation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

4 B_NUMBER[MEASURE]
. O

The O
range B_MEASURE
of O
body B_MEASURE
mass I_MEASURE
in O
overwintering O
weasels B_BIO/B_LOCATION
predicted O
by O
our O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corresponded O
very O
well O
with O
the O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
prey B_MEASURE/B_BIO
body B_MEASURE/I_BIO
mass B_MEASURE/I_BIO
in O
three B_BIO/B_LOCATION
different I_BIO/I_LOCATION
habitats I_BIO/I_LOCATION
within O
our O
study B_LOCATION/B_PERSON
area I_LOCATION/I_PERSON
. O

larger B_PERSON/B_BIO
individuals I_PERSON/I_BIO
were O
able B_TIME[MEASURE]/B_PERSON
to O
compensate O
for O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
food I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
using O
habitats B_LOCATION/B_BIO
with O
larger B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
prey I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
than O
those O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
smaller B_PERSON/B_BIO
male I_PERSON/I_BIO
weasels I_PERSON/I_BIO
. O

This O
effectively O
offset O
the O
expected B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
negative I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
association I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
body B_TIME[MEASURE]/B_LOCATION
mass B_TIME[MEASURE]/I_LOCATION
and O
winter B_DISEASE/B_MEASURE
survival I_DISEASE/I_MEASURE
predicted O
from O
considerations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
energy B_DISEASE_ADJECTIVE[DISEASE]
balance I_DISEASE_ADJECTIVE[DISEASE]
. O

5 B_NUMBER[MEASURE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
how O
energetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
constraints I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
affect O
body B_MEASURE/B_LOCATION
mass B_MEASURE/I_LOCATION
and O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
segregation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
a O
species B_BIO/B_GENE
at O
the O
intra B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
not O
only O
across O
large B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
geographical I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
ranges I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
but O
also O
within O
a O
relatively O
small B_MEASURE/B_LOCATION
area I_MEASURE/I_LOCATION
. O

Bud B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O
in O
poplar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
- O
genetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dissection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
complex B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trait I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
natural B_ORGANIZATION/B_PERSON
and O
hybrid B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
populations I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

* B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
The O
seasonal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
timing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
growth B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
crucial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
tree B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conservation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

The O
seasonal B_TIME[MEASURE]/B_LOCATION
growth B_TIME[MEASURE]/I_LOCATION
cycle B_TIME[MEASURE]/I_LOCATION
is O
strongly O
adapted O
to O
the O
local B_LOCATION/B_MEASURE
climate I_LOCATION/I_MEASURE
that O
is O
changing O
because O
of O
global B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
warming I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
studied O
bud B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
set O
as O
one B_PERSON/B_LOCATION
cornerstone I_PERSON/I_LOCATION
of O
the O
seasonal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cycle I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
an O
integrative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

* B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Bud I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O
was O
dissected O
at O
the O
phenotypic B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
into O
several B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
components B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
phenotypic B_PERSON/B_MEASURE
components I_PERSON/I_MEASURE
with O
most B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genetic B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
variation B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
identified O
. O

While O
phenotypic B_MEASURE
variation I_MEASURE
resided O
in O
the O
timing B_TIME[MEASURE]/B_LOCATION
of O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cessation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
and O
even O
so O
more O
in O
the O
duration B_TIME[MEASURE]/B_LOCATION
from O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cessation B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
to O
bud B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
the O
timing B_MEASURE
of O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cessation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
had O
a O
stronger B_MEASURE/B_PERSON
genetic I_MEASURE/I_PERSON
component I_MEASURE/I_PERSON
in O
both O
natural B_ORGANIZATION/B_PERSON
and O
hybrid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_GENE/B_PERSON
Quantitative I_GENE/I_PERSON
trait I_GENE/I_PERSON
loci I_GENE/I_PERSON
( O
QTL B_PROTEIN[GENE]/B_LOCATION
) O
were O
identified O
for O
the O
most O
discriminative B_MEASURE/B_LOCATION
phenotypic I_MEASURE/I_LOCATION
Bud I_MEASURE/I_LOCATION
- O
set B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
four B_MEASURE/B_LOCATION
poplar I_MEASURE/I_LOCATION
pedigrees I_MEASURE/I_LOCATION
. O

The O
QTL B_GENE
from O
different B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
pedigrees I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O
recurrently O
detected O
in O
six B_LOCATION
regions I_LOCATION
of O
the O
poplar B_GENE/B_LOCATION
genome I_GENE/I_LOCATION
. O

* B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
These O
regions B_LOCATION/B_DISEASE
of O
1 B_MEASURE
. O
83 B_MEASURE
- O
4 B_MEASURE
. O
25 B_MEASURE
Mbp I_MEASURE
in O
size B_MEASURE/B_LOCATION
, O
containing O
between O
202 B_MEASURE
and O
394 B_MEASURE
genes I_MEASURE
, O
form O
the O
basis B_PERSON/B_LOCATION
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dissection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
bud B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Alphacoronavirus O
transmissible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gastroenteritis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
virus B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
nsp1 O
protein O
suppresses O
protein O
translation O
in O
mammalian O
cells O
and O
in O
cell O
- O
free O
HeLa O
cell O
extracts O
but O
not O
in O
rabbit B_SPECIES[BIO]/B_DISEASE
reticulocyte O
lysate O
. O

The O
nsp1 O
protein O
of O
transmissible B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
gastroenteritis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TGEV B_DISEASE/B_SPECIES[BIO]
) O
, O
an O
alphacoronavirus O
, O
efficiently O
suppressed O
protein O
synthesis O
in O
mammalian O
cells O
. O

Unlike O
the O
nsp1 O
protein O
of O
severe B_DISEASE/B_VIRUS[BIO]
acute B_DISEASE/I_VIRUS[BIO]
respiratory B_DISEASE/I_VIRUS[BIO]
syndrome B_DISEASE/I_VIRUS[BIO]
coronavirus B_DISEASE/I_VIRUS[BIO]
, O
a O
betacoronavirus O
, O
the O
TGEV B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
nsp1 O
protein O
was O
unable O
to O
bind O
40S O
ribosomal O
subunits O
or O
promote O
host O
mRNA O
degradation O
. O

TGEV B_SPECIES[BIO]/B_DISEASE
nsp1 O
also O
suppressed O
protein O
translation O
in O
cell O
- O
free O
HeLa O
cell O
extract O
; O
however O
, O
it O
did O
not O
affect O
translation O
in O
rabbit B_SPECIES[BIO]
reticulocyte O
lysate O
( O
RRL O
) O
. O

Our O
data O
suggested O
that O
HeLa O
cell O
extracts O
and O
cultured O
host O
cells O
, O
but O
not O
RRL O
, O
contain O
a O
host O
factor O
( O
s O
) O
that O
is O
essential O
for O
TGEV B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
nsp1 O
- O
induced O
translational O
suppression O
. O

modification O
of O
nonstructural O
protein O
1 O
of O
influenza B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
SUMO1 O
. O

Nonstructural O
protein O
1 O
( O
NS1 O
) O
is O
one O
of O
the O
major O
factors O
resulting O
in O
the O
efficient O
infection O
rate O
and O
high O
level O
of O
virulence O
of O
influenza B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
A I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
consisting O
of O
only O
approximately O
230 B_NUMBER[MEASURE]
amino I_NUMBER[MEASURE]
acids I_NUMBER[MEASURE]
, O
NS1 B_PROTEIN[GENE]/B_BIO
has O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
interfere O
with O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
host B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
viral B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
defense B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
NS1 O
of O
the O
highly O
pathogenic O
avian O
influenza B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
A I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Duck I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Hubei I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
L I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
2004 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
H5N1 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
) I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
interacts O
with O
human B_SPECIES[BIO]/B_GENE
Ubc9 O
, O
which O
is O
the O
E2 O
conjugating O
enzyme O
for O
sumoylation O
, O
and O
we O
show O
that O
SUMO1 O
is O
conjugated O
to O
H5N1 B_DISEASE/B_PERSON
NS1 O
in O
both O
transfected O
and O
infected O
cells O
. O

Furthermore O
, O
two B_LOCATION/B_BIO
lysine I_LOCATION/I_BIO
residues I_LOCATION/I_BIO
in O
the O
C B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
terminus I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
NS1 B_GENE/B_BIO
were O
identified O
as O
SUMO1 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acceptor B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
the O
SUMO1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
acceptor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
removed O
by O
mutation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
NS1 B_GENE/B_BIO
underwent O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
degradation B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

Studies O
of O
different O
influenza B_DISEASE/B_SPECIES[BIO]
A B_DISEASE/I_SPECIES[BIO]
virus B_DISEASE/I_SPECIES[BIO]
strains O
of O
human B_SPECIES[BIO]/B_LOCATION
and O
avian O
origin O
showed O
that O
the O
majority O
of O
viruses O
possess O
an O
NS1 O
protein O
that O
is O
modified O
by O
SUMO1 O
, O
except O
for O
the O
recently O
emerged O
swine B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
origin B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
influenza B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
A B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
virus B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
S B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
OIV B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
) B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
H1N1 B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
) B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Interestingly O
, O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
sumoylation B_GENE
- O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
WSN I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
retarded O
compared O
to O
that O
of O
wild B_PERSON/B_BIO
- O
type B_BIO/B_MEASURE
virus B_BIO/I_MEASURE
. O

Together O
, O
these O
results O
indicate O
that O
sumoylation O
enhances O
NS1 O
stability O
and O
thus O
promotes O
rapid O
growth O
of O
influenza B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
A I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Acclimation O
to O
high O
CO2 O
in O
maize B_BIO/B_LOCATION
is O
related O
to O
water O
status O
and O
dependent O
on O
leaf O
rank O
. O

The O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
C B_PROTEIN[GENE]/B_LOCATION
( O
3 B_NUMBER[MEASURE]/B_LOCATION
) O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
rising O
atmospheric B_LOCATION/B_ORGANIZATION
CO I_LOCATION/I_ORGANIZATION
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
considered O
to O
be O
largely O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exerted O
through O
altered B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
photosynthesis B_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
nature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
C B_PROTEIN[GENE]/B_LOCATION
( O
4 B_TIME[MEASURE]/B_LOCATION
) O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
high B_LOCATION
CO I_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
remains O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
of O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]
of O
CO B_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
photosynthesis B_ORGANISM_FUNCTION/B_BIO
. O

In O
this O
study O
, O
the O
effects O
of O
atmospheric O
CO O
( O
2 O
) O
availability O
on O
the O
transcriptome O
, O
proteome O
and O
metabolome O
profiles O
of O
two O
ranks O
of O
source O
leaves O
in O
maize B_BIO
( O
Zea B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mays B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
L O
. O
) O
were O
studied O
in O
plants O
grown O
under O
ambient O
CO O
( O
2 O
) O
conditions O
( O
350 O
+ O
/ O
- O
20 O
muL O
L O
( O
- O
1 O
) O
CO O
( O
2 O
) O
) O
or O
with O
CO O
( O
2 O
) O
enrichment O
( O
700 O
+ O
/ O
- O
20 O
muL O
L O
( O
- O
1 O
) O
CO O
( O
2 O
) O
) O
. O

Growth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
at O
high B_MEASURE/B_LOCATION
CO I_MEASURE/I_LOCATION
( O
2 B_MEASURE/B_LOCATION
) O
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
photosynthesis B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
photorespiration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O
leaf B_LOCATION
C I_LOCATION
/ O
N B_LOCATION/B_MEASURE
ratios I_LOCATION/I_MEASURE
or O
anthocyanin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contents B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
leaf B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transpiration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
carbohydrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
carbonyl B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
were O
altered O
at O
high B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
CO I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_MEASURE/B_LOCATION
) O
in O
a O
leaf B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
rank B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Although O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
CO B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
leaf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcriptome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
, O
qPCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
that O
the O
abundance B_MEASURE/B_LOCATION
of O
transcripts B_GENE/B_MEASURE
encoding O
a O
Bowman B_DISEASE/B_GENE
- O
Birk B_GENE/B_TIME[MEASURE]
protease I_GENE/I_TIME[MEASURE]
inhibitor I_GENE/I_TIME[MEASURE]
and O
a O
serpin B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
changed O
by O
the O
growth B_LOCATION/B_PERSON
CO I_LOCATION/I_PERSON
( O
2 B_NUMBER[MEASURE]
) O
level B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
in O
a O
leaf B_LOCATION/B_BIO
rank B_LOCATION/I_BIO
specific B_LOCATION/I_BIO
manner B_LOCATION/I_BIO
. O

Moreover O
, O
CO B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
leaf B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteome B_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
most O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
oldest B_BIO/B_TIME[MEASURE]
source I_BIO/I_TIME[MEASURE]
leaves I_BIO/I_TIME[MEASURE]
. O

Small B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
observed O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
high B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
CO I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_MEASURE/B_LOCATION
, O
) O
particularly O
in O
the O
older B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
leaf I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
ranks I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

seasonal O
dynamics O
in O
the O
stable O
carbon O
isotope O
composition O
delta O
^ O
1 O
^ O
3C O
from O
non O
- O
leafy O
branch O
, O
trunk O
and O
coarse O
root O
CO2 O
efflux O
of O
adult O
deciduous O
( O
Fagus B_BIO/B_LOCATION
sylvatica B_BIO/I_LOCATION
) O
and O
evergreen O
( O
Picea B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
abies I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) O
trees O
. O

respiration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
substantial B_PERSON
driver I_PERSON
of O
carbon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
C B_PROTEIN[GENE]/B_LOCATION
) O
flux B_MEASURE/B_DISEASE
in O
forest B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
ecosystems I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
stable B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
isotopes I_LOCATION/I_PERSON
provide O
an O
excellent B_PERSON/B_LOCATION
tool B_PERSON/I_LOCATION
for O
its O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
studied O
seasonal O
dynamics O
in O
delta O
^ O
1 O
^ O
3C O
of O
CO2 O
efflux O
( O
delta O
^ O
1 O
^ O
3C O
( O
E O
) O
) O
from O
non O
- O
leafy O
branches O
, O
upper O
and O
lower O
trunks O
and O
coarse O
roots O
of O
adult O
trees O
, O
comparing O
deciduous O
Fagus B_BIO/B_LOCATION
sylvatica I_BIO/I_LOCATION
( O
European B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
beech I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) O
with O
evergreen O
Picea B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
abies I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
Norway B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
spruce B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
) O
. O

In O
both O
species B_BIO/B_LOCATION
, O
we O
observed O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
seasonal I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dynamics I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
delta B_PROTEIN[GENE]
^ O
1 B_PROTEIN[GENE]/B_LOCATION
^ I_PROTEIN[GENE]/I_LOCATION
3C I_PROTEIN[GENE]/I_LOCATION
( O
E B_OTHER/B_PROTEIN[GENE]
) O
of O
above O
- O
ground B_BIO/B_LOCATION
plant I_BIO/I_LOCATION
components I_BIO/I_LOCATION
, O
whereas O
delta B_PROTEIN[GENE]
^ O
1 B_PROTEIN[GENE]/B_MEASURE
^ I_PROTEIN[GENE]/I_MEASURE
3C I_PROTEIN[GENE]/I_MEASURE
( O
E B_OTHER/B_PROTEIN[GENE]
) O
of O
coarse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
roots I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O
rather O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

During O
summer B_TIME[MEASURE]/B_LOCATION
, O
delta B_MEASURE/B_PERSON
^ I_MEASURE/I_PERSON
1 I_MEASURE/I_PERSON
^ I_MEASURE/I_PERSON
3C I_MEASURE/I_PERSON
( O
E B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
trunks B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
about O
- O
28 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
( O
Beech B_BIO/B_LOCATION
) O
and O
- O
26 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
Spruce B_LOCATION/B_DISEASE
) O
. O

During O
winter B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
dormancy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O
delta B_LOCATION/B_PROTEIN[GENE]
^ O
1 B_MEASURE
^ I_MEASURE
3C I_MEASURE
( O
E B_OTHER/B_MEASURE
) O
increased O
by O
5 B_NUMBER[MEASURE]
. O
6 B_MEASURE
- O
9 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
. O

The O
observed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dynamics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
likely O
related O
to O
a O
switch B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
to O
starch B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
during O
fall B_DISEASE/B_TIME[MEASURE]
and O
remobilization B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
starch B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
low B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TCA I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
accumulation B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE
of O
malate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
PEPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
during O
winter B_TIME[MEASURE]/B_LOCATION
. O

The O
seasonal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
delta I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
^ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
^ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3C I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
E B_OTHER/B_MEASURE
) O
pattern B_MEASURE/B_DISEASE
of O
branches B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
Beech B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
upper B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
trunks B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
Spruce B_DISEASE/B_BIO
was O
less O
variable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
probably O
because O
these O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O
additionally O
supplied O
by O
winter B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
photosynthesis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pervious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
conclude O
that O
the O
pronounced O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
delta B_LOCATION/B_PROTEIN[GENE]
^ O
1 B_MEASURE/B_LOCATION
^ I_MEASURE/I_LOCATION
3C I_MEASURE/I_LOCATION
( O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
trunks B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O
the O
winter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
interrupted B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
access I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
to O
recent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
photosynthates I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
atypical O
OmpR O
/ O
PhoB O
response O
regulator O
ChxR O
from O
Chlamydia B_BACTERIUM[BIO]
trachomatis I_BACTERIUM[BIO]
forms O
homodimers O
in O
vivo O
and O
binds O
a O
direct O
repeat O
of O
nucleotide O
sequences O
. O

Two B_NUMBER[MEASURE]
- O
component B_LOCATION/B_PERSON
signal I_LOCATION/I_PERSON
transduction I_LOCATION/I_PERSON
systems I_LOCATION/I_PERSON
are O
widespread B_DISEASE_ADJECTIVE[DISEASE]
in O
bacteria B_BIO
and O
are O
essential B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
for O
many B_DISEASE/B_ORGANISM_FUNCTION
biological I_DISEASE/I_ORGANISM_FUNCTION
processes I_DISEASE/I_ORGANISM_FUNCTION
. O

These O
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
predominantly O
rely O
on O
a O
sensor B_ENZYME[GENE]/B_LOCATION
kinase I_ENZYME[GENE]/I_LOCATION
to O
phosphorylate O
a O
response B_GENE/B_MEASURE
regulator I_GENE/I_MEASURE
for O
controlling O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
, O
which O
is O
frequently O
transcriptional B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
regulation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

In O
recent B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
, O
an O
increasing O
number B_MEASURE/B_LOCATION
of O
atypical B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulators I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
discovered O
in O
phylogenetically O
diverse B_BIO
bacteria I_BIO
. O

These O
atypical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
not O
controlled O
by O
phosphorylation B_GENE
and O
exhibit B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
transcriptional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
in O
their O
wild B_BIO/B_GENE
- O
type B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

relatively O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
regarding O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utilized O
by O
these O
atypical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
conserved O
characteristics B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
atypical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
regulators I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Chlamydia B_BACTERIUM[BIO]
spp I_BACTERIUM[BIO]
. O
are O
medically O
important B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
bacteria I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
and O
encode O
an O
atypical B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
OmpR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
PhoB B_LOCATION/B_BACTERIUM[BIO]
subfamily O
response B_GENE/B_TIME[MEASURE]
regulator I_GENE/I_TIME[MEASURE]
termed O
ChxR B_GENE/B_DISEASE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
supports O
that O
ChxR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
likely O
exerting O
its O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
middle B_DISEASE_ADJECTIVE[DISEASE]
and O
late B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stages I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
chlamydial B_DISEASE/B_BIO
developmental I_DISEASE/I_BIO
cycle I_DISEASE/I_BIO
, O
stages B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
include O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
infectious B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
elementary B_DISEASE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
bodies B_DISEASE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
the O
absence B_DISEASE/B_LOCATION
of O
detectable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphorylation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
, O
ChxR B_GENE/B_BIO
formed O
homodimers B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
phosphorylated B_GENE/B_DISEASE
OmpR I_GENE/I_DISEASE
/ O
PhoB B_LOCATION
subfamily O
response B_GENE/B_MEASURE
regulator I_GENE/I_MEASURE
. O

ChxR B_GENE
was O
demonstrated O
to O
bind O
to O
its O
own B_PERSON/B_GENE
promoter I_PERSON/I_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
supporting O
the O
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ChxR B_GENE
as O
an O
autoactivator B_GENE/B_PERSON
. O

Detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
ChxR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O
its O
own B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
revealed O
a O
conserved B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cis B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
acting O
motif B_LOCATION/B_GENE
that O
includes O
a O
tandem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
repeat I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

ChxR B_GENE
binds O
specifically O
to O
each O
of O
the O
individual B_PROTEIN[GENE]/B_LOCATION
sites I_PROTEIN[GENE]/I_LOCATION
and O
exhibits O
a O
relatively O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spectrum B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
differential B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

taken O
together O
, O
these O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
ChxR B_GENE/B_DISEASE
, O
in O
the O
absence B_DISEASE/B_LOCATION
of O
phosphorylation B_GENE
, O
exhibits O
many B_NUMBER[MEASURE]/B_PERSON
of O
the O
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
phosphorylated B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
active B_DISEASE
) O
OmpR B_GENE/B_BACTERIUM[BIO]
/ O
PhoB B_LOCATION
subfamily O
response B_GENE/B_MEASURE
regulator I_GENE/I_MEASURE
. O

Cold O
stress O
contributes O
to O
aberrant O
cytokinesis O
during O
male O
meiosis O
I O
in O
a O
wheat B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
thermosensitive O
genic O
male O
sterile O
line O
. O

The O
male O
sterility O
of O
a O
wheat B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
thermosensitive O
genic O
male O
sterile O
( O
TGMS O
) O
line O
is O
strictly O
controlled O
by O
temperature O
. O

When O
the O
TGMS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
BS366 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
exposed O
to O
10 B_MEASURE/B_LOCATION
^ O
0C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
the O
pollen B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mother I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
meiosis B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
few B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pollen B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
grains B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
formed O
and O
devoid B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
starch B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
report O
here O
a O
large O
- O
scale O
transcriptomic O
study O
using O
the O
Affymetrix O
wheat B_SPECIES[BIO]/B_LOCATION
GeneChip O
to O
follow O
gene O
expression O
in O
BS366 O
line O
anthers O
in O
response O
to O
cold O
stress O
. O

notably O
, O
many B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
components I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
gradually O
induced O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cold B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BS366 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
anthers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

However O
, O
the O
cytoskeleton B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
associated O
genes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
play O
key B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
roles I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
dynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
organization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cytoskeleton B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
dramatically O
repressed O
. O

Histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
that O
the O
separation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
dyads B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
occurred O
abnormally O
during O
male B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
meiosis I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
I O
, O
indicating O
defective B_DISEASE/B_ORGANISM_FUNCTION
male I_DISEASE/I_ORGANISM_FUNCTION
meiotic I_DISEASE/I_ORGANISM_FUNCTION
cytokinesis I_DISEASE/I_ORGANISM_FUNCTION
. O

Fluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labelling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
subcellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histological I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
the O
phragmoplast B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
defectively O
formed O
and O
the O
cell B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
plate I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O
abnormally O
assembled O
during O
meiosis B_TIME[MEASURE]/B_LOCATION
I O
under O
cold B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
the O
transcriptomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
characterized B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
histological I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
cold B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repressed O
transcription B_GENE
of O
cytoskeleton B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dynamic I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
subsequently O
caused O
the O
defective B_DISEASE_ADJECTIVE[DISEASE]
cytokinesis I_DISEASE_ADJECTIVE[DISEASE]
during O
meiosis B_DISEASE/B_PROTEIN[GENE]
I O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O
explain O
the O
male B_DISEASE_ADJECTIVE[DISEASE]
sterility I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
low B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperature B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
wheat B_LOCATION/B_ORGANIZATION
TGMS I_LOCATION/I_ORGANIZATION
lines I_LOCATION/I_ORGANIZATION
. O

Characterizing O
the O
role O
of O
RNA O
silencing O
components O
in O
Cryptococcus B_DISEASE/B_SPECIES[BIO]
neoformans I_DISEASE/I_SPECIES[BIO]
. O

The O
RNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
interference B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
RNAi B_LOCATION/B_ORGANIZATION
) O
mediated O
by O
homology B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
degradation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
target B_GENE
mRNA I_GENE
with O
small B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plays O
a O
key B_PERSON/B_LOCATION
role I_PERSON/I_LOCATION
in O
controlling O
transcription B_GENE
and O
translation B_GENE/B_ORGANISM_FUNCTION
processes B_GENE/I_ORGANISM_FUNCTION
in O
a O
number B_MEASURE/B_PERSON
of O
eukaryotic B_BIO/B_LOCATION
organisms I_BIO/I_LOCATION
. O

The O
RNAi B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
machinery I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
also O
evolutionarily O
conserved O
in O
a O
wide B_MEASURE/B_ENT
variety I_MEASURE/I_ENT
of O
fungal B_BIO
species I_BIO
, O
including O
pathogenic B_SPECIES[BIO]
fungi I_SPECIES[BIO]
. O

To O
elucidate O
the O
physiological O
functions O
of O
the O
RNAi O
pathway O
in O
Cryptococcus B_SPECIES[BIO]/B_DISEASE
neoformans I_SPECIES[BIO]/I_DISEASE
that O
causes O
fungal O
meningitis O
, O
here O
we O
performed O
genetic O
analyses O
for O
genes O
encoding O
Argonaute O
( O
AGO1 O
and O
AGO2 O
) O
, O
RNA O
- O
dependent O
RNA O
polymerase O
( O
RDP1 O
) O
, O
and O
Dicers O
( O
DCR1 O
and O
DCR2 O
) O
in O
both O
serotype O
A O
and O
D O
C B_BIO/B_DISEASE
. I_BIO/I_DISEASE
neoformans I_BIO/I_DISEASE
. O

The O
present O
study O
shows O
that O
Ago1 O
, O
Rdp1 O
, O
and O
Dcr2 O
are O
the O
major O
components O
of O
the O
RNAi O
process O
occurring O
in O
C B_BIO
. I_BIO
neoformans I_BIO
. O

However O
, O
the O
RNAi B_GENE/B_BIO
machinery I_GENE/I_BIO
is O
not O
involved O
in O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
production B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
virulence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
capsule B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
melanin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
sexual B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
diverse B_DISEASE/B_ORGANISM_FUNCTION
stress I_DISEASE/I_ORGANISM_FUNCTION
response I_DISEASE/I_ORGANISM_FUNCTION
. O

Comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
serotype B_PROTEIN[GENE]/B_BACTERIUM[BIO]
A I_PROTEIN[GENE]/I_BACTERIUM[BIO]
and O
D B_PROTEIN[GENE]/B_BIO
RNAi I_PROTEIN[GENE]/I_BIO
mutants I_PROTEIN[GENE]/I_BIO
revealed O
that O
only B_DISEASE_ADJECTIVE[DISEASE]
modest I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
occur O
in O
the O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
wide B_MEASURE/B_LOCATION
transcriptome I_MEASURE/I_LOCATION
profiles I_MEASURE/I_LOCATION
when O
the O
RNAi B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
perturbed O
. O

notably O
, O
the O
serotype O
D O
rdp1Delta O
mutants O
showed O
an O
increase O
in O
transcript O
abundance O
of O
active O
retrotransposons O
and O
transposons O
, O
such O
as O
T2 O
and O
T3 O
, O
the O
latter O
of O
which O
is O
a O
novel O
serotype O
D O
- O
specific O
transposon O
of O
C B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
neoformans I_SPECIES[BIO]/I_LOCATION
. O

In O
a O
wild B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
background I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
both O
T2 B_PROTEIN[GENE]
and O
T3 B_PROTEIN[GENE]
were O
found O
to O
be O
weakly O
active B_DISEASE_ADJECTIVE[DISEASE]
mobile I_DISEASE_ADJECTIVE[DISEASE]
elements I_DISEASE_ADJECTIVE[DISEASE]
, O
although O
we O
found O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Cnl1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
retrotransposon B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
mobility B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
all O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transposable I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibited O
enhanced B_DISEASE_ADJECTIVE[DISEASE]
mobility I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
rdp1Delta B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mutant B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
strain B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
conclusion O
, O
the O
RNAi O
pathway O
plays O
an O
important O
role O
in O
controlling O
transposon O
activity O
and O
genome O
integrity O
of O
C B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
neoformans I_SPECIES[BIO]/I_GENE
. O

fur O
negatively O
regulates O
hns O
and O
is O
required O
for O
the O
expression O
of O
HilA O
and O
virulence O
in O
Salmonella B_BACTERIUM[BIO]
enterica I_BACTERIUM[BIO]
serovar O
Typhimurium O
. O

Iron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
an O
essential B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
living O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

However O
, O
excess B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iron B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
toxic B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
its O
uptake B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
exquisitely O
regulated O
by O
the O
ferric B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulator I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
fur B_GENE
. O

In O
Salmonella B_SPECIES[BIO]
, O
the O
Salmonella B_BACTERIUM[BIO]/B_GENE
pathogenicity B_BACTERIUM[BIO]/I_GENE
island B_BACTERIUM[BIO]/I_GENE
1 B_BACTERIUM[BIO]/I_GENE
( O
SPI B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
) O
encodes B_GENE/B_MEASURE
a O
type B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
three I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
secretion I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
required O
for O
invasion B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
host B_BACTERIUM[BIO]/B_DISEASE
epithelial I_BACTERIUM[BIO]/I_DISEASE
cells I_BACTERIUM[BIO]/I_DISEASE
in O
the O
small B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
intestine I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
major B_GENE/B_MEASURE
activator I_GENE/I_MEASURE
of O
SPI B_LOCATION
- O
1 B_NUMBER[MEASURE]
is O
HilA B_GENE/B_BACTERIUM[BIO]
, O
which O
is O
encoded O
within O
SPI B_LOCATION/B_ORGANIZATION
- O
1 B_NUMBER[MEASURE]
. O

One B_NUMBER[MEASURE]/B_PERSON
known O
regulator B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
hilA B_BACTERIUM[BIO]/B_DISEASE
is O
fur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
mechanism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
hilA B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regulation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
fur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
here O
that O
fur O
is O
required O
for O
virulence O
in O
Salmonella B_BACTERIUM[BIO]
enterica I_BACTERIUM[BIO]
serovar O
Typhimurium O
and O
that O
fur O
is O
required O
for O
the O
activation O
of O
hilA O
, O
as O
well O
as O
of O
other O
HilA O
- O
dependent O
genes O
, O
invF O
and O
sipC O
. O

The O
fur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
hilA B_BACTERIUM[BIO]/B_GENE
was O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
PhoP B_GENE/B_BACTERIUM[BIO]
, O
a O
known O
repressor B_GENE/B_PERSON
of O
hilA B_BACTERIUM[BIO]/B_GENE
. O

Instead O
, O
the O
expression B_GENE
of O
the O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
histone B_GENE
- O
like B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
HNS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
significantly O
derepressed O
in O
the O
fur B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mutant B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Indeed O
, O
the O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hilA B_GENE/B_BACTERIUM[BIO]
by O
fur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O
28 B_GENE/B_LOCATION
nucleotides I_GENE/I_LOCATION
located O
upstream O
of O
HNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Moreover O
, O
we O
used O
chromatin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immunoprecipitation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
show O
that O
fur B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O
, O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
to O
the O
upstream B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
HNS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fashion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Finally O
, O
deletion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fur B_GENE/B_LOCATION
in O
an O
HNS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
fur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
hilA B_GENE/B_BACTERIUM[BIO]
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
fur B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activates I_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hilA O
by O
repressing O
the O
expression B_GENE
of O
HNS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulates O
the O
type B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
III B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
system B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
through O
MexS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PtrC B_DISEASE/B_GENE
in O
Pseudomonas B_SPECIES[BIO]
aeruginosa I_SPECIES[BIO]
. O

The O
type B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
III I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
secretion I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
system I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
T3SS B_DISEASE/B_LOCATION
) O
is O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
virulence I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
factor I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
in O
Pseudomonas B_BACTERIUM[BIO]
aeruginosa I_BACTERIUM[BIO]
, O
and O
its O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
varies O
in O
different B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
isolates I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
studied O
the O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
such B_DISEASE/B_ORGANISM_FUNCTION
differences I_DISEASE/I_ORGANISM_FUNCTION
in O
two B_MEASURE/B_BACTERIUM[BIO]
laboratory I_MEASURE/I_BACTERIUM[BIO]
strains I_MEASURE/I_BACTERIUM[BIO]
, O
Pak B_PROTEIN[GENE]/B_BACTERIUM[BIO]
and O
PAO1 B_SPECIES[BIO]/B_PERSON
. O

A O
chromosomal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
library I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
high B_DISEASE/B_GENE
- O
T3SS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
producer B_LOCATION/B_PERSON
strain I_LOCATION/I_PERSON
Pak I_LOCATION/I_PERSON
was O
introduced O
into O
the O
low B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
producer B_LOCATION/B_MEASURE
strain I_LOCATION/I_MEASURE
PAO1 I_LOCATION/I_MEASURE
, O
and O
we O
found O
that O
a O
mexS B_GENE
gene I_GENE
from O
Pak B_PERSON/B_LOCATION
confers O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
T3SS I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expression I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
PAO1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
both O
mexS B_GENE/B_LOCATION
and O
its O
neighboring B_GENE/B_PERSON
mexT I_GENE/I_PERSON
gene I_GENE/I_PERSON
are O
required O
for O
the O
repression B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
T3SS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
PAO1 B_GENE
, O
while O
the O
Pak B_GENE/B_SEQUENCE[MEASURE]
genome I_GENE/I_SEQUENCE[MEASURE]
encodes O
a O
defective B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MexS I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
accounting O
for O
the O
derepression B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
Pak B_BIO
and O
the O
dominant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
it O
is O
introduced O
into O
PAO1 B_GENE
. O

MexS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
a O
probable B_ENZYME[GENE]
oxidoreductase I_ENZYME[GENE]
whose O
expression B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
is O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
LysR B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
type B_ENZYME[GENE]/B_PERSON
transcriptional I_ENZYME[GENE]/I_PERSON
regulator I_ENZYME[GENE]/I_PERSON
. O

Various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
genetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
support O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
MexS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modulates O
the O
transcriptional B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulator I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
function I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
MexT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
searching O
for O
the O
MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_GENE/B_LOCATION
repressor I_GENE/I_LOCATION
of O
the O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
a O
small B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
product I_GENE/I_MEASURE
of O
PA2486 B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ptrC B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
found O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
suppressing O
the O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
upon O
overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ptrC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
PAO1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
did O
not O
result O
in O
derepression B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
T3SS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
indicating O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
another O
repressor B_GENE/B_PERSON
for O
the O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

Interestingly O
, O
overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
functional B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mexS I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
was O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
repress O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
even O
in O
the O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
suggesting O
that O
MexS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
another O
mediator B_PERSON/B_MEASURE
of O
MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
T3SS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
repression B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

Overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mexS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
well O
- O
known O
MexT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
- O
dependent B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
, O
including O
those O
encoding O
MexEF B_ENZYME[GENE]
efflux I_ENZYME[GENE]
pump I_ENZYME[GENE]
, O
elastase B_GENE
, O
and O
pyocyanin B_ENZYME[GENE]/B_BIO
, O
indicating O
alternative B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
been O
proposed O
for O
the O
MexS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
MexT B_LOCATION/B_ORGANIZATION
- O
mediated O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
the O
T3SS B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
MexEF B_GENE
efflux I_GENE
pump I_GENE
, O
and O
the O
production B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
elastase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
and O
pyocyanin B_ENZYME[GENE]/B_BIO
. O

Complete O
genome O
sequence O
of O
the O
haloaromatic O
acid O
- O
degrading O
bacterium O
Achromobacter B_BACTERIUM[BIO]/B_LOCATION
xylosoxidans B_BACTERIUM[BIO]/I_LOCATION
A8 B_BACTERIUM[BIO]/I_LOCATION
. O

Achromobacter B_BACTERIUM[BIO]
xylosoxidans I_BACTERIUM[BIO]
strain I_BACTERIUM[BIO]
A8 I_BACTERIUM[BIO]
was O
isolated O
from O
soil O
contaminated O
with O
polychlorinated O
biphenyls O
. O

It O
can O
use O
2 B_MEASURE
- O
chlorobenzoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
- O
dichlorobenzoate B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
sole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sources I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
carbon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
energy B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
property B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
makes O
it O
a O
good B_BACTERIUM[BIO]/B_PERSON
starting I_BACTERIUM[BIO]/I_PERSON
microorganism I_BACTERIUM[BIO]/I_PERSON
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
toward O
a O
bioremediation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tool I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
genome O
of O
A B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
xylosoxidans I_BACTERIUM[BIO]
consists O
of O
a O
7 O
- O
MB O
chromosome O
and O
two O
large O
plasmids O
( O
98 O
kb O
and O
248 O
kb O
) O
. O

Besides O
genes B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
utilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
xenobiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
organic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
substrates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
contains O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
pathogenesis B_DISEASE/B_ORGANISM_FUNCTION
, O
toxin B_DISEASE/B_ORGANISM_FUNCTION
production I_DISEASE/I_ORGANISM_FUNCTION
, O
and O
resistance B_DISEASE/B_ORGANISM_FUNCTION
. O

Here O
, O
we O
report O
the O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Complete O
genome O
sequences O
of O
three O
Erwinia B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
amylovora B_BIO/I_DISEASE_ADJECTIVE[DISEASE]
phages O
isolated O
in O
north O
America O
and O
a O
bacteriophage O
induced O
from O
an O
Erwinia B_BIO/B_LOCATION
tasmaniensis B_BIO/I_LOCATION
strain O
. O

Fire O
blight O
, O
a O
plant O
disease O
of O
economic O
importance O
caused O
by O
Erwinia B_BIO
amylovora I_BIO
, O
may O
be O
controlled O
by O
the O
application O
of O
bacteriophages O
. O

Here O
, O
we O
provide O
the O
complete O
genome O
sequences O
and O
the O
annotation O
of O
three O
E B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
amylovora I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific O
phages O
isolated O
in O
North O
America O
and O
genomic O
information O
about O
a O
bacteriophage O
induced O
by O
mitomycin O
C O
treatment O
of O
an O
Erwinia B_SPECIES[BIO]
tasmaniensis I_SPECIES[BIO]
strain O
that O
is O
antagonistic O
for O
E B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
amylovora I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
American O
phages O
resemble O
two O
already O
- O
described O
viral O
genomes O
, O
whereas O
the O
E B_LOCATION/B_PERSON
. I_LOCATION/I_PERSON
tasmaniensis I_LOCATION/I_PERSON
phage O
displays O
a O
singular O
genomic O
sequence O
in O
blast O
searches O
. O

promoter O
discrimination O
at O
class O
I O
Mara O
regulon O
promoters O
mediated O
by O
glutamic O
acid O
89 O
of O
the O
Mara O
transcriptional O
activator O
of O
Escherichia B_BACTERIUM[BIO]/B_GENE
coli B_BACTERIUM[BIO]/I_GENE
. O

Three O
paralogous O
transcriptional O
activators O
Mara O
, O
SoxS O
, O
and O
Rob O
, O
activate O
> O
40 O
Escherichia B_BACTERIUM[BIO]/B_PERSON
coli I_BACTERIUM[BIO]/I_PERSON
promoters O
. O

To O
understand O
why O
MarA B_GENE/B_DISEASE
does O
not O
activate O
certain B_GENE/B_MEASURE
promoters I_GENE/I_MEASURE
as O
strongly O
as O
SoxS B_GENE/B_LOCATION
, O
we O
compared O
Mara B_PERSON/B_GENE
, O
Mara B_LOCATION/B_PERSON
mutants I_LOCATION/I_PERSON
, O
and O
SoxS B_GENE/B_BIO
for O
their O
abilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
activate O
16 B_GENE/B_PERSON
promoters I_GENE/I_PERSON
and O
to O
bind O
their O
cognate B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
marbox I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
binding O
sites B_LOCATION/B_ENT
. O

Replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
MarA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glutamic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
residue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
89 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greatly O
increased O
the O
marbox B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
activation B_GENE
of O
many B_MEASURE/B_LOCATION
class I_MEASURE/I_LOCATION
I O
promoters B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Like O
cells B_GENE/B_PERSON
constitutive I_GENE/I_PERSON
for O
SoxS B_GENE
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
expressing O
the O
MarA B_GENE/B_DISEASE
with O
the O
E89A B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
more O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
superoxides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
than O
those O
harboring O
WT B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Mara I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
activities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
several B_PERSON/B_ORGANIZATION
other I_PERSON/I_ORGANIZATION
E89 I_PERSON/I_ORGANIZATION
substitutions I_PERSON/I_ORGANIZATION
ranked O
as O
follows O
: O
E89A B_LOCATION
> I_LOCATION
E89G I_LOCATION
> I_LOCATION
E89V I_LOCATION
> O
WT B_GENE
> I_GENE
E89D I_GENE
. O

increased O
binding B_GENE
and O
activation B_GENE
occurred O
only O
at O
class B_PERSON/B_MEASURE
I O
promoters O
when O
the O
12th B_LOCATION/B_MEASURE
base I_LOCATION/I_MEASURE
of O
the O
promoter B_GENE/B_LOCATION
' O
s B_LOCATION/B_PERSON
marbox I_LOCATION/I_PERSON
( O
a O
position B_LOCATION/B_MEASURE
at O
which O
there O
is O
no O
known O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
the O
marbox B_GENE/B_LOCATION
and O
MarA B_GENE/B_DISEASE
) O
was O
not O
a O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
residue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Furthermore O
, O
WT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
MarA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
a O
synthetic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
marbox I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
enhanced O
when O
the O
phosphate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
positions B_NUMBER[MEASURE]
12 I_NUMBER[MEASURE]
and O
13 B_MEASURE
was O
eliminated O
on O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O
that O
relatively O
minor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
side B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
e O
. O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
, O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
valine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
glutamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
aspartic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
can O
strongly O
influence O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
despite O
any O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
the O
side B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
involved O
in O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
either O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
RNA B_GENE
polymerase I_GENE
. O

We O
present O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
which O
attributes O
the O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
binding O
and O
activation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
interference B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
Beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
gamma B_PROTEIN[GENE]/B_MEASURE
- O
carbons B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
position B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
89 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
phosphate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O
positions B_NUMBER[MEASURE]
12 I_NUMBER[MEASURE]
and O
13 B_MEASURE
. O

A O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
driven O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
quantify O
migration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
individual B_PERSON/B_LOCATION
, O
regional B_LOCATION/B_ORGANIZATION
and O
yearly B_MEASURE/B_LOCATION
differences B_MEASURE/I_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

Animal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
migration B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
has O
long O
intrigued O
scientists B_PERSON/B_SPORT[ENT]
and O
wildlife B_PERSON/B_ORGANIZATION
managers I_PERSON/I_ORGANIZATION
alike O
, O
yet O
migratory B_PERSON/B_BIO
species I_PERSON/I_BIO
face O
increasing O
challenges B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O
of O
habitat B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fragmentation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
climate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
over B_MEASURE/B_DISEASE
- O
exploitation B_ORGANIZATION/B_PERSON
. O

Central B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
migratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
species I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
the O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
discrimination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
migratory B_PERSON/B_LOCATION
and O
nonmigratory B_PERSON/B_LOCATION
individuals I_PERSON/I_LOCATION
in O
a O
given O
population B_PERSON/B_LOCATION
, O
quantifying O
the O
timing B_MEASURE/B_LOCATION
, O
duration B_MEASURE/B_LOCATION
and O
distance B_MEASURE/B_LOCATION
of O
migration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
predict O
migratory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movements I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

2 B_NUMBER[MEASURE]
. O

Here O
, O
we O
propose O
a O
uniform B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
statistical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
framework I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
( O
i O
) O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
migration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movement B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behaviours B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
quantify O
migration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
without O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O
arbitrary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cut O
- O
off O
criteria B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
( O
iii B_DISEASE/B_PROTEIN[GENE]
) O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
predictability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
across O
individuals B_PERSON/B_MEASURE
, O
time B_MEASURE/B_LOCATION
and O
space B_LOCATION/B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

We O
first O
validated O
our O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
simulating O
data B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
based O
on O
established O
theoretical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
then O
formulated O
the O
expected B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shapes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
squared B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displacement B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
nonlinear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
a O
suite B_MEASURE
of O
movement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
behaviours I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
test O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
our O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
between O
migratory B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
movement I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movement B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

4 B_NUMBER[MEASURE]
. O

We O
then O
tested O
our O
approached O
empirically O
using O
108 O
wild O
Global O
positioning O
System O
( O
GPS O
) O
- O
collared O
moose B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Alces I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
alces I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
in O
Scandinavia O
as O
a O
study O
system O
because O
they O
exhibit O
a O
wide O
range O
of O
movement O
behaviours O
, O
including O
resident O
, O
migrating O
and O
dispersing O
individuals O
, O
within O
the O
same O
population O
. O

applying O
our O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
87 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
67 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
our O
Swedish B_PERSON/B_LOCATION
and O
Norwegian B_PERSON/B_LOCATION
subpopulations I_PERSON/I_LOCATION
, O
respectively O
, O
can O
be O
classified O
as O
migratory B_PERSON/B_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

Using O
nonlinear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mixed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
all O
migratory B_PERSON/B_BIO
individuals I_PERSON/I_BIO
we O
showed O
that O
the O
distance B_MEASURE/B_LOCATION
, O
timing B_MEASURE/B_LOCATION
and O
duration B_MEASURE/B_LOCATION
of O
migration B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differed O
between O
the O
sexes B_BIO/B_PERSON
and O
between O
years B_TIME[MEASURE]/B_PERSON
, O
with O
additional B_MEASURE/B_PERSON
individual B_MEASURE/I_PERSON
differences B_MEASURE/I_PERSON
accounting O
for O
a O
large B_MEASURE
part I_MEASURE
of O
the O
variation B_MEASURE
in O
the O
distance B_MEASURE/B_LOCATION
of O
migration B_PERSON/B_LOCATION
but O
not O
in O
the O
timing B_MEASURE/B_LOCATION
or O
duration B_MEASURE/B_LOCATION
. O

Overall O
, O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
explained O
most B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
variation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
also O
had O
high B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predictive I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
power I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
same B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individuals B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
time B_TIME[MEASURE]/B_PERSON
( O
69 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
as O
well O
as O
between O
study B_PERSON/B_LOCATION
populations I_PERSON/I_LOCATION
( O
74 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

6 B_NUMBER[MEASURE]
. O

The O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
predictive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
ability I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
suggests O
that O
it O
can O
help O
increase O
our O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
drivers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
migration B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
could O
provide O
key B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
quantitative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
understanding O
and O
managing O
a O
broad B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
migratory B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
species I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Citrate O
uptake O
in O
exchange O
with O
intermediates O
in O
the O
citrate O
metabolic O
pathway O
in O
Lactococcus B_SPECIES[BIO]
lactis I_SPECIES[BIO]
IL1403 O
. O

Carbohydrate O
/ O
citrate O
cometabolism O
in O
Lactococcus B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
lactis I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
results O
in O
the O
formation O
of O
the O
flavor O
compound O
acetoin O
. O

resting O
cells O
of O
strain O
IL1403 B_PROTEIN[GENE]
( O
pFL3 O
) O
rapidly O
consumed O
citrate O
while O
producing O
acetoin O
when O
substoichiometric O
concentrations O
of O
glucose O
or O
l O
- O
lactate O
were O
present O
. O

A O
proton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
motive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
force I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
generated O
by O
electrogenic B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
exchange B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalyzed O
by O
the O
citrate B_ENZYME[GENE]/B_LOCATION
transporter I_ENZYME[GENE]/I_LOCATION
CitP I_ENZYME[GENE]/I_LOCATION
and O
proton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consumption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
decarboxylation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
pathway B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
the O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
l B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
consumption B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O
biphasic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

During O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
hardly O
any O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
consumed O
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
converted O
rapidly O
, O
but O
without O
the O
formation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acetoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Instead O
, O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
intermediates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyruvate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
acetolactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
end B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
excreted O
from O
the O
cells B_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
is O
shown O
that O
the O
intermediates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
acetate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
excreted O
in O
exchange B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
uptake B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalyzed O
by O
CitP B_ENZYME[GENE]/B_BACTERIUM[BIO]
. O

The O
availability B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exchangeable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cytoplasm B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
determines O
both O
the O
rate B_MEASURE
of O
citrate B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
end B_MEASURE/B_ORGANIZATION
product I_MEASURE/I_ORGANIZATION
profile I_MEASURE/I_ORGANIZATION
. O

It O
follows O
that O
citrate O
metabolism O
in O
L B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
lactis I_BACTERIUM[BIO]/I_DISEASE
IL1403 O
( O
pFL3 O
) O
splits O
up O
in O
two O
routes O
after O
the O
formation O
of O
pyruvate O
, O
one O
the O
well O
- O
characterized O
route O
yielding O
acetoin O
and O
the O
other O
a O
new O
route O
yielding O
acetate O
. O

The O
flux B_MEASURE/B_LOCATION
distribution I_MEASURE/I_LOCATION
between O
the O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
branches I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
changes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
from O
85 B_MEASURE
: O
15 B_MEASURE
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
l B_PROTEIN[GENE]/B_DISEASE
- O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
30 B_MEASURE
: O
70 B_MEASURE
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
pyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
proton B_MEASURE/B_PERSON
motive I_MEASURE/I_PERSON
force I_MEASURE/I_PERSON
generated O
was O
greatest B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
l B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
zero B_MEASURE
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggesting O
that O
the O
pathway B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
acetate O
does O
not O
generate O
proton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
motive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
force I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Interbacterial O
macromolecular O
transfer O
by O
the O
Campylobacter B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
fetus I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
subsp I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
venerealis I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
type O
IV O
secretion O
system O
. O

We O
report O
here O
the O
first O
demonstration O
of O
intra O
- O
and O
interspecies O
conjugative O
plasmid O
DNA O
transfer O
for O
Campylobacter B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fetus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Gene O
regions O
carried O
by O
a O
Campylobacter B_BACTERIUM[BIO]/B_GENE
coli B_BACTERIUM[BIO]/I_GENE
plasmid O
were O
identified O
that O
are O
sufficient O
for O
conjugative O
mobilization O
to O
Escherichia B_SPECIES[BIO]
coli I_SPECIES[BIO]
and O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
fetus I_PERSON/I_SPECIES[BIO]
recipients O
. O

A O
broader B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
range I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
predicted O
. O

efficient O
DNA O
transfer O
involves O
the O
virB9 O
and O
virD4 O
genes O
of O
the O
type O
IV O
bacterial O
secretion O
system O
encoded O
by O
a O
pathogenicity O
island O
of O
C B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
fetus I_BACTERIUM[BIO]
subsp I_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
venerealis I_BACTERIUM[BIO]
. O

Complementation O
of O
these O
phenotypes O
from O
expression O
constructions O
based O
on O
the O
promoter O
of O
the O
C B_DISEASE/B_SPECIES[BIO]
. B_DISEASE/I_SPECIES[BIO]
fetus B_DISEASE/I_SPECIES[BIO]
surface O
antigen O
protein O
( O
sap O
) O
locus O
was O
temperature O
dependent O
, O
and O
a O
temperature O
regulation O
of O
the O
sap O
promoter O
was O
subsequently O
confirmed O
under O
laboratory O
conditions O
. O

Gene O
transfer O
was O
sensitive O
to O
surface O
or O
entry O
exclusion O
functions O
in O
potential O
recipient O
cells O
carrying O
IncPalpha O
plasmid O
RP4 O
implying O
functional O
relatedness O
to O
C B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
fetus I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
proteins O
. O

The O
virB O
/ O
virD4 O
locus O
is O
also O
known O
to O
be O
involved O
in O
bacterial O
invasion O
and O
killing O
of O
cultured O
human B_SPECIES[BIO]
cells O
in O
vitro O
. O

Whether O
specifically O
secreted O
effector B_GENE
proteins I_GENE
contribute O
to O
host B_DISEASE_ADJECTIVE[DISEASE]
colonization I_DISEASE_ADJECTIVE[DISEASE]
and O
infection B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
currently O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
putative O
effector O
proteins O
carrying O
an O
FIC O
domain O
conserved O
in O
a O
few O
bacterial O
type O
III O
and O
type O
IV O
secreted O
proteins O
of O
pathogens O
were O
analyzed O
for O
secretion O
by O
the O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
fetus I_PERSON/I_SPECIES[BIO]
or O
heterologous O
conjugative O
systems O
. O

No O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
interbacterial B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
translocation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
fic B_GENE/B_BIO
proteins B_GENE/I_BIO
was O
found O
. O

canopy B_MEASURE/B_LOCATION
connectivity I_MEASURE/I_LOCATION
and O
the O
availability B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diverse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
nesting I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
resources I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
affect O
species B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
coexistence B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
arboreal B_LOCATION/B_BIO
ants I_LOCATION/I_BIO
. O

1 B_NUMBER[MEASURE]
. O

Arboreal B_BIO/B_PERSON
ants I_BIO/I_PERSON
are O
both O
diverse B_PERSON/B_LOCATION
and O
ecologically O
dominant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
tropics B_LOCATION/B_BIO
. O

Such B_NUMBER[MEASURE]/B_PERSON
ecologically O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
particularly O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
ongoing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
empirical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
understand O
the O
processes B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
regulate O
species B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
diversity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
coexistence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

2 B_NUMBER[MEASURE]
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
addresses O
how O
access B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
tree B_BIO/B_LOCATION
- O
based O
resources B_LOCATION/B_ORGANIZATION
and O
the O
diversity B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
existing O
nesting B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cavities I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
affect O
species B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
diversity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
coexistence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
tropical B_LOCATION/B_BIO
arboreal I_LOCATION/I_BIO
ant I_LOCATION/I_BIO
assemblages I_LOCATION/I_BIO
. O

We O
focus O
on O
assemblage B_LOCATION/B_MEASURE
- O
level B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
these O
variables B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
local B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scales B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
first O
surveyed O
arboreal B_LOCATION/B_BIO
ant I_LOCATION/I_BIO
diversity I_LOCATION/I_BIO
across O
three B_NUMBER[MEASURE]
naturally O
occurring O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
canopy B_MEASURE/B_LOCATION
connectivity I_MEASURE/I_LOCATION
and O
a O
gradient B_MEASURE
of O
tree B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
. O

We O
then O
conducted O
whole B_NUMBER[MEASURE]/B_LOCATION
- O
tree B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
manipulations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
canopy B_MEASURE/B_LOCATION
connectivity I_MEASURE/I_LOCATION
and O
the O
diversity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cavity B_BIO/B_LOCATION
entrance I_BIO/I_LOCATION
sizes I_BIO/I_LOCATION
. O

All O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
in O
the O
Brazilian B_LOCATION
savanna I_LOCATION
or O
' O
cerrado B_LOCATION/B_PERSON
' O
. O

3 B_NUMBER[MEASURE]
. O

Our O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggested O
that O
species B_MEASURE/B_LOCATION
richness I_MEASURE/I_LOCATION
was O
equivalent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
levels B_LOCATION
of O
connectivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
there O
was O
a O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
trend B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
species B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
density B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
low B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
canopy B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
connectivity B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

This O
was O
confirmed O
at O
the O
scale B_MEASURE/B_LOCATION
of O
individual B_MEASURE/B_BIO
trees I_MEASURE/I_BIO
, O
with O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
connectivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trees B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
having O
significantly O
fewer B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
all O
tree B_MEASURE/B_LOCATION
sizes B_MEASURE/I_LOCATION
. O

Our O
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
directly O
that O
low B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
canopy I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
connectivity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
significantly O
fewer B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexisting O
per O
tree B_BIO/B_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

A O
diverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
array I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cavity B_BIO/B_GENE
entrance I_BIO/I_GENE
sizes I_BIO/I_GENE
did O
not O
significantly O
increase O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
species B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
per O
tree B_BIO/B_LOCATION
. O

Nevertheless O
, O
cavity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diversity I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
significantly O
increase O
the O
species B_BIO/B_MEASURE
using O
new B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cavities B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O
each O
tree B_BIO/B_LOCATION
, O
the O
species B_BIO/B_MEASURE
per O
tree B_MEASURE/B_PERSON
unique I_MEASURE/I_PERSON
to O
new B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cavities I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
total B_BIO/B_MEASURE
species I_BIO/I_MEASURE
using O
new B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cavities B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
total B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cavity B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
use B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
populations B_LOCATION
of O
occupied O
cavities B_LOCATION/B_BIO
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
newly O
founded O
colonies B_LOCATION/B_BIO
and O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
nests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
established O
colonies B_LOCATION/B_BIO
from O
other B_LOCATION/B_ENT
trees I_LOCATION/I_ENT
. O

cavity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diversity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thus O
appears O
to O
greatly O
affect O
new B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
founding I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
colony B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
growth I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

5 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contribute O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
resource B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
access B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
greater B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cavity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diversity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
species B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexistence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
local B_LOCATION/B_BIO
arboreal I_LOCATION/I_BIO
ant I_LOCATION/I_BIO
assemblages I_LOCATION/I_BIO
. O

More O
generally O
, O
these O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
broadly O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
niche B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoting O
local B_BIO/B_PERSON
species I_BIO/I_PERSON
coexistence O
in O
diverse B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arboreal I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ant I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assemblages I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
contributions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
species B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexistence I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
, O
along O
with O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
focal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
this O
issue B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ontogeny B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
leaf B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
exchange B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
mediate O
the O
carbon B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
isotopic I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
signature I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
herbaceous B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
plants I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

Values B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
Delta B_PROTEIN[GENE]/B_LOCATION
( O
i B_DISEASE/B_PROTEIN[GENE]
) O
) O
predicted O
by O
a O
simplified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
photosynthetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
discrimination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
based O
only O
on O
diffusion B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
air B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
carboxylation B_BIO
, O
are O
often O
used O
to O
infer O
ecological B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
conditions I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
the O
^ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
^ I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3C I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
signature I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
plant B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
organs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
delta B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
^ I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
^ I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3C I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_PROTEIN[GENE]
) O
) O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
additional B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isotope B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discrimination B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
d B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
includes O
mesophyll B_BIO/B_ORGANISM_FUNCTION
conductance B_BIO/I_ORGANISM_FUNCTION
, O
photorespiration B_TIME[MEASURE]
and O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
respiration I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
post B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
carboxylation B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discrimination B_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
can O
strongly O
affect O
delta B_PROTEIN[GENE]/B_LOCATION
^ O
1 B_NUMBER[MEASURE]
^ O
3C B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p O
) O
; O
however O
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
its O
variability B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
plant B_BIO/B_ORGANISM_FUNCTION
ontogeny B_BIO/I_ORGANISM_FUNCTION
for O
different B_BIO/B_ENT
species I_BIO/I_ENT
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
ontogeny B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
leaf B_MEASURE/B_BIO
gas B_MEASURE/I_BIO
exchange B_MEASURE/I_BIO
rates B_MEASURE/I_BIO
, O
Delta B_PROTEIN[GENE]/B_LOCATION
( O
i B_OTHER/B_DISEASE
) O
, O
observed B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discrimination I_PROTEIN[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Delta B_PROTEIN[GENE]/B_LOCATION
( O
p B_OTHER/B_PROTEIN[GENE]
) O
) O
and O
d B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
leaf B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
phloem B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
and O
root B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
of O
seven B_BIO
herbaceous I_BIO
species I_BIO
at O
three B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
ontogenetic I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
stages I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
were O
investigated O
under O
controlled O
conditions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

functional B_TIME[MEASURE]/B_PERSON
group I_TIME[MEASURE]/I_PERSON
identity I_TIME[MEASURE]/I_PERSON
and O
ontogeny B_PERSON/B_LOCATION
significantly O
affected O
Delta B_PROTEIN[GENE]/B_MEASURE
( O
i B_PROTEIN[GENE]/B_DISEASE
) O
and O
Delta B_PROTEIN[GENE]/B_MEASURE
( O
p B_OTHER/B_MEASURE
) O
. O

However O
, O
predicted O
Delta B_PROTEIN[GENE]/B_MEASURE
( O
i B_OTHER/B_DISEASE
) O
did O
not O
match O
Delta B_PROTEIN[GENE]/B_MEASURE
( O
p B_OTHER/B_MEASURE
) O
. O

d O
, O
strongly O
affected O
by O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
identity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
ontogeny B_PERSON/B_BIO
, O
varied O
by O
up O
to O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
. O

d B_OTHER/B_DISEASE
scaled O
tightly O
with O
stomatal B_MEASURE/B_LOCATION
conductance I_MEASURE/I_LOCATION
, O
suggesting O
complex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controls I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
including O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
mesophyll B_MEASURE
conductance I_MEASURE
. O

The O
magnitude B_MEASURE
of O
the O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
delta B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
^ I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
^ I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3C I_PROTEIN[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE
) O
due O
to O
ontogeny B_BIO/B_ORGANISM_FUNCTION
was O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
due O
to O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
in O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

d O
and O
ontogeny B_LOCATION/B_PROTEIN[GENE]
should O
, O
therefore O
, O
be O
considered O
in O
ecosystem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
integrated O
in O
ecosystem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O
delta B_PROTEIN[GENE]
^ O
1 B_MEASURE/B_PROTEIN[GENE]
^ I_MEASURE/I_PROTEIN[GENE]
3C I_MEASURE/I_PROTEIN[GENE]
( O
p B_BIO/B_LOCATION
) O
and O
limit O
the O
applicability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
delta B_PROTEIN[GENE]
^ O
1 B_LOCATION
^ I_LOCATION
3C I_LOCATION
( O
leaf B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
) O
as O
a O
proxy B_MEASURE
for O
water B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
use B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
efficiency I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
herbaceous B_BIO/B_LOCATION
plants B_BIO/I_LOCATION
. O

The O
pH O
regulatory O
factor O
Pac1 O
regulates O
Tri O
gene O
expression O
and O
trichothecene O
production O
in O
Fusarium B_BIO
graminearum I_BIO
. O

fungi B_BIO
manage O
the O
adaptation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
extra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
cellular B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pH B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
the O
PacC B_GENE
transcription I_GENE
factor I_GENE
, O
a O
key B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pH B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
regulatory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

PacC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulates O
the O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
secondary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
filamentous B_BIO
fungi I_BIO
. O

In O
the O
important O
cereal O
pathogen O
Fusarium B_BIO
graminearum I_BIO
, O
the O
production O
of O
trichothecene O
is O
induced O
only O
under O
acidic O
pH O
conditions O
. O

Here O
, O
we O
examined O
the O
role O
of O
the O
PacC O
homologue O
from O
F B_BIO
. I_BIO
graminearum I_BIO
, O
FgPac1 O
, O
on O
the O
regulation O
of O
trichothecene O
production O
. O

An O
FgDeltaPac1 O
deletion O
mutant O
was O
constructed O
in O
F B_BIO
. I_BIO
graminearum I_BIO
which O
showed O
a O
reduced O
development O
under O
neutral O
and O
alkaline O
pH O
, O
increased O
sensitivity O
to O
H O
( O
2 O
) O
O O
( O
2 O
) O
and O
an O
earlier O
Tri O
gene O
induction O
and O
toxin O
accumulation O
at O
acidic O
pH O
. O

A O
strain B_BIO
expressing O
the O
FgPac1 B_GENE
( O
c B_DISEASE/B_PROTEIN[GENE]
) O
constitutively O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Pac1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
a O
strongly O
repressed B_DISEASE_ADJECTIVE[DISEASE]
Tri I_DISEASE_ADJECTIVE[DISEASE]
gene I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
and O
reduced O
toxin B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
accumulation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
at O
acidic B_TIME[MEASURE]/B_PERSON
pH I_TIME[MEASURE]/I_PERSON
. O

These O
results O
demonstrate O
that O
Pac1 O
negatively O
regulates O
Tri O
gene O
expression O
and O
toxin O
production O
in O
F B_BIO
. I_BIO
graminearum I_BIO
. O

tracking O
a O
century O
of O
global O
expansion O
and O
evolution O
of O
HIV B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
drive O
understanding O
and O
to O
combat O
disease O
. O

Since O
the O
isolation O
of O
HIV B_SPECIES[BIO]/B_DISEASE
, O
multiple O
transmissions O
are O
thought O
to O
have O
occurred O
between O
man O
and O
other O
old O
- O
world O
primates O
. O

Assessment O
of O
samples O
from O
apes O
and O
human B_PERSON/B_SPECIES[BIO]
beings O
with O
African O
equatorial O
forest O
ancestry O
has O
traced O
the O
origin O
of O
HIV B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
to O
chimpanzees B_MEASURE/B_LOCATION
, O
and O
dated O
its O
most O
recent O
common O
ancestor O
to O
1908 O
. O

The O
evolution O
of O
HIV B_DISEASE
- I_DISEASE
1 I_DISEASE
has O
been O
rapid O
, O
which O
has O
resulted O
in O
a O
complex O
classification O
, O
worldwide O
spread O
, O
and O
intermixing O
of O
strains O
; O
at O
least O
48 O
circulating O
recombinant O
forms O
are O
currently O
identified O
. O

In O
addition O
to O
posing O
a O
nearly O
insurmountable O
challenge O
for O
diagnosis O
, O
treatment O
, O
vaccine O
development O
, O
and O
prevention O
, O
this O
extreme O
and O
divergent O
evolution O
has O
led O
to O
differences O
in O
virulence O
between O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
1 I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
groups O
, O
subtypes O
, O
or O
both O
. O

Coincidental O
changes O
in O
human B_SPECIES[BIO]/B_LOCATION
migration O
in O
the O
Congo O
river O
basin O
also O
affected O
spread O
of O
disease O
. O

Research O
over O
the O
past O
25 O
years O
and O
advances O
in O
genomic O
sequencing O
methods O
, O
such O
as O
deep O
DNA O
sequencing O
, O
have O
greatly O
improved O
understanding O
and O
analysis O
of O
the O
thousands O
to O
millions O
of O
full O
infectious O
HIV B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
genomes O
. O

A O
caffeyl O
- O
coenzyme O
A O
synthetase O
initiates O
caffeate O
activation O
prior O
to O
caffeate O
reduction O
in O
the O
acetogenic O
bacterium O
Acetobacterium B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
woodii B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
anaerobic O
acetogenic O
bacterium O
Acetobacterium B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
woodii I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
couples O
the O
reduction O
of O
caffeate O
with O
electrons O
derived O
from O
hydrogen O
to O
the O
synthesis O
of O
ATP O
by O
a O
chemiosmotic O
mechanism O
using O
sodium O
ions O
as O
coupling O
ions O
, O
but O
the O
enzymes O
involved O
remain O
to O
be O
established O
. O

Previously O
, O
the O
electron B_GENE/B_DISEASE
transfer I_GENE/I_DISEASE
flavoproteins I_GENE/I_DISEASE
EtfA I_GENE/I_DISEASE
and O
EtfB B_BACTERIUM[BIO]/B_GENE
were O
found O
to O
be O
involved O
in O
caffeate B_DISEASE_ADJECTIVE[DISEASE]
respiration I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
inverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
identified O
three B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
upstream O
of O
etfA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
etfB B_BACTERIUM[BIO]/B_DISEASE
: O
carA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Carb B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
carc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Cara B_PERSON/B_GENE
encodes O
a O
potential B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
coenzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
CoA B_DISEASE/B_MEASURE
) O
transferase B_ENZYME[GENE]
, O
Carb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
an O
acyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CoA B_ENZYME[GENE]/B_PERSON
synthetase I_ENZYME[GENE]/I_PERSON
, O
and O
carC O
an O
acyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CoA B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

carA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
- O
B B_LOCATION/B_DISEASE
, O
and O
- O
C B_OTHER/B_PROTEIN[GENE]
are O
located O
together O
with O
etfA B_LOCATION
/ O
Care B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
etfB B_LOCATION
/ O
Card B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
one B_GENE/B_LOCATION
polycistronic B_GENE/I_LOCATION
message B_GENE/I_LOCATION
, O
indicating O
that O
CarA B_DISEASE/B_LOCATION
, O
CarB B_LOCATION/B_ORGANIZATION
, O
and O
CarC B_LOCATION
are O
also O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
caffeate B_LOCATION/B_MEASURE
respiration I_LOCATION/I_MEASURE
pathway I_LOCATION/I_MEASURE
. O

The O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
an O
initial B_GENE
ATP I_GENE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
caffeate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O
Carb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

To O
prove O
the O
proposed O
function O
of O
CarB O
, O
the O
protein O
was O
overproduced O
in O
Escherichia B_BIO
coli I_BIO
, O
and O
the O
recombinant O
protein O
was O
purified O
. O

Purified B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
Carb I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caffeate O
to O
caffeyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
CoA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
an O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
and O
CoA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
reaction I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

The O
enzyme B_ENZYME[GENE]
has O
broad B_MEASURE
pH I_MEASURE
and O
temperature B_MEASURE/B_LOCATION
optima I_MEASURE/I_LOCATION
and O
requires O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ B_DISEASE/B_MEASURE
) O
for O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
caffeate O
, O
it O
can O
use O
p B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
coumarate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
ferulate O
, O
and O
cinnamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
substrates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
with O
50 B_MEASURE
, O
15 B_MEASURE
, O
and O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
, O
of O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
with O
caffeate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Expression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
car B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
induced O
not O
only O
by O
caffeate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
p B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
coumarate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
ferulate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cinnamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
also O
by O
sinapate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
is O
no O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
p B_GENE
- O
hydroxybenzoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
or O
syringate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Complete O
genome O
sequence O
of O
Burkholderia B_BACTERIUM[BIO]
rhizoxinica I_BACTERIUM[BIO]
, O
an O
Endosymbiont O
of O
Rhizopus B_BIO/B_LOCATION
microsporus I_BIO/I_LOCATION
. O

Burkholderia B_BACTERIUM[BIO]
rhizoxinica I_BACTERIUM[BIO]
is O
an O
intracellular O
symbiont O
of O
the O
phytopathogenic O
fungus O
Rhizopus B_BACTERIUM[BIO]
microsporus I_BACTERIUM[BIO]
. O

The O
vertically O
transmitted O
endosymbiont B_SPECIES[BIO]/B_GENE
not O
only O
delivers O
the O
antimitotic B_BIO
macrolide I_BIO
rhizoxin I_BIO
to O
its O
host B_PERSON/B_BIO
but O
is O
also O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
vegetative B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
spore I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
formation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
fungus B_SPECIES[BIO]
. O

To O
shed O
light O
on O
the O
genetic O
equipment O
of O
this O
model O
organism O
, O
we O
sequenced O
the O
whole O
genome O
of O
B B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
rhizoxinica I_SPECIES[BIO]/I_LOCATION
HKI I_SPECIES[BIO]/I_LOCATION
0454 I_SPECIES[BIO]/I_LOCATION
, O
thus O
providing O
the O
first O
genomic O
insight O
into O
an O
intracellular O
mutualist O
of O
a O
fungal O
species O
. O

The O
3 B_MEASURE
. O
75 B_MEASURE
- O
Mb B_GENE/B_LOCATION
genome I_GENE/I_LOCATION
consists O
of O
a O
chromosome B_GENE
and O
two B_BIO/B_GENE
strain I_BIO/I_GENE
- O
specific B_LOCATION/B_PERSON
plasmids I_LOCATION/I_PERSON
. O

The O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
appears O
to O
be O
specialized O
for O
the O
uptake B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fungal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Besides O
the O
rhizoxin B_GENE/B_BIO
biosynthesis I_GENE/I_BIO
gene I_GENE/I_BIO
cluster I_GENE/I_BIO
, O
there O
are O
14 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loci I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coding I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
nonribosomal B_DISEASE/B_ENZYME[GENE]
peptide B_DISEASE/I_ENZYME[GENE]
synthetase B_DISEASE/I_ENZYME[GENE]
( O
NRPS B_DISEASE/B_LOCATION
) O
assembly B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
lines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
which O
represent O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
targets I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
for O
genomic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
mining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
cryptic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
natural B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
products B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Furthermore O
, O
the O
endosymbionts B_BIO
are O
equipped O
with O
a O
repertoire B_PERSON/B_LOCATION
of O
virulence B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- O
related O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
can O
now O
be O
studied O
to O
elucidate O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
underlying O
bacterial B_SPECIES[BIO]
- O
fungal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Network B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
topology I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
patterns B_LOCATION/B_ORGANIZATION
and O
mechanisms B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
plant B_BIO/B_DISEASE
- O
herbivore B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O
host B_BIO
- O
parasitoid B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
food I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
webs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

1 B_NUMBER[MEASURE]
. O

Biological B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
communities I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
are O
organized O
in O
complex B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
networks I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
food B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
webs B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
which O
topology O
appears O
to O
be O
non B_DISEASE
- O
random B_PERSON/B_TIME[MEASURE]
. O

Gradients B_MEASURE/B_LOCATION
, O
compartments B_LOCATION/B_ORGANIZATION
, O
nested O
subsets B_LOCATION/B_ORGANIZATION
and O
even B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
combinations I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
structures B_LOCATION/B_ORGANIZATION
have O
been O
shown O
in O
bipartite B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
networks I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
in O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
only O
one B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
tested O
against O
randomness B_PERSON
and O
mechanistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hypotheses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
generally O
lacking O
. O

2 B_NUMBER[MEASURE]
. O

Here O
we O
examined O
the O
topology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
regional B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
coexisting O
plant B_BIO/B_DISEASE
- O
herbivore B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O
host B_BIO
- O
parasitoid B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
food I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
webs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
discriminate O
between O
the O
mentioned O
network B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

We O
also O
evaluated O
the O
role B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
species B_MEASURE/B_LOCATION
body I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
, O
local B_MEASURE/B_LOCATION
abundance I_MEASURE/I_LOCATION
, O
regional B_MEASURE/B_LOCATION
frequency B_MEASURE/I_LOCATION
and O
phylogeny B_MEASURE/B_PERSON
as O
determinants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
network B_DISEASE_ADJECTIVE[DISEASE]
topology I_DISEASE_ADJECTIVE[DISEASE]
. O

3 B_NUMBER[MEASURE]
. O

We O
found O
both O
food B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
webs I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
to O
be O
compartmented O
, O
with O
interaction B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
range B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boundaries B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imposed O
by O
host B_BIO/B_MEASURE
phylogeny I_BIO/I_MEASURE
. O

Species B_MEASURE/B_ORGANIZATION
degree B_MEASURE/I_ORGANIZATION
within O
compartments B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
mostly O
related O
to O
their O
regional B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
and O
local B_MEASURE/B_LOCATION
abundance I_MEASURE/I_LOCATION
. O

Only O
one B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
compartment I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
showed O
an O
internal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nested B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
distribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
interactions B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
between O
species B_BIO/B_PERSON
, O
but O
species B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
position I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
within O
this O
compartment B_LOCATION/B_PERSON
was O
unrelated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
species B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
or O
abundance B_MEASURE/B_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
compartmentalization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
be O
more O
common B_DISEASE_ADJECTIVE[DISEASE]
than O
previously O
considered O
, O
and O
that O
network B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
is O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
multiple B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
hierarchical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
non B_DISEASE/B_LOCATION
- O
exclusive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
processes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
based O
mass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectrometric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
computational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
mitochondrial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Neurospora B_SPECIES[BIO]
. O

We O
have O
used O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoretic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
isoelectric B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
focusing O
, O
blue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
native I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
16 B_MEASURE
- O
benzyldimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
n B_MEASURE/B_OTHER
- O
hexadecylammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
SDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimensions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Laemmli I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tricine O
second B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dimensions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
separate O
the O
proteins B_PROTEIN[GENE]/B_DISEASE
from O
highly O
- O
purified O
Neurospora B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
mitochondria I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O
sub B_DISEASE
- O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fractions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( O
membrane B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
soluble B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
, O
protein B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
ribonucleoproteins B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
) O
. O

The O
products B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
260 B_GENE/B_BIO
genes I_GENE/I_BIO
, O
many B_NUMBER[MEASURE]
of O
them O
in O
multiple B_DISEASE_ADJECTIVE[DISEASE]
processed O
or O
modified O
forms B_DISEASE/B_LOCATION
, O
were O
identified O
by O
MALDI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
TOF B_MEASURE/B_DISEASE
mass I_MEASURE/I_DISEASE
spectrometry I_MEASURE/I_DISEASE
. O

This O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirms O
the O
existence B_DISEASE/B_LOCATION
, O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
mitochondrial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
products B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
55 B_GENE/B_BIO
Neurospora I_GENE/I_BIO
genes I_GENE/I_BIO
previously O
annotated O
only O
as O
predicted B_DISEASE_ADJECTIVE[DISEASE]
or O
hypothetical B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
of O
101 B_MEASURE/B_PERSON
genes I_MEASURE/I_PERSON
not O
identified O
in O
previous B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mass I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectrometry I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Combined O
with O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mass I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectrometry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
re B_LOCATION/B_DISEASE
- O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
genome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
annotations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
have O
compiled O
a O
curated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
358 B_PROTEIN[GENE]/B_BIO
proteins I_PROTEIN[GENE]/I_BIO
identified O
in O
proteomic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
bona B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fide I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mitochondrial I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
plus O
80 B_NUMBER[MEASURE]
other I_NUMBER[MEASURE]
identified O
proteins B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
be O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
computational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
Neurospora B_BIO/B_PERSON
mitochondria I_BIO/I_PERSON
also O
contain O
another O
299 B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
not O
yet O
identified O
in O
proteomics B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projects I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

taken O
together O
, O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
products B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
at O
least O
738 B_NUMBER[MEASURE]
genes I_NUMBER[MEASURE]
comprise O
the O
Neurospora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitochondrial I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Sequenced B_MEASURE/B_PERSON
dermatophyte B_MEASURE/I_PERSON
strains B_MEASURE/I_PERSON
: O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
rate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
conidiation B_DISEASE_ADJECTIVE[DISEASE]
, O
drug B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptibilities I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
virulence B_DISEASE
in O
an O
invertebrate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Although O
dermatophytes B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
are O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
cause I_DISEASE_ADJECTIVE[DISEASE]
of O
fungal B_DISEASE
infections I_DISEASE
in O
the O
world B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O
their O
basic B_DISEASE_ADJECTIVE[DISEASE]
biology I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
well O
understood O
. O

The O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
annotation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
genomes B_GENE/B_MEASURE
of O
five B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
representative I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
dermatophyte I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
species I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
allows O
for O
the O
creation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
hypotheses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O
to O
how O
they O
cause O
disease B_DISEASE
and O
have O
adapted O
to O
their O
distinct B_LOCATION
environments I_LOCATION
. O

An O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
microbiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
of O
these O
strains B_BIO/B_DISEASE
will O
be O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
testing O
these O
hypotheses B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
generally O
characterize O
these O
five B_BIO/B_MEASURE
sequenced I_BIO/I_MEASURE
strains I_BIO/I_MEASURE
of O
dermatophytes B_DISEASE/B_BACTERIUM[BIO]
for O
their O
microbiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
measured O
the O
growth O
rate O
on O
solid O
medium O
and O
found O
differences O
between O
species O
, O
with O
Microsporum B_BACTERIUM[BIO]
gypseum I_BACTERIUM[BIO]
CBS118893 O
having O
the O
fastest O
growth O
and O
Trichophyton B_BACTERIUM[BIO]/B_DISEASE
rubrum I_BACTERIUM[BIO]/I_DISEASE
CBS118892 O
the O
slowest O
. O

We O
also O
compared O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
conidia B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
found O
that O
the O
highest B_MEASURE
numbers I_MEASURE
of O
conidia B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
were O
produced O
when O
dermatophytes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
were O
grown O
on O
MAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
agar I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O

We O
determined O
the O
minimum B_MEASURE/B_LOCATION
Inhibitory B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
( O
MIC B_MEASURE/B_LOCATION
) O
of O
nine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antifungal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
confirmed O
susceptibility B_DISEASE/B_MEASURE
to O
antifungals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
commonly O
used O
as O
selectable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Finally O
, O
we O
tested O
virulence O
in O
the O
Galleria B_BIO
mellonella I_BIO
( O
wax B_SPECIES[BIO]/B_PROTEIN[GENE]
moth B_SPECIES[BIO]/I_PROTEIN[GENE]
) O
larvae O
model O
but O
found O
the O
results O
variable O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increase O
our O
understanding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
microbiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
dermatophyte B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
will O
be O
of O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
advancing O
hypothesis O
- O
driven O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
dermatophytes B_DISEASE
. O

relating O
the O
physical O
properties O
of O
Pseudomonas B_BACTERIUM[BIO]
aeruginosa I_BACTERIUM[BIO]
lipopolysaccharides O
to O
virulence O
by O
atomic O
force O
microscopy O
. O

Lipopolysaccharides O
( O
LPS O
) O
are O
an O
important O
class O
of O
macromolecules O
that O
are O
components O
of O
the O
outer O
membrane O
of O
Gram O
- O
negative O
bacteria O
such O
as O
Pseudomonas B_BACTERIUM[BIO]
aeruginosa I_BACTERIUM[BIO]
. O

P B_DISEASE/B_GENE
. B_DISEASE/I_GENE
aeruginosa B_DISEASE/I_GENE
contains O
two O
different O
sugar O
chains O
, O
the O
homopolymer O
common O
antigen O
( O
A O
band O
) O
and O
the O
heteropolymer O
O O
antigen O
( O
B O
band O
) O
, O
which O
impart O
serospecificity O
. O

The O
characteristics B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
LPS B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
generally O
assessed O
after O
isolation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rather O
than O
in O
the O
context B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
whole B_DISEASE/B_BACTERIUM[BIO]
bacteria I_DISEASE/I_BACTERIUM[BIO]
. O

Here O
we O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
probe O
the O
physical O
properties O
of O
the O
LPS O
of O
P B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
aeruginosa I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
strain I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
PA103 I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
serogroup O
O11 O
) O
in O
situ O
. O

This O
strain B_BIO/B_GENE
contains O
a O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
very O
long B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymers B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
, O
regulated O
by O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
different I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
this O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
studied O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_BIO/B_MEASURE
strain B_BIO/I_MEASURE
and O
four B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutants I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
DeltaWzz1 B_PROTEIN[GENE]/B_LOCATION
( O
producing O
only O
very O
long B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
DeltaWzz2 B_PROTEIN[GENE]/B_LOCATION
( O
producing O
only B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
DDeltaM B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
with O
both O
the O
wzz1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
wzz2 B_PROTEIN[GENE]/B_DISEASE
genes I_PROTEIN[GENE]/I_DISEASE
deleted O
) O
, O
and O
Wzy B_PROTEIN[GENE]/B_LOCATION
: O
: O
GM B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
producing O
an O
LPS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
core I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
oligosaccharide I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
plus O
one B_LOCATION/B_MEASURE
unit B_LOCATION/I_MEASURE
of O
O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) O
. O

Forces B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adhesion B_DISEASE/B_MEASURE
between O
the O
LPS B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
these O
strains B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
silicon B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitride I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AFM I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tip I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
, O
and O
the O
Alexander B_PERSON
and O
de B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Gennes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
steric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
repulsion I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
a O
flat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
surface I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
a O
polymer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
brush B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
used O
to O
calculate O
the O
LPS B_MEASURE/B_DISEASE
layer I_MEASURE/I_DISEASE
thickness I_MEASURE/I_DISEASE
( O
which O
we O
refer O
to O
as O
length B_MEASURE
) O
, O
compressibility B_MEASURE/B_LOCATION
, O
and O
spacing O
between O
the O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
molecules B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

LPS B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chains I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
longest B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_BIO/B_MEASURE
strain B_BIO/I_MEASURE
and O
DeltaWzz1 B_MEASURE/B_GENE
, O
at O
170 B_MEASURE
. O
6 B_MEASURE
and O
212 B_MEASURE
. O
4 B_MEASURE
nm I_MEASURE
, O
respectively O
, O
and O
these O
values B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
statistically O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O
one B_NUMBER[MEASURE]/B_LOCATION
another O
. O

Wzy B_PROTEIN[GENE]/B_LOCATION
: O
: O
GM B_ORGANIZATION/B_PROTEIN[GENE]
and O
DDeltaM B_ORGANIZATION/B_LOCATION
have O
reduced O
LPS B_MEASURE
lengths I_MEASURE
, O
at O
34 B_MEASURE
. O
6 B_MEASURE
and O
37 B_MEASURE
. O
7 B_MEASURE
nm I_MEASURE
, O
respectively O
. O

Adhesion O
forces O
were O
not O
correlated O
with O
LPS O
length O
, O
but O
a O
relationship O
between O
adhesion O
force O
and O
bacterial O
pathogenicity O
was O
found O
in O
a O
mouse B_SPECIES[BIO]/B_DISEASE
acute O
pneumonia O
model O
of O
infection O
. O

The O
adhesion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
forces I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
AFM B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
strains B_BIO/B_DISEASE
with O
LPS B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
suggesting O
that O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_BIO/B_GENE
strain B_BIO/I_GENE
is O
optimized O
for O
maximal B_DISEASE_ADJECTIVE[DISEASE]
adhesion I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
research O
contributes O
to O
further O
understanding O
of O
the O
role O
of O
LPS O
in O
the O
adhesion O
and O
virulence O
of O
P B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
aeruginosa I_BACTERIUM[BIO]/I_DISEASE
. O

The O
minor O
pilin O
subunit O
Sgp2 O
is O
necessary O
for O
assembly O
of O
the O
pilus O
encoded O
by O
the O
srtG O
cluster O
of O
Streptococcus B_BACTERIUM[BIO]/B_GENE
suis I_BACTERIUM[BIO]/I_GENE
. O

Gram B_PERSON/B_BACTERIUM[BIO]
- O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pili B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O
composed O
of O
covalently O
bound O
pilin B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunits B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O
assembly B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
is O
mediated O
via O
a O
pilus B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- O
specific B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sortase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
s O
) O
. O

Major B_PERSON/B_LOCATION
subunits I_PERSON/I_LOCATION
constitute O
the O
pilus B_BACTERIUM[BIO]/B_GENE
backbone B_BACTERIUM[BIO]/I_GENE
and O
are O
therefore O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
pilus B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Minor B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
subunits I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
are O
also O
incorporated O
into O
the O
pilus B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
they O
are O
considered O
to O
be O
dispensable B_DISEASE_ADJECTIVE[DISEASE]
for O
backbone B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
srtG O
cluster O
is O
one O
of O
the O
putative O
pilus O
gene O
clusters O
identified O
in O
the O
major O
swine B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogen O
Streptococcus B_BACTERIUM[BIO]/B_LOCATION
suis I_BACTERIUM[BIO]/I_LOCATION
. O

It O
consists O
of O
one B_GENE
sortase I_GENE
gene I_GENE
( O
srtG B_GENE
) O
and O
two B_NUMBER[MEASURE]/B_PERSON
putative I_NUMBER[MEASURE]/I_PERSON
pilin I_NUMBER[MEASURE]/I_PERSON
subunit I_NUMBER[MEASURE]/I_PERSON
genes I_NUMBER[MEASURE]/I_PERSON
( O
sgp1 B_PROTEIN[GENE]/B_LOCATION
and O
sgp2 B_PROTEIN[GENE]
) O
. O

In O
this O
study O
, O
by O
constructing O
mutants O
for O
each O
of O
the O
genes O
in O
the O
cluster O
and O
by O
both O
immunoblotting O
and O
immunogold O
electron O
microscopic O
analysis O
with O
antibodies O
against O
Sgp1 O
and O
Sgp2 O
, O
we O
found O
that O
the O
srtG O
cluster O
mediates O
the O
expression O
of O
pilus O
- O
like O
structures O
in O
S B_SPECIES[BIO]
. I_SPECIES[BIO]
suis I_SPECIES[BIO]
strain I_SPECIES[BIO]
89 I_SPECIES[BIO]
/ I_SPECIES[BIO]
1591 I_SPECIES[BIO]
. O

In O
this O
pilus B_LOCATION/B_PERSON
, O
Sgp1 B_PROTEIN[GENE]
forms O
the O
backbone B_LOCATION/B_MEASURE
, O
whereas O
Sgp2 B_GENE
is O
incorporated O
as O
the O
minor B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
subunit B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
accordance B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
pilus B_BACTERIUM[BIO]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
assembly B_BACTERIUM[BIO]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O
Gram B_BACTERIUM[BIO]/B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
organisms B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
the O
major B_GENE
subunit I_GENE
Sgp1 I_GENE
was O
indispensable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
backbone B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
formation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
the O
cognate B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sortase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
SrtG I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mediated O
the O
polymerization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
both O
subunits B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

However O
, O
unlike O
other B_NUMBER[MEASURE]/B_LOCATION
well O
- O
characterized O
Gram B_BACTERIUM[BIO]/B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacterial I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
pili I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
the O
minor B_GENE
subunit I_GENE
Sgp2 I_GENE
was O
required O
for O
polymerization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
major B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sgp1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Because O
Sgp2 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homologues I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
encoded O
in O
several B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
other I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
Gram I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacterial B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
pilus B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
gene B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
clusters B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
in O
some O
types B_PERSON/B_DISEASE
of O
pili B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
minor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pilin I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subunits I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
may O
contribute O
to O
backbone B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
novel B_LOCATION/B_ENZYME[GENE]
mechanism B_LOCATION/I_ENZYME[GENE]
. O

Growth O
and O
reproductive O
costs O
of O
larval O
defence O
in O
the O
aposematic O
lepidopteran O
Pieris B_SPECIES[BIO]/B_LOCATION
brassicae I_SPECIES[BIO]/I_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

utilization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
secondary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O
antipredator B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
defence B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
immature B_LOCATION
herbivorous I_LOCATION
insects I_LOCATION
. O

Such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
defences I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
may O
incur O
a O
cost B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
animal B_BIO/B_PERSON
, O
either O
in O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
rate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
or O
in O
the O
reproductive B_LOCATION/B_MEASURE
success I_LOCATION/I_MEASURE
. O

2 B_NUMBER[MEASURE]
. O

A O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lepidopterans B_BIO/B_LOCATION
is O
the O
regurgitation B_BODY_PART_OR_ORGAN_COMPONENT/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
semi B_DISEASE/B_ENZYME[GENE]
- O
digested O
material B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
the O
defensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
compounds B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
the O
food B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
plant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
defence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
has O
led O
to O
gut B_DISEASE/B_BIO
specialization I_DISEASE/I_BIO
in O
this O
order B_BIO/B_PERSON
. O

regurgitation B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
often O
swift B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
cuticular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
and O
deters O
predators B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
consuming O
or O
parasitizing O
the O
larva B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

The O
loss B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gut B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
impact O
on O
fitness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
lacking O
. O

3 B_NUMBER[MEASURE]
. O

Here O
, O
we O
raised O
larvae O
of O
the O
common O
crop O
pest O
Pieris B_BIO
brassicae I_BIO
on O
commercial O
cabbage B_BIO
leaves O
, O
simulated O
predator O
attacks O
throughout O
the O
larval O
period O
, O
and O
measured O
life O
- O
history O
responses O
. O

4 B_NUMBER[MEASURE]
. O

We O
found O
that O
the O
probability B_MEASURE/B_PERSON
of O
survival B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
pupation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreased O
with O
increasing O
frequency B_MEASURE/B_LOCATION
of O
attacks B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
this O
was O
because O
of O
regurgitation B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
rather O
than O
the O
stimulation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
itself O
. O

There O
was O
a O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cost B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
the O
defence B_PERSON/B_BIO
such I_PERSON/I_BIO
that O
the O
more O
regurgitant B_PERSON/B_BIO
that O
individuals B_PERSON/B_BIO
produced O
over O
the O
growth B_TIME[MEASURE]
period I_TIME[MEASURE]
, O
the O
smaller B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
they O
were O
at O
pupation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

The O
number B_MEASURE
of O
mature B_MEASURE/B_PERSON
eggs I_MEASURE/I_PERSON
in O
adult B_PERSON/B_BIO
females I_PERSON/I_BIO
was O
positively O
related O
to O
pupal B_DISEASE/B_MEASURE
mass I_DISEASE/I_MEASURE
, O
but O
this O
relationship B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
only O
found O
when O
individuals B_PERSON/B_BIO
were O
not O
subjected O
to O
a O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
frequency I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
predator B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
simulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

This O
suggests O
that O
there O
might O
be O
cryptic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fitness B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
common B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
defensive I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
responses I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
paid O
despite O
apparent B_MEASURE/B_LOCATION
growth B_MEASURE/I_LOCATION
rate B_MEASURE/I_LOCATION
being O
maintained O
. O

6 B_NUMBER[MEASURE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
a O
clear B_TIME[MEASURE]/B_ENT
life I_TIME[MEASURE]/I_ENT
- O
history B_MEASURE/B_LOCATION
cost B_MEASURE/I_LOCATION
of O
an O
antipredator B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
defence I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
a O
model B_BIO/B_LOCATION
pest I_BIO/I_LOCATION
species I_BIO/I_LOCATION
and O
show O
that O
under O
certain B_DISEASE_ADJECTIVE[DISEASE]
conditions I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
high B_DISEASE/B_ORGANISM_FUNCTION
predation I_DISEASE/I_ORGANISM_FUNCTION
threat I_DISEASE/I_ORGANISM_FUNCTION
, O
the O
expected O
relationship B_PERSON/B_MEASURE
between O
female B_PERSON/B_MEASURE
body I_PERSON/I_MEASURE
size I_PERSON/I_MEASURE
and O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fecundity B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
can O
be O
disrupted O
. O

Huntington B_DISEASE/B_LOCATION
' O
s O
disease B_DISEASE
: O
from O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathogenesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Huntington B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
is O
a O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
fatal B_DISEASE_ADJECTIVE[DISEASE]
, O
neurodegenerative B_DISEASE
disorder I_DISEASE
caused O
by O
an O
expanded O
CAG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
huntingtin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
encodes O
an O
abnormally O
long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polyglutamine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
huntingtin B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Huntington B_DISEASE/B_SPECIES[BIO]
' B_DISEASE/I_SPECIES[BIO]
s B_DISEASE/I_SPECIES[BIO]
disease B_DISEASE/I_SPECIES[BIO]
has O
served O
as O
a O
model B_PERSON/B_LOCATION
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
more O
common B_DISEASE/B_LOCATION
neurodegenerative I_DISEASE/I_LOCATION
disorders I_DISEASE/I_LOCATION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
Alzheimer B_DISEASE/B_GENE
' I_DISEASE/I_GENE
s I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
and O
Parkinson B_DISEASE/B_GENE
' I_DISEASE/I_GENE
s I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
. O

These O
disorders B_DISEASE
all O
share B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
features B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
including O
: O
delayed O
onset B_DISEASE/B_ORGANISM_FUNCTION
; O
selective B_DISEASE_ADJECTIVE[DISEASE]
neuronal I_DISEASE_ADJECTIVE[DISEASE]
vulnerability I_DISEASE_ADJECTIVE[DISEASE]
, O
despite O
widespread B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
disease B_DISEASE
- O
related O
proteins B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
during O
the O
whole B_TIME[MEASURE]
lifetime I_TIME[MEASURE]
; O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
processing I_DISEASE_ADJECTIVE[DISEASE]
and O
aggregation B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
; O
and O
cellular B_DISEASE_ADJECTIVE[DISEASE]
toxic I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
involving O
both O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
autonomous I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

pathogenic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Huntington B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
are O
beginning O
to O
be O
unravelled O
, O
offering O
targets B_PERSON/B_LOCATION
for O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Additionally O
, O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
genetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
neuroimaging O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
show O
that O
, O
as O
in O
some O
other B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
neurodegenerative I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disorders I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
neurodegeneration B_DISEASE
in O
affected O
individuals B_PERSON/B_BIO
begins O
many B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
before O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diagnosable B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
symptoms B_DISEASE
of O
Huntington B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
, O
and O
it O
is O
accompanied O
by O
subtle B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cognitive I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
motor B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
psychiatric B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
( O
so O
- O
called O
prodromal B_DISEASE
disease I_DISEASE
) O
. O

Thus O
, O
Huntington B_DISEASE/B_PERSON
' I_DISEASE/I_PERSON
s O
disease B_DISEASE/B_PERSON
is O
also O
emerging O
as O
a O
model B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
develop O
therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interventions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
not O
only O
to O
slow O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
manifest B_DISEASE
disease I_DISEASE
but O
also O
to O
delay O
, O
or O
ideally O
prevent O
, O
its O
onset B_DISEASE_ADJECTIVE[DISEASE]
. O

Natural O
history O
and O
intragenomic O
dynamics O
of O
the O
Transib O
transposon O
Hztransib O
in O
the O
cotton B_SPECIES[BIO]/B_LOCATION
bollworm I_SPECIES[BIO]/I_LOCATION
Helicoverpa I_SPECIES[BIO]/I_LOCATION
zea I_SPECIES[BIO]/I_LOCATION
. O

Hztransib O
, O
recently O
identified O
from O
Helicoverpa B_SPECIES[BIO]
zea I_SPECIES[BIO]
, O
represents O
the O
first O
intact O
and O
transcriptionally O
active O
Transib O
element O
. O

Its O
open O
reading O
frame O
was O
detected O
in O
Helicoverpa B_BIO
armigera I_BIO
, O
from O
which O
H B_PERSON/B_BIO
. I_PERSON/I_BIO
zea I_PERSON/I_BIO
evolved O
, O
and O
in O
Helicoverpa B_BIO/B_LOCATION
assulta I_BIO/I_LOCATION
, O
the O
common O
ancestor O
of O
H B_BIO
. I_BIO
zea I_BIO
and O
H B_BIO
. I_BIO
armigera I_BIO
, O
but O
its O
remaining O
parts O
were O
found O
only O
in O
H B_BIO/B_LOCATION
. I_BIO/I_LOCATION
armigera I_BIO/I_LOCATION
. O

Thirty O
- O
nine O
Hztransib O
insertion O
sites O
, O
all O
of O
which O
are O
polymorphic O
, O
were O
detected O
from O
eight O
populations O
of O
H B_BIO
. I_BIO
zea I_BIO
. O

Out O
of O
the O
39 B_NUMBER[MEASURE]
insertion I_NUMBER[MEASURE]
sites I_NUMBER[MEASURE]
, O
35 B_NUMBER[MEASURE]
were O
not O
frequently O
occupied O
, O
with O
1 B_MEASURE
- O
33 B_SEQUENCE[MEASURE]
occurrences I_SEQUENCE[MEASURE]
in O
a O
total B_MEASURE/B_LOCATION
of O
128 B_NUMBER[MEASURE]/B_PERSON
individuals I_NUMBER[MEASURE]/I_PERSON
from O
the O
eight B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
16 B_NUMBER[MEASURE]
larvae I_NUMBER[MEASURE]
per O
population B_PERSON/B_LOCATION
) O
. O

Its O
copy B_MEASURE
number I_MEASURE
ranged O
from O
5 B_MEASURE
. O
8 B_MEASURE
to O
14 B_MEASURE
. O
2 B_MEASURE
per O
individual B_PERSON/B_TIME[MEASURE]
, O
with O
putative B_GENE
intact I_GENE
copies I_GENE
always O
more O
abundant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
internally O
deleted O
ones B_PERSON/B_ENT
. O

Taking O
this O
evidence O
together O
, O
Hztransib O
probably O
transferred O
to O
H B_BIO/B_GENE
. B_BIO/I_GENE
zea B_BIO/I_GENE
from O
H B_BIO/B_ORGANISM_FUNCTION
. I_BIO/I_ORGANISM_FUNCTION
armigera I_BIO/I_ORGANISM_FUNCTION
and O
most O
likely O
still O
retains O
its O
capacity O
to O
maintain O
structural O
integrity O
, O
increase O
copy O
number O
and O
remobilize O
in O
H B_BIO
. I_BIO
zea I_BIO
. O

identification O
of O
an O
extracellular O
polysaccharide O
network O
essential O
for O
cytochrome O
anchoring O
and O
biofilm O
formation O
in O
Geobacter B_BIO/B_DISEASE
sulfurreducens I_BIO/I_DISEASE
. O

Transposon O
insertions O
in O
Geobacter B_BIO/B_GENE
sulfurreducens B_BIO/I_GENE
GSU1501 O
, O
part O
of O
an O
ATP O
- O
dependent O
exporter O
within O
an O
operon O
of O
polysaccharide O
biosynthesis O
genes O
, O
were O
previously O
shown O
to O
eliminate O
insoluble O
Fe O
( O
III O
) O
reduction O
and O
use O
of O
an O
electrode O
as O
an O
electron O
acceptor O
. O

Replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
GSU1501 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
a O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cassette I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
produced O
a O
similarly O
defective B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
which O
could O
be O
partially O
complemented O
by O
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
GSU1500 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
GSU1505 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
trans B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Delta1501 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O
limited B_DISEASE/B_ORGANIZATION
cell I_DISEASE/I_ORGANIZATION
- O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
agglutination I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
, O
enhanced B_DISEASE_ADJECTIVE[DISEASE]
attachment I_DISEASE_ADJECTIVE[DISEASE]
to O
negatively O
charged O
surfaces B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
poor B_DISEASE_ADJECTIVE[DISEASE]
attachment I_DISEASE_ADJECTIVE[DISEASE]
to O
positively O
charged O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
lysine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
or O
Fe B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
III B_PROTEIN[GENE]/B_LOCATION
) O
- O
coated O
surfaces B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Wild B_PERSON/B_BIO
- O
type B_MEASURE/B_LOCATION
and O
mutant B_DISEASE/B_MEASURE
cells I_DISEASE/I_MEASURE
attached O
to O
graphite B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
electrodes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
but O
when O
electrodes B_MEDICAL_DEVICE[OBJECT]/B_PERSON
were O
poised O
at O
an O
oxidizing O
potential B_MEASURE/B_PERSON
inducing O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]
surface I_DISEASE_ADJECTIVE[DISEASE]
charge I_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_MEASURE
0 I_MEASURE
. O
24 B_MEASURE
V I_MEASURE
versus I_MEASURE
the O
standard B_LOCATION/B_MEASURE
hydrogen B_LOCATION/I_MEASURE
electrode B_LOCATION/I_MEASURE
[ O
She O
] B_MEDICAL_DEVICE[OBJECT]/B_DISEASE
) O
, O
Delta1501 B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
cells I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
detached O
. O

scanning O
electron O
microscopy O
revealed O
fibrils O
surrounding O
wild O
- O
type O
G B_BIO/B_GENE
. B_BIO/I_GENE
sulfurreducens B_BIO/I_GENE
which O
were O
absent O
from O
the O
Delta1501 O
mutant O
. O

Similar B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
type B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IV B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pili B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O
associated O
cytochromes B_GENE/B_BIO
were O
detected O
on O
both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
shearing B_PERSON/B_LOCATION
released O
a O
stable B_MEASURE/B_LOCATION
matrix I_MEASURE/I_LOCATION
of O
c B_DISEASE/B_PROTEIN[GENE]
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytochromes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
other B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
bound O
to O
polysaccharides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
matrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
mutant B_DISEASE/B_BIO
contained O
60 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
less B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
was O
nearly O
devoid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
c B_DISEASE/B_PROTEIN[GENE]
- O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytochromes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
OmcZ B_GENE/B_BACTERIUM[BIO]
. O

The O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
extracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
matrix B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
to O
Delta1501 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultures B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
restored O
agglutination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
Fe B_LOCATION/B_MEASURE
( O
III B_PROTEIN[GENE]/B_LOCATION
) O
reduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
polysaccharide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Congo I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
red I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
preferentially O
bound O
wild B_PERSON/B_SPECIES[BIO]
- O
type B_MEASURE/B_LOCATION
cells I_MEASURE/I_LOCATION
and O
extracellular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
matrix I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
material I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
over O
mutant B_DISEASE/B_MEASURE
cells I_DISEASE/I_MEASURE
, O
and O
Congo B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
red I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O
agglutination B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
Fe B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
III B_PROTEIN[GENE]/B_LOCATION
) O
reduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
wild B_SPECIES[BIO]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
- O
type B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
a O
crucial B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
xap B_PROTEIN[GENE]/B_SPECIES[BIO]
( O
extracellular B_LOCATION/B_PROTEIN[GENE]
anchoring B_LOCATION/I_PROTEIN[GENE]
polysaccharide B_LOCATION/I_PROTEIN[GENE]
) O
locus B_PROTEIN[GENE]/B_LOCATION
in O
metal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
oxide B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
attachment B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
cell B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agglutination B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
localization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
essential B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytochromes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
beyond O
the O
Geobacter B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
outer I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Hyphal O
and O
cytoskeleton O
polarization O
in O
Tuber B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
melanosporum I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
: O
a O
genomic O
and O
cellular O
analysis O
. O

filamentous B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
polarized O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
involves O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
events B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
including O
polarization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cytoskeleton B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
selected O
growth B_LOCATION/B_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
, O
and O
the O
transport B_ORGANIZATION/B_ORGANISM_FUNCTION
of O
secretory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vesicles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
the O
components B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
for O
growth B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
availability B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fungal B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
recently O
led O
to O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
large B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
proteins B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
these O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

We O
have O
explored O
the O
Tuber B_SPECIES[BIO]/B_MEASURE
melanosporum I_SPECIES[BIO]/I_MEASURE
genome O
sequence O
by O
searching O
for O
homologs O
of O
genes O
known O
to O
play O
crucial O
roles O
in O
the O
morphogenesis O
and O
cell O
polarity O
of O
yeasts B_SPECIES[BIO]/B_LOCATION
and O
filamentous O
fungi O
. O

One B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
and O
forty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
genes I_NUMBER[MEASURE]
have O
been O
identified O
and O
functionally O
grouped O
according O
to O
the O
deduced O
amino B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
44 B_MEASURE
genes I_MEASURE
involved O
in O
cell B_MEASURE/B_ORGANISM_FUNCTION
polarity I_MEASURE/I_ORGANISM_FUNCTION
/ O
morphogenesis B_DISEASE/B_ORGANISM_FUNCTION
, O
39 B_MEASURE
belonging O
to O
the O
actin B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeleton I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
66 B_NUMBER[MEASURE]
involved O
in O
membrane B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
dynamics B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
septation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
exocytosis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
) O
. O

A O
detailed O
gene O
annotation O
has O
shown O
that O
most O
components O
of O
the O
cell O
polarity O
machinery O
, O
morphogenesis O
and O
cytoskeleton O
found O
in O
yeasts B_BIO/B_LOCATION
and O
filamentous O
fungi O
are O
conserved O
, O
although O
the O
degree O
of O
similarity O
varies O
from O
strong O
to O
weak O
. O

microscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
quick B_PERSON/B_LOCATION
- O
frozen O
truffle B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyphae I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
detected O
the O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
components B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
hyphal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tip B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
septate B_BIO/B_LOCATION
filamentous I_BIO/I_LOCATION
fungi I_BIO/I_LOCATION
, O
while O
transcript B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
profiles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
a O
moderately O
variable B_MEASURE/B_DISEASE
pattern I_MEASURE/I_DISEASE
during O
the O
biological B_TIME[MEASURE]
cycle I_TIME[MEASURE]
. O

Proteomics O
of O
cryoprotective O
dehydration O
in O
Megaphorura B_PERSON
arctica I_PERSON
Tullberg O
1876 O
( O
Onychiuridae O
: O
Collembola O
) O
. O

The O
Arctic B_BIO
springtail I_BIO
, O
Megaphorura B_BIO/B_LOCATION
arctica I_BIO/I_LOCATION
Tullberg O
1876 O
( O
Onychiuridae O
: O
Collembola O
) O
, O
is O
one O
of O
the O
few O
organisms O
known O
to O
survive O
the O
extreme O
stresses O
of O
its O
environment O
by O
using O
cryoprotective O
dehydration O
. O

We O
have O
undertaken O
a O
proteomics O
study O
comparing O
M B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
arctica I_SPECIES[BIO]/I_PERSON
, O
acclimated O
at O
- O
2 O
^ O
0C O
, O
the O
temperature O
known O
to O
induce O
the O
production O
of O
the O
anhydroprotectant O
trehalose O
in O
this O
species O
, O
and O
- O
6 O
^ O
0C O
, O
the O
temperature O
at O
which O
trehalose O
expression O
plateaus O
, O
against O
control O
animals O
acclimated O
at O
+ O
5 O
^ O
0C O
. O

Using O
difference B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
liquid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tandem I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
identified O
three B_MEASURE/B_LOCATION
categories B_MEASURE/I_LOCATION
of O
differentially O
expressed O
proteins B_GENE/B_DISEASE
with O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
up O
- O
regulated O
in O
both O
the O
- O
2 B_MEASURE
^ I_MEASURE
0C I_MEASURE
and O
- O
6 B_PROTEIN[GENE]/B_LOCATION
^ I_PROTEIN[GENE]/I_LOCATION
0C I_PROTEIN[GENE]/I_LOCATION
animals I_PROTEIN[GENE]/I_LOCATION
, O
that O
were O
involved O
in O
metabolism B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
membrane B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transport I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
folding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

proteins B_BIO/B_GENE
involved O
in O
cytoskeleton B_DISEASE/B_GENE
organisation I_DISEASE/I_GENE
were O
only O
up O
- O
regulated O
in O
the O
- O
6 B_PERSON/B_MEASURE
^ I_PERSON/I_MEASURE
0C I_PERSON/I_MEASURE
animals I_PERSON/I_MEASURE
. O

The O
pyrokinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
pheromone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
biosynthesis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
activating O
neuropeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PBAN B_GENE/B_LOCATION
) O
family B_PERSON/B_LOCATION
of O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
their O
receptors B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Insecta B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
evolutionary B_SPECIES[BIO]/B_LOCATION
trace I_SPECIES[BIO]/I_LOCATION
indicates O
potential B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
binding O
domains B_LOCATION
. O

The O
pyrokinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
pheromone B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
biosynthesis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
activating O
neuropeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PBAN B_LOCATION/B_ORGANIZATION
) O
family B_PERSON/B_LOCATION
of O
G B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O
coupled O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
their O
ligands B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
identified O
in O
various B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
insects I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Physiological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pyrokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
include O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
contraction B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
whereas O
PBAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulates O
, O
among O
other B_PERSON/B_LOCATION
functions I_PERSON/I_LOCATION
, O
pheromone B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
production B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
moths B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
which O
indicates O
the O
pleiotropic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
nature I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
of O
these O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
the O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
annotated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genomic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
the O
pyrokinin B_GENE/B_LOCATION
/ O
PBAN B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
have O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
corresponding B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
structures I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
capa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
periviscerokinin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
insects B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
neuromedin B_BIO/B_GENE
U I_BIO/I_GENE
receptors I_BIO/I_GENE
of O
vertebrates B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
evolutionary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
trace I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
ET B_LOCATION/B_BIO
) O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
the O
insect B_GENE/B_BIO
receptor I_GENE/I_BIO
sequences I_GENE/I_BIO
was O
conducted O
to O
predict O
the O
putative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligand I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
binding B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
ET B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
four B_BODY_PART_OR_ORGAN_COMPONENT
class I_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
several B_LOCATION/B_PERSON
amino I_LOCATION/I_PERSON
acid I_LOCATION/I_PERSON
residues I_LOCATION/I_PERSON
that O
are O
conserved O
in O
the O
transmembrane B_PROTEIN[GENE]/B_LOCATION
domains I_PROTEIN[GENE]/I_LOCATION
. O

The O
receptor B_PROTEIN[GENE]/B_LOCATION
extracellular I_PROTEIN[GENE]/I_LOCATION
domains I_PROTEIN[GENE]/I_LOCATION
exhibit O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
class B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
amino I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
acid I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
residues I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
which O
could O
indicate O
putative B_LOCATION/B_MEASURE
domains I_LOCATION/I_MEASURE
for O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
these O
receptors B_BIO/B_GENE
by O
ligand B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
binding B_TIME[MEASURE]/B_GENE
. O

acon O
- O
3 O
, O
the O
Neurospora B_SPECIES[BIO]
crassa I_SPECIES[BIO]
ortholog O
of O
the O
developmental O
modifier O
, O
medA O
, O
complements O
the O
conidiation O
defect O
of O
the O
Aspergillus B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
nidulans B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mutant O
. O

Aspergillus B_BACTERIUM[BIO]
nidulans I_BACTERIUM[BIO]
and O
Neurospora B_SPECIES[BIO]
crassa I_SPECIES[BIO]
are O
ascomycetes O
that O
produce O
asexual O
spores O
through O
morphologically O
distinct O
processes O
. O

MedA O
, O
a O
protein O
with O
unknown O
function O
, O
is O
required O
for O
normal O
asexual O
and O
sexual O
development O
in O
A B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
nidulans I_SPECIES[BIO]/I_PERSON
. O

We O
determined O
that O
the O
N B_SPECIES[BIO]
. I_SPECIES[BIO]
crassa I_SPECIES[BIO]
ortholog O
of O
medA O
is O
acon O
- O
3 O
, O
a O
gene O
required O
for O
early O
conidiophore O
development O
and O
female O
fertility O
. O

To O
test O
hypotheses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
the O
evolutionary B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
origins I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
asexual B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
development B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
distinct B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fungal I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lineages I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
it O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
understand O
the O
degree B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
conservation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
developmental B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
regulators B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
amino O
acid O
sequences O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
nidulans I_SPECIES[BIO]
MedA O
and O
N B_BACTERIUM[BIO]/B_GENE
. I_BACTERIUM[BIO]/I_GENE
crassa I_BACTERIUM[BIO]/I_GENE
ACON O
- O
3 O
shared O
37 O
% O
identity O
and O
51 O
% O
similarity O
. O

acon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_TIME[MEASURE]
is O
induced O
at O
late B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
points I_TIME[MEASURE]/I_LOCATION
of O
conidiation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
medA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
constitutively O
expressed O
and O
MedA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protein B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
localizes B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
nuclei O
in O
all O
tissue B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Nonetheless O
, O
expression O
of O
acon O
- O
3 O
using O
its O
native O
promoter O
complemented O
the O
conidiation O
defects O
of O
the O
A B_SPECIES[BIO]/B_MEASURE
. B_SPECIES[BIO]/I_MEASURE
nidulans B_SPECIES[BIO]/I_MEASURE
DeltamedA O
and O
medA15 O
mutants O
. O

We O
conclude O
that O
the O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
medA B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orthologs I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
conserved O
for O
conidiation B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Towards B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
achievement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
universal B_PERSON/B_LOCATION
health I_PERSON/I_LOCATION
care I_PERSON/I_LOCATION
in O
India B_LOCATION
by O
2020 B_MEASURE/B_ORGANIZATION
: O
a O
call B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
action B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

To O
sustain O
the O
positive B_DISEASE_ADJECTIVE[DISEASE]
economic I_DISEASE_ADJECTIVE[DISEASE]
trajectory I_DISEASE_ADJECTIVE[DISEASE]
that O
India B_LOCATION
has O
had O
during O
the O
past B_TIME[MEASURE]/B_DISEASE
decade I_TIME[MEASURE]/I_DISEASE
, O
and O
to O
honour O
the O
fundamental B_PERSON/B_LOCATION
right I_PERSON/I_LOCATION
of O
all O
citizens B_PERSON/B_LOCATION
to O
adequate B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
health B_PERSON/B_LOCATION
of O
all O
Indian B_PERSON/B_LOCATION
people I_PERSON/I_LOCATION
has O
to O
be O
given O
the O
highest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
priority I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
public B_ORGANIZATION/B_LOCATION
policy I_ORGANIZATION/I_LOCATION
. O

We O
propose O
the O
creation O
of O
the O
Integrated O
National O
Health O
System O
in O
India O
through O
provision O
of O
universal O
health O
insurance O
, O
establishment O
of O
autonomous O
organisations O
to O
enable O
accountable O
and O
evidence O
- O
based O
good O
- O
quality O
health O
- O
care O
practices O
and O
development O
of O
appropriately O
trained O
human B_PERSON/B_SPECIES[BIO]
resources O
, O
the O
restructuring O
of O
health O
governance O
to O
make O
it O
coordinated O
and O
decentralised O
, O
and O
legislation O
of O
health O
entitlement O
for O
all O
Indian O
people O
. O

The O
key B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
our O
proposal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O
to O
strengthen O
the O
public B_ORGANIZATION/B_LOCATION
health I_ORGANIZATION/I_LOCATION
system I_ORGANIZATION/I_LOCATION
as O
the O
primary B_LOCATION/B_PERSON
provider B_LOCATION/I_PERSON
of O
promotive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
preventive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
curative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
health I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
services I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
in O
India B_LOCATION
, O
to O
improve O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
reduce O
the O
out O
- O
of O
- O
pocket B_MEASURE/B_LOCATION
expenditure B_MEASURE/I_LOCATION
on O
health B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
through O
a O
well O
regulated B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
integration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
the O
private B_LOCATION/B_ORGANIZATION
sector I_LOCATION/I_ORGANIZATION
within O
the O
national B_PERSON/B_LOCATION
health I_PERSON/I_LOCATION
- O
care B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Dialogue B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
consensus B_LOCATION/B_ORGANIZATION
building I_LOCATION/I_ORGANIZATION
among O
the O
stakeholders B_PERSON/B_LOCATION
in O
the O
government B_ORGANIZATION/B_LOCATION
, O
civil B_ORGANIZATION/B_PERSON
society I_ORGANIZATION/I_PERSON
, O
and O
private B_ORGANIZATION/B_PERSON
sector I_ORGANIZATION/I_PERSON
are O
the O
next B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
steps B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
formalise O
the O
actions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
needed O
and O
to O
monitor O
their O
achievement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
our O
call B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
we O
propose O
that O
India B_LOCATION/B_PERSON
must O
achieve O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
all O
by O
2020 B_MEASURE/B_ORGANIZATION
. O

financing B_PERSON/B_ORGANIZATION
health I_PERSON/I_ORGANIZATION
care I_PERSON/I_ORGANIZATION
for O
all O
: O
challenges B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
opportunities B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

India B_LOCATION
' I_LOCATION
s O
health B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
financing I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
cause B_PERSON/B_DISEASE
of O
and O
an O
exacerbating O
factor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
challenges B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inequity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
inadequate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
availability I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
reach B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
unequal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
access I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
quality B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
costly B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
health I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- O
care B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
per O
person B_MEASURE
spending I_MEASURE
on O
health B_PERSON/B_ORGANIZATION
and O
insufficient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
public I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
expenditure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
result O
in O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
highest B_MEASURE/B_PERSON
proportions I_MEASURE/I_PERSON
of O
private B_PERSON
out O
- O
of O
- O
pocket B_MEASURE/B_LOCATION
expenses B_MEASURE/I_LOCATION
in O
the O
world B_LOCATION/B_ORGANIZATION
. O

Citizens B_PERSON
receive O
low B_MEASURE/B_PERSON
value B_MEASURE/I_PERSON
for O
money B_ORGANIZATION/B_PERSON
in O
the O
public B_ORGANIZATION/B_LOCATION
and O
the O
private B_ORGANIZATION/B_LOCATION
sectors I_ORGANIZATION/I_LOCATION
. O

financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
against O
medical B_DISEASE
expenditures I_DISEASE
is O
far O
from O
universal B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
with O
only O
10 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
population B_PERSON/B_LOCATION
having O
medical B_PERSON/B_ORGANIZATION
insurance I_PERSON/I_ORGANIZATION
. O

The O
Government B_ORGANIZATION/B_PERSON
of O
India B_LOCATION
has O
made O
a O
commitment B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
increase O
public B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spending I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
health B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
from O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
1 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
to O
3 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
gross B_MEASURE/B_ORGANIZATION
domestic I_MEASURE/I_ORGANIZATION
product I_MEASURE/I_ORGANIZATION
during O
the O
next B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
few I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
years I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

increased O
public B_ORGANIZATION/B_PERSON
funding I_ORGANIZATION/I_PERSON
combined O
with O
flexibility B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
financial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
transfers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
from O
centre B_LOCATION/B_ORGANIZATION
to O
state B_LOCATION/B_ORGANIZATION
can O
greatly O
improve O
the O
performance B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
state B_LOCATION/B_ORGANIZATION
- O
operated O
public B_ORGANIZATION/B_LOCATION
systems I_ORGANIZATION/I_LOCATION
. O

Enhanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
public B_ORGANIZATION/B_PERSON
spending I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O
be O
used O
to O
introduce O
universal B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medical I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insurance I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
can O
help O
to O
substantially O
reduce O
the O
burden B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
private B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
out O
- O
of O
- O
pocket B_LOCATION/B_MEASURE
expenditures I_LOCATION/I_MEASURE
on O
health B_PERSON/B_ORGANIZATION
. O

increased O
public B_MEASURE/B_ORGANIZATION
spending B_MEASURE/I_ORGANIZATION
can O
also O
contribute O
to O
quality B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
assurance I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
in O
the O
public B_ORGANIZATION/B_LOCATION
and O
private B_ORGANIZATION/B_LOCATION
sectors I_ORGANIZATION/I_LOCATION
through O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
regulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
oversight B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
public B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
expenditures I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
on O
health B_PERSON/B_LOCATION
, O
the O
Government B_ORGANIZATION/B_PERSON
of O
India B_LOCATION/B_PERSON
will I_LOCATION/I_PERSON
, O
however O
, O
need O
to O
introduce O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
contain O
costs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
improve O
the O
efficiency B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
spending B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increase O
accountability B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
, O
and O
monitor O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
expenditures B_DISEASE/B_ORGANIZATION
on O
health B_PERSON/B_ORGANIZATION
. O

Continuing O
challenge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
infectious B_DISEASE/B_PERSON
diseases I_DISEASE/I_PERSON
in O
India B_LOCATION
. O

In O
India B_LOCATION
, O
the O
range B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
infectious B_DISEASE
diseases I_DISEASE
are O
enormous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

The O
administrative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
responsibilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
health B_ORGANIZATION/B_LOCATION
system I_ORGANIZATION/I_LOCATION
are O
shared O
between O
the O
central B_LOCATION/B_ORGANIZATION
( O
federal B_ORGANIZATION/B_LOCATION
) O
and O
state B_LOCATION/B_ORGANIZATION
governments I_LOCATION/I_ORGANIZATION
. O

Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diseases B_DISEASE
and O
outbreaks B_DISEASE
is O
the O
responsibility B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
central B_ORGANIZATION/B_PERSON
Ministry I_ORGANIZATION/I_PERSON
of O
Health B_PERSON/B_ORGANIZATION
, O
which O
lacks O
a O
formal B_ORGANIZATION/B_LOCATION
public I_ORGANIZATION/I_LOCATION
health I_ORGANIZATION/I_LOCATION
department I_ORGANIZATION/I_LOCATION
for O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

tuberculosis O
, O
malaria O
, O
filariasis O
, O
visceral O
leishmaniasis O
, O
leprosy O
, O
HIV B_DISEASE
infection O
, O
and O
childhood O
cluster O
of O
vaccine O
- O
preventable O
diseases O
are O
given O
priority O
for O
control O
through O
centrally O
managed O
vertical O
programmes O
. O

Control O
of O
HIV B_DISEASE
infection O
and O
leprosy O
, O
but O
not O
of O
tuberculosis O
, O
seems O
to O
be O
on O
track O
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
malaria B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
not O
sustained O
, O
and O
visceral B_DISEASE_ADJECTIVE[DISEASE]
leishmaniasis I_DISEASE_ADJECTIVE[DISEASE]
prevalence I_DISEASE_ADJECTIVE[DISEASE]
has O
increased O
. O

inadequate O
containment O
of O
the O
vector O
has O
resulted O
in O
recurrent O
outbreaks O
of O
dengue O
fever O
and O
re O
- O
emergence O
of O
Chikungunya B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
virus I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
disease O
and O
typhus O
fever O
. O

Other O
infectious O
diseases O
caused O
by O
faecally O
transmitted O
pathogens O
( O
enteric O
fevers O
, O
cholera O
, O
hepatitis B_DISEASE/B_PROTEIN[GENE]
A B_DISEASE/I_PROTEIN[GENE]
and O
E B_VIRUS[BIO]/B_LOCATION
viruses I_VIRUS[BIO]/I_LOCATION
) O
and O
zoonoses O
( O
rabies O
, O
leptospirosis O
, O
anthrax O
) O
are O
not O
in O
the O
process O
of O
being O
systematically O
controlled O
. O

big B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gaps I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
system I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
infectious B_DISEASE/B_PERSON
diseases I_DISEASE/I_PERSON
need O
to O
be O
addressed O
. O

replication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
vertical B_DISEASE
single I_DISEASE
- O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
all O
infectious B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
diseases I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
will O
not O
be O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
viable B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
. O

India B_LOCATION
needs O
to O
rethink O
and O
revise O
its O
health B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
policy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
broaden O
the O
agenda B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

A O
comprehensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
redesign B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
is O
needed O
urgently O
to O
ensure O
equity B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
health B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
recommend O
the O
creation B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
functional B_LOCATION/B_ORGANIZATION
public I_LOCATION/I_ORGANIZATION
health I_LOCATION/I_ORGANIZATION
infrastructure I_LOCATION/I_ORGANIZATION
that O
is O
shared O
between O
central B_LOCATION/B_ORGANIZATION
and O
state B_LOCATION
governments I_LOCATION
, O
with O
professional B_PERSON
leadership I_PERSON
and O
a O
formally O
trained O
public B_ORGANIZATION/B_PERSON
health B_ORGANIZATION/I_PERSON
cadre B_ORGANIZATION/I_PERSON
of O
personnel B_PERSON
who O
manage O
an O
integrated B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
control B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
mechanism B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
diseases B_DISEASE
in O
districts B_LOCATION/B_PERSON
that O
includes O
infectious B_DISEASE
and O
non B_DISEASE/B_MEASURE
- O
infectious B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
diseases I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
and O
injuries B_DISEASE
. O

ATP O
citrate O
lyase O
is O
required O
for O
normal O
sexual O
and O
asexual O
development O
in O
Gibberella B_SPECIES[BIO]/B_PERSON
zeae I_SPECIES[BIO]/I_PERSON
. O

adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triphosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
citrate B_ENZYME[GENE]
lyase I_ENZYME[GENE]
( O
ACL B_DISEASE/B_LOCATION
) O
is O
a O
key B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
enzyme I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
the O
production B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cytosolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
CoA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
which O
is O
crucial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
de B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
novo I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lipid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
histone B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
acetylation I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
in O
mammalian B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study O
, O
we O
characterized O
the O
mechanistic O
roles O
of O
ACL O
in O
the O
homothallic O
ascomycete O
fungus O
Gibberella B_SPECIES[BIO]
zeae I_SPECIES[BIO]
, O
which O
causes O
Fusarium O
head O
blight O
in O
major O
cereal O
crops O
. O

Deletion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ACL B_GENE/B_DISEASE
in O
the O
fungus B_SPECIES[BIO]
resulted O
in O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
self B_PERSON/B_BIO
and O
female B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fertility I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
asexual B_DISEASE/B_ORGANISM_FUNCTION
reproduction I_DISEASE/I_ORGANISM_FUNCTION
, O
virulence B_DISEASE/B_ORGANISM_FUNCTION
, O
and O
trichothecene B_DISEASE/B_BIO
production I_DISEASE/I_BIO
. O

When O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_MEASURE/B_BIO
strain I_MEASURE/I_BIO
was O
spermatized O
with O
the O
ACL B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deletion B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
produced O
viable B_BIO/B_DISEASE
ascospores B_BIO/I_DISEASE
, O
however O
ascospore B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
delimitation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O
not O
properly O
regulated O
. O

Although O
lipid B_ORGANISM_FUNCTION/B_GENE
synthesis I_ORGANISM_FUNCTION/I_GENE
was O
not O
affected O
by O
ACL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deletion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
histone B_GENE/B_ORGANISM_FUNCTION
acetylation B_GENE/I_ORGANISM_FUNCTION
was O
dramatically O
reduced O
in O
the O
ACL B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
deletion I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mutants I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
sexual B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
development I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
suggesting O
that O
the O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
sexual B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
reproduction I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
were O
caused O
by O
the O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
histone B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetylation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
the O
first B_SEQUENCE[MEASURE]
report I_SEQUENCE[MEASURE]
demonstrating O
a O
link B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
sexual B_DISEASE/B_GENE
development B_DISEASE/I_GENE
and O
ACL B_GENE/B_DISEASE
- O
mediated O
histone B_DISEASE/B_GENE
acetylation I_DISEASE/I_GENE
in O
fungi B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

expression O
of O
a O
Brassica B_BIO
napus I_BIO
heme O
oxygenase O
confers O
plant O
tolerance O
to O
mercury O
toxicity O
. O

Plant B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
heme B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
oxygenases I_PERSON
( O
hos B_GENE/B_MEASURE
) O
regulate O
biosynthesis B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_ENZYME[GENE]
of O
phytochrome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
which O
accounts O
for O
photo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
acceptance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
- O
morphogenesis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
demonstrated O
that O
plant B_BIO/B_GENE
HOs I_BIO
also O
regulate O
many B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
other B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
physiological B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
processes B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
including O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
environmental B_DISEASE_ADJECTIVE[DISEASE]
stimuli I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
elucidate O
the O
mechanism O
by O
which O
HOs O
regulate O
plant O
adaptation O
to O
heavy O
metal O
exposure O
, O
three O
novel O
HOs O
genes O
were O
isolated O
from O
rapeseed B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Brassica B_BIO/B_LOCATION
napus B_BIO/I_LOCATION
) O
and O
their O
expression O
patterns O
were O
analysed O
. O

alignment O
of O
deduced O
protein O
sequences O
revealed O
that O
the O
three O
BnHOs O
share O
high O
identity O
with O
their O
corresponding O
orthologos O
( O
AtHO1 O
- O
3 O
) O
from O
Arabidopsis B_BIO
. O

To O
investigate O
whether O
the O
BnHO O
regulates O
plant O
tolerance O
to O
Hg O
toxicity O
, O
we O
constructed O
B B_BIO/B_NUMBER[MEASURE]
. B_BIO/I_NUMBER[MEASURE]
napus B_BIO/I_NUMBER[MEASURE]
transgenic O
plants O
overexpressing O
BnHO O
- O
1 O
. O

Under O
Hg B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
transgenic B_BIO
plants I_BIO
had O
1 B_MEASURE/B_LOCATION
. O
41 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
59 B_MEASURE
folds I_MEASURE
higher I_MEASURE
biomass I_MEASURE
than O
the O
untransformants B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
BnHO B_DISEASE/B_GENE
- O
1 B_NUMBER[MEASURE]
resulted O
in O
less B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
accumulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
Hg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
some O
lines B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transformants B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
untransformants B_BIO/B_MEASURE
. O

The O
transgenic B_BIO/B_GENE
plants I_BIO/I_GENE
show O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abundance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
reactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
species I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
attenuated O
oxidative B_DISEASE/B_ORGANISM_FUNCTION
injury I_DISEASE/I_ORGANISM_FUNCTION
compared O
with O
the O
untransgenic B_BIO/B_PERSON
plants B_BIO/I_PERSON
. O

We O
cloned O
the O
promoter O
sequences O
of O
BnHO O
- O
1 O
from O
B B_SPECIES[BIO]
. I_SPECIES[BIO]
napus I_SPECIES[BIO]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O
that O
the O
1119 B_GENE/B_LOCATION
bp I_GENE/I_LOCATION
fragment I_GENE/I_LOCATION
contains O
a O
conserved B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cd I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsive I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CdRE B_LOCATION/B_ORGANIZATION
) O
and O
others B_LOCATION/B_GENE
responding O
to O
multiple B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
environmental I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stimuli I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transient O
expression O
in O
tobacco B_ORGANIZATION/B_BIO
leaves O
showed O
differential O
responses O
to O
heavy O
metals O
( O
Zn O
, O
cu O
, O
Pb O
, O
Hg O
and O
CD O
) O
. O

The O
rate B_MEASURE/B_LOCATION
- O
limiting O
step B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
CO B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
assimilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
at O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
temperatures B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
is O
influenced O
by O
the O
leaf B_MEASURE/B_LOCATION
nitrogen I_MEASURE/I_LOCATION
content I_MEASURE/I_LOCATION
in O
several B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
C I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
3 B_NUMBER[MEASURE]/B_LOCATION
) O
crop B_BIO/B_LOCATION
species B_BIO/I_LOCATION
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
nitrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
supply B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
limiting O
step B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CO B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
assimilation B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
at O
380 B_MEASURE/B_LOCATION
mumol I_MEASURE/I_LOCATION
mol I_MEASURE/I_LOCATION
( O
- O
1 B_MEASURE
) O
CO B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
concentration B_MEASURE
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
380 B_MEASURE/B_LOCATION
) O
) O
at O
several B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
leaf B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
temperatures B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
studied O
in O
several B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
crops I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
since O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
nutrition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
alters O
N B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
allocation I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
photosynthetic B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

contents B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
leaf B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
ribulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
* O
5 B_MEASURE
- O
bisphosphate B_ENZYME[GENE]
carboxylase I_ENZYME[GENE]
/ O
oxygenase B_ENZYME[GENE]/B_DISEASE
( O
Rubisco B_PERSON/B_PROTEIN[GENE]
) O
and O
cytochrome B_ENZYME[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
f O
( O
cyt B_PROTEIN[GENE]/B_LOCATION
f O
) O
increased O
with O
increasing O
N B_MEASURE
supply I_MEASURE
, O
but O
the O
cyt B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
f O
/ O
Rubisco B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
. O

Large B_DISEASE/B_MEASURE
leaf I_DISEASE/I_MEASURE
N I_DISEASE/I_MEASURE
content I_DISEASE/I_MEASURE
was O
linked O
to O
a O
high B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
stomatal I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
g B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
s O
) O
) O
and O
mesophyll B_BIO/B_MEASURE
conductance B_BIO/I_MEASURE
( O
g B_OTHER/B_PROTEIN[GENE]
( O
m B_MEASURE/B_DISEASE
) O
) O
, O
but O
resulted O
in O
a O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
intercellular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
C B_OTHER/B_LOCATION
( O
i B_DISEASE/B_PROTEIN[GENE]
) O
) O
and O
chloroplast B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
CO I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_MEASURE/B_LOCATION
) O
concentration B_MEASURE/B_LOCATION
( O
C B_OTHER/B_LOCATION
( O
c B_PROTEIN[GENE]/B_DISEASE
) O
) O
because O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
g B_PROTEIN[GENE]/B_MEASURE
( O
s O
) O
and O
g B_PROTEIN[GENE]/B_MEASURE
( O
m B_PROTEIN[GENE]/B_DISEASE
) O
was O
insufficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
compensate O
for O
change B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
380 B_MEASURE/B_LOCATION
) O
. O

The O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
C B_PROTEIN[GENE]/B_MEASURE
( O
c B_MEASURE/B_DISEASE
) O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
used O
to O
estimate O
the O
maximum B_MEASURE
rate I_MEASURE
of O
RuBP B_LOCATION/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
carboxylation B_LOCATION/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
( O
V B_MEASURE/B_PROTEIN[GENE]
( O
Cmax B_MEASURE/B_LOCATION
) O
) O
and O
chloroplast B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
electron I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
transport I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
( O
J B_OTHER/B_PROTEIN[GENE]
( O
max B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
) O
. O

The O
J B_OTHER/B_PROTEIN[GENE]
( O
max B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
/ O
V B_OTHER/B_LOCATION
( O
Cmax B_MEASURE/B_LOCATION
) O
ratio B_MEASURE/B_PERSON
decreased O
with O
reductions B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
leaf B_MEASURE/B_ORGANIZATION
N I_MEASURE/I_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
, O
which O
was O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cyt B_GENE/B_MEASURE
f O
/ O
Rubisco B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
C B_PROTEIN[GENE]/B_LOCATION
( O
3 B_MEASURE
) O
photosynthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
indicated O
that O
A B_OTHER/B_LOCATION
( O
380 B_NUMBER[MEASURE]
) O
tended O
to O
be O
limited O
by O
RuBP B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylation B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grown O
at O
low B_DISEASE_ADJECTIVE[DISEASE]
N I_DISEASE_ADJECTIVE[DISEASE]
concentration I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
it O
was O
limited O
by O
RuBP B_LOCATION/B_BACTERIUM[BIO]
regeneration I_LOCATION/I_BACTERIUM[BIO]
in O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grown O
at O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
N I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
concentration I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
the O
limiting O
step B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
380 B_MEASURE/B_LOCATION
) O
depends O
on O
leaf B_MEASURE/B_ORGANIZATION
N I_MEASURE/I_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
and O
is O
mainly O
determined O
by O
N B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partitioning O
between O
Rubisco B_BIO/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
electron B_PERSON/B_LOCATION
transport I_PERSON/I_LOCATION
components I_PERSON/I_LOCATION
. O

Comparative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ionomics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
metabolomics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
extremophile B_BIO/B_LOCATION
and O
glycophytic B_BIO
Lotus I_BIO
species I_BIO
under O
salt B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O
the O
metabolic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adaptation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
hypothesis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
legume B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genus B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lotus B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
includes O
glycophytic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
forage I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
crops I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
other B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
adapted O
to O
extreme B_LOCATION/B_MEASURE
environments I_LOCATION/I_MEASURE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
saline B_LOCATION
soils I_LOCATION
. O

Understanding O
salt B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tolerance I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
will O
contribute O
to O
the O
discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
new B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
traits I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
may O
enhance O
the O
breeding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
efforts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
towards O
improved B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
performance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
legumes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
in O
marginal B_LOCATION
agricultural I_LOCATION
environments I_LOCATION
. O

Here O
, O
we O
used O
a O
combination O
of O
ionomic O
and O
gas O
chromatography O
- O
mass O
spectrometry O
( O
GC O
- O
MS O
) O
- O
based O
metabolite O
profilings O
of O
complete O
shoots O
( O
pooling O
leaves O
, O
petioles O
and O
stems O
) O
to O
compare O
the O
extremophile O
Lotus B_BIO/B_GENE
creticus I_BIO/I_GENE
, O
adapted O
to O
highly O
saline O
coastal O
regions O
, O
and O
two O
cultivated O
glycophytic O
grassland O
forage O
species O
, O
Lotus B_BIO/B_LOCATION
corniculatus I_BIO/I_LOCATION
and O
Lotus B_BIO/B_LOCATION
tenuis I_BIO/I_LOCATION
. O

L B_BIO/B_PERSON
. I_BIO/I_PERSON
creticus I_BIO/I_PERSON
exhibited O
better O
survival O
after O
exposure O
to O
long O
- O
term O
lethal O
salinity O
and O
was O
more O
efficient O
at O
excluding O
Cl O
- O
from O
the O
shoots O
than O
the O
glycophytes O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Na B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
extremophile B_BIO/B_DISEASE
under O
both O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
salt B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
trait B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
often O
observed O
in O
halophytes B_BIO/B_LOCATION
. O

Ionomics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrated O
a O
differential B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rearrangement I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
shoot B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nutrient I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
extremophile B_BIO/B_DISEASE
upon O
salt B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

Metabolite O
profiling O
showed O
that O
responses O
to O
NaCl O
in O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
creticus I_BIO/I_PERSON
shoots O
were O
globally O
similar O
to O
those O
of O
the O
glycophytes O
, O
providing O
little O
evidence O
for O
metabolic O
pre O
- O
adaptation O
to O
salinity O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
salt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acclimation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
extremophile B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
and O
non B_DISEASE
- O
extremophile B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
legumes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
challenges O
the O
generalization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
metabolic B_DISEASE_ADJECTIVE[DISEASE]
salt I_DISEASE_ADJECTIVE[DISEASE]
pre I_DISEASE_ADJECTIVE[DISEASE]
- O
adaptation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

The O
rise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
chronic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
non I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
communicable B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diseases I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
southeast B_LOCATION/B_PERSON
Asia I_LOCATION/I_PERSON
: O
time B_LOCATION
for O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Southeast B_LOCATION
Asia I_LOCATION
faces O
an O
epidemic B_DISEASE
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]
non I_DISEASE_ADJECTIVE[DISEASE]
- O
communicable B_DISEASE
diseases I_DISEASE
, O
now O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
deaths B_DISEASE/B_PERSON
in O
the O
region B_LOCATION
. O

The O
problem O
stems O
from O
environmental O
factors O
that O
promote O
tobacco B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
, O
unhealthy O
diet O
, O
and O
inadequate O
physical O
activity O
. O

Disadvantaged B_PERSON/B_LOCATION
populations I_PERSON/I_LOCATION
are O
the O
hardest O
hit O
, O
with O
death B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inversely O
proportional B_MEASURE/B_PERSON
to O
a O
country B_LOCATION/B_PERSON
' O
s B_MEASURE/B_DISEASE
gross I_MEASURE/I_DISEASE
national I_MEASURE/I_DISEASE
income I_MEASURE/I_DISEASE
. O

Families B_PERSON/B_SOCIAL_CIRCUMSTANCES
shoulder O
the O
financial B_DISEASE_ADJECTIVE[DISEASE]
burden I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
entire B_PERSON
economies I_PERSON
suffer O
as O
well O
. O

Although O
attempts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
control O
non B_DISEASE
- O
communicable B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
diseases I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
increasing O
, O
more B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
needs I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
done O
. O

Health B_PERSON/B_LOCATION
- O
care B_ORGANIZATION/B_PERSON
systems I_ORGANIZATION/I_PERSON
need O
to O
be O
redesigned O
to O
deliver O
chronic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
that O
is O
founded O
on O
existing O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
care B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facilities I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
supported O
by O
good B_ORGANIZATION/B_PERSON
referral I_ORGANIZATION/I_PERSON
systems I_ORGANIZATION/I_PERSON
. O

Surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
key B_DISEASE/B_PERSON
modifiable I_DISEASE/I_PERSON
risk I_DISEASE/I_PERSON
factors I_DISEASE/I_PERSON
is O
needed O
to O
monitor O
the O
magnitude B_MEASURE/B_LOCATION
of O
the O
problem B_DISEASE
and O
to O
study O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
interventions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

All O
branches B_LOCATION
of O
government B_ORGANIZATION/B_LOCATION
and O
all O
sectors B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
society B_ORGANIZATION/B_LOCATION
have O
to O
get O
involved O
in O
establishing O
environments B_LOCATION/B_ORGANIZATION
that O
are O
conducive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
healthy B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
living I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
Association B_ORGANIZATION
of O
Southeast B_PERSON/B_ORGANIZATION
Asian I_PERSON/I_ORGANIZATION
Nations I_PERSON/I_ORGANIZATION
is O
in O
a O
unique B_PERSON
position I_PERSON
to O
make O
a O
united B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stand I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
against O
chronic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
non I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
communicable B_DISEASE/B_PERSON
diseases I_DISEASE/I_PERSON
in O
the O
region B_LOCATION
. O

Inaction B_DISEASE/B_PERSON
will O
affect O
millions B_MEASURE/B_LOCATION
of O
lives B_PERSON/B_LANGUAGE
- O
often O
, O
the O
lives B_PERSON/B_LANGUAGE
of O
those O
who O
have O
the O
least B_DISEASE
. O

Aberrant O
genome O
size O
and O
instability O
of O
Phytophthora B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
ramorum B_BIO/I_DISEASE_ADJECTIVE[DISEASE]
oospore O
progenies O
. O

The O
functionality O
of O
the O
sexual O
cycle O
in O
the O
heterothallic O
pathogen O
Phytophthora B_BACTERIUM[BIO]
ramorum I_BACTERIUM[BIO]
, O
causal O
agent O
of O
sudden O
Oak O
Death O
, O
has O
recently O
been O
demonstrated O
. O

Sexual B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproduction I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
could O
create O
genotypic B_DISEASE/B_BIO
variation I_DISEASE/I_BIO
and O
increase O
the O
pathogen B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
s I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
ability I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
to O
adapt O
to O
other B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
host I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
plants I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
or O
changing O
environments B_LOCATION
. O

Genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
co B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dominant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microsatellite I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
markers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
single B_MEASURE/B_PERSON
- O
oospore B_BIO/B_LOCATION
progeny I_BIO/I_LOCATION
of O
crosses B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
a O
European B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolate O
and O
North B_LOCATION/B_NUMBER[MEASURE]
American I_LOCATION/I_NUMBER[MEASURE]
or O
European B_PERSON/B_LOCATION
A2 I_PERSON/I_LOCATION
isolates I_PERSON/I_LOCATION
revealed O
a O
considerable B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
non B_DISEASE
- O
Mendelian B_GENE/B_PERSON
inheritance I_GENE/I_PERSON
events I_GENE/I_PERSON
. O

This O
includes O
inheritance B_PERSON/B_DISEASE
of O
more B_MEASURE
than O
two B_PERSON/B_NUMBER[MEASURE]
alleles I_PERSON/I_NUMBER[MEASURE]
at O
a O
locus B_GENE/B_MEASURE
and O
non B_DISEASE
- O
inheritance B_PERSON/B_DISEASE
of O
alleles B_GENE/B_PERSON
from O
one B_PERSON/B_LOCATION
parent I_PERSON/I_LOCATION
at O
another O
locus B_LOCATION/B_MEASURE
. O

The O
progenies B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
were O
mitotically O
unstable B_DISEASE_ADJECTIVE[DISEASE]
: O
zoospore B_BIO
and O
hyphal B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tip B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
derivatives B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
the O
progenies B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
showed O
genotypic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rearrangements B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phenotypic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
confirmed O
variation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
instability B_DISEASE/B_MEASURE
in O
DNA B_MEASURE/B_LOCATION
content I_MEASURE/I_LOCATION
of O
the O
single B_NUMBER[MEASURE]/B_PERSON
- O
oospore B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
progenies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

This O
indicates O
that O
single B_MEASURE/B_PERSON
- O
oospore B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progenies I_BIO/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
not O
only O
display O
aberrant B_GENE/B_DISEASE
genomic I_GENE/I_DISEASE
and O
phenotypic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
due O
to O
meiotic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irregularities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
also O
extra B_MEASURE/B_LOCATION
variation I_MEASURE/I_LOCATION
as O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
post B_DISEASE/B_MEASURE
- O
meiotic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
genomic B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
rearrangements B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Independent O
duplications O
of O
alpha O
- O
amylase O
in O
different O
strains O
of O
Aspergillus B_BACTERIUM[BIO]
oryzae I_BACTERIUM[BIO]
. O

Aspergillus B_BACTERIUM[BIO]/B_PERSON
oryzae I_BACTERIUM[BIO]/I_PERSON
is O
a O
filamentous O
fungus O
that O
has O
arisen O
through O
the O
ancient O
domestication O
of O
Aspergillus B_BIO/B_LOCATION
flavus I_BIO/I_LOCATION
for O
making O
traditional O
Oriental O
foods O
and O
beverages O
. O

In O
the O
many O
centuries O
A B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oryzae B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
used O
for O
fermenting O
the O
starch O
in O
rice O
to O
simple O
sugars O
, O
it O
has O
undergone O
selection O
for O
increased O
secretion O
of O
starch O
- O
degrading O
enzymes O
. O

In O
particular O
, O
all O
A B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
oryzae I_BACTERIUM[BIO]
strains O
investigated O
thus O
far O
have O
two O
or O
more O
copies O
of O
a O
gene O
encoding O
alpha O
- O
amylase O
, O
whereas O
A B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
flavus I_SPECIES[BIO]/I_PERSON
has O
only O
one O
. O

Here O
we O
investigate O
the O
duplications O
leading O
to O
these O
copies O
in O
three O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
oryzae I_SPECIES[BIO]
strains O
. O

We O
find O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
at O
least O
three B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
separate B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duplications B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
alpha B_PROTEIN[GENE]/B_DISEASE
- O
amylase B_GENE
, O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
parallel B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_ORGANISM_FUNCTION
evolution I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_ORGANISM_FUNCTION
in O
a O
micro B_MEASURE/B_GENE
- O
organism B_BIO/B_GENE
under O
artificial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
selection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

At O
least O
two B_NUMBER[MEASURE]
of O
these O
duplications B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
appear O
to O
be O
associated O
with O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
transposable B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
elements I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
the O
Tc1 B_GENE/B_BIO
/ O
mariner B_MEASURE
class I_MEASURE
. O

Both O
involve O
a O
9 B_MEASURE
. O
1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kb I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
terminates O
in O
inverted B_GENE
repeats I_GENE
, O
encodes O
a O
putative B_GENE
transposase I_GENE
and O
another O
putative B_ENZYME[GENE]/B_MEASURE
protein I_ENZYME[GENE]/I_MEASURE
of O
unknown B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
and O
contains O
an O
unusual B_MEASURE/B_LOCATION
arrangement B_MEASURE/I_LOCATION
of O
four B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
short B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
internal B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
imperfect B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
repeats B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Although O
& O
quot O
; O
unusual O
Mariners O
& O
quot O
; O
of O
this O
size O
have O
previously O
been O
identified O
in O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
oryzae I_SPECIES[BIO]
, O
Aspergillus B_SPECIES[BIO]
fumigatus I_SPECIES[BIO]
and O
Aspergillus B_BACTERIUM[BIO]
nidulans I_BACTERIUM[BIO]
, O
this O
is O
the O
first O
evidence O
we O
know O
of O
that O
at O
least O
some O
of O
them O
are O
active O
in O
modern O
times O
and O
that O
their O
activity O
can O
contribute O
to O
beneficial O
genetic O
changes O
. O

Response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ecosystems B_LOCATION/B_PERSON
to O
realistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
extinction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggests O
that O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
species B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
loss B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
on O
the O
structure B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
functioning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ecosystems B_LOCATION/B_BIO
will O
critically O
depend O
on O
the O
order B_MEASURE/B_PERSON
with O
which O
species B_BIO/B_PERSON
go O
extinct B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
there O
are O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
natural B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ecosystems I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
to O
realistic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
extinction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
sequences I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Using O
an O
extinction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scenario I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
the O
International B_ORGANIZATION/B_LOCATION
Union I_ORGANIZATION/I_LOCATION
for O
Conservation B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nature B_LOCATION/B_DISEASE
( O
IUCN B_DISEASE/B_GENE
) O
Red B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
de B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Visser I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
sequentially O
deleted O
species B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
topological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
Serengeti B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
food I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
web I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Under O
this O
scenario B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
bodied B_BIO/B_MEASURE
species I_BIO/I_MEASURE
like O
top B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
predators I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
mega B_BIO/B_DISEASE
- O
herbivores B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
go O
extinct B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
first O
. O

The O
resulting O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
trophic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
food B_LOCATION/B_ORGANIZATION
web I_LOCATION/I_ORGANIZATION
might O
affect O
the O
robustness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
ecosystem B_LOCATION/B_BIO
to O
future B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
disturbances I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Host B_EDU[ORGANIZATION]/B_PERSON
characteristics I_EDU[ORGANIZATION]/I_PERSON
and O
environmental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
differentially O
drive O
the O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O
pathogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
an O
ectoparasite B_SPECIES[BIO]/B_DISEASE
: O
a O
multilevel B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causal I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

1 B_NUMBER[MEASURE]
. O

Understanding O
the O
ecological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
driving O
the O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O
pathogenicity B_DISEASE_ADJECTIVE[DISEASE]
of O
parasites B_DISEASE
is O
challenging B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Indeed O
, O
the O
dynamics B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
host B_SPECIES[BIO]
- O
parasite B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
driven O
by O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
organized O
across O
nested B_LOCATION/B_BIO
hierarchical I_LOCATION/I_BIO
levels I_LOCATION/I_BIO
( O
e B_GENE/B_DISEASE
. O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
hosts B_PERSON/B_LOCATION
, O
localities B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
indirect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
expected O
owing O
to O
interactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
levels B_LOCATION/B_PERSON
. O

2 B_NUMBER[MEASURE]
. O

In O
this O
study O
, O
we O
combined O
Bayesian O
multilevel O
models O
, O
path O
analyses O
and O
a O
model O
selection O
procedure O
to O
account O
for O
these O
complexities O
and O
to O
decipher O
the O
relative O
effects O
of O
host O
- O
and O
environment O
- O
related O
factors O
on O
the O
burden O
and O
the O
pathogenicity O
of O
an O
ectoparasite O
( O
Tracheliastes O
polycolpus O
) O
on O
its O
fish O
host O
( O
Leuciscus B_BIO
leuciscus I_BIO
) O
. O

We O
also O
tested O
the O
year B_TIME[MEASURE]/B_LOCATION
- O
to O
- O
year B_TIME[MEASURE]
consistency I_TIME[MEASURE]
of O
the O
relationships B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
linking O
these O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O
the O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O
the O
pathogenic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
T B_PROTEIN[GENE]/B_LOCATION
. O
polycolpus B_DISEASE/B_SPECIES[BIO]
. O

3 B_NUMBER[MEASURE]
. O

We O
found O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
relationships I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
parasite B_MEASURE/B_GENE
burden B_MEASURE/I_GENE
and O
host B_PERSON/B_DISEASE
- O
related O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
body B_MEASURE/B_PERSON
length I_MEASURE/I_PERSON
and O
age B_MEASURE/B_BIO
were O
positively O
related O
to O
parasite B_DISEASE/B_MEASURE
burden I_DISEASE/I_MEASURE
and O
heterozygous B_PERSON/B_BIO
hosts I_PERSON/I_BIO
displayed O
a O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
parasite I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
burden I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
host B_PERSON/B_BIO
- O
and O
environment B_BIO/B_DISEASE
- O
related O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
linked O
to O
pathogenic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

pathogenicity B_DISEASE
was O
correlated O
negatively O
with O
host B_MEASURE/B_DISEASE
body I_MEASURE/I_DISEASE
length I_MEASURE/I_DISEASE
and O
positively O
with O
age B_TIME[MEASURE]/B_DISEASE
; O
this O
illustrates O
that O
some O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
e O
. O
g B_DISEASE/B_MEASURE
. O
body B_MEASURE/B_BIO
length I_MEASURE/I_BIO
) O
showed O
inverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
parasite B_DISEASE/B_MEASURE
burden I_DISEASE/I_MEASURE
and O
pathogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

pathogenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
stronger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cooler B_LOCATION/B_BIO
upstream I_LOCATION/I_BIO
sites I_LOCATION/I_BIO
and O
where O
host B_MEASURE/B_LOCATION
density I_MEASURE/I_LOCATION
was O
lower B_MEASURE
. O

Path B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
that O
these O
relationships B_PERSON/B_LOCATION
between O
environment B_PERSON/B_BIO
- O
related O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathogenic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
not O
indirect B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
by O
the O
host B_PERSON/B_LOCATION
characteristics I_PERSON/I_LOCATION
. O

Finally O
, O
we O
found O
that O
the O
strength B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
shape B_MEASURE
of O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
across O
years B_TIME[MEASURE]/B_PERSON
, O
while O
they O
were O
clearly O
not O
for O
some O
others B_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
illustrates O
that O
considering O
conjointly O
causal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
relationships I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O
factors B_ORGANIZATION/B_BIO
and O
the O
hierarchical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
host B_SPECIES[BIO]
- O
parasite B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
appropriate B_DISEASE_ADJECTIVE[DISEASE]
for O
dissecting O
the O
complex B_LOCATION/B_ORGANIZATION
links I_LOCATION/I_ORGANIZATION
between O
hosts B_BIO/B_DISEASE
, O
parasites B_BIO/B_DISEASE
and O
their O
common B_LOCATION/B_PERSON
environment I_LOCATION/I_PERSON
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
emergent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
facilitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
: O
promoting O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
an O
invertebrate B_BIO/B_PERSON
predator I_BIO/I_PERSON
by O
killing O
its O
prey B_BIO/B_PERSON
. O

1 B_NUMBER[MEASURE]
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
theoretical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
insights I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
shown O
that O
predator B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O
help O
each O
other B_NUMBER[MEASURE]/B_DISEASE
to O
persist O
by O
size B_MEASURE/B_DISEASE
- O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
foraging B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
shared O
prey B_BIO/B_LOCATION
. O

By O
feeding O
on O
a O
certain B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
prey I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
stage I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
predator B_BIO/B_PERSON
may O
induce O
a O
compensatory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
another O
stage B_ENT/B_MEASURE
of O
the O
same B_BIO
prey I_BIO
species I_BIO
, O
thereby O
favouring O
other B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
predators B_BIO/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
a O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
referred O
to O
as O
emergent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
facilitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

2 B_NUMBER[MEASURE]
. O

To O
test O
whether O
emergent O
facilitation O
may O
occur O
in O
a O
natural O
system O
, O
we O
performed O
an O
enclosure O
experiment O
where O
we O
mimicked O
fish O
predation O
by O
selectively O
removing O
large O
zooplankton O
and O
subsequently O
following O
the O
response O
of O
the O
invertebrate O
predator O
Bythotrephes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
longimanus I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

3 B_NUMBER[MEASURE]
. O

positive O
responses O
to O
harvest O
were O
observed O
in O
the O
biomass O
of O
juvenile O
individuals O
of O
the O
dominant O
zooplankton O
Holopedium B_BIO/B_LOCATION
gibberum I_BIO/I_LOCATION
and O
in O
Bythotrephes O
densities O
. O

Hence O
, O
by O
removing O
large B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
prey I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
increased O
the O
biomass B_MEASURE/B_PERSON
of O
small B_BIO/B_PERSON
prey I_BIO/I_PERSON
, O
i O
. O
e O
. O
stage B_ENT/B_DISEASE
- O
specific B_NUMBER[MEASURE]
biomass I_NUMBER[MEASURE]
overcompensation I_NUMBER[MEASURE]
was O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
juvenile B_BIO/B_DISEASE
stage I_BIO/I_DISEASE
of O
Holopedium B_BIO/B_PERSON
. O

This O
favoured O
Bythotrephes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
which O
preferentially O
feed O
on O
small B_BIO
Holopedium I_BIO
. O

4 B_NUMBER[MEASURE]
. O

We O
argue O
that O
the O
stage B_ENT/B_TIME[MEASURE]
- O
specific B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
overcompensation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
as O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
increased O
per O
capita B_MEASURE/B_PERSON
fecundity I_MEASURE/I_PERSON
of O
adult B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Holopedium I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
as O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
competitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
release B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
following O
harvest B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

If O
shown O
to O
be O
common B_DISEASE_ADJECTIVE[DISEASE]
, O
emergent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
facilitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O
be O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
behind O
observed B_MEASURE
predator I_MEASURE
extinctions I_MEASURE
and O
patterns B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
predator B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
clone B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
based O
transcriptomics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
approach O
for O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genes B_GENE/B_MEASURE
relevant I_GENE/I_MEASURE
for O
itaconic B_DISEASE/B_ORGANISM_FUNCTION
acid I_DISEASE/I_ORGANISM_FUNCTION
production I_DISEASE/I_ORGANISM_FUNCTION
in O
Aspergillus B_BIO
. O

Several B_BIO/B_PERSON
Aspergillus I_BIO/I_PERSON
species I_BIO/I_PERSON
are O
well O
- O
known O
for O
the O
production B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
variety B_ENT/B_MEASURE
of O
organic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
a O
cloned B_GENE
based O
transcriptomics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O
used O
to O
identify O
genes B_GENE
crucial I_GENE
in O
the O
biosynthesis B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
for O
one B_NUMBER[MEASURE]/B_PERSON
of O
these O
acids B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
itaconic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
a O
number O
of O
different O
Aspergillus B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
terreus B_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
controlled O
batch O
fermentations O
, O
those O
cultures O
with O
the O
largest O
difference O
in O
itaconic O
acid O
titer O
and O
productivity O
were O
selected O
for O
mRNA O
isolation O
. O

cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
derived O
from O
these O
mRNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
used O
for O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
glass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
slide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
arrays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
based O
on O
a O
collection B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
5000 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
13 B_GENE/B_LOCATION
cDNA I_GENE/I_LOCATION
clones I_GENE/I_LOCATION
resulting O
in O
the O
strongest B_TIME[MEASURE]
( O
> B_NUMBER[MEASURE]
10 I_NUMBER[MEASURE]
- O
fold B_MEASURE
) O
differential B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
identified O
and O
subsequently O
the O
inserts B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
clones B_GENE/B_DISEASE
were O
sequenced O
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
the O
presence B_LOCATION/B_DISEASE
of O
in O
total B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
five B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inserts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
among O
the O
sequenced B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
clones B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

From O
one B_NUMBER[MEASURE]
of O
these O
sequences B_DISEASE/B_GENE
, O
encoding O
a O
gene B_PERSON/B_GENE
of O
the O
MmgE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
PrpD B_GENE/B_LOCATION
family I_GENE/I_LOCATION
, O
the O
full B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
length I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
shown O
to O
encode O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
crucial B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itaconic B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
aconitate B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
by O
heterologous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Escherichia B_BIO
coli I_BIO
. O

expression O
of O
this O
gene O
in O
Aspergillus B_BIO
niger I_BIO
, O
which O
is O
a O
natural O
citric O
acid O
producer O
, O
resulted O
in O
itaconate O
production O
. O

genome O
analysis O
suggests O
that O
in O
A B_BIO
. I_BIO
terreus I_BIO
the O
cis O
- O
aconitate O
decarboxylase O
gene O
is O
part O
of O
an O
itaconate O
acid O
related O
gene O
cluster O
including O
genes O
encoding O
two O
pathway O
specific O
transporters O
and O
a O
zinc O
finger O
protein O
. O

Interestingly O
, O
this O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
directly O
linked O
to O
the O
large B_LOCATION/B_GENE
lovastatin I_LOCATION/I_GENE
gene I_LOCATION/I_GENE
cluster I_LOCATION/I_GENE
. O

The O
outcome O
of O
competition O
between O
the O
two O
chrysomonads O
Ochromonas O
SP O
. O
and O
Poterioochromonas B_BACTERIUM[BIO]
malhamensis I_BACTERIUM[BIO]
depends O
on O
pH O
. O

We O
investigated O
the O
effect O
of O
pH O
on O
the O
competition O
of O
two O
closely O
related O
chrysomonad O
species O
, O
Poterioochromonas B_LOCATION/B_NUMBER[MEASURE]
malhamensis B_LOCATION/I_NUMBER[MEASURE]
originating O
from O
circumneutral O
Lake O
Constance O
, O
and O
Ochromonas O
SP O
. O
isolated O
from O
a O
highly O
acidic O
mining O
lake O
in O
Austria O
( O
pH O
- O
2 O
. O
6 O
) O
. O

We O
performed O
pairwise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
these O
two B_BIO/B_DISEASE
species I_BIO/I_DISEASE
at O
four B_MEASURE/B_LOCATION
different I_MEASURE/I_LOCATION
pH I_MEASURE/I_LOCATION
ranging I_MEASURE/I_LOCATION
from O
2 B_MEASURE
. O
5 B_MEASURE
to O
7 B_MEASURE
. O
0 B_MEASURE
. O

Heterotrophic B_BIO/B_PERSON
bacteria B_BIO/I_PERSON
served O
as O
food B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
both O
flagellates B_BIO
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
compared O
to O
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measured O
earlier O
in O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
species I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
experiments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
over O
the O
same B_TIME[MEASURE]/B_LOCATION
pH I_TIME[MEASURE]/I_LOCATION
range I_TIME[MEASURE]/I_LOCATION
. O

We O
tested O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
acidotolerant B_BACTERIUM[BIO]
species O
benefits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
competitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
release I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
under O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acid B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
neutrophilic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numerically O
dominated O
over O
the O
acidotolerant B_BACTERIUM[BIO]/B_MEASURE
strain I_BACTERIUM[BIO]/I_MEASURE
at O
pH B_MEASURE
7 I_MEASURE
. O
0 B_MEASURE
, O
but O
was O
the O
inferior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
competitor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
pH B_MEASURE
2 I_MEASURE
. O
5 B_MEASURE
. O

At O
pH B_MEASURE
3 I_MEASURE
. O
5 B_MEASURE
and O
5 B_MEASURE
. O
0 B_MEASURE
both O
strains B_BIO/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexisted O
. O

surprisingly O
, O
P B_BACTERIUM[BIO]/B_LOCATION
. I_BACTERIUM[BIO]/I_LOCATION
malhamensis I_BACTERIUM[BIO]/I_LOCATION
prevailed O
over O
Ochromonas O
SP O
. O
under O
moderately O
acidic O
conditions O
, O
i O
. O
e O
. O
at O
the O
pH O
where O
growth O
rates O
of O
the O
latter O
peaked O
when O
grown O
alone O
. O

Since O
bacterial B_LOCATION/B_MEASURE
food I_LOCATION/I_MEASURE
was O
not O
limiting O
, O
resource B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
competition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
is O
improbable B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
appears O
more O
likely O
that O
P B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
malhamensis I_SPECIES[BIO]/I_PERSON
ingested O
cells O
of O
its O
slightly O
smaller O
competitor O
. O

Adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
via O
allelopathy B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O
either O
directly O
on O
the O
competing O
flagellate B_BIO/B_PERSON
or O
indirectly O
by O
affecting O
its O
bacterial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
food I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
might O
also O
have O
affected O
the O
outcome B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
competition B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Differentially O
expressed O
genes O
in O
silkworm B_SPECIES[BIO]
cell O
cultures O
in O
response O
to O
infection O
by O
Wolbachia O
and O
Cardinium O
endosymbionts O
. O

Wolbachia B_BACTERIUM[BIO]
and O
Cardinium B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
are O
bacterial B_BIO
endosymbionts I_BIO
that O
are O
widely O
distributed O
amongst B_BIO/B_LOCATION
arthropods B_BIO/I_LOCATION
. O

Both O
cause O
reproductive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alterations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
cytoplasmic B_DISEASE/B_ORGANISM_FUNCTION
incompatibility I_DISEASE/I_ORGANISM_FUNCTION
, O
parthenogenesis B_DISEASE/B_ORGANISM_FUNCTION
and O
feminization B_DISEASE/B_ORGANISM_FUNCTION
. O

Here O
we O
studied O
differentially O
expressed O
genes O
in O
Wolbachia O
- O
and O
Cardinium O
- O
infected O
Bm O
- O
aff3 O
silkworm B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
cells O
using O
a O
silkworm B_BIO/B_GENE
microarray O
. O

Wolbachia B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
alter O
gene B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
induce O
or O
suppress O
immune B_DISEASE/B_GENE
responses I_DISEASE/I_GENE
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
Cardinium B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
many B_DISEASE
immune I_DISEASE
- O
related O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
including O
antimicrobial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
pattern B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
serine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protease I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

host B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
immune I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
differed O
, O
possibly O
because O
of O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wall I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Wolbachia B_BACTERIUM[BIO]
and O
Cardinium B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
because O
the O
former B_BIO/B_DISEASE
lacks O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O
lipopolysaccharide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
components I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
racemases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
peptidoglycan B_DISEASE_ADJECTIVE[DISEASE]
formation I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
few B_NUMBER[MEASURE]/B_PERSON
possibly O
non O
- O
immune B_DISEASE/B_ORGANISM_FUNCTION
- O
related O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
differentially O
expressed O
, O
but O
their O
involvement B_PERSON/B_DISEASE
in O
host B_DISEASE/B_LOCATION
reproductive I_DISEASE/I_LOCATION
alteration I_DISEASE/I_LOCATION
was O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

neuropeptide B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Y I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
signalling I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
nutritionally O
mediated O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
expression B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
in O
the O
honey B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
bee I_BODY_PART_OR_ORGAN_COMPONENT/I_SPECIES[BIO]
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
led O
to O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
derived O
traits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
arise O
through O
the O
evolution B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
novel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
roles I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
conserved B_PERSON/B_GENE
genes I_PERSON/I_GENE
. O

We O
explored O
whether O
neuropeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Y O
( O
NPY B_GENE/B_DISEASE
) O
- O
like B_PROTEIN[GENE]/B_MEASURE
signalling I_PROTEIN[GENE]/I_MEASURE
, O
a O
conserved B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
regulates O
food B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
related O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O
is O
involved O
in O
a O
derived O
, O
nutritionally O
- O
related O
trait B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
the O
division B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
labour B_ORGANISM_FUNCTION/B_BIO
in O
worker B_SPECIES[BIO]
honey I_SPECIES[BIO]
bees I_SPECIES[BIO]
. O

transcripts B_GENE/B_MEASURE
encoding O
two B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NPY I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
expressed O
in O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
populations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurosecretory I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
endocrine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

NPY B_DISEASE/B_GENE
- O
related O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
upregulated O
in O
the O
brains B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
older B_PERSON/B_BIO
foragers B_PERSON/I_BIO
compared O
with O
younger B_PERSON/B_BIO
bees I_PERSON/I_BIO
performing O
brood B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
' O
nurses B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
) O
. O

A O
subset B_MEASURE/B_PERSON
of O
these O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
attributed O
to O
nutrition B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
neuropeptide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
F I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
peptide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
did O
not O
influence O
sugar B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contrast O
with O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
robust I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
associations I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
division B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
labour B_ORGANISM_FUNCTION
and O
the O
related B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
signalling O
pathway B_LOCATION/B_BIO
and O
suggest O
that O
some O
elements B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
feeding B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behaviour I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
more O
evolutionarily O
labile B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
than O
others B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

apolipoprotein B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
E I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
in O
Alzheimer B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
and O
other B_DISEASE/B_PERSON
neurological I_DISEASE/I_PERSON
disorders I_DISEASE/I_PERSON
. O

apolipoprotein B_PROTEIN[GENE]/B_ORGANIZATION
E I_PROTEIN[GENE]/I_ORGANIZATION
( O
APOE B_GENE/B_LOCATION
) O
is O
a O
299 B_MEASURE
- O
aminoacid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoded O
by O
the O
APOE B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Three B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
common I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
polymorphisms I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
APOE B_GENE
gene I_GENE
, O
epsilo2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epsilo3 B_PROTEIN[GENE]
, O
and O
epsilo4 B_GENE/B_BACTERIUM[BIO]
, O
result O
in O
a O
single B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminoacid I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
APOE B_GENE/B_MEASURE
protein I_GENE/I_MEASURE
. O

APOE B_GENE
epsilo2 I_GENE
, O
epsilo3 B_GENE
, O
and O
epsilo4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alleles I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strongly O
alter O
, O
in O
a O
dose B_MEASURE
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
likelihood B_MEASURE
of O
developing O
Alzheimer B_DISEASE/B_GENE
' I_DISEASE/I_GENE
s I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
and O
cerebral B_DISEASE
amyloid I_DISEASE
angiopathy I_DISEASE
. O

In O
particular B_DISEASE/B_PERSON
, O
APOE B_DISEASE/B_LOCATION
epsilo4 I_DISEASE/I_LOCATION
is O
associated O
with O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O
Alzheimer B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
whereas O
APOE B_GENE/B_DISEASE
epsilo2 B_GENE/I_DISEASE
is O
associated O
with O
decreased O
risk B_DISEASE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
APOE B_DISEASE/B_GENE
genotype B_DISEASE/I_GENE
on O
risk B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
diseases B_DISEASE
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
mediated O
by O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
APOE B_GENE
on O
amyloid B_GENE/B_DISEASE
- O
Beta B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
its O
vasculature B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Response B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
Alzheimer B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
might O
differ O
according O
to O
APOE B_DISEASE_ADJECTIVE[DISEASE]
genotype I_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
convincing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
ties O
the O
APOE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
risk B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
Alzheimer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
cerebral B_DISEASE
amyloid I_DISEASE
angiopathy I_DISEASE
, O
APOE B_GENE/B_ORGANIZATION
has O
been O
studied O
in O
other B_DISEASE/B_PERSON
neurological B_DISEASE/I_PERSON
diseases B_DISEASE/I_PERSON
. O

APOE B_DISEASE/B_GENE
epsilo4 I_DISEASE/I_GENE
is O
associated O
with O
poor B_DISEASE
outcome I_DISEASE
after O
traumatic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
brain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
brain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haemorrhage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
although O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
underlying O
these O
associations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
APOE B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
these O
and O
other B_DISEASE
neurological I_DISEASE
diseases I_DISEASE
has O
been O
of O
great B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
interest I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
but O
convincing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
associations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
not O
yet O
emerged O
. O

Titrating O
the O
cost B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
plant B_PERSON/B_LOCATION
toxins I_PERSON/I_LOCATION
against O
predators B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
determining O
the O
tipping B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
foraging O
herbivores B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

1 B_NUMBER[MEASURE]
. O

Foraging O
herbivores B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
must O
deal O
with O
plant B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
characteristics I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
that O
inhibit O
feeding B_ORGANISM_FUNCTION/B_BIO
and O
they O
must O
avoid O
being O
eaten O
. O

principally O
, O
toxins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
limit O
food B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
intake I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
predation B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alters O
how O
long B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
prepared B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
harvest O
resources B_BIO/B_MEASURE
. O

Each O
of O
these O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strongly O
affects O
how O
herbivores B_BIO/B_PERSON
use O
food B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
patches B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
and O
both O
constraints B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
pose O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
proximate I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
costs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
fitness B_SPORT[ENT]/B_PERSON
. O

2 B_NUMBER[MEASURE]
. O

Using O
a O
generalist O
mammalian O
herbivore O
, O
the O
common B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
brushtail I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
possum I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Trichosurus B_BIO/B_LOCATION
vulpecula B_BIO/I_LOCATION
) O
, O
our O
aim O
was O
to O
quantitatively O
compare O
the O
influence O
of O
plant O
toxin O
and O
predation O
risk O
on O
foraging O
decisions O
. O

3 B_NUMBER[MEASURE]
. O

We O
performed O
a O
titration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
offering O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
choice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
between O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
toxic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
food I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
risky B_MEASURE/B_LOCATION
patch I_MEASURE/I_LOCATION
paired O
with O
food B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
five B_PERSON/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxin I_PERSON/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_PERSON/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
patch B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
allowed O
us O
to O
identify O
the O
tipping B_LOCATION/B_PERSON
point B_LOCATION/I_PERSON
, O
where O
the O
cost B_MEASURE
of O
toxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
food I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
patch I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
equivalent B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
perceived O
predation B_MEASURE/B_DISEASE
risk B_MEASURE/I_DISEASE
in O
the O
alternative B_LOCATION/B_BIO
patch I_LOCATION/I_BIO
. O

4 B_NUMBER[MEASURE]
. O

At O
low B_TIME[MEASURE]/B_LOCATION
toxin I_TIME[MEASURE]/I_LOCATION
concentration I_TIME[MEASURE]/I_LOCATION
, O
animals B_BIO/B_PERSON
ate O
more O
from O
the O
safe B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
the O
risky B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patch I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
toxin B_MEASURE/B_BIO
concentration B_MEASURE/I_BIO
increased O
at O
the O
safe B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
patch B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
intake B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shifted O
until O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ate O
mainly O
from O
the O
risky B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
patch I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

This O
shift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
behavioural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
animals B_BIO/B_PERSON
spent O
more B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
and O
fed O
longer O
at O
the O
risky B_LOCATION/B_MEASURE
patch I_LOCATION/I_MEASURE
, O
while O
vigilance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O
at O
both O
risky B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

5 B_NUMBER[MEASURE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
the O
variation B_MEASURE
in O
toxin B_MEASURE/B_BIO
concentration I_MEASURE/I_BIO
, O
which O
occurs O
intraspecifically O
among O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
can O
critically O
influence O
the O
relative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cost I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
predation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O
foraging B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
show O
that O
herbivores B_BIO/B_PERSON
quantify O
, O
compare O
and O
balance O
these O
two B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
proximate O
costs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
altering O
their O
foraging B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
process B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

This O
has O
potential B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
ecological I_EDU[ORGANIZATION]/I_DISEASE_ADJECTIVE[DISEASE]
and O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
production B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plant B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
defence I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
compounds I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
in O
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
spatial B_DISEASE_ADJECTIVE[DISEASE]
variation I_DISEASE_ADJECTIVE[DISEASE]
in O
predation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
herbivores B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

What O
determines O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
home B_MEASURE
range I_MEASURE
size I_MEASURE
across O
spatiotemporal B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scales I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
large B_LOCATION/B_PERSON
browsing I_LOCATION/I_PERSON
herbivore I_LOCATION/I_PERSON
. O

1 B_NUMBER[MEASURE]
. O

Most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intraspecific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
home B_MEASURE/B_PERSON
range B_MEASURE/I_PERSON
size B_MEASURE/I_PERSON
have O
investigated O
only O
a O
single B_MEASURE/B_PERSON
or O
a O
few B_MEASURE/B_PERSON
factors I_MEASURE/I_PERSON
and O
often O
at O
one B_MEASURE
specific I_MEASURE
scale I_MEASURE
. O

However O
, O
considering O
multiple B_MEASURE/B_LOCATION
spatial I_MEASURE/I_LOCATION
and O
temporal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scales I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
defining O
a O
home B_MEASURE/B_LOCATION
range B_MEASURE/I_LOCATION
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
affect O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
home B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
may O
differ O
depending O
on O
the O
scale B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

2 B_NUMBER[MEASURE]
. O

We O
aim O
to O
quantify O
the O
relative O
effect O
of O
various O
individual O
, O
forage O
and O
climatic O
determinants O
of O
variation O
in O
home O
range O
size O
across O
multiple O
spatiotemporal O
scales O
in O
a O
large O
browsing O
herbivore O
, O
the O
Moose O
( O
Alces B_PERSON/B_BIO
alces I_PERSON/I_BIO
) O
, O
living O
at O
the O
southern O
limit O
of O
its O
distribution O
in O
Norway O
. O

3 B_NUMBER[MEASURE]
. O

Total B_MEASURE/B_LOCATION
home B_MEASURE/I_LOCATION
range B_MEASURE/I_LOCATION
size B_MEASURE/I_LOCATION
and O
core B_MEASURE/B_LOCATION
home I_MEASURE/I_LOCATION
range I_MEASURE/I_LOCATION
areas I_MEASURE/I_LOCATION
were O
estimated O
for O
daily O
to O
monthly B_MEASURE
scales I_MEASURE
in O
summer B_TIME[MEASURE]
and O
winter B_TIME[MEASURE]/B_LOCATION
using O
both O
local B_MEASURE/B_LOCATION
convex I_MEASURE/I_LOCATION
hull I_MEASURE/I_LOCATION
( O
LoCoH B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
fixed B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kernel B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
home B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
range B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

variance B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
home B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
range I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
size I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
analysed O
using O
linear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mixed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
repeated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

4 B_NUMBER[MEASURE]
. O

reproductive B_TIME[MEASURE]/B_PERSON
status B_TIME[MEASURE]/I_PERSON
was O
the O
most O
influential B_PERSON/B_LOCATION
individual B_PERSON/I_LOCATION
- O
level B_TIME[MEASURE]/B_LOCATION
factor I_TIME[MEASURE]/I_LOCATION
explaining O
variance B_MEASURE
in O
Moose B_MEASURE/B_PERSON
home B_MEASURE/I_PERSON
range B_MEASURE/I_PERSON
size B_MEASURE/I_PERSON
, O
with O
females B_PERSON
accompanied O
by O
a O
calf B_BIO/B_PERSON
having O
smaller B_MEASURE/B_PERSON
summer I_MEASURE/I_PERSON
ranges I_MEASURE/I_PERSON
across O
all O
scales B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Variation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
home B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
was O
strongly O
correlated O
with O
spatiotemporal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
quantity B_MEASURE/B_LOCATION
and O
quality B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
natural B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
food I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
resources I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Home B_MEASURE/B_PERSON
range B_MEASURE/I_PERSON
size B_MEASURE/I_PERSON
decreased O
with O
increasing O
browse B_MEASURE
density I_MEASURE
at O
daily B_TIME[MEASURE]/B_PERSON
scales I_TIME[MEASURE]/I_PERSON
, O
but O
the O
relationship B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O
to O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
longer B_TIME[MEASURE]/B_LOCATION
temporal I_TIME[MEASURE]/I_LOCATION
scales I_TIME[MEASURE]/I_LOCATION
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
browse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
consistently O
negatively O
correlated O
with O
home B_MEASURE/B_ORGANISM_FUNCTION
range I_MEASURE/I_ORGANISM_FUNCTION
size I_MEASURE/I_ORGANISM_FUNCTION
except O
at O
the O
monthly B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
during O
winter B_TIME[MEASURE]/B_LOCATION
when O
depletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
quality B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
forage B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
occurs O
. O

Local B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
climate I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
affected O
total B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
home B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
range B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
size B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
more B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
core B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
areas I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

temperature B_TIME[MEASURE]/B_LOCATION
, O
precipitation B_LOCATION/B_DISEASE
and O
snow B_MEASURE/B_LOCATION
depth B_MEASURE/I_LOCATION
influenced O
home B_MEASURE/B_LOCATION
range B_MEASURE/I_LOCATION
size B_MEASURE/I_LOCATION
directly O
at O
short B_TIME[MEASURE]/B_LOCATION
temporal I_TIME[MEASURE]/I_LOCATION
scales I_TIME[MEASURE]/I_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

The O
relative B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
intrinsic B_TIME[MEASURE]/B_EDU[ORGANIZATION]
and O
extrinsic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinants B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
variation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
home B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
differed O
with O
spatiotemporal B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
, O
providing O
clear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
home B_MEASURE
range I_MEASURE
size I_MEASURE
is O
scale B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
large B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
browser I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

insight B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
behavioural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
populations B_LOCATION/B_BIO
to O
climatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stochasticity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
forage B_MEASURE/B_LOCATION
variability I_MEASURE/I_LOCATION
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
current B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
climate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
change I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
especially O
for O
populations B_LOCATION/B_BIO
with O
thermoregulatory B_BIO/B_LOCATION
restrictions I_BIO/I_LOCATION
living O
at O
the O
southern B_LOCATION/B_MEASURE
limit I_LOCATION/I_MEASURE
of O
their O
distribution B_ORGANIZATION/B_LOCATION
. O

Npc1 O
is O
involved O
in O
sterol O
trafficking O
in O
the O
filamentous O
fungus O
Fusarium B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
graminearum B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
ortholog O
of O
the O
human B_SPECIES[BIO]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene O
NPC1 O
was O
identified O
in O
the O
plant O
pathogenic O
, O
filamentous O
fungus O
Fusarium B_BIO
graminearum I_BIO
by O
shared O
amino O
acid O
sequence O
, O
protein O
domain O
structure O
and O
cellular O
localization O
of O
the O
mature O
fungal O
protein O
. O

The O
FusariumNpc1 O
gene O
shares O
34 O
% O
amino O
acid O
sequence O
identity O
and O
51 O
% O
similarity O
to O
the O
human B_BIO/B_GENE
gene O
, O
has O
similar O
domain O
structure O
and O
is O
constitutively O
expressed O
, O
although O
up O
- O
regulated O
in O
ungerminated O
macroconidia O
and O
ascospores O
. O

GFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tagged O
Npc1p B_GENE
localizes O
to O
the O
fungal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vacuolar I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

cultures B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O
from O
a O
Deltanpc1 B_GENE/B_BIO
mutant I_GENE/I_BIO
strain I_GENE/I_BIO
contain O
significantly O
more O
ergosterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
cultures B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
wildtype B_SPECIES[BIO]/B_PERSON
. O

Staining O
with O
the O
fluorescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
filipin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
shows O
that O
ergosterol B_DISEASE_ADJECTIVE[DISEASE]
accumulates I_DISEASE_ADJECTIVE[DISEASE]
in O
vacuoles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
of O
the O
Deltanpc1 B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
the O
wildtype B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
strain I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
Deltanpc1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O
a O
temperature B_DISEASE_ADJECTIVE[DISEASE]
dependent I_DISEASE_ADJECTIVE[DISEASE]
reduction I_DISEASE_ADJECTIVE[DISEASE]
in O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
greater B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
ergosterol B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
inhibiting O
fungicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tebuconazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
the O
wildtype B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
strain I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O
the O
mutant B_PERSON/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
complemented O
with O
wildtype B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Npc1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mutant O
also O
is O
significantly O
reduced O
in O
pathogenicity O
to O
wheat B_BIO
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
Npc1p B_GENE
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
transport B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
ergosterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
the O
vacuole B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
proper B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
membrane B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
function B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
under O
particular B_DISEASE_ADJECTIVE[DISEASE]
environmental I_DISEASE_ADJECTIVE[DISEASE]
conditions I_DISEASE_ADJECTIVE[DISEASE]
. O

Genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diversity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
phylogenetic B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position B_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
subclass B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Astomatia I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
Ciliophora B_MEASURE/B_BIO
) O
based O
on O
a O
sampling B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
six B_BIO/B_PERSON
genera I_BIO/I_PERSON
from O
West B_LOCATION/B_MEASURE
African I_LOCATION/I_MEASURE
oligochaetes I_LOCATION/I_MEASURE
( O
Glossoscolecidae B_SPECIES[BIO]/B_LOCATION
, O
Megascolecidae B_LOCATION/B_MEASURE
) O
, O
including O
description B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
new B_BIO/B_GENE
genus B_BIO/I_GENE
Paraclausilocola B_BIO/I_GENE
n B_BIO/I_GENE
. O
gen B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
more O
confidently O
assess O
phylogenetic O
relationships O
among O
astome O
ciliates O
, O
we O
obtained O
small O
subunit O
( O
SSU O
) O
rRNA O
sequences O
from O
nine O
species O
distributed O
in O
six O
genera O
and O
three O
families O
: O
Almophrya B_SPECIES[BIO]
bivacuolata I_SPECIES[BIO]
, O
Eudrilophrya B_BACTERIUM[BIO]/B_LOCATION
complanata I_BACTERIUM[BIO]/I_LOCATION
, O
Metaracoelophrya O
SP O
. O

1 B_NUMBER[MEASURE]
, O
Metaracoelophrya B_BACTERIUM[BIO]
SP I_LOCATION
. O

2 O
, O
Metaracoelophrya B_MEASURE/B_PERSON
intermedia I_MEASURE/I_PERSON
, O
Metaradiophrya O
SP O
. O
, O
Njinella B_NUMBER[MEASURE]
prolifera I_NUMBER[MEASURE]
, O
Paraclausilocola B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
constricta I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
gen I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
sp I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
Paraclausilocola B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
elongata I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
n I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
sp I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
two B_BIO/B_ENT
new I_BIO/I_ENT
species I_BIO/I_ENT
in O
the O
proposed O
new B_PERSON/B_BIO
clausilocolid I_PERSON/I_BIO
genus I_PERSON/I_BIO
Paraclausilocola I_PERSON/I_BIO
n I_PERSON/I_BIO
. O
gen B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

are O
astomes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
with O
no O
attachment B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
apparatus I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
two B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
files B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
contractile B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vacuoles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
an O
arc B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
anterior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
suture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
that O
has O
differentiations B_LOCATION
of O
thigmotactic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
ciliature I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
on O
the O
anterior B_LOCATION
ends I_LOCATION
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kineties I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
undertaken O
using O
neighbor B_PERSON/B_LOCATION
- O
joining O
, O
Bayesian B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inference I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
maximum B_MEASURE
likelihood I_MEASURE
, O
and O
maximum B_MEASURE
parsimony I_MEASURE
. O

The O
nine B_BIO/B_PERSON
species I_BIO/I_PERSON
of O
astomes B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
formed O
a O
strongly O
supported O
clade B_BIO/B_LOCATION
, O
showing O
the O
subclass B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Astomatia I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O
be O
monophyletic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
a O
weakly O
supported O
sister B_PERSON/B_BIO
clade I_PERSON/I_BIO
to O
the O
scuticociliates B_BACTERIUM[BIO]/B_MEASURE
. O

There O
were O
two B_NUMBER[MEASURE]/B_LOCATION
strongly O
supported O
clades B_LOCATION/B_ORGANIZATION
within O
the O
astomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
genera B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
assigned O
to O
the O
same B_PERSON/B_ORGANIZATION
family I_PERSON/I_ORGANIZATION
were O
found O
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
clades I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
and O
genera B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
assigned O
to O
the O
same B_PERSON/B_MEASURE
order I_PERSON/I_MEASURE
were O
found O
in O
both O
clades B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
astome B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
taxa I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
appear O
to O
be O
paraphyletic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
when O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
used O
to O
assign O
species B_BIO/B_PERSON
to O
genera B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

negotiating O
a O
noisy B_DISEASE_ADJECTIVE[DISEASE]
, O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
rich B_LOCATION/B_ORGANIZATION
environment I_LOCATION/I_ORGANIZATION
in O
search B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
cryptic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
prey I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
: O
olfactory B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
predators I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
need O
patchiness B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
prey B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cues I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

1 B_NUMBER[MEASURE]
. O

olfactory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predator I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
differ O
fundamentally O
to O
those O
based O
on O
vision B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
particularly O
when O
odour B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cues I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
deposited O
rather O
than O
airborne B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
or O
emanating O
from O
a O
point B_LOCATION/B_PERSON
source B_LOCATION/I_PERSON
. O

When O
searching O
for O
visually O
cryptic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
prey I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
have O
moved O
some O
distance B_MEASURE/B_LOCATION
from O
a O
deposited B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
odour I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cue I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cue B_MEASURE/B_LOCATION
context I_MEASURE/I_LOCATION
and O
spatial B_MEASURE/B_LOCATION
variability I_MEASURE/I_LOCATION
are O
the O
most O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sources I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
about O
prey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
location B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
an O
olfactory B_PERSON/B_BIO
predator I_PERSON/I_BIO
. O

2 B_NUMBER[MEASURE]
. O

We O
tested O
whether O
the O
house B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Mus B_LOCATION/B_BIO
domesticus I_LOCATION/I_BIO
) O
, O
a O
model O
olfactory O
predator O
, O
would O
use O
cue O
context O
and O
spatial O
variability O
when O
searching O
for O
buried O
food O
items O
; O
specifically O
, O
we O
tested O
the O
effect O
of O
varying O
cue O
patchiness O
, O
odour O
strength O
, O
and O
cue O
- O
prey O
association O
on O
mouse B_BIO/B_DISEASE
foraging O
success O
. O

3 B_NUMBER[MEASURE]
. O

Within O
mouse B_BIO/B_DISEASE
- O
and O
predator O
- O
proof O
enclosures O
, O
we O
created O
grids O
of O
100 O
sand O
- O
filled O
Petri O
dishes O
and O
buried O
peanut B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pieces O
in O
a O
set O
number O
of O
these O
patches O
to O
represent O
visually O
cryptic O
' O
prey O
' O
. O

By O
adding O
peanut B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
oil O
to O
selected O
dishes O
, O
we O
varied O
the O
spatial O
distribution O
of O
prey O
odour O
relative O
to O
the O
distribution O
of O
prey O
patches O
in O
each O
grid O
, O
to O
reflect O
different O
levels O
of O
cue O
patchiness O
( O
Experiment O
1 O
) O
, O
odour O
strength O
( O
Experiment O
2 O
) O
and O
cue O
- O
prey O
association O
( O
Experiment O
3 O
) O
. O

We O
measured O
the O
overnight O
foraging O
success O
of O
individual O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
percentage O
of O
searched O
patches O
containing O
prey O
) O
, O
as O
well O
as O
their O
foraging O
activity O
( O
percentage O
of O
patches O
searched O
) O
, O
and O
prey O
survival O
( O
percentage O
of O
unsearched O
prey O
patches O
) O
. O

4 B_NUMBER[MEASURE]
. O

Mouse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
foraging O
success O
was O
highest O
where O
odour O
cues O
were O
patchy O
rather O
than O
uniform O
( O
Experiment O
1 O
) O
, O
and O
where O
cues O
were O
tightly O
associated O
with O
prey O
location O
, O
rather O
than O
randomly O
or O
uniformly O
distributed O
( O
Experiment O
3 O
) O
. O

However O
, O
when O
cues O
at O
prey O
patches O
were O
ten O
times O
stronger O
than O
a O
uniformly O
distributed O
weak O
background O
odour O
, O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
improve O
their O
foraging O
success O
over O
that O
experienced O
when O
cues O
were O
of O
uniform O
strength O
and O
distribution O
( O
Experiment O
2 O
) O
. O

5 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
context I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
means I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O
which O
olfactory B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
predators I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O
use O
deposited B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
odour I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
cues I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
locate O
visually O
cryptic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
prey I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

They O
also O
indicate O
that O
chemical B_BIO/B_PERSON
crypsis I_BIO/I_PERSON
can O
disrupt O
these O
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
processes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
effectively O
as O
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
matching B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
visually O
based O
predator B_BIO/B_PERSON
- O
prey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

behaviour O
during O
elevated O
water O
temperatures O
: O
can O
physiology O
explain O
movement O
of O
juvenile O
Atlantic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
salmon I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
cool O
water O
. O

1 B_NUMBER[MEASURE]
. O

temperature B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
governs I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
most O
physiological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ectotherms B_BIO/B_PERSON
behaviourally O
thermoregulate O
by O
selecting O
habitats B_LOCATION/B_PERSON
with O
temperatures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
regulating O
their O
body B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperature B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
optimal B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
physiological B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
functioning B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

However O
, O
ectotherms B_BIO/B_PERSON
can O
experience O
temperature B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extremes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
forcing O
the O
organisms B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
to O
seek O
temperature B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
refuge B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

2 B_NUMBER[MEASURE]
. O

Fish B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actively O
avoid O
potentially O
lethal B_DISEASE
temperatures I_DISEASE
by O
moving O
to O
cool B_LOCATION/B_PERSON
- O
water B_LOCATION/B_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
created O
by O
inflowing O
tributaries B_LOCATION
and O
groundwater B_LOCATION
seeps I_LOCATION
. O

juvenile O
Atlantic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
salmon I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Salmo B_DISEASE/B_LOCATION
salar B_DISEASE/I_LOCATION
) O
of O
different O
age O
classes O
exhibit O
different O
behavioural O
responses O
to O
elevated O
temperatures O
( O
> O
23 O
^ O
0C O
) O
. O

Yearling O
( O
1 O
+ O
) O
and O
2 O
- O
year O
- O
old O
( O
2 O
+ O
) O
Atlantic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
salmon I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
often O
cease O
feeding O
, O
abandon O
territorial O
behaviour O
and O
swim O
continuously O
in O
aggregations O
in O
cool O
- O
water O
sites O
; O
whereas O
young O
- O
of O
- O
the O
- O
year O
( O
0 O
+ O
) O
fish O
continue O
defending O
territories O
and O
foraging O
. O

3 B_NUMBER[MEASURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
determined O
whether O
the O
behavioural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
older B_LOCATION
individuals I_LOCATION
( O
2 B_PERSON/B_LOCATION
+ I_PERSON/I_LOCATION
) O
occurred O
when O
basal B_MEASURE/B_BIO
metabolic B_MEASURE/I_BIO
rate B_MEASURE/I_BIO
, O
driven O
by O
increasing O
water B_MEASURE/B_DISEASE
temperature I_MEASURE/I_DISEASE
, O
reached O
the O
maximum B_MEASURE/B_LOCATION
metabolic B_MEASURE/I_LOCATION
rate B_MEASURE/I_LOCATION
such B_MEASURE/I_LOCATION
that O
anaerobic B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pathways I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
recruited O
to O
provide O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
support O
vital B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
processes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

behaviour O
( O
feeding O
and O
stress O
responses O
) O
, O
oxygen O
consumption O
, O
muscle O
lactate O
and O
glycogen O
, O
and O
circulating O
blood O
lactate O
and O
glucose O
concentrations O
were O
measured O
in O
wild O
0 O
+ O
and O
2 O
+ O
Atlantic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
salmon I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
acclimated O
to O
water O
temperatures O
between O
16 O
and O
28 O
^ O
0C O
. O

4 B_NUMBER[MEASURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
2 B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
with O
temperature B_MEASURE/B_LOCATION
and O
reached O
a O
plateau B_LOCATION/B_MEASURE
at O
24 B_TIME[MEASURE]/B_LOCATION
^ I_TIME[MEASURE]/I_LOCATION
0C I_TIME[MEASURE]/I_LOCATION
, O
a O
temperature B_MEASURE/B_LOCATION
that O
corresponded O
to O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
feeding B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O
a O
significant B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
and O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lactate I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
levels I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
contrast B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
0 B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
reach O
a O
plateau B_MEASURE/B_DISEASE
, O
feeding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
continued O
and O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lactate B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
did O
not O
increase O
, O
even O
at O
the O
highest B_MEASURE/B_LOCATION
temperatures I_MEASURE/I_LOCATION
tested O
( O
28 B_MEASURE
^ O
0C B_MEASURE
) O
. O

5 B_NUMBER[MEASURE]
. O

To O
conclude O
, O
the O
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
that O
the O
0 B_TIME[MEASURE]/B_PERSON
+ I_TIME[MEASURE]/I_PERSON
and O
2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
different B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
physiological B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
responses B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperatures B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
suggest O
that O
wild O
2 O
+ O
Atlantic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
salmon I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
employ O
behavioural O
responses O
( O
e O
. O
g O
. O
movement O
to O
cool O
- O
water O
sites O
) O
at O
elevated O
temperatures O
in O
an O
effort O
to O
mitigate O
physiological O
imbalances O
associated O
with O
an O
inability O
to O
support O
basal O
metabolism O
through O
aerobic O
metabolic O
processes O
. O

Food B_ORGANIZATION/B_LOCATION
web O
complexity B_MEASURE/B_EDU[ORGANIZATION]
and O
allometric B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scaling B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
stream B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mesocosms I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
: O
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
experimentation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

1 B_NUMBER[MEASURE]
. O

Mesocosms B_BIO/B_MEASURE
are O
used O
extensively O
by O
ecologists B_PERSON
to O
gain O
a O
mechanistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
ecosystems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
based O
on O
the O
often O
untested B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assumption I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
these O
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
replicate O
the O
key B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attributes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assemblages I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

2 B_NUMBER[MEASURE]
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
stream B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesocosm I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utility I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
explored O
community B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
composition I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
but O
here O
for O
the O
first B_SEQUENCE[MEASURE]/B_ENT
time I_SEQUENCE[MEASURE]/I_ENT
, O
we O
extend O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
consider O
the O
replicability B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
realism B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
food B_LOCATION/B_ORGANIZATION
webs I_LOCATION/I_ORGANIZATION
in O
four B_LOCATION/B_MEASURE
outdoor I_LOCATION/I_MEASURE
channels I_LOCATION/I_MEASURE
( O
4 B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
( O
2 B_MEASURE/B_LOCATION
) O
) O
. O

3 B_NUMBER[MEASURE]
. O

The O
four B_LOCATION/B_BIO
food I_LOCATION/I_BIO
webs I_LOCATION/I_BIO
were O
similarly O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
consisting O
of O
diverse B_BIO/B_LOCATION
assemblages I_BIO/I_LOCATION
( O
61 B_MEASURE
- O
71 B_MEASURE
taxa I_MEASURE
) O
with O
dense B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feeding I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
directed O
connectance B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
09 B_MEASURE
- O
0 B_MEASURE
. O
11 B_MEASURE
) O
. O

Mesocosm B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
food I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
web O
structural B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attributes B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
within O
the O
range B_LOCATION/B_MEASURE
reported O
for O
82 B_TIME[MEASURE]/B_PERSON
well O
- O
characterized O
food B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
webs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
from O
natural B_LOCATION
streams I_LOCATION
and O
rivers B_LOCATION
. O

When O
compared O
with O
112 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
additional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
food I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
webs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O
standing O
freshwater B_LOCATION/B_BIO
, O
marine B_LOCATION
, O
estuarine B_LOCATION/B_BIO
and O
terrestrial B_LOCATION/B_PERSON
environments I_LOCATION/I_PERSON
, O
stream B_LOCATION/B_BIO
food I_LOCATION/I_BIO
webs I_LOCATION/I_BIO
( O
including O
mesocosms B_BIO/B_LOCATION
) O
had O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
characteristic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
path I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lengths I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
but O
typically O
lower B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
food B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
exponents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
species B_BIO/B_MEASURE
- O
link B_MEASURE/B_LOCATION
relationship I_MEASURE/I_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

Body B_MEASURE/B_LOCATION
size B_MEASURE/I_LOCATION
( O
M B_OTHER/B_LOCATION
) O
abundance B_MEASURE
( O
N B_OTHER/B_LOCATION
) O
allometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scaling O
coefficients B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
trivariate B_MEASURE/B_BIO
taxonomic I_MEASURE/I_BIO
mesocosm I_MEASURE/I_BIO
food I_MEASURE/I_BIO
webs I_MEASURE/I_BIO
( O
- O
0 B_MEASURE
. O
53 B_MEASURE
to O
- O
0 B_NUMBER[MEASURE]
. O
49 B_MEASURE
) O
and O
individual B_LOCATION/B_BIO
size I_LOCATION/I_BIO
distributions I_LOCATION/I_BIO
( O
- O
0 B_NUMBER[MEASURE]
. O
60 B_MEASURE
to O
- O
0 B_NUMBER[MEASURE]
. O
58 B_MEASURE
) O
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
from O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
suggesting O
that O
patterns B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
energy B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flux B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
mesocosm B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
consumers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
resources B_PERSON/B_LOCATION
were O
realistic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
approximations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
stream B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mesocosms I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
scale B_LOCATION/B_BIO
can O
support O
replicate B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
food I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
webs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
degree B_MEASURE/B_LOCATION
of O
biocomplexity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
that O
is O
comparable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
' O
natural B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
' O
streams B_LOCATION/B_BIO
. O

The O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
highlight O
the O
potential B_MEASURE
value I_MEASURE
of O
mesocosms B_BIO/B_LOCATION
as O
model B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
performing O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manipulations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
test O
ecological B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
theories I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
at O
spatiotemporal B_MEASURE/B_LOCATION
scales I_MEASURE/I_LOCATION
of O
relevance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
natural B_BIO/B_EDU[ORGANIZATION]
ecosystems I_BIO/I_EDU[ORGANIZATION]
. O

Tuberculosis B_DISEASE
. O

Tuberculosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
an O
estimated O
1 B_MEASURE
* O
7 B_MEASURE/B_DISEASE
million I_MEASURE/I_DISEASE
deaths I_MEASURE/I_DISEASE
each O
year B_TIME[MEASURE]
and O
the O
worldwide B_MEASURE
number I_MEASURE
of O
new B_PERSON/B_DISEASE
cases I_PERSON/I_DISEASE
( O
more B_MEASURE
than O
9 B_TIME[MEASURE]
million I_TIME[MEASURE]
) O
is O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
at O
any O
other B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
in O
history B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

22 B_MEASURE/B_PERSON
low I_MEASURE/I_PERSON
- O
income B_ORGANIZATION/B_LOCATION
and O
middle B_MEASURE/B_PERSON
- O
income B_LOCATION/B_PERSON
countries B_LOCATION/I_PERSON
account O
for O
more B_MEASURE/B_PERSON
than O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
world B_LOCATION
. O

Due O
to O
the O
devastating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HIV B_DISEASE
on O
susceptibility B_DISEASE
to O
tuberculosis O
, O
sub B_DISEASE/B_LOCATION
- O
Saharan B_LOCATION/B_ORGANIZATION
Africa I_LOCATION/I_ORGANIZATION
has O
been O
disproportionately O
affected O
and O
accounts B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
four B_NUMBER[MEASURE]/B_LOCATION
of O
every O
five B_TIME[MEASURE]/B_PERSON
cases B_TIME[MEASURE]/I_PERSON
of O
HIV B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
tuberculosis B_DISEASE
. O

In O
many B_LOCATION/B_PERSON
regions I_LOCATION/I_PERSON
highly O
endemic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
for O
tuberculosis B_DISEASE
, O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
continues O
to O
rely O
on O
century B_TIME[MEASURE]
- O
old B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sputum B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
there O
is O
no O
vaccine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
adequate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effectiveness I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
tuberculosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regimens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
protracted B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
have O
a O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
toxic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

increasing O
rates B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
resistant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tuberculosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
eastern B_LOCATION
Europe I_LOCATION
, O
Asia B_LOCATION
, O
and O
sub B_DISEASE/B_LOCATION
- O
Saharan B_LOCATION
Africa I_LOCATION
now O
threaten O
to O
undermine O
the O
gains B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
made O
by O
worldwide B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tuberculosis I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
control I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
programmes I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Moreover O
, O
our O
fundamental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
pathogenesis B_DISEASE
of O
this O
disease B_DISEASE
is O
inadequate B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
increased O
investment B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
allowed O
basic B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
science I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
translational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
applied O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
produce O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
to O
promising B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progress I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
development B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
improved B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tuberculosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diagnostics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
biomarkers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
disease B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
vaccines B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
growing O
scientific B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
momentum I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
must O
be O
accompanied O
by O
much O
greater B_ORGANIZATION/B_PERSON
investment I_ORGANIZATION/I_PERSON
and O
political B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
commitment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
meet O
this O
huge B_DISEASE_ADJECTIVE[DISEASE]
persisting O
challenge B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
public B_ORGANIZATION/B_PERSON
health I_ORGANIZATION/I_PERSON
. O

Our O
seminar B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presents O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
scale B_TIME[MEASURE]/B_LOCATION
of O
the O
epidemic B_DISEASE/B_BIO
, O
the O
pathogen B_BIO
and O
the O
host B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
present B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
emerging O
methods B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
including O
diagnostics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
biomarkers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
vaccines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
the O
ongoing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tuberculosis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adults B_PERSON/B_LOCATION
in O
the O
21st B_LOCATION/B_TIME[MEASURE]
century I_LOCATION/I_TIME[MEASURE]
. O

characterization O
of O
an O
Omega O
- O
class O
glutathione O
S O
- O
transferase O
in O
the O
stress O
response O
of O
the O
silkmoth B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
transferase B_ENZYME[GENE]/B_MEASURE
( O
GST B_GENE/B_LOCATION
) O
superfamily O
is O
involved O
in O
detoxification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
xenobiotics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
real O
- O
time O
PCR O
, O
mRNA O
encoding O
an O
Omega O
- O
class O
GST O
of O
Bombyx B_SPECIES[BIO]
mori I_SPECIES[BIO]
( O
bmGSTO O
) O
was O
shown O
to O
be O
induced O
after O
exposure O
to O
various O
environmental O
stresses O
. O

A O
soluble O
form O
of O
recombinant O
protein O
( O
rbmGSTO O
) O
was O
functionally O
overexpressed O
in O
Escherichia B_SPECIES[BIO]
coli I_SPECIES[BIO]
cells O
and O
purified O
to O
homogeneity O
. O

Cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
38 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
and O
Pro B_MEASURE/B_PERSON
39 I_MEASURE/I_PERSON
were O
found O
to O
be O
highly O
conserved O
in O
omega B_MEASURE/B_PROTEIN[GENE]
- O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GSTs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
their O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
investigated O
by O
site B_LOCATION/B_BIO
- O
directed O
mutagenesis B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
38 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
and O
Pro B_MEASURE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
39 I_MEASURE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
residues I_MEASURE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
affected O
the O
catalytic B_MEASURE/B_LOCATION
efficiency B_MEASURE/I_LOCATION
of O
enzymes B_ENZYME[GENE]
, O
indicating O
that O
the O
presence B_LOCATION/B_DISEASE
of O
Cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
38 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
and O
Pro B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
39 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
residues I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
bmGSTO B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
bmGSTO B_GENE/B_PERSON
could O
contribute O
to O
increasing O
the O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stress I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
resistance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
lepidopteran B_BIO
insects I_BIO
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
advances I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
neonatal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuroprotection I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
neurointensive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Knowledge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
nature B_DISEASE
, O
prognosis B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
ways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O
treat O
brain B_DISEASE
lesions I_DISEASE
in O
neonatal B_PERSON/B_DISEASE
infants I_PERSON/I_DISEASE
has O
increased O
remarkably O
. O

Neonatal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypoxic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
ischaemic B_DISEASE
encephalopathy I_DISEASE
( O
HIE B_LOCATION/B_ORGANIZATION
) O
in O
term B_PERSON/B_BIO
infants I_PERSON/I_BIO
, O
mirrors O
a O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cascade B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
excito B_DISEASE_ADJECTIVE[DISEASE]
- O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
that O
unfold O
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
after O
an O
asphyxial B_DISEASE_ADJECTIVE[DISEASE]
insult I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
laboratory B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O
this O
cascade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
can O
be O
blocked O
to O
protect O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
the O
process B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
neuroprotection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

However O
, O
proof B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
lacking O
until O
the O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
three B_NUMBER[MEASURE]
positive I_NUMBER[MEASURE]
randomised O
controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
moderate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypothermia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
term B_PERSON/B_BIO
infants I_PERSON/I_BIO
with O
HIE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
have O
greatly O
improved O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
prospects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
babies B_PERSON
with O
asphyxia B_DISEASE/B_GENE
and O
altered O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
theory B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neuroprotection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
moderate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hypothermia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
within O
6 B_NUMBER[MEASURE]
h O
of O
asphyxia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improves O
survival B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
without O
cerebral B_DISEASE
palsy I_DISEASE
or O
other B_DISEASE
disability I_DISEASE
by O
about O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
reduces O
death B_DISEASE
or O
neurological B_DISEASE
disability I_DISEASE
by O
nearly O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

The O
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
on O
to O
discover O
adjuvant B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatments I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
can O
further O
enhance O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypothermia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Origin B_TIME[MEASURE]/B_DISEASE
and O
evolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
canal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
raphe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
diatoms B_LOCATION
. O

One B_BIO/B_NUMBER[MEASURE]
lineage B_BIO/I_NUMBER[MEASURE]
of O
pennate B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diatoms I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
slit B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
through O
the O
siliceous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
called O
a O
' O
raphe B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
' O
that O
functions B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
motility B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_BIO
. O

Raphid B_PERSON/B_LOCATION
pennate I_PERSON/I_LOCATION
diatoms O
number O
in O
the O
perhaps O
tens B_MEASURE/B_LOCATION
of O
thousands B_MEASURE/B_ORGANIZATION
of O
species B_BIO/B_TIME[MEASURE]
, O
with O
the O
diversity B_MEASURE/B_PERSON
of O
raphe B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentially O
matching O
this O
number B_MEASURE/B_PERSON
. O

Three B_NUMBER[MEASURE]/B_BIO
lineages I_NUMBER[MEASURE]/I_BIO
- O
the O
Bacillariales B_SPECIES[BIO]/B_PERSON
, O
Rhopalodiales B_BACTERIUM[BIO]/B_PERSON
, O
and O
Surirellales B_BACTERIUM[BIO]
- O
possess O
a O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
presumably O
highly O
derived O
raphe B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
physically O
separated O
from O
the O
cell B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
interior B_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
, O
most O
often O
by O
a O
set B_GENE/B_LOCATION
of O
siliceous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
braces B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Because O
the O
relationship B_PERSON
among O
these O
three B_BIO/B_LOCATION
lineages B_BIO/I_LOCATION
is O
unclear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
number B_MEASURE/B_LOCATION
of O
origins B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
canal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
raphe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
homology B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
it O
and O
its O
constitutive B_LOCATION/B_DISEASE
parts I_LOCATION/I_DISEASE
among O
these O
lineages B_BIO/B_NUMBER[MEASURE]
, O
is O
equally O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
reconstructed O
the O
phylogeny B_BIO/B_GENE
of O
raphid B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pennate I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diatoms I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
included O
, O
for O
the O
first B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
, O
members B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
three B_BIO/B_PERSON
canal I_BIO/I_PERSON
raphid I_BIO/I_PERSON
diatom I_BIO/I_PERSON
lineages I_BIO/I_PERSON
, O
and O
used O
the O
phylogeny B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O
test O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
hypotheses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
about O
the O
origin B_DISEASE/B_LOCATION
of O
the O
canal B_BIO/B_DISEASE
raphe I_BIO/I_DISEASE
. O

The O
canal B_LOCATION/B_DISEASE
raphe I_LOCATION/I_DISEASE
appears O
to O
have O
evolved O
twice O
, O
once O
in O
the O
common B_PERSON/B_BIO
ancestor I_PERSON/I_BIO
of O
Bacillariales B_SPECIES[BIO]
and O
once O
in O
the O
common B_PERSON/B_BIO
ancestor I_PERSON/I_BIO
of O
Rhopalodiales B_BACTERIUM[BIO]
and O
Surirellales B_SPECIES[BIO]/B_LOCATION
, O
which O
form O
a O
monophyletic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
our O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recommend O
careful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O
- O
up O
morphogenesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
canal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
raphe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O
these O
two B_BIO/B_PERSON
lineages B_BIO/I_PERSON
to O
determine O
the O
underlying B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
developmental I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
basis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
this O
remarkable B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
parallel B_DISEASE
evolution I_DISEASE
. O

Osteoporosis B_TIME[MEASURE]/B_LOCATION
: O
now O
and O
the O
future B_TIME[MEASURE]/B_LOCATION
. O

osteoporosis B_DISEASE/B_LOCATION
is O
a O
common B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
characterised O
by O
a O
systemic B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
of O
bone B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
microarchitecture B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
that O
results O
in O
fragility B_DISEASE
fractures I_DISEASE
. O

With O
an O
ageing O
population B_PERSON/B_ORGANIZATION
, O
the O
medical B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
socioeconomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
osteoporosis B_DISEASE
, O
particularly O
postmenopausal B_DISEASE/B_PERSON
osteoporosis I_DISEASE/I_PERSON
, O
will O
increase O
further O
. O

A O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
knowledge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
bone B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insights I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O
the O
communication B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
forming O
osteoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
resorbing O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
the O
orchestrating O
signalling B_LOCATION
network I_LOCATION
has O
led O
to O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapeutic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
targets I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
developed O
that O
aim O
to O
inhibit O
excessive B_DISEASE/B_GENE
bone I_DISEASE/I_GENE
resorption I_DISEASE/I_GENE
and O
increase O
bone B_DISEASE_ADJECTIVE[DISEASE]
formation I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
most O
promising B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
novel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O
: O
denosumab B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
receptor B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activator B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
NF B_DISEASE/B_GENE
- O
kappaB B_PROTEIN[GENE]/B_LOCATION
ligand I_PROTEIN[GENE]/I_LOCATION
, O
a O
key B_GENE
osteoclast I_GENE
cytokine I_GENE
; O
odanacatib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
osteoclast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protease I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cathepsin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
K I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
and O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
the O
proteins B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sclerostin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
dickkopf B_GENE
- O
1 B_MEASURE
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
endogenous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
bone B_DISEASE/B_GENE
formation B_DISEASE/I_GENE
. O

This O
overview B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
discusses O
these O
novel B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
explains O
their O
underlying B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
physiology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

increasing O
burden B_DISEASE_ADJECTIVE[DISEASE]
of O
liver B_DISEASE
disease I_DISEASE
in O
patients B_PERSON
with O
HIV B_DISEASE
infection I_DISEASE
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combined O
antiretroviral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
made O
HIV B_DISEASE/B_PERSON
infection I_DISEASE/I_PERSON
a O
chronic B_DISEASE_ADJECTIVE[DISEASE]
illness I_DISEASE_ADJECTIVE[DISEASE]
. O

substantial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
number B_MEASURE
of O
AIDS B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
related O
deaths B_PERSON/B_DISEASE
have O
been O
accompanied O
by O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
liver B_DISEASE
- O
related O
morbidity B_DISEASE
and O
mortality B_DISEASE/B_MEASURE
due O
to O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
chronic B_DISEASE
hepatitis I_DISEASE
B I_DISEASE
and O
C B_DISEASE
viruses I_DISEASE
. O

Increases B_DISEASE_ADJECTIVE[DISEASE]
in O
non B_DISEASE
- O
alcoholic B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DISEASE_ADJECTIVE[DISEASE]
liver I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
and O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hepatotoxicity B_DISEASE
, O
together O
with O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
hepatocellular B_DISEASE
carcinoma I_DISEASE
, O
also O
potentiate O
the O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
liver B_DISEASE
disease I_DISEASE
in O
individuals B_PERSON/B_BIO
with O
HIV B_DISEASE
infection I_DISEASE
. O

We O
provide O
an O
overview B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
key B_DISEASE_ADJECTIVE[DISEASE]
causes I_DISEASE_ADJECTIVE[DISEASE]
, O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pathogenesis B_DISEASE
, O
and O
recommendations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
options I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
including O
the O
evolving O
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
liver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplantation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

adaptive O
trade O
- O
offs O
in O
juvenile O
salmonid O
metabolism O
associated O
with O
habitat O
partitioning O
between O
coho B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
salmon I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
steelhead B_BIO/B_LOCATION
trout I_BIO/I_LOCATION
in O
coastal O
streams O
. O

1 B_NUMBER[MEASURE]
. O

adaptive B_LOCATION/B_PERSON
trade I_LOCATION/I_PERSON
- O
offs B_SPORT[ENT]/B_LOCATION
are O
fundamental B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
evolution B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
diversity B_PERSON/B_BIO
and O
the O
coexistence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
similar B_BIO/B_MEASURE
taxa I_BIO/I_MEASURE
and O
occur O
when O
complimentary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combinations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
traits B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maximize O
efficiency B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
resource B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
exploitation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
or O
survival B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
different B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
environmental B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradients I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

2 B_NUMBER[MEASURE]
. O

Standard B_TIME[MEASURE]/B_ORGANIZATION
metabolic I_TIME[MEASURE]/I_ORGANIZATION
rate I_TIME[MEASURE]/I_ORGANIZATION
( O
SMR B_LOCATION/B_ORGANIZATION
) O
is O
a O
key B_MEASURE
physiological I_MEASURE
trait I_MEASURE
that O
reflects O
adaptations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
baseline O
metabolic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
whereas O
active B_DISEASE/B_PROTEIN[GENE]
metabolism B_DISEASE/I_PROTEIN[GENE]
reflects O
adaptations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
variable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
metabolic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
output I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
associated O
with O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
related O
to O
foraging B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
predator B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
avoidance B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
aggressive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
migratory B_DISEASE/B_ORGANISM_FUNCTION
movements I_DISEASE/I_ORGANISM_FUNCTION
. O

benefits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
SMR B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
active B_DISEASE/B_LOCATION
metabolism B_DISEASE/I_LOCATION
may O
change O
along O
a O
resource B_LOCATION/B_MEASURE
( O
productivity B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
gradient B_LOCATION/B_MEASURE
, O
indicating O
that O
a O
trade B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
off B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O
among O
active B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
resting O
metabolism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
energy B_MEASURE/B_ORGANISM_FUNCTION
intake I_MEASURE/I_ORGANISM_FUNCTION
. O

3 B_NUMBER[MEASURE]
. O

We O
measured O
and O
compared O
SMR O
, O
maximal O
metabolic O
rate O
( O
MMR O
) O
, O
aerobic O
scope O
( O
AS O
) O
, O
swim O
performance O
( O
UCrit O
) O
and O
growth O
of O
juvenile O
hatchery O
and O
wild O
steelhead B_BIO/B_LOCATION
and O
coho B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salmon I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
held O
on O
high O
- O
and O
low O
- O
food O
rations O
in O
order O
to O
better O
understand O
the O
potential O
significance O
of O
variation O
in O
SMR O
to O
growth O
, O
differentiation O
between O
species O
, O
and O
patterns O
of O
habitat O
use O
along O
a O
productivity O
gradient O
. O

4 B_NUMBER[MEASURE]
. O

We O
found O
that O
differences O
in O
SMR O
, O
MMR O
, O
AS O
, O
swim O
performance O
and O
growth O
rate O
between O
steelhead B_SPECIES[BIO]/B_LOCATION
trout I_SPECIES[BIO]/I_LOCATION
and O
coho B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salmon I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reduced O
in O
hatchery O
- O
reared O
fish O
compared O
with O
wild O
fish O
. O

Wild O
steelhead B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
higher O
MMR O
, O
AS O
, O
swim O
performance O
and O
growth O
rate O
than O
wild O
coho B_BIO/B_GENE
, O
but O
adaptations O
between O
species O
do O
not O
appear O
to O
involve O
differences O
in O
SMR O
or O
to O
trade O
- O
off O
increased O
growth O
rate O
against O
lower O
swim O
performance O
, O
as O
commonly O
observed O
for O
high O
- O
growth O
strains O
. O

Instead O
, O
we O
hypothesize O
that O
wild O
steelhead B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
trading O
off O
higher O
growth O
rate O
for O
lower O
food O
consumption O
efficiency O
, O
similar O
to O
strategies O
adopted O
by O
anadromous O
vs O
. O
resident O
brook B_BIO/B_LOCATION
trout I_BIO/I_LOCATION
and O
Atlantic B_BIO/B_LOCATION
salmon B_BIO/I_LOCATION
vs O
. O
brook B_SPECIES[BIO]/B_LOCATION
trout I_SPECIES[BIO]/I_LOCATION
. O

This O
highlights O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
food B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
consumption I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O
digestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
as O
cryptic B_LOCATION
adaptations I_LOCATION
ecologically O
differentiating O
salmonid B_BIO/B_LOCATION
species I_BIO/I_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

We O
hypothesize O
that O
divergent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
digestive I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strategies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
well O
documented O
among O
terrestrial B_SPECIES[BIO]/B_PERSON
vertebrates I_SPECIES[BIO]/I_PERSON
, O
may O
be O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
overlooked B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adaptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
juvenile B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
salmonids I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
fish B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
in O
general B_PERSON/B_LOCATION
. O

natal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
alter O
age B_MEASURE/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
but O
not O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
or O
senescence O
in O
a O
long O
- O
lived O
bird B_BIO/B_MEASURE
of O
prey B_SPECIES[BIO]/B_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

natal B_DISEASE/B_TIME[MEASURE]
conditions I_DISEASE/I_TIME[MEASURE]
and O
senescence B_DISEASE/B_LOCATION
are O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
major I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
shaping O
life B_TIME[MEASURE]/B_PERSON
- O
history B_MEASURE/B_LOCATION
traits B_MEASURE/I_LOCATION
of O
wild B_BIO
animals I_BIO
. O

However O
, O
such B_PERSON
factors I_PERSON
have O
rarely O
been O
investigated O
together O
, O
and O
it O
remains O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
whether O
they O
interact O
to O
affect O
age B_TIME[MEASURE]/B_PERSON
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

2 B_NUMBER[MEASURE]
. O

We O
used O
27 O
years O
of O
longitudinal O
data O
collected O
on O
tawny B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
owls I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
with O
estimates O
of O
prey O
density O
( O
field O
voles O
) O
from O
Kielder O
Forest O
( O
UK O
) O
to O
investigate O
how O
prey O
density O
at O
birth O
affects O
ageing O
patterns O
in O
reproduction O
and O
survival O
. O

3 B_NUMBER[MEASURE]
. O

Natal O
conditions O
experienced O
by O
tawny B_PERSON/B_LOCATION
owls I_PERSON/I_LOCATION
, O
measured O
in O
terms O
of O
vole O
density O
, O
dramatically O
varied O
among O
cohorts O
and O
explained O
87 O
% O
of O
the O
deviance O
in O
first O
- O
year O
apparent O
survival O
( O
annual O
estimates O
ranging O
from O
0 O
* O
07 O
to O
0 O
* O
33 O
) O
. O

4 B_NUMBER[MEASURE]
. O

We O
found O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
senescence B_DISEASE_ADJECTIVE[DISEASE]
in O
survival B_TIME[MEASURE]/B_DISEASE
for O
females B_PERSON/B_BIO
as O
well O
as O
for O
males B_PERSON/B_DISEASE
. O

Model B_PERSON
- O
averaged O
estimates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
showed O
that O
adult B_MEASURE/B_PERSON
survival I_MEASURE/I_PERSON
probability I_MEASURE/I_PERSON
declined O
linearly O
with O
age B_MEASURE
for O
females B_PERSON/B_BIO
from O
age B_PERSON
1 I_PERSON
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
male B_MEASURE/B_PERSON
survival B_MEASURE/I_PERSON
probability B_MEASURE/I_PERSON
, O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on O
average B_TIME[MEASURE]/B_PERSON
than O
for O
female B_PERSON
, O
declined O
after O
a O
plateau B_MEASURE/B_DISEASE
at O
age B_MEASURE/B_PERSON
1 I_MEASURE/I_PERSON
- O
3 B_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

We O
also O
found O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
reproductive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
senescence I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
number B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
offspring O
) O
. O

For O
females B_PERSON
, O
reproductive B_PERSON/B_DISEASE
performance B_PERSON/I_DISEASE
increased O
until O
age B_PERSON
9 I_PERSON
then O
declined O
. O

Males B_PERSON
showed O
an O
earlier B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
reproductive B_PERSON/B_MEASURE
performance B_PERSON/I_MEASURE
with O
an O
onset B_DISEASE_ADJECTIVE[DISEASE]
of O
senescence B_DISEASE/B_ORGANISM_FUNCTION
at O
age B_PERSON/B_TIME[MEASURE]
3 B_PERSON/I_TIME[MEASURE]
. O

6 B_NUMBER[MEASURE]
. O

Long O
- O
lasting B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
natal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
environmental I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Female B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
performance I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O
substantially O
related O
to O
natal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
conditions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
difference B_MEASURE
of O
0 B_MEASURE
* O
24 B_MEASURE/B_ENT
fledgling I_MEASURE/I_ENT
per O
breeding B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
females B_PERSON/B_BIO
born O
in O
the O
first B_SEQUENCE[MEASURE]
or O
third B_SEQUENCE[MEASURE]/B_LOCATION
quartile I_SEQUENCE[MEASURE]/I_LOCATION
of O
vole B_TIME[MEASURE]/B_PERSON
density I_TIME[MEASURE]/I_PERSON
) O
, O
whereas O
male B_MEASURE/B_ORGANISM_FUNCTION
performance B_MEASURE/I_ORGANISM_FUNCTION
was O
not O
. O

We O
found O
no O
evidence O
for O
tawny B_BIO/B_PERSON
owls I_BIO/I_PERSON
born O
in O
years O
with O
low O
prey O
density O
having O
accelerated O
rates O
of O
senescence O
. O

7 B_NUMBER[MEASURE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
combined O
with O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
suggest O
the O
way B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
natal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
environmental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
conditions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
affect O
senescence B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
varies O
not O
only O
across O
species B_BIO/B_PERSON
but O
also O
within O
species B_BIO/B_PERSON
according O
to O
gender B_PERSON/B_LOCATION
and O
the O
demographic B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trait B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O
. O

Post B_DISEASE
- O
splenectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
hyposplenic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
states B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
spleen B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
is O
crucial B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
regulating O
immune B_DISEASE/B_ORGANISM_FUNCTION
homoeostasis I_DISEASE/I_ORGANISM_FUNCTION
through O
its O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
link O
innate B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
adaptive B_DISEASE_ADJECTIVE[DISEASE]
immunity I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
protecting O
against O
infections B_DISEASE
. O

The O
impairment B_DISEASE_ADJECTIVE[DISEASE]
of O
splenic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
is O
defined O
as O
hyposplenism B_DISEASE
, O
an O
acquired O
disorder B_DISEASE
caused O
by O
several B_DISEASE_ADJECTIVE[DISEASE]
haematological I_DISEASE_ADJECTIVE[DISEASE]
and O
immunological B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diseases B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
term B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
asplenia I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
refers O
to O
the O
absence B_DISEASE
of O
the O
spleen B_BODY_PART_OR_ORGAN_COMPONENT
, O
a O
condition B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
rarely O
congenital B_DISEASE_ADJECTIVE[DISEASE]
and O
mostly O
post B_DISEASE
- O
surgical B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Although O
hyposplenism B_DISEASE
and O
asplenia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
might O
predispose O
individuals B_PERSON/B_DISEASE
to O
thromboembolic B_DISEASE
events I_DISEASE
, O
in O
this O
Review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
we O
focus O
on O
infectious B_DISEASE
complications I_DISEASE
, O
which O
are O
the O
most O
widely O
recognised O
consequences B_DISEASE
of O
these O
states B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Because O
of O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mortality I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
the O
fulminant B_DISEASE/B_MEASURE
course I_DISEASE/I_MEASURE
, O
and O
the O
refractoriness B_DISEASE_ADJECTIVE[DISEASE]
to O
common B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
overwhelming B_DISEASE
infections I_DISEASE
caused O
by O
encapsulated B_BACTERIUM[BIO]/B_DISEASE
bacteria I_BACTERIUM[BIO]/I_DISEASE
, O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
through O
vaccination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
antibiotic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
prophylaxis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
the O
basis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
patients B_PERSON
who O
have O
had O
splenectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O
have O
hyposplenism B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
this O
Review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
critically O
assess O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
splenic B_DISEASE
dysfunction I_DISEASE
and O
highlight O
new B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perspectives I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
overwhelming B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
splenectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
infections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

priority B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
actions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
the O
non O
- O
communicable B_PERSON/B_ENT
disease I_PERSON/I_ENT
crisis I_PERSON/I_ENT
. O

The O
UN B_MEASURE/B_LOCATION
High I_MEASURE/I_LOCATION
- O
Level B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Meeting I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
Non B_DISEASE/B_PERSON
- O
Communicable B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Diseases I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
NCDs B_ORGANIZATION/B_LOCATION
) O
in O
September B_TIME[MEASURE]/B_LOCATION
, O
2011 B_MEASURE
, O
is O
an O
unprecedented B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
opportunity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
create O
a O
sustained B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
global I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
movement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
against O
premature B_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
and O
preventable B_DISEASE_ADJECTIVE[DISEASE]
morbidity I_DISEASE_ADJECTIVE[DISEASE]
and O
disability B_DISEASE/B_MEASURE
from O
NCDs B_DISEASE/B_PERSON
, O
mainly O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
stroke B_DISEASE
, O
cancer B_DISEASE
, O
diabetes B_DISEASE
, O
and O
chronic B_DISEASE
respiratory I_DISEASE
disease I_DISEASE
. O

The O
increasing O
global O
crisis O
in O
NCDs O
is O
a O
barrier O
to O
development O
goals O
including O
poverty O
reduction O
, O
health O
equity O
, O
economic O
stability O
, O
and O
human B_PERSON/B_BIO
security O
. O

The O
Lancet O
NCD O
Action O
Group O
and O
the O
NCD O
Alliance O
propose O
five O
overarching O
priority O
actions O
for O
the O
response O
to O
the O
crisis O
- O
- O
leadership O
, O
prevention O
, O
treatment O
, O
international O
cooperation O
, O
and O
monitoring O
and O
accountability O
- O
- O
and O
the O
delivery O
of O
five O
priority O
interventions O
- O
- O
tobacco B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O
, O
salt O
reduction O
, O
improved O
diets O
and O
physical O
activity O
, O
reduction O
in O
hazardous O
alcohol O
intake O
, O
and O
essential O
drugs O
and O
technologies O
. O

The O
priority B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interventions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
chosen O
for O
their O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
cost B_MEASURE/B_LOCATION
- O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
costs I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
implementation B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
political B_ORGANIZATION/B_PERSON
and O
financial B_ORGANIZATION/B_PERSON
feasibility I_ORGANIZATION/I_PERSON
. O

The O
most O
urgent O
and O
immediate O
priority O
is O
tobacco B_ORGANIZATION/B_DISEASE
control O
. O

We O
propose O
as O
a O
goal O
for O
2040 O
, O
a O
world O
essentially O
free O
from O
tobacco B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
where O
less O
than O
5 O
% O
of O
people O
use O
tobacco O
. O

Implementation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
priority B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interventions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
at O
an O
estimated O
global B_MEASURE/B_ORGANIZATION
commitment I_MEASURE/I_ORGANIZATION
of O
about O
US B_LOCATION/B_MEASURE
$ O
9 B_MEASURE
billion I_MEASURE
per O
year B_TIME[MEASURE]/B_PERSON
, O
will O
bring O
enormous B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefits I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
social B_ORGANIZATION/B_LOCATION
and O
economic B_ORGANIZATION/B_LOCATION
development I_ORGANIZATION/I_LOCATION
and O
to O
the O
health B_LOCATION/B_ORGANIZATION
sector I_LOCATION/I_ORGANIZATION
. O

If O
widely O
adopted O
, O
these O
interventions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
will O
achieve O
the O
global B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
reducing O
NCD B_DISEASE
death I_DISEASE
rates I_DISEASE
by O
2 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
per O
year B_TIME[MEASURE]/B_PERSON
, O
averting O
tens B_MEASURE/B_PERSON
of O
millions B_MEASURE/B_PERSON
of O
premature B_DISEASE/B_PERSON
deaths I_DISEASE/I_PERSON
in O
this O
decade B_LOCATION
. O

serotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
replacement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
disease B_DISEASE/B_PERSON
after O
pneumococcal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
vaccination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Vaccination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
heptavalent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pneumococcal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
conjugate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vaccine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PCV7 B_DISEASE/B_BIO
) O
has O
significantly O
reduced O
the O
burden B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pneumococcal B_DISEASE
disease I_DISEASE
and O
has O
had O
an O
important B_DISEASE_ADJECTIVE[DISEASE]
public I_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
benefit I_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
this O
vaccine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
targets O
only O
seven B_NUMBER[MEASURE]
of O
the O
more B_MEASURE
than O
92 B_MEASURE
pneumococcal I_MEASURE
serotypes I_MEASURE
, O
concerns B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
been O
raised O
that O
non B_DISEASE/B_MEASURE
- O
vaccine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serotypes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NVTs B_DISEASE/B_PROTEIN[GENE]
) O
could O
increase O
in O
prevalence B_MEASURE/B_DISEASE
and O
reduce O
the O
benefits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
vaccination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Indeed O
, O
among O
asymptomatic B_PERSON/B_BIO
carriers I_PERSON/I_BIO
, O
the O
prevalence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
NVTs B_DISEASE
has O
increased O
substantially O
, O
and O
consequently O
, O
there O
has O
been O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
no O
net B_MEASURE
change I_MEASURE
in O
the O
bacterial B_MEASURE/B_DISEASE
carriage I_MEASURE/I_DISEASE
prevalence I_MEASURE/I_DISEASE
. O

In O
many B_LOCATION/B_PERSON
populations I_LOCATION/I_PERSON
, O
pneumococcal B_DISEASE
disease I_DISEASE
caused O
by O
NVT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
increased O
, O
but O
in O
most B_PERSON/B_LOCATION
cases I_PERSON/I_LOCATION
this O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
has O
been O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
NVT B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
carriage B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
review O
the O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
serotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
replacement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
carriage B_DISEASE
and O
disease B_DISEASE
, O
and O
address O
the O
surveillance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biases I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
might O
affect O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

We O
then O
discuss O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reasons I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
discrepancy B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
near O
- O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
carriage B_DISEASE
and O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
disease B_DISEASE
, O
including O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
invasiveness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
vaccine B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
serotypes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
contend O
that O
the O
magnitude B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
serotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
replacement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
disease B_DISEASE/B_LOCATION
can O
be O
attributed O
, O
in O
part B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
a O
combination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
invasiveness B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
replacing O
serotypes B_BIO/B_DISEASE
, O
biases B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
vaccine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
carriage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
unmasking O
) O
, O
and O
biases B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
could O
underestimate O
the O
true B_MEASURE
amount I_MEASURE
of O
replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
by O
discussing O
the O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
serotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
replacement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
disease B_DISEASE/B_LOCATION
and O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
continuing O
surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Stillbirths B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
how O
can O
health O
systems B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deliver O
for O
mothers B_PERSON
and O
babies B_PERSON
. O

The O
causes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
stillbirths B_DISEASE/B_ORGANISM_FUNCTION
are O
inseparable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
the O
causes B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
maternal B_PERSON
and O
neonatal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
deaths I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
focuses O
on O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
stillbirths B_DISEASE
by O
scale B_MEASURE/B_LOCATION
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
mothers B_PERSON
and O
babies B_PERSON
at O
the O
health B_PERSON/B_LOCATION
- O
system B_LOCATION/B_ORGANIZATION
level I_LOCATION/I_ORGANIZATION
, O
with O
consideration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
effects B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cost B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
countries B_LOCATION/B_PERSON
with O
high B_DISEASE/B_LOCATION
mortality I_DISEASE/I_LOCATION
rates I_DISEASE/I_LOCATION
, O
emergency B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obstetric I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
the O
greatest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
maternal B_PERSON
and O
neonatal B_PERSON/B_DISEASE
deaths I_PERSON/I_DISEASE
, O
and O
on O
stillbirths B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

syphilis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
moderate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
but O
of O
lower B_MEASURE
cost I_MEASURE
and O
is O
highly O
feasible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Advanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antenatal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
including O
induction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
post B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_DISEASE/B_ORGANISM_FUNCTION
pregnancies I_DISEASE/I_ORGANISM_FUNCTION
, O
and O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hypertensive B_DISEASE
disease I_DISEASE
, O
fetal B_DISEASE
growth I_DISEASE
restriction I_DISEASE
, O
and O
gestational B_DISEASE
diabetes I_DISEASE
, O
will O
further O
reduce O
mortality B_DISEASE
, O
but O
at O
higher B_MEASURE
cost I_MEASURE
. O

These O
interventions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
are O
best O
packaged O
and O
provided O
through O
linked O
service B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
delivery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
tailored O
to O
suit O
existing O
health B_PERSON
- O
care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

If O
99 B_MEASURE/B_PERSON
% B_MEASURE/I_PERSON
coverage B_MEASURE/I_PERSON
is O
reached O
in O
68 B_LOCATION/B_MEASURE
priority B_LOCATION/I_MEASURE
countries B_LOCATION/I_MEASURE
by O
2015 B_MEASURE
, O
up O
to O
1 B_MEASURE
* O
1 B_TIME[MEASURE]
million I_TIME[MEASURE]
( O
45 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
third B_SEQUENCE[MEASURE]/B_LOCATION
- O
trimester B_ENT/B_MEASURE
stillbirths B_ENT/I_MEASURE
, O
201 B_MEASURE
000 I_MEASURE
( O
54 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
maternal B_DISEASE/B_PERSON
deaths I_DISEASE/I_PERSON
, O
and O
1 B_NUMBER[MEASURE]
* O
4 B_TIME[MEASURE]
million I_TIME[MEASURE]
( O
43 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
neonatal B_PERSON/B_LOCATION
deaths I_PERSON/I_LOCATION
could O
be O
saved O
per O
year B_TIME[MEASURE]/B_PERSON
at O
an O
additional B_MEASURE/B_ORGANIZATION
total I_MEASURE/I_ORGANIZATION
cost I_MEASURE/I_ORGANIZATION
of O
US B_LOCATION/B_MEASURE
$ O
10 B_MEASURE
* O
9 B_MEASURE
billion I_MEASURE
or O
$ O
2 B_MEASURE
* O
32 B_MEASURE
per O
person B_PERSON
, O
which O
is O
in O
the O
range B_MEASURE/B_LOCATION
of O
$ O
0 B_MEASURE
* O
96 B_MEASURE
- O
2 B_MEASURE
* O
32 B_MEASURE
for O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ingredients I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
- O
based O
intervention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
packages I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
with O
only B_MEASURE/B_DISEASE
recurrent I_MEASURE/I_DISEASE
costs I_MEASURE/I_DISEASE
. O

The O
contribution O
of O
the O
S O
- O
phase O
checkpoint O
genes O
MEC1 O
and O
SGS1 O
to O
genome O
stability O
maintenance O
in O
Candida B_SPECIES[BIO]
albicans I_SPECIES[BIO]
. O

genome O
rearrangements O
, O
a O
common O
feature O
of O
Candida B_BACTERIUM[BIO]/B_DISEASE
albicans I_BACTERIUM[BIO]/I_DISEASE
isolates O
, O
are O
often O
associated O
with O
the O
acquisition O
of O
antifungal O
drug O
resistance O
. O

In O
Saccharomyces B_SPECIES[BIO]
cerevisiae I_SPECIES[BIO]
, O
perturbations O
in O
the O
S O
- O
phase O
checkpoints O
result O
in O
the O
same O
sort O
of O
Gross O
Chromosomal O
Rearrangements O
( O
GCRs O
) O
observed O
in O
C B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
albicans I_SPECIES[BIO]/I_DISEASE
. O

Several O
proteins O
are O
involved O
in O
the O
S B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cerevisiae B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cell O
cycle O
checkpoints O
, O
including O
Mec1p O
, O
a O
protein O
kinase O
of O
the O
PIKK O
( O
phosphatidyl O
inositol O
3 O
- O
kinase O
- O
like O
kinase O
) O
family O
and O
the O
central O
player O
in O
the O
DNA O
damage O
checkpoint O
. O

Sgs1p B_MEASURE/B_LOCATION
, O
the O
ortholog B_GENE/B_PERSON
of O
BLM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
Bloom B_GENE/B_DISEASE
' I_GENE/I_DISEASE
s I_GENE/I_DISEASE
syndrome I_GENE/I_DISEASE
gene I_GENE/I_DISEASE
, O
is O
a O
RecQ B_DISEASE/B_GENE
- O
related O
DNA B_ENZYME[GENE]/B_MEASURE
helicase I_ENZYME[GENE]/I_MEASURE
; O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
BLM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
characterized O
by O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
genome B_DISEASE/B_GENE
instability I_DISEASE/I_GENE
. O

Yeast B_SPECIES[BIO]
strains O
bearing O
deletions O
in O
MEC1 O
or O
SGS1 O
are O
viable O
( O
in O
contrast O
to O
the O
inviability O
seen O
with O
loss O
of O
MEC1 O
in O
S B_BIO/B_PERSON
. I_BIO/I_PERSON
cerevisiae I_BIO/I_PERSON
) O
but O
the O
different O
deletion O
mutants O
have O
significantly O
different O
phenotypes O
. O

The O
mec1Delta B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Delta B_PROTEIN[GENE]/B_BIO
colonies I_PROTEIN[GENE]/I_BIO
have O
a O
wild B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
colony B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
morphology B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
while O
the O
sgs1Delta B_GENE/B_DISEASE
/ O
Delta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
slow O
- O
growing O
, O
producing O
wrinkled O
colonies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O
pseudohyphal B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
like B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cells B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
mec1Delta B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Delta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
only O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
ethylmethane O
sulfonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EMS B_LOCATION/B_ORGANIZATION
) O
, O
methylmethane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MMS B_LOCATION/B_ORGANIZATION
) O
, O
and O
hydroxyurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Hu B_PERSON/B_LOCATION
) O
but O
the O
sgs1Delta B_PROTEIN[GENE]/B_DISEASE
/ O
Delta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O
a O
high B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_DISEASE_ADJECTIVE[DISEASE]
to O
all O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
damaging O
agents B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tested O
. O

In O
an O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
chromosome B_DISEASE/B_GENE
1 I_DISEASE/I_GENE
integrity I_DISEASE/I_GENE
, O
the O
mec1Delta B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Delta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
genome B_DISEASE_ADJECTIVE[DISEASE]
instability I_DISEASE_ADJECTIVE[DISEASE]
; O
no O
change B_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
the O
sgs1Delta B_PROTEIN[GENE]/B_DISEASE
/ O
Delta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Finally O
, O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
MEC1 B_GENE
does O
not O
affect O
sensitivity B_DISEASE
to O
the O
antifungal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluconazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
SGS1 B_GENE/B_DISEASE
leads O
to O
an O
increased O
susceptibility B_DISEASE
to O
fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Neither O
deletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
elevated O
the O
level B_MEASURE
of O
antifungal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
drug I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acquisition I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

postural B_DISEASE
deformities I_DISEASE
in O
Parkinson B_PERSON/B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

postural B_DISEASE/B_MEASURE
deformities I_DISEASE/I_MEASURE
are O
frequent B_DISEASE_ADJECTIVE[DISEASE]
and O
disabling O
complications B_DISEASE_ADJECTIVE[DISEASE]
of O
Parkinson B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
and O
atypical B_DISEASE
parkinsonism I_DISEASE
. O

These O
deformities B_DISEASE
include O
camptocormia B_DISEASE
, O
antecollis B_DISEASE
, O
Pisa B_DISEASE
syndrome I_DISEASE
, O
and O
scoliosis B_DISEASE
. O

Recognition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
specific B_DISEASE/B_GENE
postural I_DISEASE/I_GENE
syndromes I_DISEASE/I_GENE
might O
have O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diagnostic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
value I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
patients B_PERSON/B_BIO
presenting O
with O
parkinsonism B_DISEASE
. O

The O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
date B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O
that O
postural B_DISEASE/B_BIO
deformities I_DISEASE/I_BIO
have O
a O
multifactorial B_DISEASE_ADJECTIVE[DISEASE]
pathophysiology I_DISEASE_ADJECTIVE[DISEASE]
. O

contributing O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
include O
muscular B_DISEASE
rigidity I_DISEASE
; O
axial B_DISEASE
dystonia I_DISEASE
; O
weakness B_DISEASE
caused O
by O
myopathy B_DISEASE
; O
body B_DISEASE
scheme I_DISEASE
defects I_DISEASE
due O
to O
centrally O
impaired B_DISEASE_ADJECTIVE[DISEASE]
proprioception I_DISEASE_ADJECTIVE[DISEASE]
; O
and O
structural B_DISEASE
changes I_DISEASE
in O
the O
spine B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
relative B_MEASURE
contribution I_MEASURE
of O
these O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
varies O
between O
patients B_PERSON/B_LOCATION
and O
across O
specific B_LOCATION/B_ORGANIZATION
syndromes I_LOCATION/I_ORGANIZATION
. O

Improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mechanisms B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underlying O
postural B_DISEASE
deformities I_DISEASE
in O
PD B_DISEASE/B_LOCATION
might O
ultimately O
lead O
us O
to O
more O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
strategies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
these O
disabling B_DISEASE_ADJECTIVE[DISEASE]
and O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
refractory B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
. O

Tortricid O
moths O
reared O
from O
the O
invasive O
weed O
Mexican B_BIO
palo I_BIO
verde I_BIO
, O
Parkinsonia B_LOCATION
aculeata I_LOCATION
, O
with O
comments O
on O
their O
host O
specificity O
, O
biology O
, O
geographic O
distribution O
, O
and O
systematics O
. O

As O
part O
of O
efforts O
to O
identify O
native O
herbivores O
of O
Mexican B_LOCATION
palo I_LOCATION
verde I_LOCATION
, O
Parkinsonia B_PERSON
aculeata I_PERSON
L O
. O

( O
Leguminosae O
: O
Caesalpinioideae O
) O
, O
as O
potential O
biological O
control O
agents O
against O
this O
invasive O
weed O
in O
Australia O
, O
ten O
species O
of O
Tortricidae O
( O
Lepidoptera O
) O
were O
reared O
from O
Guatemala O
, O
Mexico O
, O
Nicaragua O
, O
and O
Venezuela O
: O
Amorbia O
concavana O
( O
Zeller O
) O
, O
Platynota O
rostrana O
( O
Walker O
) O
, O
Platynota O
helianthes O
( O
Meyrick O
) O
, O
Platynota B_PERSON/B_LOCATION
stultana I_PERSON/I_LOCATION
Walsingham O
( O
all O
Tortricinae O
: O
Sparganothini O
) O
, O
Rudenia O
leguminana O
( O
Busck O
) O
, O
Cochylis O
SP O
. O

( O
both O
Tortricinae B_BIO/B_PERSON
: O
Cochylini B_LOCATION/B_PERSON
) O
, O
Ofatulena B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duodecemstriata I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Walsingham B_LOCATION/B_PERSON
) O
, O
O O
. O
luminosa B_PERSON
Heinrich I_PERSON
, O
Ofatulena B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SP I_LOCATION
. O

( O
all O
Olethreutinae B_BIO/B_PERSON
: O
Grapholitini B_BACTERIUM[BIO]/B_LOCATION
) O
, O
and O
Crocidosema B_LOCATION/B_BIO
lantana I_LOCATION/I_BIO
Busck I_LOCATION/I_BIO
( O
Olethreutinae B_BIO/B_LOCATION
: O
Eucosmini B_LOCATION/B_PERSON
) O
. O

Significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
geographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
range I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
extensions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
provided O
for O
O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
duodecemstriata B_DISEASE/B_PERSON
and O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
leguminana B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
. O

These O
are O
the O
first O
documented O
records O
of O
P B_BIO
. I_BIO
aculeata I_BIO
as O
a O
host O
plant O
for O
all O
but O
O O
. O
luminosa O
. O

The O
four B_BIO/B_ENT
species I_BIO/I_ENT
of O
Sparganothini B_SPECIES[BIO]/B_LOCATION
are O
polyphagous B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
; O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
two B_NUMBER[MEASURE]/B_BIO
Cochylini I_NUMBER[MEASURE]/I_BIO
and O
three B_PERSON/B_BIO
Grapholitini I_PERSON/I_BIO
likely O
are O
specialists B_PERSON/B_LOCATION
on O
Leguminosae B_BIO/B_LOCATION
. O

Ofatulena O
luminosa O
is O
possibly O
host O
specific O
on O
P B_BIO/B_LOCATION
. I_BIO/I_LOCATION
aculeata I_BIO/I_LOCATION
. O

host B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
Rudenia B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
leguminana I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
also O
provide O
some O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
historical B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rearing I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
records I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
examine O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
R B_OTHER/B_LOCATION
. O
leguminana B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
is O
a O
complex B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
species B_BIO
, O
two B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sets I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
molecular B_GENE/B_BIO
markers I_GENE/I_BIO
were O
examined O
: O
( O
1 B_SEQUENCE[MEASURE]
) O
a O
combined O
data B_LOCATION/B_ORGANIZATION
set I_LOCATION/I_ORGANIZATION
of O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitochondrial I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
a O
781 B_MEASURE
- O
basepair B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
cytochrome B_ENZYME[GENE]
c O
oxidase B_ENZYME[GENE]
I I_ENZYME[GENE]
( O
COI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
a O
685 B_MEASURE
- O
basepair B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
cytochrome B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c O
oxidase B_ENZYME[GENE]
II I_ENZYME[GENE]
) O
and O
one B_GENE/B_NUMBER[MEASURE]
nuclear I_GENE/I_NUMBER[MEASURE]
marker I_GENE/I_NUMBER[MEASURE]
( O
a O
531 B_MEASURE
- O
basepair B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
the O
28S B_GENE/B_MEASURE
domain I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
) O
; O
and O
( O
2 O
) O
the O
650 B_MEASURE
- O
basepair B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
& O
quot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
barcode B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
& O
quot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
region B_LOCATION/B_MEASURE
of O
COI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
both O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
strongly O
suggest O
that O
individuals B_PERSON/B_BIO
examined O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
belong O
to O
more B_MEASURE/B_PERSON
than O
one B_NUMBER[MEASURE]/B_PERSON
species I_NUMBER[MEASURE]/I_PERSON
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
the O
higher B_MEASURE/B_PERSON
importance I_MEASURE/I_PERSON
of O
signal B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
size I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
over O
body B_MEASURE/B_PERSON
size I_MEASURE/I_PERSON
in O
aposematic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
signaling B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
insects B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
understand O
the O
evolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
warning O
coloration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
it O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
between O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
aspects I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
conspicuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
color I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
patterns I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

As O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
both O
pattern B_MEASURE/B_LOCATION
element I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
and O
body B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
of O
prey B_BIO/B_PERSON
have O
been O
shown O
to O
enhance O
the O
effectiveness B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
warning O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
. O

However O
, O
it O
is O
unclear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
whether O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
body B_MEASURE/B_COLOR
size I_MEASURE/I_COLOR
is O
merely O
a O
side B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
proportionally O
increasing O
pattern B_MEASURE/B_PERSON
elements I_MEASURE/I_PERSON
, O
or O
if O
there O
is O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
body B_MEASURE/B_COLOR
size I_MEASURE/I_COLOR
per O
se B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
possibilities O
were O
evaluated O
by O
offering O
different O
sized O
artificial O
caterpillars O
with O
either O
fixed O
or O
proportionally O
increasing O
aposematic O
color O
signal O
elements O
to O
wild O
great B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tits I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
Parus B_BACTERIUM[BIO]/B_LOCATION
major B_BACTERIUM[BIO]/I_LOCATION
L B_BACTERIUM[BIO]/I_LOCATION
. B_BACTERIUM[BIO]/I_LOCATION
. O

( O
Passeriformes B_LOCATION/B_PERSON
: O
Paridae B_LOCATION/B_BIO
) O
. O

The O
birds B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hesitation B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
attack O
each O
& O
quot B_MEASURE/B_PERSON
; O
caterpillar B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
& O
quot B_MEASURE/B_LOCATION
; O
was O
used O
as O
a O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
warning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
hesitation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
positive B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
- O
dependence B_DISEASE/B_MEASURE
with O
the O
caterpillars B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
whose O
pattern B_MEASURE/B_LOCATION
elements I_MEASURE/I_LOCATION
increased O
proportionally O
with O
their O
body B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
size B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dependence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
found O
in O
the O
larvae B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
fixed O
- O
size B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
signal B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
elements B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Such B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
difference B_MEASURE
in O
mortality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
curves I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
pattern B_MEASURE/B_DISEASE
element I_MEASURE/I_DISEASE
size I_MEASURE/I_DISEASE
is O
a O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
body B_MEASURE
size I_MEASURE
in O
enhancing O
a O
warning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
body B_MEASURE/B_BIO
size I_MEASURE/I_BIO
per O
se B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
signal B_MEASURE/B_BIO
efficiency B_MEASURE/I_BIO
was O
found O
, O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
does O
not O
support O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
aposematic B_BIO/B_PERSON
insects B_BIO/I_PERSON
gain O
more O
from O
large B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
cryptic B_BIO/B_PERSON
ones I_BIO/I_PERSON
. O

Wolbachia O
wSinvictaA B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O
in O
natural O
populations O
of O
the O
fire B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ant I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Solenopsis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
invicta I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O
testing O
for O
phenotypic O
effects O
. O

Wolbachia B_BACTERIUM[BIO]/B_PERSON
are O
intracellular B_SPECIES[BIO]
bacteria I_SPECIES[BIO]
that O
commonly O
infect O
many B_SPECIES[BIO]
arthropods I_SPECIES[BIO]
and O
some O
nematodes B_BIO/B_DISEASE
. O

In O
arthropods B_BIO
, O
these O
maternally O
transmitted O
bacteria B_BIO/B_DISEASE
often O
induce O
a O
variety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
phenotypic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
enhance O
their O
own B_DISEASE
spread I_DISEASE
within O
host B_MEASURE/B_PERSON
populations I_MEASURE/I_PERSON
. O

Wolbachia B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
phenotypic I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
effects I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
generally O
either O
provide O
benefits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
infected B_DISEASE/B_BIO
host B_DISEASE/I_BIO
females B_DISEASE/I_BIO
( O
cytoplasmic B_DISEASE/B_ORGANISM_FUNCTION
incompatibility I_DISEASE/I_ORGANISM_FUNCTION
, O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fitness I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
bias B_MEASURE/B_LOCATION
host B_MEASURE/I_LOCATION
sex B_MEASURE/I_LOCATION
ratio B_MEASURE/I_LOCATION
in O
favor B_PERSON/B_MEASURE
of O
females B_PERSON/B_DISEASE
( O
male B_PERSON/B_BIO
- O
killing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
parthenogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O
feminization B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
) O
, O
all O
of O
which O
increase O
the O
relative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
production I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
infected B_PERSON/B_BIO
females B_PERSON/I_BIO
in O
host B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Wolbachia B_PERSON/B_BIO
surveys I_PERSON/I_BIO
have O
found O
infections B_DISEASE/B_SPECIES[BIO]
to O
be O
exceedingly O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
ants B_SPECIES[BIO]/B_PERSON
, O
but O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
at O
this O
juncture B_MEASURE/B_LOCATION
as O
to O
what O
phenotypic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
if O
any O
, O
they O
induce O
in O
this O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Previous O
studies O
have O
demonstrated O
that O
individuals O
from O
native O
populations O
of O
the O
invasive O
fire B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
ant I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
Solenopsis I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
invicta I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
commonly O
harbor O
one O
or O
more O
of O
three O
Wolbachia O
variants O
. O

One O
of O
the O
variants O
, O
wSinvictaA O
, O
typically O
occurs O
at O
low O
prevalence O
in O
S B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
invicta I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations O
, O
appears O
to O
have O
been O
transmitted O
horizontally O
into O
S B_PERSON/B_BIO
. I_PERSON/I_BIO
invicta I_PERSON/I_BIO
three O
or O
more O
times O
, O
and O
has O
been O
lost O
repeatedly O
from O
host O
lineages O
over O
time O
. O

In O
order O
to O
determine O
the O
phenotypic O
effects O
and O
likely O
population O
dynamics O
of O
wSinvictaA B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O
in O
these O
ants O
, O
brood O
production O
patterns O
of O
newly O
mated O
fire B_BIO/B_PERSON
ant I_BIO/I_PERSON
Queens O
were O
studied O
during O
simulated O
claustral O
founding O
and O
measured O
wSinvictaA B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
transmission O
fidelity O
within O
mature O
single O
- O
queen O
families O
. O

No O
clear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
found O
for O
Wolbachia B_BIO/B_PERSON
- O
induced O
cytoplasmic B_DISEASE/B_ORGANISM_FUNCTION
incompatibility I_DISEASE/I_ORGANISM_FUNCTION
, O
significant B_DISEASE_ADJECTIVE[DISEASE]
fitness I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
male B_PERSON/B_DISEASE
- O
killing B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

maternal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
transmission I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
was O
perfect B_DISEASE_ADJECTIVE[DISEASE]
to O
both O
virgin B_PERSON/B_LOCATION
Queens I_PERSON/I_LOCATION
and O
males B_PERSON
. O

Possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
how O
this O
variant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
maintained O
in O
host B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Growth O
inhibition O
of O
Beauveria B_BIO
bassiana I_BIO
by O
bacteria O
isolated O
from O
the O
cuticular O
surface O
of O
the O
corn B_BIO
leafhopper I_BIO
, O
Dalbulus B_BIO
maidis I_BIO
and O
the O
planthopper O
, O
Delphacodes B_BIO/B_LOCATION
kuscheli I_BIO/I_LOCATION
, O
two O
important O
vectors O
of O
maize O
pathogens O
. O

The O
phytosanitary O
importance O
of O
the O
corn B_BIO/B_LOCATION
leafhopper O
, O
Dalbulus O
maidis O
( O
De O
Long O
and O
Wolcott O
) O
( O
Hemiptera O
: O
Cicadellidae O
) O
and O
the O
planthopper O
, O
Delphacodes O
kuscheli O
Fennah O
( O
Hemiptera O
: O
Delphacidae O
) O
lies O
in O
their O
ability O
to O
transmit O
phloem O
- O
associated O
plant O
pathogens O
, O
mainly O
viruses O
and O
mollicutes O
, O
and O
to O
cause O
considerable O
mechanical O
damage O
to O
corn O
plants O
during O
feeding O
and O
oviposition O
. O

fungi B_BACTERIUM[BIO]/B_PERSON
, O
particularly O
some O
members B_PERSON/B_BIO
of O
the O
Ascomycota B_BIO/B_PERSON
, O
are O
likely B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
candidates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
biocontrol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
agents I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
against O
these O
insect B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
pests I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
their O
failure B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
invade O
the O
insect B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cuticle I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O
because O
of O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
inhibitory B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
phenols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
quinones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
lipids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
also O
by O
the O
antibiosis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
microbiota B_BACTERIUM[BIO]
living O
on O
the O
cuticular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
surface B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
host B_BIO
. O

The O
present O
work O
aims O
to O
understand O
interactions O
between O
the O
entomopathogenic O
fungus O
Beauveria B_BIO
bassiana I_BIO
( O
Balsamao O
- O
Crivelli O
) O
Vuillemin O
( O
Hypocreales O
: O
Cordycipitaceae O
) O
and O
bacterial O
antagonists O
isolated O
from O
the O
cuticular O
surface O
of O
D B_BIO
. I_BIO
maidis I_BIO
and O
D B_BIO
. I_BIO
kuscheli I_BIO
. O

A O
total O
of O
155 O
bacterial O
isolates O
were O
recovered O
from O
the O
insect O
' O
s O
cuticle O
and O
tested O
against O
B B_SPECIES[BIO]
. I_SPECIES[BIO]
bassiana I_SPECIES[BIO]
. O

ninety O
- O
one O
out O
of O
155 O
strains O
inhibited O
the O
growth O
of O
B B_SPECIES[BIO]
. I_SPECIES[BIO]
bassiana I_SPECIES[BIO]
. O

bacterial O
strains O
isolated O
from O
D B_BIO
. I_BIO
maidis I_BIO
were O
significantly O
more O
antagonistic O
against O
B B_SPECIES[BIO]
. I_SPECIES[BIO]
bassiana I_SPECIES[BIO]
than O
those O
isolates O
from O
D B_PERSON/B_BIO
. I_PERSON/I_BIO
kuscheli I_PERSON/I_BIO
. O

Among O
the O
most O
effective O
antagonistic O
strains O
, O
six O
isolates O
of O
Bacillus B_BACTERIUM[BIO]/B_PERSON
thuringiensis I_BACTERIUM[BIO]/I_PERSON
Berliner O
( O
Bacillales O
: O
Bacillaeae O
( O
after O
B B_MEASURE
. I_MEASURE
subtilis I_MEASURE
) O
) O
, O
one O
isolate O
of O
B B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
mycoides I_BACTERIUM[BIO]/I_PERSON
Flugge O
, O
eight O
isolates O
of O
B B_PERSON/B_BACTERIUM[BIO]
. I_PERSON/I_BACTERIUM[BIO]
megaterium I_PERSON/I_BACTERIUM[BIO]
de O
Bary O
, O
five O
isolates O
of O
B B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
pumilus I_BACTERIUM[BIO]
Meyer O
and O
Gottheil O
, O
one O
isolate O
of O
B B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
licheniformis I_BACTERIUM[BIO]/I_PERSON
( O
Weigmann O
) O
Chester O
, O
and O
four O
isolates O
of O
B B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
subtilis I_BACTERIUM[BIO]/I_PERSON
( O
Ehrenberg O
) O
Cohn O
were O
identified O
. O

Mig1 O
is O
involved O
in O
mycelial O
formation O
and O
expression O
of O
the O
genes O
encoding O
extracellular O
enzymes O
in O
Saccharomycopsis B_BACTERIUM[BIO]/B_GENE
fibuligera I_BACTERIUM[BIO]/I_GENE
A11 O
. O

The O
MIG1 O
gene O
of O
Saccharomycopsis B_VIRUS[BIO]/B_GENE
fibuligera I_VIRUS[BIO]/I_GENE
A11 O
was O
cloned O
from O
its O
genomic O
DNA O
using O
the O
degenerated O
primers O
and O
inverse O
PCR O
. O

The O
MIG1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1152bp B_GENE
, O
accession B_TIME[MEASURE]/B_BIO
number I_TIME[MEASURE]/I_BIO
: O
HM450676 B_MEASURE
) O
encoded O
a O
384 B_MEASURE
- O
amino B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
very O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
Mig1s B_GENE/B_BIO
from O
other B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fungi I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Besides O
their O
highly O
conserved O
zinc B_LOCATION/B_PERSON
fingers I_LOCATION/I_PERSON
, O
the O
Mig1 B_BIO/B_GENE
proteins I_BIO/I_GENE
displayed O
short B_LOCATION
conserved I_LOCATION
motifs I_LOCATION
of O
possible B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
glucose B_DISEASE/B_BIO
repression I_DISEASE/I_BIO
. O

The O
MIG1 O
gene O
in O
S B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
fibuligera B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
A11 O
was O
disrupted O
by O
integrating O
the O
HPT O
( O
hygromycin O
B O
phosphotransferase O
) O
gene O
into O
ORF O
( O
Open O
Reading O
frame O
) O
of O
the O
MIG1 O
gene O
. O

The O
disruptant B_PROTEIN[GENE]/B_DISEASE
A11 I_PROTEIN[GENE]/I_DISEASE
- O
c B_PROTEIN[GENE]/B_DISEASE
obtained O
could O
grow O
in O
the O
media B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
containing O
hygromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
2 B_MEASURE
- O
deoxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
respectively O
. O

alpha B_PROTEIN[GENE]
- O
amylase B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
glucoamylse B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
acid B_ENZYME[GENE]/B_BACTERIUM[BIO]
protease I_ENZYME[GENE]/I_BACTERIUM[BIO]
and O
Beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
glucosidase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
production I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
disruptant B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
expression B_GENE
of O
their O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
disruptant B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
were O
greatly O
enhanced O
. O

This O
confirms O
that O
Mig1 O
, O
the O
transcriptional O
repressor O
, O
indeed O
regulates O
expression O
of O
the O
genes O
and O
production O
of O
the O
extracellular O
enzymes O
in O
S B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
. B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
fibuligera B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
A11 O
. O

At O
the O
same B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
, O
it O
was O
found O
that O
cell B_DISEASE/B_ORGANISM_FUNCTION
budding I_DISEASE/I_ORGANISM_FUNCTION
was O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mycelial B_DISEASE_ADJECTIVE[DISEASE]
formation I_DISEASE_ADJECTIVE[DISEASE]
was O
reduced O
in O
the O
disruptant B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Morphological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
molecular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogeny I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
freshwater B_LOCATION/B_BIO
blooming O
species B_BIO
, O
Peridiniopsis B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
spp O
. O

( O
Dinophyceae B_MEASURE/B_BIO
) O
from O
China B_LOCATION
. O

In O
2008 B_TIME[MEASURE]
- O
2010 B_MEASURE
, O
several B_DISEASE/B_BIO
freshwater I_DISEASE/I_BIO
dinoflagellate I_DISEASE/I_BIO
blooms I_DISEASE/I_BIO
caused O
by O
Peridiniopsis B_LOCATION/B_BACTERIUM[BIO]
spp I_LOCATION/I_BACTERIUM[BIO]
. O
were O
observed O
in O
China B_LOCATION
. O

P B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
penardii I_SPECIES[BIO]/I_PERSON
and O
P B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
niei I_SPECIES[BIO]/I_PERSON
sampled O
from O
various O
geographical O
localities O
were O
examined O
by O
means O
of O
light O
and O
scanning O
electron O
microscopy O
. O

After O
comparing O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
new B_LOCATION/B_PERSON
freshwater I_LOCATION/I_PERSON
variety I_LOCATION/I_PERSON
Peridiniopsis I_LOCATION/I_PERSON
penardii I_LOCATION/I_PERSON
var I_LOCATION/I_PERSON
. O
robusta B_BIO/B_GENE
var B_BIO/I_GENE
. O
Nov B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
Peridiniales B_LOCATION/B_PERSON
, O
Dinophyceae B_MEASURE/B_LOCATION
) O
found O
in O
Manwan B_LOCATION
Reservoir I_LOCATION
, O
Yunnan B_LOCATION
Province I_LOCATION
was O
described O
. O

The O
new B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
variety I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
differed O
from O
P B_OTHER/B_LOCATION
. O
penardii B_SPECIES[BIO]/B_DISEASE
since O
it O
possessed O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
robust B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antapical B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
spines B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
a O
conspicuous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
apical I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
spine I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Molecular O
phylogenetic O
analyses O
based O
on O
SSU O
, O
LSU O
and O
Its O
indicated O
P B_BIO/B_LOCATION
. B_BIO/I_LOCATION
niei B_BIO/I_LOCATION
, O
P O
. O
penardii O
and O
P O
. O
penardii O
var O
. O
robusta O
were O
closely O
related O
with O
P O
. O
kevei O
, O
and O
clustered O
into O
a O
monophyletic O
clade O
. O

The O
new O
variety O
possessed O
an O
endosymbiotic O
diatom O
which O
was O
similar O
to O
P O
. O
penardii O
and O
P O
. O
kevei O
, O
whereas O
the O
endosymbiont O
was O
not O
present O
in O
cells O
of O
P B_BIO
. I_BIO
niei I_BIO
. O

The O
endosymbiont B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SSU I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Its O
phylogenies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O
that O
the O
endosymbionts B_BIO/B_GENE
of O
these O
three B_BIO
dinoflagellates I_BIO
were O
closely O
related O
to O
members B_PERSON/B_BIO
of O
Thalassiosirales B_SPECIES[BIO]
. O

Furthermore O
it O
was O
concluded O
that O
the O
endosymbionts B_BIO
might O
originate O
from O
Discostella B_BACTERIUM[BIO]
- O
like B_BIO
species I_BIO
. O

Beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Thymosin B_GENE
is O
upregulated O
by O
the O
steroid B_MEASURE
hormone I_MEASURE
20 I_MEASURE
- O
hydroxyecdysone B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
microorganisms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

Thymosins B_PERSON/B_GENE
have O
diverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biological I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
including O
actin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
sequestering B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
tissue B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
repair B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
vertebrates B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
there O
is O
little B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
information I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
about O
the O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
thymosins B_GENE/B_BIO
in O
invertebrates B_SPECIES[BIO]
. O

We O
isolated O
a O
Beta O
- O
thymosin O
gene O
in O
Helicoverpa B_SPECIES[BIO]
armigera I_SPECIES[BIO]
. O

It O
has O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
HaTHY1 B_PROTEIN[GENE]/B_LOCATION
and O
HaTHY2 B_GENE/B_DISEASE
, O
encoding O
19 B_MEASURE
. O
0 B_MEASURE
kDa I_MEASURE
and O
14 B_MEASURE
. O
5 B_MEASURE
kDa I_MEASURE
peptides I_MEASURE
, O
respectively O
. O

HaTHY1 B_GENE
was O
mainly O
transcribed O
in O
the O
integument B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
midgut B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
while O
HaTHY2 B_GENE
was O
principally O
presented O
in O
the O
fat B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
body I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
and O
haemocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

The O
transcript B_MEASURE/B_LOCATION
levels B_MEASURE/I_LOCATION
of O
HaTHY2 B_GENE
showed O
some O
fluctuation B_DISEASE_ADJECTIVE[DISEASE]
; O
there O
was O
an O
obvious B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
metamorphic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stage I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
integument B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
fat B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
body I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

HaTHY B_GENE
was O
able B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
upregulated O
by O
20 B_MEASURE
- O
hydroxyecdysone B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
by O
bacterial B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
viral B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
HaTHY B_GENE
is O
upregulated O
by O
the O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
by O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
microorganism B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cell O
cycle O
gene O
MoCDC15 O
regulates O
hyphal O
growth O
, O
asexual O
development O
and O
plant O
infection O
in O
the O
rice B_BIO/B_LOCATION
blast I_BIO/I_LOCATION
pathogen I_BIO/I_LOCATION
Magnaporthe I_BIO/I_LOCATION
oryzae I_BIO/I_LOCATION
. O

Rice O
blast O
, O
caused O
by O
the O
pathogen O
Magnaporthe B_BIO
oryzae I_BIO
, O
is O
a O
serious O
hindrance O
to O
rice B_BIO/B_LOCATION
production O
and O
has O
emerged O
as O
an O
important O
model O
for O
the O
characterization O
of O
molecular O
mechanisms O
relevant O
to O
pathogenic O
development O
in O
plants O
. O

Similar O
to O
other O
pathogenic O
fungi O
, O
conidiation O
plays O
a O
central O
role O
in O
initiation O
of O
M B_SPECIES[BIO]
. I_SPECIES[BIO]
oryzae I_SPECIES[BIO]
infection O
and O
spread O
over O
a O
large O
area O
. O

However O
, O
relatively O
little O
is O
known O
regarding O
the O
molecular O
mechanisms O
that O
underlie O
conidiation O
in O
M B_BIO
. I_BIO
oryzae I_BIO
. O

To O
better O
characterize O
these O
mechanisms O
, O
we O
identified O
a O
conidiation O
- O
defective O
mutant O
, O
ATMT0225B6 B_DISEASE/B_LOCATION
( O
MoCDC15 B_PROTEIN[GENE]/B_BIO
( I_PROTEIN[GENE]/I_BIO
T I_PROTEIN[GENE]/I_BIO
- I_PROTEIN[GENE]/I_BIO
DNA I_PROTEIN[GENE]/I_BIO
) I_PROTEIN[GENE]/I_BIO
) O
, O
in O
which O
a O
T O
- O
DNA O
insertion O
disrupted O
a O
gene O
that O
encodes O
a O
homolog O
of O
fission O
yeast B_SPECIES[BIO]/B_GENE
cdc15 O
, O
and O
generated O
a O
second O
strain O
containing O
a O
disruption O
in O
the O
same O
allele O
( O
DeltaMoCDC15 O
( O
T O
- O
DNA O
) O
) O
. O

The O
cdc15 O
gene O
has O
been O
shown O
to O
act O
as O
a O
coordinator O
of O
the O
cell O
cycle O
in O
yeast B_SPECIES[BIO]
. O

functional O
analysis O
of O
the O
MoCDC15 O
( O
T O
- O
DNA O
) O
and O
DeltaMoCDC15 O
( O
T O
- O
DNA O
) O
mutants O
revealed O
that O
MoCDC15 O
is O
required O
for O
conidiation O
, O
preinfection O
development O
and O
pathogenicity O
in O
M B_BIO
. I_BIO
oryzae I_BIO
. O

Conidia B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
these O
mutants B_BIO/B_DISEASE
were O
viable B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
failed O
to O
adhere O
to O
hydrophobic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surface B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
a O
crucial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
required O
for O
subsequent B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
pathogenic I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

All O
phenotypic O
defects O
observed O
in O
mutants O
were O
rescued O
in O
a O
strain O
complemented O
with O
wild B_GENE
type I_GENE
MoCDC15 I_GENE
. O

Together O
, O
these O
data O
indicate O
that O
MoCDC15 O
functions O
as O
a O
coordinator O
of O
several O
biological O
processes O
important O
for O
pathogenic O
development O
in O
M B_SPECIES[BIO]
. I_SPECIES[BIO]
oryzae I_SPECIES[BIO]
. O

Inactivation O
of O
a O
macronuclear O
intra O
- O
S O
- O
phase O
checkpoint O
in O
Tetrahymena B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermophila B_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
caffeine O
affects O
the O
integrity O
of O
the O
micronuclear O
genome O
. O

Aphidicolin O
( O
APH O
) O
, O
an O
inhibitor O
of O
DNA O
polymerase O
alpha O
, O
arrested O
cell O
divisions O
in O
Tetrahymena B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
thermophila B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

surprisingly O
, O
low B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
APH B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
macronuclear B_DISEASE_ADJECTIVE[DISEASE]
DNA I_DISEASE_ADJECTIVE[DISEASE]
content I_DISEASE_ADJECTIVE[DISEASE]
and O
cell B_MEASURE
size I_MEASURE
in O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dividing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

In O
spite B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increase B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
most B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
basal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bodies I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ciliogenesis B_DISEASE/B_ORGANISM_FUNCTION
and O
development B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
new B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
primordia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
prevented O
by O
the O
aph B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
division B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrest I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
by O
aph B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
partly O
overridden O
by O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
caf B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
caused O
the O
fragmentation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
' O
pulverization B_DISEASE_ADJECTIVE[DISEASE]
' O
) O
of O
the O
chromosomes B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
G2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
micronuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

Somatic B_MEASURE/B_PERSON
progeny I_MEASURE/I_PERSON
of O
dividers B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
pulverized B_DISEASE/B_GENE
micronuclei I_DISEASE/I_GENE
( O
aph B_DISEASE/B_PROTEIN[GENE]
+ B_DISEASE/I_PROTEIN[GENE]
caf B_DISEASE/I_PROTEIN[GENE]
strains B_DISEASE/I_PROTEIN[GENE]
) O
contained O
aneuploid B_DISEASE_ADJECTIVE[DISEASE]
and O
amicronucleate B_DISEASE_ADJECTIVE[DISEASE]
cells I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
amicronucleate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
after O
losing O
their O
oral B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
structures I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
most B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
cilia B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
and O
undergoing O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
disorganization B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
cortical B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
structures I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
assumed O
an O
irregular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
shape B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
' O
crinkled O
' O
) O
and O
were O
nonviable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

' O
Crinkled B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cells I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
not O
formed O
after O
aph B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
+ I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
caf I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
amicronuclear B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
BI3840 B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
strain B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
contains O
some O
mic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
its O
macronucleus B_GENE/B_SPECIES[BIO]
. O

Most B_NUMBER[MEASURE]/B_PERSON
of O
the O
APH B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
+ I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
CAF I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
had O
a O
typical B_DISEASE/B_GENE
' O
* O
' O
- O
like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
conjugation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
they O
did O
not O
produce O
pronuclei B_BIO
, O
but O
received O
them O
unilaterally O
from O
their O
mates B_PERSON
and O
retained O
old B_BIO/B_PERSON
macronuclei B_BIO/I_PERSON
. O

However O
, O
4 B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
100 B_PERSON
APH I_PERSON
+ I_PERSON
CAF I_PERSON
clones I_PERSON
induced O
arrest B_DISEASE
at O
meiotic B_MEASURE
metaphase I_MEASURE
I O
in O
their O
wt B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
mates I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

It O
is O
likely B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
origin B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
such B_DISEASE/B_GENE
clones I_DISEASE/I_GENE
was O
enhanced O
by O
chromosome B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pulverization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Analysis O
of O
the O
Fusarium B_BIO
graminearum I_BIO
species I_BIO
complex I_BIO
from O
wheat B_BIO
, O
barley B_BIO
and O
maize B_BIO
in O
South O
Africa O
provides O
evidence O
of O
species O
- O
specific O
differences O
in O
host O
preference O
. O

Species O
identity O
and O
trichothecene O
toxin O
potential O
of O
560 O
members O
of O
the O
Fusarium B_BIO/B_LOCATION
graminearum I_BIO/I_LOCATION
species I_BIO/I_LOCATION
complex I_BIO/I_LOCATION
( O
FGSC B_DISEASE/B_LOCATION
) O
collected O
from O
diseased O
wheat B_BIO
, O
barley B_BIO
and O
maize B_BIO
in O
South O
Africa O
was O
determined O
using O
a O
microsphere O
- O
based O
multilocus O
genotyping O
assay O
. O

Although O
three B_BIO/B_NUMBER[MEASURE]
trichothecene B_BIO/I_NUMBER[MEASURE]
types B_BIO/I_NUMBER[MEASURE]
( O
3 B_MEASURE
- O
ADON B_DISEASE/B_MEASURE
, O
15 B_MEASURE
- O
ADON B_DISEASE/B_PROTEIN[GENE]
and O
NIV B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
represented O
among O
these O
isolates B_BIO
, O
strains B_BIO/B_DISEASE
with O
the O
15 B_MEASURE
- O
ADON B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
type B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
predominated O
on O
all O
three B_BIO/B_LOCATION
hosts I_BIO/I_LOCATION
. O

A O
significant O
difference O
, O
however O
, O
was O
identified O
in O
the O
composition O
of O
FGSC B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
pathogens O
associated O
with O
Gibberella O
ear O
rot O
( O
GER O
) O
of O
maize B_BIO
as O
compared O
to O
Fusarium O
head O
blight O
( O
FHB O
) O
of O
wheat B_BIO
or O
barley B_BIO
( O
P O
& O
Lt O
; O
0 O
. O
001 O
) O
. O

F B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
graminearum I_BACTERIUM[BIO]
accounted O
for O
more O
than O
85 O
% O
of O
the O
FGSC B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
isolates O
associated O
with O
FHB O
of O
wheat B_BIO
and O
barley B_BIO
( O
N O
= O
425 O
) O
, O
and O
was O
also O
the O
dominant O
species O
among O
isolates O
from O
maize B_BIO
roots O
( O
N O
= O
35 O
) O
. O

However O
, O
with O
the O
exception O
of O
a O
single O
isolate O
identified O
as O
an O
interspecific O
hybrid O
between O
Fusariumboothii B_BIO
and O
F B_BIO
. I_BIO
graminearum I_BIO
, O
GER O
of O
maize B_BIO/B_PERSON
( O
N O
= O
100 O
) O
was O
exclusively O
associated O
with O
F B_BIO
. I_BIO
boothii I_BIO
. O

The O
predominance O
of O
F B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
graminearum I_BACTERIUM[BIO]
among O
FHB O
isolates O
, O
and O
the O
near O
exclusivity O
of O
F B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
boothii I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
among O
GER O
isolates O
, O
was O
observed O
across O
all O
cultivars O
, O
collection O
dates O
, O
and O
provinces O
sampled O
. O

Because O
these O
results O
suggest O
a O
difference O
in O
host O
preference O
among O
species O
of O
the O
FGSC B_BIO/B_DISEASE
, O
we O
hypothesize O
that O
F B_BIO/B_PERSON
. I_BIO/I_PERSON
graminearum I_BIO/I_PERSON
may O
be O
less O
well O
adapted O
to O
infect O
maize B_SPECIES[BIO]/B_PERSON
ears O
than O
other O
members O
of O
the O
FGSC B_DISEASE/B_BIO
. O

Suitability O
of O
different O
media O
for O
in O
vitro O
cultivation O
of O
the O
ruminal O
protozoa O
species O
Entodinium B_BACTERIUM[BIO]
caudatum I_BACTERIUM[BIO]
, O
Eudiplodinium B_BACTERIUM[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
maggii I_BACTERIUM[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
Epidinium B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ecaudatum I_BACTERIUM[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
protozoal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
cultivation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
media I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
tested O
to O
determine O
the O
medium B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O
best O
facilitated O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
viability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
key B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
type B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
ciliates I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
isolated O
from O
the O
sheep B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
rumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Entodinium B_BACTERIUM[BIO]
caudatum I_BACTERIUM[BIO]
and O
Eudiplodinium B_BIO
maggii I_BIO
were O
grown O
anaerobically O
in O
50 O
- O
ml O
flasks O
for O
32 O
days O
in O
Caudatum O
- O
type O
( O
C O
) O
, O
Kisidayova O
( O
K O
) O
or O
Dehority O
( O
M O
) O
medium O
. O

On O
day O
32 O
, O
in O
media O
K O
and O
M O
, O
E B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
caudatum I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
cell O
counts O
were O
high O
with O
5 O
. O
6x10 O
( O
3 O
) O
and O
7 O
. O
8x10 O
( O
3 O
) O
mL O
( O
- O
1 O
) O
, O
respectively O
, O
and O
the O
proportion O
of O
dead O
cells O
was O
low O
with O
0 O
. O
6 O
and O
1 O
. O
4 O
% O
, O
respectively O
. O

E B_BIO/B_MEASURE
. I_BIO/I_MEASURE
maggii I_BIO/I_MEASURE
concentrations O
when O
grown O
in O
medium O
M O
and O
C O
were O
2 O
. O
7x10 O
( O
3 O
) O
and O
2 O
. O
4x10 O
( O
3 O
) O
mL O
( O
- O
1 O
) O
, O
respectively O
, O
with O
3 O
. O
9 O
and O
14 O
. O
1 O
% O
dead O
cells O
. O

Medium O
M O
, O
which O
favoured O
growth O
of O
both O
protozoa O
species O
, O
was O
tested O
again O
and O
Epidinium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ecaudatum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
included O
. O

Protozoa B_BIO/B_PERSON
were O
grown O
for O
a O
4 B_NUMBER[MEASURE]
- O
month B_TIME[MEASURE]
period I_TIME[MEASURE]
and O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
taken O
in O
the O
last B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
two I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
months I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O
days B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
7 B_MEASURE
, O
35 B_MEASURE
and O
57 B_MEASURE
. O

Average O
cell O
concentrations O
were O
10 O
. O
0 O
, O
0 O
. O
8 O
and O
0 O
. O
5x10 O
( O
3 O
) O
mL O
( O
- O
1 O
) O
for O
E B_BIO
. I_BIO
caudatum I_BIO
, O
E B_BIO
. I_BIO
maggii I_BIO
, O
and O
E B_BIO
. I_BIO
ecaudatum I_BIO
, O
respectively O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
appear O
to O
be O
the O
best B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
cultivating O
these O
three B_BIO/B_DISEASE
species I_BIO/I_DISEASE
in O
one B_LOCATION/B_PERSON
medium I_LOCATION/I_PERSON
. O

Synganglion O
transcriptome O
and O
developmental O
global O
gene O
expression O
in O
adult O
females O
of O
the O
American B_SPECIES[BIO]
dog I_SPECIES[BIO]
tick I_SPECIES[BIO]
, O
Dermacentor B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
variabilis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Acari O
: O
Ixodidae O
) O
. O

454 O
Pyrosequencing O
was O
used O
to O
characterize O
the O
expressed O
genes O
from O
the O
synganglion O
and O
associated O
neurosecretory O
organs O
of O
unfed O
and O
partially O
fed O
virgin O
and O
mated O
replete O
females O
of O
the O
American B_SPECIES[BIO]
dog I_SPECIES[BIO]
tick I_SPECIES[BIO]
, O
Dermacentor B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
variabilis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
total B_MEASURE/B_LOCATION
of O
14 B_MEASURE
, O
881 B_MEASURE
contiguous I_MEASURE
sequences I_MEASURE
( O
contigs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
was O
assembled O
, O
with O
an O
average B_MEASURE
size I_MEASURE
of O
229 B_NUMBER[MEASURE]
BP I_NUMBER[MEASURE]
. O

Gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ontology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
terms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
Level B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
2 B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
biological B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
processes B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
assigned O
to O
4366 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contigs I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Seven B_TIME[MEASURE]/B_ORGANIZATION
acetylcholinesterases I_TIME[MEASURE]/I_ORGANIZATION
, O
a O
muscarinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetylcholine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
ACh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
receptor B_GENE
, O
two B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nicotinic I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ACh I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Beta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
subunits B_MEASURE
, O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ACh I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
unc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
18 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
regulators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
receptors B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GABA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transporters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
norepinephrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transporters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
an O
octopamine B_GENE/B_PERSON
receptor I_GENE/I_PERSON
are O
described O
. O

microarrays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
conducted O
to O
examine O
global B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
quantitative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chain B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
to O
verify O
expression B_GENE
of O
selected B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neuropeptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clustering I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
all O
differentially O
expressed O
transcripts B_GENE/B_BIO
grouped O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
fed O
and O
replete B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ticks I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
as O
being O
more O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
terms B_LOCATION/B_MEASURE
of O
differentially O
expressed O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
unfed B_BIO/B_PERSON
ticks I_BIO/I_PERSON
as O
the O
outgroup B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Nine B_NUMBER[MEASURE]/B_BIO
putative I_NUMBER[MEASURE]/I_BIO
neuropeptides I_NUMBER[MEASURE]/I_BIO
( O
allatostatin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
bursicon B_GENE/B_BIO
- O
Beta B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
preprocorazonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
glycoprotein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
orcokinins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
preprosulphakinin B_GENE
) O
and O
a O
gonadotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
releasing O
hormone B_GENE
receptor I_GENE
were O
differentially O
expressed O
, O
and O
their O
developmental B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
reproduction B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
was O
investigated O
. O

The O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
eclosion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
corazonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
bursicon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
synganglion B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
in O
insects B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulate O
behaviour B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cuticle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
development I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
associated O
with O
moulting B_PERSON/B_ORGANISM_FUNCTION
, O
suggest O
that O
this O
system B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
be O
used O
in O
ticks B_SPECIES[BIO]
to O
regulate O
blood B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
feeding B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
cuticle B_LOCATION/B_ORGANISM_FUNCTION
expansion B_LOCATION/I_ORGANISM_FUNCTION
and O
development B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
related O
to O
female B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
reproduction B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
; O
adult B_BIO/B_PERSON
ticks I_BIO/I_PERSON
do O
not O
moult O
. O

Endogenous O
regulation O
of O
the O
growth O
- O
rate O
responses O
of O
a O
spring O
- O
dwelling O
strain O
of O
the O
freshwater O
alga O
, O
Chlorella B_SPECIES[BIO]/B_LOCATION
minutissima I_SPECIES[BIO]/I_LOCATION
, O
to O
light O
and O
temperature O
. O

The O
paper O
presents O
a O
laboratory O
investigation O
of O
the O
temperature O
- O
and O
light O
- O
dependence O
of O
autotrophic O
growth O
of O
the O
alga O
Chlorella B_BIO
minutissima I_BIO
. O

It O
was O
isolated O
from O
the O
storage B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
basin I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
a O
spring B_TIME[MEASURE]/B_LOCATION
in O
the O
mountains B_LOCATION
of O
the O
Massif B_LOCATION
Central I_LOCATION
, O
France B_LOCATION
. O

The O
alga B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
grown O
at O
temperatures B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
between O
( O
10 B_MEASURE
and O
35 B_MEASURE
^ I_MEASURE
0C I_MEASURE
) O
and O
under O
irradiances B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
30 B_MEASURE
to O
550 B_MEASURE/B_LOCATION
mumol I_MEASURE/I_LOCATION
m I_MEASURE/I_LOCATION
( O
- O
2 B_MEASURE
) O
s O
( O
- O
1 B_MEASURE
) O
, O
under O
a O
light B_COLOR/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
dark B_LOCATION/B_ENT
cycle I_LOCATION/I_ENT
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
fitted O
to O
selected O
descriptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
seeking O
to O
express O
, O
as O
far O
as O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
observed B_MEASURE
physiological I_MEASURE
behaviour I_MEASURE
of O
the O
strain B_BIO
and O
the O
minimum B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiance B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
to O
sustain O
net B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

At O
all O
temperatures O
, O
the O
maximum O
rates O
of O
growth O
observed O
are O
strikingly O
slower O
than O
those O
of O
other O
Chlorella B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
of O
other O
small O
algae O
, O
reported O
in O
the O
literature O
, O
even O
when O
correction O
is O
made O
for O
continuous O
light O
. O

The O
Q10 B_MEASURE
statistic I_MEASURE
for O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
at O
temperatures B_LOCATION/B_ORGANIZATION
& O
GT B_ORGANIZATION/B_PROTEIN[GENE]
; O
20 B_MEASURE/B_LOCATION
^ I_MEASURE/I_LOCATION
0C I_MEASURE/I_LOCATION
rates I_MEASURE/I_LOCATION
is O
also O
noticeably O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
other B_MEASURE/B_LOCATION
species I_MEASURE/I_LOCATION
, O
while O
the O
apparent B_MEASURE
threshold I_MEASURE
of O
any O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
about O
8 B_MEASURE
^ O
0C B_MEASURE
. O

Growth B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
readily O
light B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
saturated O
at O
all O
temperatures B_MEASURE/B_LOCATION
but O
with O
little B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
adaptation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
photosynthesis B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
photon I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
flux B_MEASURE
rates I_MEASURE
. O

No O
short B_MEASURE/B_LOCATION
- O
term B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
flexibility I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
these O
properties B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
over O
a O
time B_MEASURE
- O
scale B_MEASURE/B_LOCATION
of O
days B_TIME[MEASURE]
) O
was O
demonstrated O
during O
the O
course B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
our O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
deduce O
that O
the O
algal B_BIO/B_DISEASE
strain I_BIO/I_DISEASE
had O
become O
genetically O
adapted O
to O
the O
relatively O
constant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
even B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
temperature B_MEASURE/B_LOCATION
and O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
light B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
spring B_LOCATION
- O
water B_LOCATION/B_TIME[MEASURE]
habitat I_LOCATION/I_TIME[MEASURE]
whence O
it O
was O
originally O
isolated O
. O

characterization O
of O
the O
oxysterol O
- O
binding O
protein O
gene O
family O
in O
the O
yellow B_SPECIES[BIO]
fever I_SPECIES[BIO]
mosquito I_SPECIES[BIO]
, O
Aedes B_SPECIES[BIO]/B_PROTEIN[GENE]
aegypti B_SPECIES[BIO]/I_PROTEIN[GENE]
. O

The O
oxysterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
protein B_BIO/B_PROTEIN[GENE]
( O
OSBP B_DISEASE/B_GENE
) O
and O
OSBP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
related O
proteins B_PROTEIN[GENE]/B_DISEASE
( O
ORPs B_LOCATION/B_DISEASE
) O
are O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
binding O
proteins B_BIO/B_PROTEIN[GENE]
that O
may O
be O
involved O
in O
cellular B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
sterol B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
transportation B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
sterol B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
and O
signal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
transduction B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Four O
ORP O
genes O
were O
cloned O
from O
Aedes B_SPECIES[BIO]/B_GENE
aegypti I_SPECIES[BIO]/I_GENE
. O

Based O
on O
amino O
acid O
sequence O
homology O
to O
human B_PERSON/B_SPECIES[BIO]
proteins O
, O
they O
are O
AeOSBP O
, O
AeORP1 O
, O
AeORP8 O
and O
AeORP9 O
. O

Splicing B_NUMBER[MEASURE]/B_LOCATION
variants B_NUMBER[MEASURE]/I_LOCATION
of O
AeOSBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
AeORP8 B_GENE
were O
identified O
. O

The O
temporal B_MEASURE/B_DISEASE
and O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
members B_PERSON/B_BIO
of O
the O
AeOSBP B_BIO/B_GENE
gene I_BIO/I_GENE
family I_BIO/I_GENE
through O
developmental B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
stages B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
the O
gonotrophic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
profiled O
. O

AeORP1 B_GENE/B_PERSON
transcription I_GENE/I_PERSON
seemed O
to O
be O
head B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
whereas O
AeOSBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
AeORP9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
induced O
by O
a O
bloodmeal B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Furthermore O
, O
over O
- O
expression O
of O
AeORPs O
facilitated O
[ O
( O
3 O
) O
H O
] O
- O
cholesterol O
uptake O
in O
Ae B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
aegypti B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cultured O
Aag O
- O
2 O
cells O
. O

identification O
and O
expression O
analysis O
of O
nervous O
wreck O
, O
which O
is O
preferentially O
expressed O
in O
the O
brain O
of O
the O
male O
silkworm B_SPECIES[BIO]/B_PERSON
moth I_SPECIES[BIO]/I_PERSON
, O
Bombyx B_BIO/B_GENE
mori B_BIO/I_GENE
. O

sexually O
dimorphic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
neural I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
circuits I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
reproductive B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
behaviour B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

The O
molecular O
basis O
of O
sexual O
dimorphism O
in O
the O
silkworm B_SPECIES[BIO]
moth I_SPECIES[BIO]
( O
Bombyx B_BIO/B_PROTEIN[GENE]
mori B_BIO/I_PROTEIN[GENE]
) O
brain O
, O
however O
, O
is O
unclear O
. O

We O
conducted O
cDNA O
subtraction O
screening O
and O
identified O
nervous O
wreck O
( O
Bmnwk O
) O
, O
a O
synaptic O
growth O
regulatory O
gene O
, O
whose O
expression O
is O
higher O
in O
the O
male O
brain O
than O
in O
the O
female O
brain O
of O
the O
silkworm B_SPECIES[BIO]/B_PERSON
. O

Bmnwk B_GENE
was O
preferentially O
expressed O
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
at O
the O
late B_PERSON
pupae I_PERSON
and O
adult B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
stages I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

In O
situ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
Bmnwk B_GENE/B_LOCATION
is O
highly O
expressed O
in O
the O
optic B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
male B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
moth I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
suggest O
that O
Bmnwk O
has O
a O
role O
in O
the O
development O
and O
/ O
or O
maintenance O
of O
the O
optic O
lobe O
in O
the O
male O
silkworm B_SPECIES[BIO]/B_PERSON
brain O
. O

Infraciliature O
of O
eight O
Triplumaria O
species O
( O
Ciliophora O
, O
Entodiniomorphida O
) O
from O
Asian B_LOCATION
elephants I_LOCATION
with O
the O
description O
of O
six O
new O
species O
. O

Intestinal O
ciliates O
excreted O
in O
the O
feces O
of O
Asian B_SPECIES[BIO]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elephants I_SPECIES[BIO]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
surveyed O
. O

Fourteen B_BIO/B_PERSON
species I_BIO/I_PERSON
in O
the O
order B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Entodiniomorphida B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
detected O
. O

Nine B_BIO/B_PERSON
Triplumaria B_BIO/I_PERSON
species B_BIO/I_PERSON
in O
the O
family B_LOCATION
Cycloposthiidae I_LOCATION
were O
found O
. O

Using O
the O
silver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
impregnation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
two B_NUMBER[MEASURE]/B_PERSON
known O
species B_BIO/B_PERSON
, O
T B_OTHER/B_PROTEIN[GENE]
. O
antis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
T B_OTHER/B_GENE
. O
dvoinosi B_PERSON/B_SPECIES[BIO]
, O
were O
redescribed O
and O
six B_BIO/B_MEASURE
new B_BIO/I_MEASURE
species B_BIO/I_MEASURE
, O
T B_PROTEIN[GENE]/B_OTHER
. O
sukuna B_SPECIES[BIO]/B_GENE
n O
. O

sp B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O
, O
T B_OTHER/B_GENE
. O
zuze B_PERSON/B_SPECIES[BIO]
n O
. O

SP B_LOCATION/B_PERSON
. O
, O
T B_OTHER/B_GENE
. O
solea B_BACTERIUM[BIO]/B_LOCATION
n I_LOCATION
. O

sp B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O
, O
T B_OTHER/B_GENE
. O
suwako B_SPECIES[BIO]/B_LOCATION
n I_LOCATION
. O

SP B_LOCATION/B_PERSON
. O
, O
T B_OTHER/B_GENE
. O
fulgora B_SPECIES[BIO]/B_GENE
n I_SPECIES[BIO]/I_GENE
. O

sp B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O
, O
and O
T B_OTHER/B_GENE
. O
harpagonis B_PERSON/B_LOCATION
n B_PERSON/I_LOCATION
. O

SP B_LOCATION/B_GENE
. O
, O
were O
described O
. O

T B_OTHER/B_PROTEIN[GENE]
. O
sukuna B_PERSON/B_SPECIES[BIO]
, O
T B_OTHER/B_PROTEIN[GENE]
. O
zuze B_PERSON/B_SPECIES[BIO]
, O
T B_OTHER/B_PROTEIN[GENE]
. O
solea B_SPECIES[BIO]/B_PERSON
, O
and O
T B_OTHER/B_LOCATION
. O
suwako B_PERSON/B_SPECIES[BIO]
have O
the O
perivestibular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
polybrachykinety B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
along O
the O
vestibular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
opening I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
buccal O
infraciliary O
bands O
of O
T O
. O
suwako O
are O
similar O
to O
those O
of O
T B_BIO/B_PERSON
. I_BIO/I_PERSON
selenica I_BIO/I_PERSON
found O
from O
elephants O
and O
the O
buccal O
infraciliary O
bands O
of O
T O
. O
sukuna O
, O
T O
. O
zuze O
, O
and O
T O
. O
solea O
are O
similar O
to O
those O
of O
T O
. O
grypoclunis O
described O
from O
rhinoceroses O
. O

T B_PROTEIN[GENE]/B_OTHER
. O
antis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
dvoinosi B_PERSON/B_SPECIES[BIO]
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
fulgora B_SPECIES[BIO]/B_LOCATION
, O
and O
T B_OTHER/B_GENE
. O
harpagonis B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
have O
the O
vestibular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
polybrachykinety I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
extending O
down O
inside O
the O
vestibulum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
as O
found O
in O
rumen B_BIO/B_PERSON
ciliates I_BIO/I_PERSON
in O
the O
family B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
Ophryoscolecidae I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
caudalial B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
ciliary B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
zones B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
T B_OTHER/B_LOCATION
. O
dvoinosi B_PERSON/B_SPECIES[BIO]
and O
T B_OTHER/B_PROTEIN[GENE]
. O
fulgora B_SPECIES[BIO]/B_LOCATION
were O
retractable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
found O
in O
rumen B_SPECIES[BIO]/B_PERSON
ophryoscolecids I_SPECIES[BIO]/I_PERSON
. O

Raabena B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
bella B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
and O
Pseudoentodinium O
elephantis O
showed O
high O
composition O
values O
over O
30 O
% O
. O

Ciliate B_BACTERIUM[BIO]/B_MEASURE
densities I_BACTERIUM[BIO]/I_MEASURE
in O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fecal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
0 B_MEASURE
. O
15 B_MEASURE
, O
1 B_MEASURE
. O
09 B_MEASURE
, O
and O
2 B_MEASURE
. O
07x10 B_MEASURE
( O
4 B_MEASURE/B_LOCATION
) O
/ O
ml B_MEASURE/B_PERSON
. O

Prolixicin O
: O
a O
novel O
antimicrobial O
peptide O
isolated O
from O
Rhodnius B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolixus I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
differential O
activity O
against O
bacteria O
and O
Trypanosoma B_SPECIES[BIO]
cruzi I_SPECIES[BIO]
. O

We O
identified O
and O
characterized O
the O
activity O
of O
prolixicin O
, O
a O
novel O
antimicrobial O
peptide O
( O
AMP O
) O
isolated O
from O
the O
hemipteran O
insect O
, O
Rhodnius B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolixus I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
one B_LOCATION
region I_LOCATION
of O
prolixicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O
may O
be O
related O
to O
the O
diptericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
/ O
attacin B_PERSON/B_LOCATION
family I_PERSON/I_LOCATION
of O
AMPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Prolixicin B_PROTEIN[GENE]/B_PERSON
is O
an O
11 B_NUMBER[MEASURE]
- O
kDa B_PROTEIN[GENE]
peptide I_PROTEIN[GENE]
containing O
a O
putative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
21 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
signal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
putative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
no O
glycosylation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
produced O
by O
both O
adult B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fat I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
body I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
midgut B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
bacterial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
haemolymph B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
or O
the O
midgut B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Unlike O
most O
insect B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
antibacterial I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
peptides I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
prolixicin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
seem O
to O
be O
regulated O
by O
NF B_GENE/B_DISEASE
- O
kappaB B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
its O
promoter B_LOCATION/B_GENE
region I_LOCATION/I_GENE
contains O
several B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GATA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Recombinant O
prolixicin O
has O
strong O
activity O
against O
the O
Gram O
- O
negative O
bacterium O
Escherichia B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coli B_BACTERIUM[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differential O
activity O
against O
several O
Gram O
- O
negative O
and O
Gram O
- O
positive O
bacteria O
. O

No O
significant O
toxicity O
was O
demonstrated O
against O
Trypanosoma B_SPECIES[BIO]/B_DISEASE
cruzi I_SPECIES[BIO]/I_DISEASE
, O
the O
human B_PERSON/B_SPECIES[BIO]
parasite O
transmitted O
by O
R B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPECIES[BIO]
. B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_SPECIES[BIO]
prolixus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_SPECIES[BIO]
. O

Development O
Time O
and O
Body O
size O
in O
Eupolyphaga B_LOCATION
sinensis I_LOCATION
Along O
a O
Latitudinal O
gradient O
From O
China O
. O

The O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
organisms B_BIO/B_GENE
to O
temperature B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
may O
be O
via O
short B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
term I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
responses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
the O
phenotype B_GENE/B_DISEASE
( O
phenotypic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasticity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
or O
they O
could O
involve O
long B_TIME[MEASURE]
- O
term B_TIME[MEASURE]/B_LOCATION
evolutionary I_TIME[MEASURE]/I_LOCATION
change I_TIME[MEASURE]/I_LOCATION
and O
adaptation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
via O
selection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
) O
to O
the O
genotype B_GENE/B_LOCATION
. O

These O
could O
involve O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
mean B_MEASURE
size I_MEASURE
of O
the O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
to O
the O
thermal B_MEASURE/B_LOCATION
reaction I_MEASURE/I_LOCATION
norm I_MEASURE/I_LOCATION
. O

We O
examined O
the O
effects O
of O
various O
temperatures O
( O
of O
22 O
, O
25 O
, O
28 O
, O
and O
31 O
^ O
0C O
) O
on O
development O
time O
, O
adult O
body O
size O
and O
preadult O
survivorship O
in O
three O
populations O
of O
the O
cockroach O
, O
Eupolyphaga B_BIO/B_LOCATION
sinensis B_BIO/I_LOCATION
( O
Walker O
) O
, O
collected O
at O
different O
latitudes O
. O

We O
found O
substantial O
temperature O
- O
induced O
plasticity O
in O
development O
time O
, O
body O
size O
, O
and O
preadult O
survivorship O
, O
indicating O
that O
developmental O
temperatures O
have O
strong O
impacts O
on O
growth O
and O
life O
history O
traits O
of O
E B_BIO
. I_BIO
sinensis I_BIO
. O

Genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
development B_MEASURE/B_PERSON
time I_MEASURE/I_PERSON
, O
body B_MEASURE/B_PERSON
size I_MEASURE/I_PERSON
, O
and O
preadult B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survivorship B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
detected O
among O
populations B_LOCATION/B_PERSON
, O
and O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
traits I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
exhibited O
highly O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
populations I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
to O
various B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conditions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
indicating O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
differences B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
among O
populations B_LOCATION/B_PERSON
in O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
thermal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
reaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
norms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

We O
also O
found O
that O
two B_PERSON/B_BIO
populations I_PERSON/I_BIO
seem O
to O
support O
the O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acclimation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
whereas O
the O
third B_MEASURE/B_LOCATION
mid B_MEASURE/I_LOCATION
- O
latitude B_LOCATION/B_MEASURE
population I_LOCATION/I_MEASURE
does O
not O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
likely B_DISEASE_ADJECTIVE[DISEASE]
because O
of O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
season B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
and O
voltinism B_MEASURE/B_EDU[ORGANIZATION]
, O
indicating O
that O
not O
only O
temperature B_TIME[MEASURE]/B_BIO
regime I_TIME[MEASURE]/I_BIO
but O
also O
its O
interactions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
generation B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
( O
and O
development B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
) O
, O
voltinism B_MEASURE/B_EDU[ORGANIZATION]
, O
and O
season B_TIME[MEASURE]/B_LOCATION
length B_TIME[MEASURE]/I_LOCATION
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
have O
considerable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
insect B_MEASURE/B_ORGANISM_FUNCTION
development I_MEASURE/I_ORGANISM_FUNCTION
time I_MEASURE/I_ORGANISM_FUNCTION
and O
body B_MEASURE
size I_MEASURE
. O

Overall O
, O
changes O
in O
development O
time O
, O
body O
size O
, O
and O
preadult O
survivorship O
in O
E B_BIO/B_LOCATION
. I_BIO/I_LOCATION
sinensis I_BIO/I_LOCATION
can O
all O
be O
regarded O
as O
adaptations O
to O
changing O
thermal O
regimes O
. O

Culture O
Independent O
Survey O
of O
the O
Microbiota O
of O
the O
Glassy B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Winged I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sharpshooter I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Homalodisca B_MEASURE/B_DISEASE
vitripennis I_MEASURE/I_DISEASE
) O
Using O
454 O
Pyrosequencing O
. O

The O
glassy B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
winged I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sharpshooter I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Homalodisca B_BIO/B_LOCATION
vitripennis I_BIO/I_LOCATION
( I_BIO/I_LOCATION
Germar I_BIO/I_LOCATION
) I_BIO/I_LOCATION
, O
is O
an O
invasive O
pest O
that O
has O
spread O
across O
the O
southern O
and O
western O
United O
States O
. O

H B_PERSON/B_BIO
. I_PERSON/I_BIO
vitripennis I_PERSON/I_BIO
is O
highly O
polyphagous O
and O
voracious O
, O
feeding O
on O
at O
least O
100 O
plant O
species O
and O
consuming O
up O
to O
100 O
times O
its O
weight O
in O
xylem O
fluid O
daily O
. O

The O
insect O
is O
a O
vector O
of O
the O
phytopathogen O
Xylella B_BACTERIUM[BIO]
fastidiosa I_BACTERIUM[BIO]
( I_BACTERIUM[BIO]
Wells I_BACTERIUM[BIO]
) I_BACTERIUM[BIO]
, O
which O
is O
the O
causative O
agent O
of O
Pierce O
' O
s O
disease O
in O
grapevines O
. O

To O
evaluate O
the O
microbial O
flora O
associated O
with O
H B_SPECIES[BIO]/B_DISEASE
. B_SPECIES[BIO]/I_DISEASE
vitripennis B_SPECIES[BIO]/I_DISEASE
, O
total O
DNA O
extracts O
from O
hemolymph O
, O
alimentary O
canal O
excretions O
, O
and O
whole O
insect O
bodies O
were O
subjected O
to O
16S O
rDNA O
pyrosequencing O
using O
the O
bTEFAP O
methodology O
and O
the O
resulting O
sequences O
( O
370 O
- O
520 O
BP O
in O
length O
) O
were O
compared O
with O
a O
curated O
high O
quality O
16S O
database O
derived O
from O
GenBank O
http O
: O
/ O
/ O
www O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
. O

Species O
from O
the O
genera O
Wolbachia O
, O
Delftia O
( O
formerly O
Pseudomonas O
) O
, O
Pectobacterium O
, O
Moraxella O
, O
Serratia O
, O
Bacillus O
, O
and O
many O
others O
were O
detected O
and O
a O
comprehensive O
picture O
of O
the O
microbiome O
associated O
with O
H B_DISEASE/B_BIO
. I_DISEASE/I_BIO
vitripennis I_DISEASE/I_BIO
was O
established O
. O

Some O
of O
the O
bacteria B_BIO
identified O
in O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
initial B_DISEASE_ADJECTIVE[DISEASE]
discoveries I_DISEASE_ADJECTIVE[DISEASE]
; O
providing O
a O
breadth B_LOCATION/B_MEASURE
of O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
microbial B_BIO/B_ORGANIZATION
flora I_BIO/I_ORGANIZATION
of O
this O
insect B_BIO/B_LOCATION
pest I_BIO/I_LOCATION
can O
serve O
as O
a O
reservoir B_LOCATION/B_PERSON
of O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
for O
developing O
biological B_LOCATION/B_ORGANIZATION
control B_LOCATION/I_ORGANIZATION
strategies B_LOCATION/I_ORGANIZATION
. O

infection O
by O
Mycorrhizal O
fungi O
increases O
Natural O
Enemy O
abundance O
on O
Tobacco O
( O
Nicotiana B_BIO/B_LOCATION
rustica B_BIO/I_LOCATION
) O
. O

The O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
arbuscular B_BIO
mycorrhizal I_BIO
fungi I_BIO
( O
AMF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
influences B_DISEASE_ADJECTIVE[DISEASE]
plant I_DISEASE_ADJECTIVE[DISEASE]
nutrient I_DISEASE_ADJECTIVE[DISEASE]
uptake I_DISEASE_ADJECTIVE[DISEASE]
, O
growth B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
plant B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defensive I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemistry I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thereby O
directly O
influencing O
multi B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
trophic B_DISEASE_ADJECTIVE[DISEASE]
interactions I_DISEASE_ADJECTIVE[DISEASE]
. O

Different B_BIO/B_PERSON
fungal I_BIO/I_PERSON
isolates I_BIO/I_PERSON
( O
genotypes B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
same B_BIO
fungal I_BIO
species I_BIO
) O
have O
been O
shown O
to O
differ O
in O
nutrient B_DISEASE_ADJECTIVE[DISEASE]
uptake I_DISEASE_ADJECTIVE[DISEASE]
ability I_DISEASE_ADJECTIVE[DISEASE]
. O

plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infected O
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
AMF B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
genotypes B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
may O
vary O
in O
foliar B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nutrient B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
defensive B_MEASURE/B_DISEASE
chemical I_MEASURE/I_DISEASE
levels I_MEASURE/I_DISEASE
, O
potentially O
influencing O
multi B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
trophic B_DISEASE_ADJECTIVE[DISEASE]
interactions I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
a O
completely O
randomized O
design O
, O
we O
compared O
the O
effect O
of O
two O
isolates O
of O
the O
mycorrhizal O
fungus O
Glomus B_BIO/B_LOCATION
etunicatum I_BIO/I_LOCATION
W O
. O

N B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Becker O
& O
amp O
; O
Gerdemann O
on O
silver B_BIO
leaf I_BIO
whitefly I_BIO
( O
Bemisia B_PERSON/B_BIO
argentifolii I_PERSON/I_BIO
Bellows O
& O
amp O
; O
Perring O
) O
( O
Hemiptera O
: O
Aleyrodidae O
) O
and O
parasitic O
wasp O
( O
Eretmocerus B_PERSON/B_DISEASE
eremicus I_PERSON/I_DISEASE
Rose O
& O
amp O
; O
Zolnerowich O
) O
( O
Hymenoptera O
: O
Aphelinidae O
) O
abundance O
. O

Whitefly B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
populations I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
not O
influenced O
by O
AMF B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
infection B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

parasite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
populations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on O
plants B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infected O
with O
the O
isolate B_BIO
collected O
from O
Georgia B_LOCATION/B_BIO
, O
even O
after O
controlling O
for O
whitefly B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
abundance I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
plant B_BIO/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
architecture B_BIO/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
propose O
that O
AMF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indirectly O
influences O
parasite B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
abundance I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
parasitism B_DISEASE_ADJECTIVE[DISEASE]
through O
a O
change B_MEASURE
in O
leaf B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
surface I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
chemicals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O
affect O
parasitic B_DISEASE/B_ORGANISM_FUNCTION
wasps I_DISEASE/I_ORGANISM_FUNCTION
. O

Because O
of O
the O
ubiquity B_LOCATION/B_MEASURE
of O
and O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
AMF B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
multi B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
trophic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
strongly O
influenced O
by O
belowground B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
processes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
ability O
of O
selected O
pupal O
parasitoids O
( O
hymenoptera O
: O
pteromalidae O
) O
to O
locate O
stable B_SPECIES[BIO]/B_PERSON
fly I_SPECIES[BIO]/I_PERSON
hosts O
in O
a O
soiled O
equine O
bedding O
substrate O
. O

The O
ability O
of O
Spalangia B_SPECIES[BIO]/B_LOCATION
cameroni B_SPECIES[BIO]/I_LOCATION
Perkins O
, O
Spalangia B_PERSON
endius I_PERSON
Walker O
, O
and O
Muscidifurax B_BIO/B_LOCATION
raptorellus I_BIO/I_LOCATION
Kogan O
and O
Legner O
to O
locate O
and O
attack O
stable B_SPECIES[BIO]/B_PERSON
fly I_SPECIES[BIO]/I_PERSON
hosts O
was O
evaluated O
under O
laboratory O
conditions O
. O

Postfeeding O
third O
- O
instar O
stable B_SPECIES[BIO]/B_PERSON
fly I_SPECIES[BIO]/I_PERSON
larvae O
were O
released O
and O
allowed O
to O
pupate O
in O
two O
arena O
types O
: O
large O
4 O
. O
8 O
liter O
chambers O
containing O
a O
field O
- O
collected O
, O
soiled O
equine O
bedding O
substrate O
; O
or O
120 O
- O
ml O
plastic O
cups O
containing O
wood O
chips O
. O

At O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
fly B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pupariation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
parasitoids B_SPECIES[BIO]/B_PERSON
were O
released O
and O
permitted O
72 B_MEASURE/B_LOCATION
h O
to O
locate O
and O
attack B_DISEASE/B_LOCATION
hosts I_DISEASE/I_LOCATION
. O

On O
average O
, O
parasitism O
rates O
of O
freely O
accessible O
stable B_BIO/B_PERSON
fly I_BIO/I_PERSON
pupae O
in O
cups O
were O
not O
significantly O
different O
between O
parasitoid O
species O
. O

However O
, O
parasitism O
rates O
in O
chambers O
containing O
either O
Spalangia O
spp O
. O
were O
= O
50 O
- O
fold O
more O
than O
M B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
raptorellus I_SPECIES[BIO]/I_LOCATION
. O

Additional O
intraspecies O
analysis O
revealed O
that O
parasitism O
rates O
both O
by O
S B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
cameroni I_PERSON/I_SPECIES[BIO]
and O
S B_PERSON/B_BIO
. I_PERSON/I_BIO
endius I_PERSON/I_BIO
were O
not O
significantly O
different O
when O
pupae O
were O
freely O
accessible O
or O
within O
bedding O
, O
whereas O
M B_BIO/B_PERSON
. I_BIO/I_PERSON
raptorellus I_BIO/I_PERSON
attacked O
significantly O
more O
pupae O
in O
cups O
than O
in O
the O
larger O
chambers O
where O
hosts O
were O
distributed O
within O
bedding O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
Spalangia B_LOCATION/B_BIO
spp I_LOCATION/I_BIO
. O
are O
more O
suited O
to O
successfully O
locate O
and O
attack O
hosts B_SPECIES[BIO]
in O
habitats B_LOCATION
created O
by O
equine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
husbandry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
Florida B_LOCATION/B_BIO
. O

Therefore O
, O
commercially O
available B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
parasitoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mixtures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
Muscidifurax B_LOCATION/B_SPECIES[BIO]
spp I_LOCATION/I_SPECIES[BIO]
. O
may O
be O
ineffective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
if O
used O
as O
a O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
measure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O
Florida B_LOCATION/B_TIME[MEASURE]
equine B_LOCATION/I_TIME[MEASURE]
facilities B_LOCATION/I_TIME[MEASURE]
. O

